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ABSTRACT

Wright, Kyle J. Ph.D., Purdue University, December 2016. Synthesis and
Performance of Novel Supramolecular Tools for Single-Particle Cryogenic
Electron Microscopy and Drug and Gene Delivery. Major Professor: David H.
Thompson.

High-resolution biomacromolecular structure elucidation is fundamentally important
to structure-based drug design and basic research into complex biochemical processes.
Cryo-EM is an emerging alternative to XRD and NMR that is complementary in many
ways relative to XRD and NMR. Materials approaches to cryo-EM are anticipated to
greatly facilitate the cryo-EM process, allowing progress toward a more high-throughput
application of cryo-EM to address challenges in structural biology.
Various affinity-based approaches inspired by approaches previously introduced for
2D crystallization were developed for facilitation of cryo-EM. A library of affinity
lipopolymer constructs were synthesized consisting of lipopolymers of various PEG
molecular weights conjugated to lipids displaying varied affinity or covalently-active
moieties at their distal termini. Modified-EM grids with stabilized lipid coatings were
then used to capture His6-T7 bacteriophage and His6-RplL from cell lysates, purified
His8-GFPuv, and nanodisc embedded His6-MalFGK2. Graphene-oxide-NTA-based
affinity grids were fabricated via covalent modification of graphene-oxide and monolayer

xxviii
fabrication on a Langmuir trough. These monolayers were characterized by AFM, SEM,
and evaluated for specific capture of his-tagged protein targets. These materials were also
used to capture his6-GroEL from clarified cell lysates and used to generate a cryo-EM
dataset yielding a map with a gold standard resolution of 8.1 Å. A library of
polyrotaxanes based on PEG, α-CD and various endcaps and rotaxanation methods was
synthesized. Several of these compounds were further modified with NTA moieties to
impart affinity interactions on the tubular polyrotaxane templates which might be used
for isolation of proteins and assisted cryo-EM. The laterally- and rotationally-mobile
NTA-CD ligating groups enabled the capture of his-tagged proteins of substantially
different sizes and facilitated their imaging via AFM, cryo-TEM, and TEM. This material
may greatly facilitate cryo-EM analysis of his-tagged proteins by concentrating them into
large and readily detectable clusters that enables projection images of the protein
structure in all possible 3D orientations.
.

Several families of diblock copolymer-based drug and gene delivery systems were

also developed utilizing organocatalytic ring-opening polymerization (ROP) catalyzed by
common amidine and guanidine bases. A library of mPEG-b-polycarbonate pendant
polymers was synthesized and evaluated as part of a non-viral gene delivery system. The
diblock copolymers showed the ability to form nanoparticles, typically 100-250 nm in
size, with slightly positive surface zeta-potentials, effectively condensed pDNA at N/P
ratios above 10, and showed comparable transfection efficiencies to Lipofectamine-2000
in HeLa Cells. Organocatalytic ROP was also utilized to synthesize small libraries of
mPEG-b-poly(ε-caprolactone), mPEG-b-poly(trimethylene carbonate) and mPEG-bpoly(lactide-co-glycolide) diblock copolymers including a novel collagen-binding

xxix
peptide-diblock copolymer conjugate (SILY-PEG-b-PCL) utilizing organocatalytic ROP
from a heterobifunctional PEG derivative. A facile and widely applicable synthetic
procedure for the synthesis of cyclic amino-acid-N-carboxyanhydride monomers for
synthesis of polypeptides utilizing tetrahydrofuran (THF) as solvent was developed and
used to synthesize a small library of some novel and previously reported NCA monomers
in superior yield and purity.
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CHAPTER ONE:
MATERIALS APROACHES TO FACILITATION OF SINGLE PARTICLE CRYO-EM

1.1 High-Resolution Biomacromolecular Structure Elucidation
High resolution structural information is a valuable asset for studies of biological
systems and processes including: cellular trafficking and infrastructure, enzymatic
processes, interactions between multiprotein complexes and infectious particles1, as well
as for structure-based, or rational, drug design efforts2. X-ray crystallography (XRD), and
nuclear magnetic resonance (NMR)-based methods account for the majority of published
biomacromolecular structures3 to date (Table 1.1). Although tens of thousands of protein
structures have been solved at or near atomic resolution, there are many targets of interest
as pharmaceutical leads or for basic research, such as integral membrane proteins (IMP),
which have not been solved with sufficient resolution to enable structure-based drug
design or adequate conformational information.
Structure-based drug design and high-throughput screening are the main tools
used for identification of new pharmaceutical lead compounds. High-throughput
screening involves the production and testing of very large libraries of compounds
against an appropriate cell type or disease model to determine bioactivity and efficacy.
Once an active compound is discovered, the process may be further refined by testing
against a library of structurally-related compounds. In the case of structure-based drug
design2b, where approaches like molecular docking are used to design ligands and

2
estimate binding affinities, high resolution structural information often dictates accuracy
and validity of results or even the ability to engage in this effort at all. Bakheet et al.2a
estimate that 57% of human drug targets are IMP’s (Figure 1.1). Thus, facilitation of
novel structure-based drug design will require high resolution structural information on
these types of biomacromolecules.

Figure 1.1 Sub-Cellular Locations of Proteins. (A) Drug targets and (B) Non-drug
targets2a.

A thorough structural understanding of biological systems is highly advantageous
and often essential for progress in theoretical or applied efforts relating to the system of
interest. Dynamic processes and complex multiprotein interactions are particularly
informed through high-resolution structural information. For example, Chang et al.1 have
elucidated information regarding the mechanism by which some viruses package and

3
release their genome during infection via asymmetric single-particle cryo-EM
reconstruction.

Table 1.1 Statistics of PDB Entries by Experimental Method (Nov. 8, 2016).

1.1.1 X-Ray Crystallography
XRD is currently the most widely used and cost-effective method for
determination of protein structures (Table 1.1). The combination of electron density map
information obtained from x-ray diffraction patterns of high quality protein crystals with
known protein amino acid sequence allows for determination of the protein’s threedimensional structure (Figure 1.2A). X-ray crystallography (XRD) is based on
observation of x-ray diffraction patterns from large well-ordered 3D crystals4. Protein
crystals are typically grown from supersaturated solutions of the protein. Supersaturation
is usually induced via addition of inorganic salts (e.g. (NH4)2SO4, NaCl, KCl, CaCl2,
etc.), volatile organic solvents (e.g. ethanol, acetonitrile, acetone, etc.), or polymers (e.g.
polyethylene glycol (PEG)) as precipitants to concentrate the protein solution. Crystal
formation is limited to cases where strong intermolecular contacts can be made to form
an extended lattice. Proteins often show complex phase diagrams, are highly sensitive to
solution conditions (e.g. pH, salinity, temperature, etc.), and may be difficult to obtain in
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high purity due to proteolytic degradation or limitations in removal of occult impurities.
The protein crystallization process is often approached by varying experimental variables
(e.g. pH, salinity, temperature, precipitant, humidity, etc.) systematically across a wide
parameter space using different crystallization methods. Generally, the highest quality
protein crystals, that is, those that are the most well-ordered, are obtained when the
nucleation and crystal growth steps are kinetically well separated5.
Proteins may also have a high degree of conformational flexibility, which can
produce misfolded states. As a result, each molecule has regions on its surface that vary
from particle to particle, which impedes stabilization from intermolecular contacts and
impairs crystallization. This might be a result of a hinge between domains or other
flexible motifs. Proteins are also typically difficult to concentrate under mild conditions
and tend to form crystals that are fragile due to high water content. The larger and more
structurally irregular the macromolecular complex is, the less likely it is that it will form
crystals such that the contact area is large in comparison with the total area of the
molecular assembly itself6.
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Figure 1.2 High Resolution Tools in Structural Biology7. (A) X-ray crystallography
(XRD). (B) Nuclear magnetic resonance spectroscopy (NMR). (C) Single-particle cryoEM.

Other molecules may be unstable to crystallization conditions or be more likely to
precipitate due to denaturation. Lipid membranes are also likely to impede crystallization
due to their dynamic nature. IMP’s and some viruses fall into this class. IMP’s are
generally not amenable to crystallization and there is no guarantee that they will
crystallize in their native conformation8. Often, crystallization efforts and structural
studies of IMP’s may involve focusing on partial structures. Also, crystallization happens
over an extended time span, thus, dynamic events that happen on short time scales do not
lend themselves to study by XRD. In crystallography, many conditions are often
investigated. This requires a large quantity of sample, which is often impractical.

6
Crystallization also requires a highly pure sample. Since many samples are not amenable
to extensive purification, crystallization may be impossible. Furthermore, extensive
handling of human infectious particles is highly undesirable, but unavoidable during
crystallographic screening.

1.1.2 Nuclear Magnetic Resonance (NMR)
NMR-based techniques involve multidimensional NMR either in solution, or in
the solid-state9. Unlike XRD, NMR does not require crystallization and the sample is
examined in solution. Protein-NMR relies on 2D Nuclear Overhauser Enhancement
Spectroscopy (NOESY) to observe interactions between proximal hydrogen atoms of the
polypeptide chain (less than 5 Å apart). Proteins isotopically labeled with 15N- and 13Cenriched amino acids are used to aid resolutions of overlapping peaks in multidimensional NOESY spectra. The combination of large numbers of NOE proximity
relationships along with knowledge of the protein sequence allow for elucidation of the
3D structure of the protein (Figure 1.2B).
The foundations of NMR structural analysis rely on high quality NMR spectra
recorded with good sensitivity and spectral resolution7b. These limitations become harder
to overcome with increasing molecular weight). This is due to low sensitivity and line
broadening due to rapid transverse spin relaxation and extensive signal overlap due to
highly complex spectra. Most published structures of biomolecules studied by NMR have
molecular weights less than 25 kDa9. Isotopic labeling has been employed to overcome
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this problem10, but this process is very time-consuming and requires extensive
biochemical manipulation11.
NMR structural studies of biomolecules require a very concentrated sample
(~1mM). This means that a large amount of highly purified material is required. This is
impractical in many cases and highly concentrated solutions are incompatible with many
targets due to aggregation or denaturation. Frequently, NMR is used as a complement to
low resolution crystal structures. Artificial conditions and sample preparation mean that
there is no guarantee of native conformation from NMR structures.

1.1.3 Electron Microscopy
Electron microscopy is an emerging tool for the elucidation of high resolution
structural information. Electron diffraction has long been successfully used to determine
3D structures of 2D crystalline samples up to a resolution of 1.9 Å12. Cryo-electron
microscopy in combination with single-particle 3D reconstruction, collectively referred to
as cryo-EM, has played an increasingly important role in determination of 3D structures
up to subnanometer resolution13. Currently the highest obtained resolution from cryo-EM
is the 2.2 Å structure of E. coli β-galactosidase in complex with the cell-permeant
inhibitor phenethyl-β-D-thiogalactopyranoside (PETG) (Figure 1.3).
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Figure 1.3. 2.2 Å Structure of β-Galactosidase-PETG Reported by Bartesaghi et. al13a.

Observation of multi-protein interactions is essential for fundamental
understanding of biochemistry and cell biology, but, like IMP’s, structural studies of
large macromolecular machines are rarely attainable using XRD or NMR-based methods.
This is largely due to the size, irregular shape, and flexibility of these species. For
example, a large macromolecular protein machine, the proteasome14 has recently been a
subject of structural study due to the link between the ubiquitin-proteasome pathway15
and its relation to the mitotic cycle and oncogenesis16. The intact complex, referred to as
the 26S Proteasome, along with the ubiquitin-conjugating system comprises the
ubiquitin-proteasome system16, which is the major extralysosomal pathway for
intracellular protein degradation in eukaryotes. Like IMP’s, large macromolecular
complexes like the proteasome are impractical for study by XRD or NMR. Recently,
efforts have focused on cryo-electron microscopy (cryo-EM)17.
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1.2 Single-Particle Cryo-EM
Three dimensional structure determinations based on cryogenic electron
microscopy (cryo-EM) have become a common tool to structural biologists in recent
years12, 18. The technique has become more viable for high-resolution structure
elucidation due to advances in instrumentation19, experimental techniques, and improved
software for single-particle reconstruction12, 20 that is more accessible and more powerful.
As a result, the number of protein structures solved by cryo-EM has increased steadily
since 2007 (Figure 1.4).

Figure 1.4 Growth of Structures Solved by Cryo-EM. (A) Growth of structures solved by
cryo-EM since 2007 based on PDB and EMDB entries. (B) Growth of structures
submitted to the PDB since 2002 by resolution21.
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Cryo-EM tends to generate higher resolution structures when the target is high
molecular weight or consists of symmetrical multi-protein subunits. As a result, many of
the first cryo-EM structures were viral particles. These targets are generally challenging
for XRD and are too large for NMR. As cryo-EM develops as a technique, access to
high-resolution structural information on these targets is expected to reveal new insights
for biology and drug design (Figure 1.5).

Figure 1.5 Added Value of Cryo-EM in Structural Biology22.

In cryo-EM, highly pure samples are preferable although, moderately pure
samples are tolerable depending on imaging conditions due to particle selection during
image processing. Generally, a cryo-EM based project begins with isolation and
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purification of the particle of interest (Figure 1.6). Cryo-EM sample preparation involves
the application of a solution of the purified particle to a TEM grid. This solution is
wicked away, allowed to dry shortly, and then flash-frozen in a solution of liquid ethane
cooled with liquid nitrogen forming a thin layer of vitreous ice containing imbedded
particles (Figure 1.7). An advantage of cryo-EM is that a relatively small amount of
sample is required to collect a significant amount of data. One can take several
micrographs from a single grid which requires only about 5 µL of sample at moderate
concentrations. Since samples are flash frozen, relatively delicate samples are applicable
to cryo-EM since the particles are preserved in a layer of vitreous ice. Also, events that
happen on small time-scales may be observed since flash-freezing of the sample
effectively preserves a snapshot of molecular conformations at the time of freezing.
These advantages are particularly desirable for observing interactions between
macromolecules or observing large delicate samples.
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Figure 1.6 Pipeline in Biological Cryo-EM.
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Figure 1.7 Vitrification Process During Cryo-EM Sample Preparation.

This sample is then imaged under low dose conditions to prevent sample
degradation due to radiation damage. Radiation damage is one of the major drawbacks of
electron optics applied to organic and biological systems. Primary events result in the
formation of reactive species such as free radicals, which then undergo a secondary
chemical event that promotes structural denaturation. Accumulated electrons also lead to
the phenomenon known as charging, in which areas of accumulated charge distort the
electron optics and lead to aberrations.
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In traditional transmission electron microscopy, stains are used to improve
contrast. These stains are composed of heavy metal salts. This is because contrast is
mostly due to phase contrast in EM, which increases with increasing Z (atomic number).
Higher Z elements scatter electrons mote effectively, which leads to high contrast in areas
where the high Z elements are localized. In cryo-EM, typically no stains are used
although the technique has been applied23. An absence of staining is preferable, since
staining can lead to deformation, and phase contrast from protein atoms is necessary if
atomic-scale resolution is the ultimate goal of the study.
2D particle projection images are then analyzed using reconstruction software to
derive a reconstructed 3D image of the particle. One limitation of cryo-EM is the large
number of particles necessary for a high resolution 3D structure to be obtained. The
number depends on the geometry, size, and conformational flexibility of the particle, but
tens of thousands of particles may be required. For example, a 6 Å structure of the
molecular chaperone GroEL was obtained from 39,085 particles selected from 42
micrographs24.

1.2.1 3D Reconstruction of Biomacromolecules and Complexes
Reconstruction strategies often involve geometrical averaging of particle
orientations during 3D reconstruction, which simplifies the process. In fact, 3D
reconstruction is generally more easily accomplished for highly symmetrical particles,
but is theoretically applicable to any particle geometry (Figure 1.8). Structural studies of
the Epsilon-15 virus by cryo-EM have determined the viral capsid structure at 4.5 Å
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imposing icosahedral symmetry25 while the structure was solved at 20 Å using an
asymmetric approach26. Cryo-EM has been frequently employed for studies of virus
structure due to the high symmetry of these particles.

Figure 1.8 Importance of Symmetry in Cryo-EM. 20 Å asymmetric reconstruction24 and
4.5 Å icosahedral reconstruction23 of Epsilon-15 virus.

The 3D reconstruction process depends on the method and varies from different
developers and software. Generally, particles are selected manually using an image
processing program. Most reconstruction software packages contain all of the necessary
tools for a reconstruction project. More recently, automated particle selection programs
have been developed to simplify the process27. However, automated particle selection
often falls short of manual particle selection because automated programs tend to pick
anomalies, and distorted particles. Including anomalous particles in a reconstruction data
set can dramatically limit the minimum attainable resolution of the reconstruction. This
also points out that conformational flexibility is not desirable in cryo-EM studies. As a
result, manual particle selection is sometimes necessary. For reconstruction to be
successful, the particle needs to be represented by many particles in many different
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rotational orientations. This can be an issue since it has been noted that some particles
adopt preferred orientations during cryo-EM sample preparation. For example, the
molecular chaperone GroEL is a barrel shaped protein and particle images of the protein
on its side are much more prevalent in micrographs than images of the two ends of the
protein23b, 28.
The particles are grouped into classes of similar orientation. The basic principle of
3D reconstruction involves Fourier transform of the 2D projection images of the 3D
particle. These 2D Fourier transforms can then be combined in Fourier space to produce
the 3D Fourier-space representation of the phase contrast from cryo-EM imaging. This
can then undergo Fourier inversion to give the real-space 3D reconstruction.
Cryo-EM has become more popular and more viable in recent years due to
advances in electron microscope technology as well as reconstruction algorithms29 and
software30. Development of software for reconstructions involving more diverse particle
symmetries20c and more user friendly software20a, 20b, 30b are among the many
developments of late in cryo-EM software development. In particular, much effort has
centered around accurate determination of the contrast transfer function (CTF) that
corrects the 2D images for the experimental out of focus distance, accurate determination
of the relative orientation of individual particles, and the use of larger particle sets. This
has led to routine reconstructions of suitable targets at 10 Å resolution, which is expected
to continue to improve to in the near future.
Cryo-EM shows a great deal of promise for biomacromolecular structure
elucidation, especially at moderate resolution and hybrid methods, which combine EMbased studies of fragile complexes with XRD or NMR analyses of individual components
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are promising but laborious processes7a, 31. In many ways cryo-EM is a complementary
technique to XRD and NMR. It works well for large fragile targets, provides a very good
mimic of the targets native environment, and studies require a very small amount of pure
material. To push EM-based structure determination further, materials approaches need to
be invented that can facilitate cryo-EM-based 3D reconstruction.

1.3 Materials Approaches to Single-Particle Cryo-EM
Materials methods have previously been applied to structural studies focusing on
electron microscopy-based structure determination. The concept of interfacial templating
was first applied to 2D crystallography and the techniques were later applied to cryo-EM
to expand the scope of cryo-EM in terms of expanding practical targets for cryo-EM and
allowing for observation of dynamic events that would not otherwise be observed under
conventional cryo-EM sample preparation and imaging conditions.

1.3.1 2D Crystallization of Proteins at Lipid Interfaces
Electron diffraction has regularly been successfully used to determine 3D
structures of 2D crystalline samples up to a resolution of 1.9 Å12. For compounds with
convoluted topologies and internal degrees of freedom which are unable to form ordered
diffraction-quality 3D crystals, 1D and 2D templating approaches have been developed
by orienting the protein with respect to the interface and limiting 2D diffusion. 1D and
2D substrates like lipid lamellar phases, lipid monolayers, and lipid cubic phases have
been used to produce 2D crystals of both soluble proteins and IMP’s. These interfaces
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provide large surface areas for protein adsorption, can be utilized with a wide variety of
lipid conjugates allowing for tunable binding interactions, and are compatible with
microfluidic interfaces.
2D crystals grown at interfaces are only a single molecular layer in thickness,
making them extremely challenging for analysis by conventional XRD. If the 2D crystals
are analyzed by tilt-series electron crystallography, the reconstructed volume invariably
contains the “missing cone” defect due to practical limitations of projecting the electron
beam through the sample at high tilt angles. 1D substrates allow for analysis by helical
reconstruction32, however, this method requires strict control of the 1D substrate
diameter, which is often impractical and is dependent on the nature of the substrate.

Figure 1.9 Lipid Monolayer Formation Using a Langmuir Trough33. (A) A typical
Langmuir trough setup. (B) Pressure-area isotherm relationship to 2D lipid phase.

Most interfacial templating approaches have focused on lipid monolayer-based
substrates5. Lipid monolayer-based approaches involve formation of a monolayer film at
the air-water interface. This is typically accomplished by spreading an organic solution of
the lipids on a Langmuir trough (Figure 1.9A). As the solvent evaporates, the lipids form
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a monolayer at the air-water interface with the polar head groups orient toward the
aqueous subphase and the hydrophobic lipid tails orient toward the air where they can
interact through dispersion forces with the lipid chains of neighboring molecules. The
monolayer film can then be compressed allowing for phase control of the lipid
monolayer. As the monolayer is compressed, the lipids form 2D gas-, fluid-, or solid-state
films at the air-water interface (Figure 1.9B).
If the protein of interest is present in the aqueous subphase, it can become
concentrated at the surface of the Langmuir trough if it possesses an affinity for the lipids
of the substrate. Thus, the general consideration for 2D crystallization is the generation of
an interface that can produce enrichment of the protein at the interface. The combined
elevated protein concentration, enhanced protein alignment, and fluid dynamics of the
film, which allows for lateral mobility, contribute to the formation of 2D crystals. By
designing the lipid components to have specific interactions with the protein of interest,
samples of lower purity may be acceptable for 2D crystallization.
2D crystallization typically involves simple experimental protocols, and a wide
range of monolayer compositions may be utilized to take advantage of specific tunable
monolayer properties.

1.3.2 Interfacial Templating
The first effort of this type was reported by Kornberg34 and coworkers who used
antibody-based affinity interactions to concentrate protein targets on affinity lipid
monolayer surfaces (Figure 1.10A). In this example, a monolayer of DNP-modified
phasphatidylethanolamine (PE) lipid (Figure 1.11A) in a mixed monolayer of 1:1 DNP-
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PE and PC was used to produce 2D crystals of anti-DNP IgG through the specific DNPantibody interaction. This ligand affinity technique was later adapted to structural
characterization of RNA polymerase II through electrostatic interaction with cationiclipid-containing monolayers, 2D crystallization of streptavidin on monolayers containing
biotinylated lipids, and 2D crystallization of DNA gyrase on monolayers containing an
ATP-lipid conjugate5. Many different material interfaces have been employed utilizing
interactions from electrostatics to coordination complexation to highly specific ligandreceptor type interactions5, 35. Many of these interactions are based on methods developed
for affinity purification of biomolecules36.

Figure 1.10 Conceptual Models of 2D Crystallization: (A) The original Uzgiris and
Kornberg model using an antigenic lipid (DNP-PE), to concentrate anti-DNP antibodies
at the air-water interfaces34. (B) Application of IMAC chemistry to induce 2D
crystallization of recombinant histidine-tagged proteins37.
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Figure 1.11 Molecular Structures of Some Lipids Used for 2D Crystallization Studies.
(A) some ligand-lipid conjugates utilized for ligand-specific immobilization and
crystallization and (B) some NTA-lipids synthesized for IMAC-based immobilization
and crystallization of histidine-tagged proteins.
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The interfacial templating approach to 2D crystallization was later adapted to
incorporate affinity interactions from immobilized metal affinity chromatography
(IMAC) chemistry (Figure 1.10B). These approaches generally rely on affinity
interaction between nitrilotriacetic acid- (NTA) or iminodiacetic acid- (IDA)-lipid
conjugates with divalent metal ions (e.g. Ni(II), Cu(II), Co(II), etc.) and a genetically
engineered histidine tag (his-tag) of the protein of interest. Thompson and coworkers37
used a nitriloltriacetic acid (NTA) containing mixed monolayer to capture and orient Nterminal his-tagged Moloney murine leukemia virus capsids forming 2D crystals for 2D
electron crystallography. A similar approach was used to analyze HIV-1 capsid by 2D
electron crystallography on NTA-lipid-containing surfaces38. Several NTA-containing
lipids have been reported (Figure 1.11B). NTA forms a tetradentate complex with many
divalent metal ions like Ni(II), Cu(II), etc.39 This leaves two vacant coordination sites for
an oligo-histidine tag (his-tag) to bind (Figure 1.12). Equilibrium constants KD of 10-7 M
for the his6:protein:M2+ and 8x10-13 M for NTA:Ni2+ have been reported39-40.

Figure 1.12 Binding Interaction of NTA:Ni2+:His6 in IMAC Chemistry41.
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Zhou et al. introduced the site-hopping concept for 2D crystallization of histagged proteins42. This concept involves substrates composed of acylated cyclodextrins
(CD). These compounds formed stable monolayers exposing the CD cavity. CD cavities
have varying binding affinity for various small molecular guests43. The second
component of the system consists of an NTA-conjugate of a specific molecule possessing
binding affinity for the CD cavity. By mixing the NTA-conjugate with the his-tagged
protein of interest, a transient interaction with the monolayer is established. This
approach may allow for more favorable kinetics of nucleation with respect to crystal
growth due to the enhanced lateral mobility of protein at the 2D surface (Figure 1.13).
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Figure 1.13 Site-Hopping Concept for 2D Crystallization Using Acylated-CyclodextrinBased Monolayers. (A) Site-Hopping concept for 2D Protein Crystallization. (B)
Molecular structures of β-CD-lipid and some guest-NTA compounds.

1.3.3 The Affinity Grid
As cryo-EM became a more reliable and high-resolution tool, it was natural that
the 2D crystallization strategy was adapted to address sample requirements for cryo-EM.
By using TEM grids modified with 2D monolayer surfaces, the same affinity interactions
could be utilized to generate diffuse bound particles for cryo-EM as opposed to 2D
crystals. This approach allows for single-step purification and grid preparation and may
allow for cryo-EM analysis of challenging samples (e.g. low concentration, transient
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intermediates, etc.) and ultimately allow cryo-EM to become a more high-throughput
technique.

1.3.3.1 Lipid Monolayer-Based Affinity Grids
The first direct application of the techniques of interfacial templating developed
and implemented for 2D crystallization were first applied to cryo-EM when Kelly et al.
developed the concept of monolayer purification44 and the affinity grid45. The method
involves the transfer of a mixed monolayer of lipids doped with a lipid with an NTA
chelator head (Figure 1.14A) followed by capture and imaging of the adsorbed his-tagged
proteins. An adaptation of this method utilizing a his-tagged adaptor protein bound to
specific antibodies for the protein of interest has also been reported (Figure 1.14B)46. The
affinity grids were reported to be shelf-stable for several months and able to capture and
prepare samples for cryo-EM within minutes.
These materials were used to capture his-tagged rpl3, the human homolog of the
E. coli 50 S ribosomal subunit rplC with or without associated RNA depending on
sample preparation protocols. Cryo-EM data obtained using the modified grids were used
to generate reconstructions of the 50 S ribosomal subunit, the 70 S ribosome and the 30 S
ribosomal subunit from images from the same sample. This demonstrates the utility of
this approach for study of dynamic processes within living systems that would be
unobtainable if the target of interest is subjected to conventional sample preparation,
particularly chromatographic purification. These materials were also shown to be stable
in the presence of glycerol and detergents. This property was exploited to capture histagged aquaporin-9 (AQP9) from detergent-solubilized membrane fractions of sf9 insect
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cells. This example demonstrates the utility of this approach for isolation of an IMP, a
limitation for conventional cryo-EM.
Although this approach has shown several advantageous properties for cryo-EM,
there are still several limitations to this approach. The monolayers are relatively unstable
and tend to degrade in film quality following consecutive washes. The close proximity of
the NTA moiety to the 2D surface allows relatively little rotational mobility for targets
that contain a single his-tag. This limitation may lead to orientational bias and overall
lower possible resolution for targets with only a single his-tag. The presence of antibody
may lead to lower resolution or conformational changes relative to the native protein
structure. Furthermore, the low electrical conductivity of the lipid monolayer may lead to
charging effects. In order to address these limitations, novel affinity grids composed of
lipopolymers47 and based on graphene-oxide48 have been designed and evaluated for
cryo-EM. More recently, Sharma et al49. used the affinity grid approach to show that
PKC βII binds to the small ribosomal subunit (40S) and interacts with RACK1, a seven
bladed β-propeller protein present on the 40S and binds to two different regions close to
blades 3 and 4 of RACK1. This study was a step toward understanding the molecular
framework of PKC βII-RACK1 interaction and its role in translation.
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Figure 1.14 The Affinity Grid Approach to Cryo-EM. (A) affinity grids approach based
on IMAC chemistry45 and (B) alternate approach enabling capture of non-his-tagged
proteins46.

1.3.3.2 Antibody-Based Affinity Grids
In another interesting variant of the affinity grid concept, Yu et al. introduced the
antibody-based affinity grid and the concept of cryo-SPIEM. This technique applied the
traditional concept of solid-phase immune electron microscopy (SPIEM) to cryo-EM50.
This approach involves direct non-covalent modification of carbon-coated TEM grids
with antibodies. This approach was used to isolate and generate 3D reconstructions of
native protein targets from pure samples and cellular lysates.

1.3.4 Other Approaches
In a particularly interesting example, Sigworth and coworker have developed a novel
spherical reconstruction algorithm that allowed for determination of the BK potassium
channel at 30 Å resolution as an IMP imbedded in a tethered proteoliposome formulation
(Figure 1.15). This method allowed for moderate resolution reconstruction of an IMP,
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which has previously eluded efforts by XRD by building off of an existing platform that
had been developed to grow 2D streptavidin crystals at biotinylated lipid interfaces which
can then be transferred to TEM grids51. The method highlights the flexibility of cryo-EMbased reconstruction.
The channel was reconstituted into liposomes doped with PEG-ylated lipids bearing a
biotin at their termini. EM grids were prepared and a monolayer 2D crystal of
streptavidin was transferred to the grid. The grids were then treated with the liposome
formulation and imaged. Images were collected of the protein imbedded in the
liposome29. This case required the development of a novel spherical reconstruction
algorithm20c, which illustrates the inherent challenges and flexibility of cryo-EM software
development.
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Figure 1.15 The Proteoliposome-Based Approach Developed by Sigworth et al27.

Finally, Turberfield and coworkers52 recently have described the use of twodimensional DNA templates for site-specific scaffolding of G-protein-coupled membrane
receptor complexes for SPA, however, the resolution possible with these templates is not
yet known.
1.4 Conclusions
High-resolution biomacromolecular structure elucidation is fundamentally
important to structure-based drug design and basic research into complex biochemical
processes. XRD and NMR account for the majority of the reported protein structures on
the protein data Bank (PDB). Cryo-EM is an emerging alternative to XRD and NMR that
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is complementary in terms of sample applicability relative to XRD and NMR. TEM grid
modification approaches originally developed for 2D crystallization studies have been
applied to cryo-EM to extend the breadth of the technique. The affinity grid concept
based on IMAC chemistry and antibody interactions has been used to isolate cryo-EM
samples directly from cellular lysates or purified samples. Further exploration of this
approach should continue to allow for application of the cryo-EM technique to
challenging samples and targets that may not be readily amenable to XRD, NMR, or
traditional cryo-EM samples preparation techniques. This could allow for access to highresolution structural data on targets that are not currently accessible furthering molecular
therapeutic and basic biochemical research efforts.
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CHAPTER TWO:
DEVELOPMENT OF NON-FOULING AFFINITY LIPOPOLYMER-BASED
AFFINITY GRIDS FOR SINGLE PARTICLE CRYO-EM

2.1 Introduction
Single-particle cryogenic electron microscopy (cryoEM) is a rapidly advancing
method of protein structure elucidation that is now capable of producing structures with
resolutions approaching 2.2 Å, provided that thousands of single particle images can be
collected.1 At present, this is achieved by collecting and class averaging images from
many different carbon-coated grid preparations that randomly adsorb and present the
protein target in multiple orientations for cryoEM imaging. Since many protein target
candidates exist in low copy number, may be highly labile, and/or are derived from
infectious agents that are in low supply, there is significant motivation for the
development of new sample preparation methods to improve the throughput and
predictability of this technique.
Lipid monolayers have been used to concentrate proteins at interfaces for structure
determination, as first described by Uzgiris and Kornberg.2 Subsequent affinity
monolayer developments explored a variety of affinity lipid-ligand interactions such as
biotin-streptavidin, ATP lipid-ATP binding protein, Ni2+:nitrilotriacetic acid (NTA)hexahistidine-tagged (His6-tag) protein, or Cu2+:iminodiacetic acid-His6-tag protein.3
Many of these efforts were focused on the development two-dimensional crystallization
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methods using nitriloltriacetic acid (NTA)-modified lipid conjugates,4 with some cases
showing the potential of NTA lipids for structure elucidation with resolutions in the 10 –
25Å regime.4b
NTA lipid monolayers were extended to the realm of single-particle cryo-EM by
Walz and coworkers, with the structures for 50S ribosomal subunits,5 transferrintransferrin receptor complex,6 and human RNA polymerase II7 reported using a
commercially available NTA lipid conjugate, 1,2-dioleoyl-sn-glycero-3-[((N-(5-amino-1carboxypentyl)iminodiacetic acid)succinyl] (DGS-NTA), in mixed monolayers with 1,2lauroyl-sn-glycero-3-phosphocholine (DLPC). This report also extended this technique to
the retrieval of protein targets from cell lysates;6a, 7 however, the potential of the approach
is currently limited by the low stability,5 non-specific fouling,6a and preferred orientation8
limitations of DGS-NTA:DLPC monolayers.

2.2 Design of Novel Non-Fouling Affinity Grids
Herein, a novel system was developed to address these challenges by depositing nonfouling PEG-lipid9 coatings containing common affinity ligands like NTA3, 4e, 4f, 10 onto
TEM grids.11 These coatings are prepared by compression of lipid films generated using a
Langmuir trough whose capture ligand surface density and PEG mushroom-brush
conformational state can be controlled by initial film composition and applied surface
pressures prior to deposition onto the EM grid. Brush conformation methoxypolyethylene
glycol (mPEG) coatings are highly non-fouling,12 thereby enabling the application of cell
lysates directly onto the grid and removal of the non-specifically bound material in
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subsequent buffer washing steps (Figure 2.1). Since the moiety bearing the affinity
interaction exists at terminus of the lipopolymer, it is anticipated that this approach will
allow for increased rotational degrees of freedom allowing for the potential of decreased
sample orientation bias. In addition to the reduced sample quantity demands required for
cryoEM analysis, the shortened sample processing times also limit the opportunities for
proteolytic degradation and/or protein unfolding of the His6-target that may occur during
standard sample processing protocols.

Figure 2.1 Conceptual Diagram Showing Lipopolymer-Based Affinity Grid Fabrication
and Affinity Capture from Crude Cell Lysates.
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Figure 2.2 Chemical Structures of Targeted Affinity Lipopolymer Library. (A) Targeted
PEG molecular weights. (B) Lipid structures. (C) affinity moieties and reactive termini.

A small library of affinity lipopolymer constructs was designed to maintain the
essential monolayer purification capability while incorporating a surface PEG brush, to
prevent non-specific adsorption, and a polymerizable lipid component which undergoes
topochemical polymerization13 upon exposure to UV light forming a more stable
substrate for affinity grid sample preparation. Structures of the targeted library are
depicted in Figure 2.2. Like the original approach introduced by Walz14, our approach
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consists of a mixed monolayer film consisting of two lipopolymer components. The first
component is an mPEG-PE-lipid conjugate where the PE-lipid is either 1,2-(tricosa10’,12’-diynoyl)-sn-glycero-3-phosphoethanolamine (DTPE) or – 1,2-(distearoyl)-snglycero-3-phosphoethanolamine (DSPE) and the mPEG is relatively low molecular
weight (e.g. ~350-750 Da). This component is designed to function as the non-fouling
brush component of the monolayer, preventing non-specific adsorption and typically
composes 90-99 % of the molar lipid concentration of the monolayer. When DTPE is the
lipid component, a topochemical polymerization13, 15, induced by UV light (Figure 2.3),
may be utilized to produce a conjugated 2D polymer, which should be more stable than a
lipid monolayer and may allow for charge dissipation during electron imaging, which
may lead to defects16 and lower overall possible resolution during 3D reconstruction of
affinity grid-based cryo-EM.

Figure 2.3 Topochemical Polymerization of Diacetylenic Lipids13.

The minor component of the lipopolymer-based affinity grid approach is similar,
but is composed of a higher molecular weight polymer (2-5 kDa) whose persistence
length is significantly longer than the major component. The lipids utilized are either
DTPE or DSPE. The distal terminus of this component is designed to incorporate various

41
affinity chemistries and covalently-active functionalities to enable selective capture of a
wide range of targets using the lipopolymer-based affinity grid concept. NTA and trisNTA are useful for capture of his-tagged proteins using IMAC17 chemistry, glutathione is
a useful handle for affinity purification of glutathione-S-transferase- (GST)-tagged
proteins18, biotin may be utilized to take advantage of its affinity interaction with avidinor streptavidin-fusions19 or for characterizing IMP’s via the proteoliposome-based
spherical reconstruction approach to cryo-EM introduced by Sigworth and Wang20.
The proposed materials are designed to be formulated into monolayers using a
Langmuir trough. Since the relative molar compositions of the monolayer are completely
tunable, relative particle surface density can be tuned to yield optimal particle spacing for
3D reconstruction and automated particle selection21.

2.3 Synthesis and Characterization of Affinity Lipopolymer Constructs

2.3.1 Synthesis of Functional mPEG Derivatives
A small library of functional mPEG derivatives (Scheme 2.1) was synthesized
following modified protocols previously reported for end group modification of higher
molecular weight bifunctional PEG22. mPEG of various molecular weight (~350-5,000
Da) 1a-e was converted to the mesylate (2a-e) via treatment with methansulfonyl
chloride in dichloromethane (DCM) in the presence of triethylamine with average yields
of 90-99 %. The mesylates were converted to azide-terminal-mPEG (3a-e) via SN2
displacement by sodium azide in N,N-dimethylformamide (DMF) in 83-95 % average
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yield. Reduction using hydrogen gas (1 atm) and 10 mol % palladium on carbon (Pd/C)
support in ethyl acetate (EtOAc) gave the terminal amine (4a-e) in 82-94 % average
yields.
Carboxyl-terminal mPEG were obtained via Jones oxidation of 1a-e, giving 5a-e
in 89-94 % average yields. Conversion was determined via TLC analysis combined with
staining with bromocresol green to verify oxidation. An alternative route to amine
terminal mPEG through an aldehyde-terminal intermediate was also utilized. The
aldehyde-terminal mPEG derivatives were obtained via Albright-Goldman oxidation of
1a-e to give 6a-e in 89-94 % average yield. The aldehyde-terminal mPEG were then
converted to the amine 7a-e via reductive amination mediated by sodium
cyanoborohydride and ammonia in methanol in 90-98 % overall yield. Reported yields
are given as percent recovery. Polymers were purified via extractions and precipitation
into diethyl ether depending on the polymer molecular weight (PEG with molecular
weight < ~2 kDa exists as an oil or liquid and cannot be precipitated). For lower
molecular weight polymers, TLC and TLC staining was utilized to monitor conversion to
determine optimal reaction times. The efficiency of conversion for Jones oxidation is
near complete22b. Conversions reported for the Albright-Goldman and reductive
amination protocols are 78-86 %22b.
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Scheme 2.1 Synthesis of Functional mPEG Derivatives.

2.3.2 Synthesis of mPEG-Lipid Conjugates
mPEG-lipid conjugates were synthesized via a two-step process (Scheme 2.2).
Carboxyl terminal mPEG 5a was converted to the active N-hydroxysuccinimidyl ester 8
mediated by N-ethyl-N’-(3-dimethylaminopropyl)-carbodiimide (EDC) and Nhydroxysuccinimide (NHS) in the presence of diisopropylethylamine (DIEA) in DMF.
Compound 8 was obtained in 84.4 % yield. Direct coupling of the carboxyl-terminal
polymer and PE lipid was not performed in order to avoid activation of the phosphate
groups of the lipids. The lipid conjugates 9a-c were synthesized via NHS-displacement
upon treatment of the active ester of PEG with the phosphoethanolamine lipid in the
presence of base. After chromatographic purification, mPEG conjugates of DTPE (9a),
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DSPE (9b) and DPPE (9c) were synthesized. The lipid conjugates were obtained in
varying yields from 31.1-72.3 %.

Scheme 2.2 Synthesis of mPEG-Lipid Conjugates.

2.3.3 Synthesis of Biotin-PEG-lipids
Biotin terminal lipopolymers (11a-b) were synthesized via treatment of
commercial heterobifunctional biotin-PEG-NHS 10 with the phosphoethanolamine lipid
(Scheme 2.3). After chromatographic purification, conjugates of DTPE (11a) and DSPE
(11b) were synthesized in 75.3 and 56.4 % yield, respectively. In this case, PEG
molecular weight was (~2.0 kDa).
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Scheme 2.3 Synthesis of Biotin-PEG-Lipids.

2.3.4 Synthesis of Functional t-butyl-NTA and tris-NTA Derivatives
A small library of functional t-butyl-protected NTA and tris-NTA derivatives
were also prepared (Scheme 2.4). The protocols used to synthesize these materials were
based on previously reported protocols with modification23.
H-Lys(Z)-OH (12) was converted to the t-butyl ester 13 by transesterification of tbutyl acetate catalyzed by perchloric acid in 78.7 % yield. Compound 13 was then
dialkylated by t-butyl bromoacetate in the presence of DIEA in DMF to give Compound
14 in 84.4 % yield after chromatographic purification. Compound 14 was debenzylated
by reductive hydrogenation on palladium on carbon support to give Compound 15 in 99.7
% yield. Carboxyl-NTA 16 was synthesized from Compound 15 via acylation by succinic
anhydride in the presence of organic base in DCM in 99.7 % yield after chromatographic
purification. Alkyne-NTA derivative 17 was synthesized from Compound 16 via EDC-
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mediated coupling with propargylamine in the presence of N-hydroxybenzotriazole
(HOBt) and DIEA in DMF in 88.5 % yield after chromatographic purification.

Scheme 2.4 Synthesis of Functional t-butyl-NTA Derivatives.

Z-protected NTA derivative 18 was synthesized via direct dialkylation of
Compound 12 by bromoacetic acid in aqueous sodium hydroxide solution to give
Compound 18 in 96.3 % yield without chromatographic purification. Compound 18 may
also be converted to the fully deprotected lysine-NTA derivative 19 via hydrogenation
using palladium on carbon under 1 atm of hydrogen gas in aqueous solution in 96.3 %
yield.
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Scheme 2.5 Synthesis of Functional t-butyl-tris-NTA Derivatives.

Z-protected tris-NTA 20 was synthesized by EDC coupling of Compounds 15 and
18 in the presence of HOBt and DIEA in DMF in 88.4 % yield after chromatographic
purification. Hydrogenation of 20 by Pd/C under 1 atm of hydrogen gas gave 21 in 97.6
% yield. A similar functionalization strategy to generate carboxyl- and alkynyl-
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functional-NTA derivatives was also employed for tris-NTA. Compound 21 was
converted to a carboxyl-functional derivative via acylation by succinic anhydride in the
presence of base in DCM to give Compound 22 in 87.4 % yield after chromatographic
purification. Compound 22 was then converted to an alkynyl derivative via EDCmediated coupling with propargylamine in the presence of HOBt and DIEA in DMF to
give Compound 23 in 76.4 % yield after chromatographic purification (Scheme 2.5).

Scheme 2.6 Synthesis of PNP-Activated t-butyl-Protected NTA and tris-NTA
Derivatives.

Reactive p-nitrophenyl carbamate derivatives of Compounds 15 and 21 were
synthesized via treatment of the respective primary amines with p-nitrophenyl
chloroformate in the presence of DIEA in DCM to give Compounds 24 and 25 in 44.8 %
and 73.1 % yields, respectively, after chromatographic purification (Scheme 2.6).
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2.3.5 Initial Synthesis of DTPE-PEG-NTA.
Initial efforts to synthesize NTA-terminal lipopolymers were only moderately
successful due to low overall yield and side reactions associated with DTPE. Commercial
heterobifunctional PEG derivative 26 containing t-butyl carbamate (Boc) and Nhydroxysuccinimidyl-ester termini was used to acylate DTPE in the presence of base in
DCM under dark conditions. Lipopolymer conjugate 27 was obtained in 87.8 % yield
after chromatographic purification. Removal of Boc was effected by treatment with
trifluoroacetic acid (TFA) in DCM in the presence of triethylsilane as a cation scavenger
to give 28 in 91.3 % yield. Treatment of 28 with p-nitrophenylcarbamate 24 in the
presence of base in DCM gave Compound 29 in 26.9 % yield after chromatographic
purification. Compound 29 was then treated with TFA and triethylsilane in DCM to give
Compound 30 in 62.1 % yield.

Scheme 2.7 Initial Synthesis of DTPE-PEG-NTA.
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2.3.6 Synthesis of Thiol-Functional NTA and tris-NTA Derivatives.
When working with polymers, small changes in end group or conjugation of a
small-molecule tend to cause little change in the retention-factor of the product relative to
the starting material. Thus, reactions that are highly efficient are best. For synthesizing
affinity lipopolymer constructs, a synthetic pathway was designed that utilized thiolmaleimide chemistry as the final step in the pathway to conjugate various affinity
moieties. Although thiol-containing derivatives of NTA have been synthesized and
reported24 by groups in the past, the synthetic routes to these compounds are
unnecessarily complicated, use starting materials uncommon to other NTA synthetic
routes and the target compounds are quite hydrophobic since they have long alkyl chains
as tethers between the NTA and thiol functionalities.
A simpler synthesis that utilizing t-butyl-protected-lysine-NTA derivative 15 and
S-trityl-3-mercaptopropionic acid 32 as starting materials was devised where a global
TFA-mediated deprotection could yield the fully deprotected 34 (Scheme 2.8). 3Mercaptopropionic acid 31 was trityl-protected via treatment with trityl chloride in DCM
to give 32 in 93.2 % yield. Coupling between Compounds 15 and 32 was accomplished
by EDC-mediated coupling in the presence of HOBt and DIEA in DMF to give
Compound 33 in 53.4 % yield after chromatographic purification. Global deprotection
was effected by treatment of Compound 33 with TFA in the presence of triethylsilane in
DCM to give Compound 34 in 92.7 % yield.
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Scheme 2.8 Synthesis of Thiol-NTA.

Following a similar strategy, with a global TFA-mediated deprotection as the final
step a thiol-containing derivative of tris-NTA was synthesized. Tris-NTA is used for
affinity interaction with his-tagged protein in the same way as NTA, but tris-NTA has
much higher binding affinities for his-tags (nM) as compared to NTA (µM).
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Scheme 2.9 Synthesis of Thiol-tris-NTA.

S-Trityl-L-cysteine (35) was dialkylated under basic conditions by bromoacetic
acid in a mixture of water and methanol to give Compound 36 in 82.0 % yield. EDCmediated coupling between Compounds 36 and 15 in the presence of HOBt and DIEA in
DMF gave Compound 37 in 76.1 % yield after chromatographic purification. Global
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deprotection of Compound 37 by TFA in the presence of triethylsilane in DCM gave
Compound 38 in 92.2 % yield. Both Compounds 34 and 38 were highly water soluble,
making them suitable for aqueous conjugation reactions (Scheme 2.9).

2.3.7 Synthesis of DSPE-PEG-Maleimide and DSPE-PEG-NTA.
A mild synthesis of NTA-containing lipopolymer was accomplished using thiolmaleimide Michael-addition chemistry (Scheme 2.10). Commercial heterobifunctional
PEG Compounds 39a-b containing maleimide- and N-hydroxysuccinimidyl esterterminal functionalities was conjugated to DSPE in the presence of DIEA in chloroform
to give Compounds 40a-b in 43.4 % and 30.1 %, respectively after chromatographic
purification. Thiol-NTA derivative 34 was then conjugated to the lipopolymer via
Michael-addition in the presence of triethylamine (TEA) in DMF to give 41a-b in 89.8 %
and 53.3 % yields, respectively
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Scheme 2.10 Synthesis of DSPE-PEG-Maleimide and DSPE-PEG-NTA.

An alternative synthetic pathway to DSPE-PEG-maleimide was also utilized, but
the overall yield of 45.8 % over three steps was only slightly improved over the singlestep direct conjugation of the phosphoethanolamine-containing lipid to the
heterobifunctional PEG derivative, maleimide-PEG-NHS (Scheme 2.11). This pathway
utilized the Diels-Alder adduct formation between 2.5-dimethylfuran and maleimide25,
which is subject to thermodynamic control. Compound 39a and 2.5-dimethylfuran were
mixed at 40 °C to form the Diels-Alder adduct 42. Compound 42 was then conjugated to
DSPE in the presence of DIEA in chloroform to give 43 in 75.8 % yield. The RetroDiels-Alder reaction was effected by heating isolated Compound 43 in toluene at 80 °C
to give Compound 44 in 61.5 % yield.
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Scheme 2.11 Alternative Synthesis of DSPE-PEG-Maleimide Utilizing Diels-Alder as a
Protection Strategy.

2.3.8 Synthesis of DSPE-PEG-tris-NTA
A similar strategy for the synthesis of Compound 41 was employed to generate
tris-NTA-terminal lipopolymer construct (Scheme 2.12). Compounds 40a-b were
conjugated to thiol-containing tris-NTA construct 38 via Michael addition in the presence
of TEA in DMF to give 45a-b in 87.7 % and 40.2 % yield, respectively.
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Scheme 2.12 Synthesis of DSPE-PEG-tris-NTA.

2.3.9 Synthesis of DSPE-PEG-Glutathione
A similar approach was used to generate a lipopolymer conjugate of glutathione.
Glutathione-S-transferase (GST) binds glutathione with high affinity and can be
engineered as a fusion protein with a target protein of interest26. Therefore, glutathioneterminal lipopolymer constructs may be useful for cryo-EM analysis of protein targets
that bind glutathione or can be engineered to be GST-tagged. Compound 40a was
coupled to L-glutathione via Michael addition in the same manner as the thiol-NTA and
thiol-tris-NTA derivatives. Compound 46 was obtained in 93.1 % yield.
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Scheme 2.13 Synthesis of DSPE-PEG-Glutathione.

2.4 Performance of PEG-NTA-Based Affinity Grids
Langmuir-Schaefer deposition of a mixed monolayer containing two synthetic
polymerizable lipids – 1,2-(tricosa-10’,12’-diynoyl)-sn-glycero-3-phosphoethanolamineN (methoxypolyethylene glycolamide 350) (9a, mPEG350-DTPE) and either 1,2(tricosa-10’,12’-diynoyl)-sn-glycero-3-phosphoethanolamine-N-[(5-amido-1carboxypentyl)iminodiacetic acid]polyethylene glycolamide 2000) (30, NTA-PEG2000DTPE) or 1,2-distearoyl–sn-glycerol-3-phosphoethanolamine-N-[(5-amido-1carboxypentyl)iminodiacetic acid]polyethylene glycolamide 2000) (41a, NTA-PEG2000DSPE) – prior to treatment with a 10 min, 254 nm light exposure was used to prepare
stabilized affinity monolayers supported on carbon coated EM grids. These grids were
then used to capture His6-T7 bacteriophage and His6-RplL from cell lysates, as well as
purified histidine-tagged green fluorescent protein (His8-GFP) and nanodisc embedded
His6-MalFGK2. Findings indicate that polymerized NTA lipid monolayers are capable of
capturing His6-protein targets in a manner that controls their areal densities, while
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efficiently blocking non-specific adsorption and limiting film degradation upon
prolonged detergent exposure.

2.4.1 Affinity Lipopolymer Monolayer Formation and Characterization
CHCl3 stock solutions of the lipid mixtures were prepared, spread at the air-water
interface at 20 C, a 5 min incubation period allowed for evaporation of the solvent, and
the films compressed at a rate of 10 Å2/molecule until collapse at 30 mN/m – 35 mN/m
for the mixed monolayers and 40 mN/m for pure mPEG350-DTPE monolayers. The
pressure-area isotherms shown in Figure 2.4 for 1:99 and 5:95 NTA-PEG2000DTPE:mPEG350-DTPE lipid mixtures displayed gradually increasing surface pressures
upon film compression, except that the onset of surface pressure occurred at larger
molecular areas as the NTA-PEG2000-DTPE composition in the film increased. We
attribute this observation to the displacement of surface-adsorbed NTA-PEG2000 from
the air-water interface as previously described27 for mixed mPEG2000-lipid monolayers.
As this desorption process progresses, the majority component, mPEG350, undergoes a
mushroom-brush regime transition upon compression to 30 mN/m while the NTAPEG2000 fraction remains in the mushroom configuration. The extension of the
PEG2000 polymer mushroom conformation from the surface of the film can be
calculated by Lo = αN(α/D)2/3, where Lo = the length of PEG graft, α = length of PEG
monomer (3.5 Å), N = number of ethylene glycol units in the PEG chain (i.e., 45), and D
= the distance between grafting sites. For a lipid film containing 1% NTA-PEG2000DTPE, the grafting site separation is estimated to be 47 Å and the Lo = 2.8 nm. Fully
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compressed 5:95 NTA-PEG2000-DTPE:mPEG350-DTPE monolayers are estimated to
have a grafting site separation of 9.4 Å and a NTA-PEG2000 graft extension of 8.2 nm.
As the lipid film is compressed below 113 Å2/molecule, the mPEG350 fraction enters the
brush regime, while the NTA-PEG2000 polymer chain accommodates further
compression by extending farther away from the air-water interface in a concentrationdependent manner. Consequently, a longer NTA-PEG was prepared for these studies
since it would confer greater conformational freedom to the immobilized histidine-tagged
target and present it in a greater diversity of possible orientations for cryoEM single
particle analysis.

Figure 2.4 Pressure-Area Isotherm for 1:99 (black) and 5:95 (red) NTA-PEG2000DSPE:mPEG350-DTPE Monolayers at 20 C. The mushroom to brush regime is
estimated to be approximately 75 Å2/molecule (green line) for mPEG350-DTPE-rich
monolayers.
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Since the lipid films typically collapsed at surface pressures above 30 mN/m, the
monolayers were compressed to 30 mN/m prior to Langmuir-Schaefer (LS) transfer onto
carbon-coated grids that were not subjected to glow discharge before LS deposition. This
method produced transfer ratios between 0.89 – 0.97 for the LS deposition step.
Photopolymerization of the lipid monolayer was initiated by placing the grids ~6 – 8 cm
from a handheld UV lamp and irradiated for 10 min. Grid performance as a function of
varied irradiation time suggested that a 10 min exposure was most favorable.
After monolayer film transfer onto 400 mesh grids and staining with freshly
prepared 1% UO2(OAc)2, TEM images revealed the presence of large continuous areas
exceeding 900 m2 in size that were punctuated by much smaller zones of higher contrast
(Figure 2.5). We infer from these findings that the large area regions were monolayer
films with occasional, interspersed domains of bilayer and trilayer films arising from
partial monolayer collapse during compression that were preserved by the
photopolymerization process. Sufficiently large areas of the grid were coated by
stabilized monolayer film structures to make them suitable for negative stain and cryoEM
studies; however, the multi-layer sections of the film were helpful for monitoring the
stability of the film in the presence of detergents as described below.
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Figure 2.5 Characterization of Affinity Lipopolymer Monolayers by TEM. (A) Negative
Stain TEM Images of Grids Coated with 1:99 NTA-PEG2000-DSPE:mPEG350-DTPE
Monolayers. (B) Some sections of the monolayer-coated grid display areas with stepwise
contrast that is suggestive of monolayer (1L), bilayer (2L) and trilayer (3L) lipid films.
Scale bar: 400 nm.

2.4.2 Evaluation of Affinity Lipopolymer Non-Fouling Properties
The anti-fouling properties of the mPEG350 brush layer within the stabilized
monolayer coating was probed qualitatively using fluorescence microscopy analysis of
His8-GFPuv adsorption onto these modified surfaces. Wide field and line scan
fluorescence microscopy analysis revealed that glow discharged bare amorphous carbon
surfaces possessed nearly 20-fold greater fluorescence intensities after exposure to His8GFPuv than grids bearing mPEG350 brush regime coatings (>8000 RFU and ~400 RFU,
respectively; Figure 2.6). Our data shows that the fluorescence distribution was uniform
over both types of surfaces, however, in rare instances there were small variations in
fluorescence observed. In those cases, we attribute the areas of decreased fluorescence to
grid regions with an incomplete carbon coating, whereas zones of substantially increased
fluorescence were ascribed to incomplete LS transfer of the brush layer mPEG350DTPE. We infer from these findings that non-specific binding of protein on the brush
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regime mPEG350-DTPE coated grids is much lower than that of glow discharged bare
carbon films due to the combined effects of molecular weight, polymer hydration,
excluded volume, elastic restoration, and grafting density on the surface that enhance the
antifouling properties of the mPEG coating.12b, 28 In some cases, low molecular weight
PEG polymers such as mPEG350 display greater antifouling properties than their higher
molecular weight counterparts since the shorter PEG chains are better able to form a
more densely packed layer.29 Based on these findings, we concluded that brush regime
mPEG350-DTPE monolayers, deposited onto a carbon coated surface by LS transfer,
would be a good candidate for blocking non-specific adsorption of macromolecules onto
EM grid surfaces. To test this assumption, we conducted a comparative study between
DLPC monolayers and mPEG350-DTPE stabilized monolayers, both deposited via LS
transfer, using bare carbon grids as a control.
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Figure 2.6 Fluorescence Microscopy of Uncoated and Stabilized Monolayer-Coated TEM
Grids. Fluorescence microscopy analysis of EM grids exposed to 2.0 mg/mL His8-GFPuv
for 2 min, followed by three MilliQ water rinses to remove unbound protein. (A) Bare
carbon coated grids (glow discharged) and (B) 100% mPEG350-DTPE coated grids
prepared by compression to the brush regime of mPEG350, LS transfer onto carbon
coated grids, and photopolymerization as described in the Experimental Section. (C) Line
scans of the regions highlighted in (A) and (B), showing CCD pixel intensity as a
function of position along the grid using the same protein source, protein deposition time,
rinsing conditions, and fluorescence imaging settings. Substantially lower His8-GFPuv
fluorescence was found on the mPEG350-DTPE coated grids than in the bare carbon
coated grids. The abrupt reduction in pixel intensity centered at 76 m in the bare carbon
surface line scan is attributed to an absence of carbon coating on this section of the TEM
grid.

His8-GFPuv capture on grids bearing stabilized 1:99 and 5:95 Ni2+:NTAPEG2000-DTPE:mPEG350-DTPE monolayers was first demonstrated by fluorescence
microscopy. Wide-field fluorescence images (Figure 2.6) of Ni2+:NTA-PEG2000DTPE:mPEG350-DTPE modified grids reveal a non-uniform, concentration-dependent
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GFP fluorescence. Some spots of bright fluorescence, suggestive of GFP aggregation,
were also observed. The observed pixel intensities in the fluorescence line scan analyses
were higher for the grids bearing a 5:95 Ni2+:NTA-PEG2000-DTPE:mPEG350-DTPE
coating than the grids coated with a 1:99 monolayer. In both cases, the bound His8GFPuv could be removed from the grid surface after a brief 5 min exposure to either 500
mM imidazole or 150 mM EDTA to remove Ni2+ from the His8:Ni2+:NTA complex to
enable elution of the immobilized protein target from stabilized, Ni2+ activated 1:99 and
5:95 Ni2+:NTA-PEG2000-DTPE:mPEG350-DTPE monolayers. These findings indicate
that His-tag targets can be captured in an NTA concentration-dependent manner, with
higher NTA loadings producing greater target protein concentrations on TEM coated
with stabilized, Ni2+-activated NTA-PEG2000-DTPE:mPEG350-DTPE monolayers.
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Figure 2.7 Fluorescence Microscopy of TEM Grids Coated with Stabilized NTAPEG2000-DSPE:mPEG350-DTPE Monolayers. Fluorescence microscopy analysis of EM
grids coated with 1:99 or 5:95 NTA-PEG2000-DSPE:mPEG350-DTPE after compression
to the brush regime of mPEG350, LS transfer onto carbon coated grids,
photopolymerization, and Ni2+ activation as described in the Experimental Section. The
grids were then exposed to 2.0 mg/mL His8-GFPuv for 2 min, followed by three MilliQ
water rinses to remove unbound protein. (A) Appearance of 1:99 coating before and (C)
after 500 mM imidazole, pH 7.2 treatment. (B) Appearance of 5:95 coating before and
(D) after 500 mM imidazole, pH 7.2 treatment. (E) Cartoon illustrating varying surface
density of bound target with varying monolayer composition. (F) Line scans of the
regions highlighted in (A) - (D), showing CCD pixel intensity as a function of position
along the grid using the same protein source, protein deposition time, rinsing conditions,
and fluorescence imaging settings.

Purified His6-T7 bacteriophage (1011 – 1012 particles/mL) was used to probe the
non-specific adsorption properties of DLPC and mPEG350-DTPE stabilized monolayercoated grids at higher resolution, with carbon coated, glow-discharged grids serving as a
control. The sample precipitated on grids lacking modified DLPC or mPEG350
monolayers (Figure 2.8A). We identified virus-like particles on these grids, as shown in
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Figure 2.8A (inset); however, the poor sample quality produced on unmodified, glowdischarged grids made accurate quantification of adsorbed virus particles impossible.
Therefore, we only quantified virus adsorption onto DLPC and mPEG350 modified grids,
as discrete particles could be discerned in both cases. DLPC coated grids were found to
decrease the amount of T7 that was adsorbed to the grid relative to bare carbon grids
(Figure 2.8B), indicating that interactions between T7 bacteriophage and the DLPC
monolayer are not as favorable. Nonetheless, a significant amount of occult debris
remained on the DLPC monolayer coated grids. Grids coated with mPEG350-DTPE
stabilized monolayers; however, displayed a greatly reduced accumulation of both T7 and
debris (Figure 2.8C). The appearance of the virus particles in these samples included
round-like objects as well as more familiar hexagonal projections of the mature
icosahedral form of the virus. The T7 phage particle here represents the immature form
where an absence of mature capsid shell protein gives results in the rounded appearance
of these particles.30 The low abundance of T7 phage particles in this image highlights the
antifouling opportunities of these PEGylated surfaces. Quantitative comparisons of the
T7 particle densities on DLPC and mPEG350 monolayers revealed an accumulation of
~110 particle/1 μm2, and 5 particle/1 μm2, respectively. We infer from these findings that
mPEG350-DTPE stabilized monolayers are the most effective toward blocking nonspecific adsorption of T7 bacteriophage (Figure 2.8D). Low magnification images of
purified T7 deposited onto both DLPC and mPEG-DTPE stabilized monolayer coated
grids reveal a substantially lower background in the case of mPEG350-DTPE coated
grids (Figure 2.8E and 2.8F).
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Figure 2.8 Comparative Performance of Uncoated (bare carbon, glow-discharge), DLPC,
and mPEG350-DTPE Coated Grids Toward Non-Specific Protein Adsorption (i.e.,
lacking NTA groups to promote specific binding). The capacity of these grids to reject
non-specific protein adsorption was tested by negative stain TEM analysis using His6-T7
bacteriophage in purified form or within cell lysates. (A) Purified His6-T7 bacteriophage
on glow-discharged bare carbon grid; (B) purified His6-T7 bacteriophage on 100% DLPC
monolayer coated grid; (C) His6-T7 bacteriophage on stabilized 100% mPEG350-DTPE
monolayer coated grid; (D) number of non-specific contaminants adsorbed from purified
His6-T7 bacteriophage solution onto bare carbon grids (blue), DLPC coated grids (red),
and mPEG350-DTPE coated grids (green) as determined by counting 60 randomly
selected fields across 3 different grids for each grid type; (E) His6-T7 bacteriophage in
cell lysate applied to 100% DLPC coated grid; and (F) His6-T7 bacteriophage in cell
lysate applied to stabilized 100% mPEG350-DTPE coated grid.
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2.4.3 Affinity Capture of His-Tagged Proteins Using Affinity Lipopolymers Grids
After evaluating the capacity of these grids to inhibit non-specific adsorption, we
next turned our attention to their ability to direct affinity-guided interactions with NTAmodified grids. First, we used fluorescence microscopy to monitor His8-GFPuv capture on
grids bearing stabilized 1:99 and 5:95 Ni2+:NTA-PEG2000-DTPE:mPEG350-DTPE
monolayers. Wide-field fluorescence images (Figure 2.7) of Ni2+:NTA-PEG2000DTPE:mPEG350-DTPE modified grids reveal a non-uniform, concentration-dependent
GFP fluorescence. Occasional spots of bright fluorescence, suggestive of GFP aggregation,
were also observed. The observed average pixel intensities in the fluorescence line scan
analyses were higher for the grids bearing a 5:95 Ni2+:NTA-PEG2000-DTPE:mPEG350DTPE coating than the grids coated with a 1:99 monolayer. In both cases, the bound His8GFPuv could be removed from the grid surface after a brief 5 min exposure to either 500
mM imidazole or 150 mM EDTA to remove Ni2+ from the His8:Ni2+:NTA complex to
enable elution of the immobilized protein target from stabilized, Ni2+ activated 1:99 and
5:95 Ni2+:NTA-PEG2000-DTPE:mPEG350-DTPE monolayers. These findings indicate
that histidine-tagged targets can be captured in an NTA concentration-dependent manner,
with higher NTA loadings producing greater target protein concentrations on TEM grids
coated

with

stabilized,

Ni2+-activated

NTA-PEG2000-DTPE:mPEG350-DTPE

monolayers.
Affinity capture of His6-T7 bacteriophage from cell lysates was then tested by
negative stain and cryoelectron microscopy using grids modified with mPEG350-DTPE
stabilized

monolayers,

Ni2+:NTA-PEG2000-DTPE:mPEG350-DTPE

stabilized

monolayers, and Ni2+:NTA-PEG2000-DTPE:mPEG350-DTPE stabilized monolayers
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rinsed with 500 mM imidazole after lysate exposure (Figure 2.9). In the presence of
mPEG350-DTPE stabilized monolayers, we observed minimal binding of His6-T7
bacteriophage and very low levels of debris from the lysate onto the grid (Figure 2.9A).
Background adsorption of non-T7 phage debris is highlighted in the inset of this image. In
some cases, T7 particles were not observed on the brush polymer surface even at low
magnification, suggesting a complete blockage of non-specific adsorption. Grids bearing
Ni2+-charged 1:99 NTA-PEG2000-DTPE:mPEG350-DTPE stabilized monolayers were
capable of capturing His6-T7 bacteriophage from cell lysate while limiting the background
adsorption of undesired non-target cellular components (Figure 2.9B). It is worth noting
that T7 viral particles often give mixed results of negative-stain and positive-stained
particles since uranyl salts may positively stain packaged nucleic acid within the capsid
structure.31 Exposure of these samples to 500 mM imidazole led to greatly decreased
surface adsorption of His6-T7 bacteriophage, suggesting that the interaction of phage
particles with the supported NTA-lipid monolayer is Ni2+ specific (Figure 2.9C). We
attribute the occurrence of the few remaining particles to either non-specific adsorption to
uncoated grid regions or particles that are avidly bound due to multivalent interactions
between the phage particles and the NTA-PEG grafted surface. To compensate for particle
capture efficiency limitations in samples prepared for cryogenic imaging5 due to
unfavorable kinetics and/or modest ligand-receptor affinities,32 we examined 1:99 and 5:95
Ni2+:NTA-PEG2000-DTPE:mPEG350-DTPE stabilized monolayer coated grids to
determine whether the areal density of NTA ligands had a detectable influence on His6-T7
bacteriophage capture efficiency. Using identical sample processing methods and
incubation times, we qualitatively observed an increase in particle surface density with
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increasing Ni2+:NTA-PEG2000-DTPE composition (unpublished data). Since this
comparison was not performed in a side-by-side manner between 1:99 and 5:95 Ni2+:NTAPEG2000-DTPE:mPEG350-DTPE stabilized monolayers with the same lysate, it is
conceivable that these findings may be the result of different virus titers in the His6-T7
bacteriophage preparations. Nonetheless, these findings are consistent with the His8GFPuv experiments described above (Figure 2.7) showing that higher surface
concentrations of affinity capture lipid produces greater areal densities of immobilized
target on the NTA-modified surface, with the 5:95 Ni2+:NTA-PEG2000-DTPE:mPEG350DTPE stabilized monolayer coated grids being more suitable for cryoEM sample
preparation (Figure 2.9D). The immobilization of both mature and immature T7 phage
from lysate samples (Figure 2.9F) highlights the potential of rapid purification using
affinity grids for the study of dynamic processes, which may not be possible when
visualizing purified samples generated using standard TEM sample preparations.
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Figure 2.9 Effect of NTA Surface Density on His-T7 Bacteriophage Captured from Cell
Lysates Using Negative Stain and Cryo-EM Analysis. (A) Negative stain TEM
appearance of grid coated with stabilized 100% mPEG350-DTPE monolayer after 2 min
exposure to cell lysate containing His-T7 bacteriophage; (B) same as in (A), except that
the grid was coated with stabilized 1:99 Ni2+:NTA-PEG2000-DSPE:mPEG350-DTPE
monolayer; (C) same as in (B), except that the grid was rinsed with 500 mM imidazole,
pH = 7.4 after the 2 min lysate exposure step; and (D) cryoEM appearance of grid coated
with stabilized 5:95 Ni2+:NTA-PEG2000-DSPE:mPEG-350-DTPE monolayer after 2 min
exposure to cell lysate containing His-T7 bacteriophage. (E) Schematic of T7
bacteriophage organization and structure. (F) Cryo-EM image of his-T7 bacteriophage
revealing different stages of maturation.

We next demonstrated the capture of the 50S E. coli ribosomal subunit,5 His6RplL, directly from cell lysates onto grids coated with Ni2+:NTA-PEG2000DTPE:mPEG350-DTPE stabilized monolayers. Negative stain EM images of His6-RplL
lysate deposited onto grids coated with mPEG350-DTPE stabilized monolayers showed
no appreciable target-specific adsorption onto the grid (Figure 2.10A). After LS
deposition of 1:99 Ni2+:NTA-PEG2000-DTPE:mPEG350-DTPE stabilized monolayers

72
onto the grids, particles consistent with the size and various shapes of the 50S subunit
were observed on the grid surface (Figure 2.10B). When 500 mM imidazole was added to
samples containing the captured ribosomal particles on 1:99 Ni2+:NTA-PEG2000DTPE:mPEG350-DTPE stabilized monolayers, the previously adsorbed particles were
eluted from the surface of the TEM grid (Figure 2.10C), consistent with the expectation
that the interaction of His6-RplL with the surface of the grid is Ni2+ specific. Using the
same sample preparation procedure, cryo-EM analysis revealed the capture of His6-RplL
from E. coli lysates (Figure 2.10D) as crown-like projections in some images (Figure
5D). These have frequently been reported and are attributed to the 50S ribosomal subunit.
The earliest reported TEM images of ribosomes were small, featureless bumps on the
grid surface;33 however, more powerful tools eventually led to the revelation of several
features in the ribosomal units such as ‘crown-like’ and ‘duck-like’ projections for the
50S and 30S subunits, respectively.34 Since the RplL protein carries the hexahistidine tag
on the 50S subunit in our construct, we identified many more of these particles bound to
the grid than the 30S subunit. Crown-like projections are clearly seen from the side view
of the 50S particle with a central protuberance, a ridge, a stalk, and two groove-like
features.
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Figure 2.10 Affinity Capture of His-RplL from Cell Lysates onto Stabilized Ni2+:NTAPEG2000-DTPE:mPEG-350-DTPE Monolayer Coated Grids. (A) Negative stain TEM of
grid coated with stabilized 100% mPEG350-DTPE after 2 min exposure to cell lysate
containing His-RplL; (B) negative stain TEM of grid coated with 1:99 Ni2+:NTAPEG2000-DSPE:mPEG350-DTPE after 2 min exposure to cell lysate containing HisRplL; (C) same as in (B), except that the grid was rinsed with 500 imidazole, pH=7.4
after the 2 min exposure to cell lysate containing His-RplL; and (D): cryoEM image of
grid coated with stabilized 5:95 Ni2+:NTA-PEG2000-DSPE:mPEG-350-DTPE
monolayer after 2 min exposure to cell lysate containing His-RplL.

A key design feature of these stabilized affinity coatings is their utilization of two
different types of poly(ethylene glycol)-modified lipids, one high molar ratio brush layer
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short segment to block non-specific adsorption and facilitate stabilization via
photopolymerization (i.e., mPEG350-DTPE) and a second low molar ratio component to
enable multiple orientations of the captured protein target to avoid preferred orientations
at the monolayer interface and provide a more representative single particle
reconstruction analysis data set. We tested this hypothesis by preparing dozens of TEM
grids bearing stabilized Ni2+:NTA-PEG2000-DSPE:mPEG350-DTPE coatings that had
been treated with His6-RplL containing lysates. CryoEM evaluation of these grids
confirmed that the NTA-PEG2000 tether is capable of both capturing and presenting
multiple orientations of the bound His6-RplL target as demonstrated by the overlay of the
known 50S subunit and 70S complex structures in different rotational configurations onto
the corresponding EM images shown in Figures 2.11A-D.
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Figure 2.11 Cryo-EM Images and Conformational Overlay Showing Representative
Views of His-tag RplL from Cell Lysates onto Stabilized 5:95 Ni2+-NTA-PEG2000DSPE:mPEG350-DTPE Monolayer Coated Grids. (A, B) Projections of different
ribosomal large subunit (50S) orientations onto corresponding cryo-EM images; (C, D):
projections of different full ribosomal (70S) particle orientations onto corresponding
cryoEM images.

Membrane scaffold proteins (MSP) have become an increasingly popular tool for
stabilizing membrane protein dispersions since it provides a platform in which the local
environment of solubilized membrane proteins resemble the natural environment of the
lipid bilayer in cells.35 MSP are used to corral lipids and membrane proteins within disklike structures containing a lipid bilayer interior that can host reconstituted membrane
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proteins for structure analysis by electron microscopy,36 protein modification studies,37 and
protein activation analysis.38 We used the purified hexahistidine-tagged maltose
transporter, His6-MalFGK2, solubilized in MSP lipid nanodisc, for evaluating their affinity
capture properties on NTA-modified stabilized affinity grids. Although His-tag MSP can
be used for affinity purification,39 we used a His6-MalFGK2 construct for nanodisc
reconstitution to ensure that only nanodisc containing His6-MalFGK2 are surface
immobilized. We found that mPEG350-DTPE stabilized monolayer coated grids treated
with His6-MalFGK2 nanodisc appeared to have fewer particles bound to the grid surface
(Figure 2.12A) than the grids coated with 1:99 Ni2+:NTA-PEG2000-DTPE:mPEG350DTPE stabilized monolayers (Figure 2.12B). Treatment of the His6-MalFGK2-immobilized
grids with 500 mM imidazole produced a decrease in MSP nanodisc binding to the surface
(Figure 2.12C), further suggesting that the interaction between nanodisc solubilized His6MalFGK2 and the NTA-modified surface is Ni2+ specific. High magnification images of
nanodisc solubilized His6-MalFGK2 immobilized onto 5:95 Ni2+:NTA-PEG2000DTPE:mPEG350-DTPE stabilized monolayers (Figure 2.12D) reveal a set of disc-like
features in the size range of other lipid nanodisc dispersions (7 – 13 nm in diameter).40
Although the His6-MalFGK2 within the MSP nanodiscs is not directly observed due to its
small size relative to the nanodiscs, the fact that these features elute with 500 mM imidazole
strongly corroborates the assumption that they contain His6-MalFGK2. In addition, our
images show predominantly top/bottom views of the particles, i.e., a disk-like appearance
in TEM micrographs (Figure 2.12D), suggesting that a longer PEG spacer is needed to
collect a greater number of side views for this solubilized target.
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Figure 2.12 Affinity Capture of MSP Nanodisc Containing Purified His6-MalFGK2. (A)
Negative stain TEM of stabilized 100% mPEG350-DTPE monolayer-coated grid after
treatment with His-MalFGK2 in nanodiscs; (B) negative stain TEM of His-MalFKG2 in
nanodisc captured on stabilized 1:99 Ni2+:NTA-PEG2000-DSPE:mPEG350-DTPE
monolayer-coated grid; (C) same as in (B), except that the grid was rinsed with 500 mM
imidazole, pH = 7.4 after the His-MalFGK2 in nanodisc exposure step; and (D) cryoEM
of His-MalFGK2 in nanodisc captured on stabilized 5:95 Ni2+:NTA-PEG2000DSPE:mPEG-350-DTPE monolayer-coated grid. (E) Schematic of MSP nanodisc 3D
structure. (F) Schematic illustration of preparation of MSP nanodisc from detergent
solubilized protein.

2.4.4 Affinity Lipopolymer Grid Stability Against Detergent Exposure
In order to test the durability of the stabilized monolayers toward detergent
exposure, the modified grids were treated with either 0.03% Triton X-100 (CAC =
0.015%), 0.014% Tween 20 (CAC = 0.0072%), or 0.5% CHAPS (CMC=0.49%)
solutions for varying periods of time before TEM observation. Lipid monolayers
adsorbed to solid substrates display better detergent resistance than lipid bilayers that are
prone to disruption via lipid flip-flop.41 Initial encounter of detergents with the outer
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bilayer leaflet results in fluidization and lipid flip-flop from the inner leaflet to the outer
leaflet, eventually leading to complete solubilization of the bilayer structure.41b Inhibition
of flip-flop due to adsorption of a highly compressed monolayer onto the solid carbon
substrate inhibits flip-flop processes, leading to improved detergent resistance.
Despite some evidence of enhanced detergent resistant of supported DLPC
monolayers, prior attempts to produce TEM grids coated with mixed Ni2+:NTADSG:DPLC monolayers showed that their exposure to harsher detergents such as Triton
X-100, Tween-20, and CHAPS led to monolayer solubilization.5 We tested the detergent
resistance of our stabilized Ni2+:NTA-PEG2000-DTPE:mPEG350-DTPE monolayer
coatings under conditions where DLPC monolayers failed by using 0.03% Triton X-100
(CMC = 0.015%), 0.014% Tween 20 (CMC = 0.0072%), or 0.5% CHAPS (CMC =
0.49%) at 5, 15, and 30 min exposures to the detergent solutions. Negative stain TEM
observation of the coatings after detergent exposure indicated that stabilized Ni2+:NTAPEG2000-DTPE:mPEG350-DTPE monolayer coatings remain intact after 30 minutes of
incubation with Triton X-100, Tween-20, and CHAPS (Figure 2.13). In the case of Triton
X-100, some holes in the monolayer were occasionally observed, but none were apparent
in grids treated with Tween 20 or CHAPS. The capacity of these coatings to immobilize
purified His6-T7 bacteriophage after detergent exposure for 20 min indicated that a
modest reduction in phage binding to the grid occurred, however, the immobilized His6T7 bacteriophage particles were bound specifically as indicated by their ability to be
removed by elution with 500 mM imidazole.
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Figure 2.13 Negative Stain TEM Images of TEM Grids Coated with 1:99 NTAPEG2000-DSPE:mPEG350-DTPE After Exposure to Different Detergents. Negative
stain TEM analysis of EM grids coated with 1:99 NTA-PEG2000-DSPE:mPEG350DTPE after compression to the brush regime of mPEG350, LS transfer onto carbon
coated grids, photopolymerization, and exposure to different detergent solutions for
varying periods of time prior to TEM analysis. (A – C): A 0.03% Triton X-100 solution
(10 L) was placed in contact with the grids for (A) 5, (B) 15, or (C) 30 min. (D – F): A
0.014% Tween 20 solution (10 L) was placed in contact with the grids for (D) 5, (E) 15,
or (F) 30 min. (G – I): A 0.5% CHAPS solution (10 L) was placed in contact with the
grids for (G) 5, (H) 15, or (I) 30 min. The scale bars in all images are 400 nm. A defocus
of > 10 μm was used to improve visualization of the monolayer film coatings.
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Fluorescence microscopy analysis of detergent-treated Ni2+:NTA-PEG2000DTPE:mPEG350-DTPE monolayers revealed that the stabilized Ni2+ lipid monolayer
coatings retained their ability to capture His8-GFPuv. Pixel intensity data was collected
over the entire fluorescence image (Figure 2.14) to best represent the overall specific
capture capacity of the coating, regardless of whether it had been detergent compromised
or not. In the case of Triton X-100 exposed samples, the fluorescence was occasionally
enhanced near the grid edges, possibly as a result of solubilized or damaged monolayer
near the center of the grid holes that were unable to capture His8-GFPuv in those regions.
We did not see this phenomenon with either CHAPS- or Tween 20-treated surfaces. These
grids exhibited a uniform distribution of His8-GFPuv fluorescence over the grid holes until
the surfaces were treated with 500 mM imidazole to displace the immobilized protein.
Despite the limitations of these stabilized Ni2+:NTA-PEG2000-DTPE:mPEG350-DTPE
monolayer coatings toward prolonged Triton X-100 exposure, our data indicates that
histidine-tagged proteins can be reversibly immobilized even after detergent exposure. We
infer from these findings that both the integrity of the stabilized lipid monolayer and the
specific affinity capture of the grids remains intact after exposure to detergents that has
proven detrimental to previously reported mixed Ni2+:NTA-DGS:DLPC monolayers.5
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Figure 2.14 Effect of Detergent Exposure on 1:99 Ni2+:NTA-PEG2000-DSPE:mPEG350DTPE Stabilized Monolayer Affinity Grids as Determined by Fluorescence Microscopy
Using His8-GFP as a probe for NTA Monolayer Retention.

2.5 Conclusions
A library of affinity lipopolymer constructs was synthesized consisting of
lipopolymers of various PEG molecular weights conjugated to DTPE or DSPE as lipid
anchors and NTA, tris-NTA, biotin and glutathione as affinity moieties or maleimide as a
covalent functionality. This strategy is expected to be effective for specific capture of other
targets of interest by varying the composition of the PEG terminus. Specific targets to
expand the library include dibenzocycloctynyl and other specific ligands. This strategy
may also be useful for screening of a molecular drug target by incorporating the drug target
into the affinity lipopolymer constructs.
Langmuir-Schaefer transfer of compressed, mixed lipid monolayers containing
Ni2+:NTA-PEG2000:mPEG350 head groups in 1:99 and 5:95 molar ratios are capable of
capturing His-tag protein targets from cell lysates with controllable areal densities and low
degrees of non-specific protein adsorption. Photopolymerization of the mPEG350-DTPE
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component in these monolayers by irradiating for 10 min at 254 nm produced EM grids
with stabilized lipid coatings that were used to then used to capture His6-T7 bacteriophage
and His6-RplL from cell lysates, purified His8-GFPuv, and nanodisc embedded His6MalFGK2. Our data indicate that the crosslinked lipid coating maintains the non-fouling
properties of the monolayer and provides multiple orientations of the captured target on the
surface, while also affording greater mechanical and detergent resistance than previously
reported for EM grid-supported DLPC monolayers.

2.6 Future Directions
To further advance this project, we are interested in the synthesis of novel
lipopolymer constructs with terminal moieties which impart specificity for binding or
covalent reaction with a specific target or class of targets. For instance, by generating a
library of lipopolymer drug conjugates, a screening array could be constructed for
simultaneous identification and structural characterization by cryo-EM. This could be a
powerful new approach for drug discovery. As another example, dibenzocycloctynyllipopolymer conjugate 47 could allow for selective capture of azide-containing targets.
We are interested in exploring affinity grid performance with polymer conjugates of other
types of lipids which may provide better monolayer performance. We are also interested
in exploring the relation of parameters like PEG molecular weight, lipid composition and
modification of other surfaces to affinity grid performance, as well.
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Figure 2.15. Proposed Affinity Lipopolymer for Immobilization of Azide-Containing
Targets, DSPE-PEG-DBCO.

2.7 Experimental Methods
All reactions were carried out under a blanket of N2 or argon gas. Reaction
progress was monitored by thin-layer chromatography (TLC) analysis. TLC spots were
visualized either by UV light (254nm), exposure by ninhydrin staining, staining with
phosphomolybdic acid (PMA), staining by bromocresol green, or by staining with I2.
Flash column chromatography was carried out using 230-400 mesh silica gel and
analytical grade solvents. Solvents were purchased from Mallinckrodt/Baker and used
without further purification unless noted. Toluene was purchased from Fisher. mPEG
polymers were from Sigma-Aldrich and were purified before use via precipitation N-(3dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC), Nε((benzyloxy)carbonyl)-l-lysine (H-Lys(Z)-OH) and H-Cys(Trt)-OH were purchased from
Advanced Chemtech. Heterobifunctional PEG derivatives were purchased from JenKem
Technology USA. 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) and 1,2(tricosa-10’,12’-diynoyl)-sn-glycero-3-phosphoethanolamine (DTPE) were purchased
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from Avanti Polar Lipids. All other chemicals were purchased from Sigma Aldrich and
used without further purification. Dichloromethane (DCM), and toluene were distilled
from CaH2. Triethylamine (TEA) was distilled from CaH2 and stored over BaO.
Tetrahydrofuran (THF) was distilled from sodium-benzophenone ketyl. α-methoxypolyethylene glycol (mPEG350) was purchased from Sigma Aldrich and purified by
azeotropic drying with toluene. Jones’ reagent (1.25 M in CrO3) was prepared by
dissolving 17.5 g CrO3 in 125 mL water plus 16 mL conc. H2SO4.
1

H and 13C nuclear magnetic resonance (NMR) spectra were recorded on either a

Bruker AV500HD (500MHz) or a Bruker ARX400 spectrometer (400 MHz). Chemical
shifts are reported in ppm relative to the residual solvent peaks as internal standard

2.7.1 Synthesis of Affinity Lipopolymer Constructs
mPEG-mesylate (2a-e). mPEG was dried azeotropically with toluene several times and
dried in vacuo for 18 hours. As a representative reaction, mPEG (6.00 g) was dissolved in
DCM (85 mL) and triethylamine (1.5 equiv.) was added. The solution was cooled to 0 °C
in an ice bath and methansulfonyl chloride (MsCl, 1.1 equiv.) was added dropwise over
10 minutes. The reaction was stirred for an additional 30 minutes at 0 °C. The solution
was transferred to a separatory funnel with an additional 50 mL DCM. The solution was
washed with 100 mL ice water followed by 100 mL 5 % HCl solution. The organic
solution was dried with anhydrous sodium sulfate and concentrated in vacuo. For mPEG
< 2.0 kDa the oily residue was further dried in vacuo. For mPEG > 2.0 kDa, the oily
residue was precipitated into cold diethyl ether (500-800 mL), filtered and dried in vacuo.
Yield: (90-98 %); TLC: Rf= 0.66 (3:17 MeOH:DCM) for mPEG350.
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mPEG-azide (3a-e). mPEG-mesylate 2a-e (6.69 g) was dissolved in DMF (150 mL) and
sodium azide (10.0 equiv.) was added. The solution was stirred for 90 °C for 48 hours.
DMF was evaporated in vacuo. The residue was dissolved in DCM ((200 mL), filtered
and washed with deionized water (150 mL) twice. The aqueous washes were extracted
with DCM (100 mL) twice each and the organic extracts were combined with the original
organic solution and concentrated in vacuo. For mPEG < 2.0 kDa the oily residue was
further dried in vacuo. For mPEG > 2.0 kDa, the oily residue was precipitated into cold
diethyl ether (500-800 mL), filtered and dried in vacuo. Yield: (83-95 %); TLC: Rf= 0.63
(3:17 MeOH:DCM) for mPEG350.

mPEG-amine (4a-e). mPEG-azide 3a-e (5.52 g) was dissolved in ethyl acetate (50 mL)
and 10% palladium on carbon (wet type) was added via spatula. The flask was equipped
with a three-way adapter and a hydrogen balloon. The flask was evacuated and purged
with hydrogen three times and stirred vigorously under 1 atm hydrogen atmosphere for
24 hours at ambient temperature. The solution was gravity filtered through celite and
concentrated in vacuo. For mPEG < 2.0 kDa the oily residue was further dried in vacuo.
For mPEG > 2.0 kDa, the oily residue was precipitated into cold diethyl ether (500-800
mL), filtered and dried in vacuo. Yield: (82-94 %); TLC: Rf= 0.06 (3:17 MeOH:DCM)
for mPEG350.

mPEG-carboxylic acid (5a-e). Jones oxidation was used to produce carboxylic acidterminal mPEG. As a representative reaction, mPEG (5.00 g) was dissolved in 280 mL
acetone. Jones’ Reagent (1.1 equiv) was added to a 500 mL round bottom flask and the
mPEG solution was added to this flask dropwise over 1 h via addition funnel. The
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resulting solution was stirred at 20 °C for 1 h before quenching the excess Jones reagent
with a few mL of iPrOH. The resulting green precipitate was removed by decantation of
the liquid solution. The volatiles were removed under reduced pressure and the residue
dissolved in 150 mL H2O. The aqueous phase was extracted with DCM (4 x 120 mL).
Depending of mPEG molecular weight, it may be necessary to add MeOH (100-200 mL)
to effect phase separation. The organic layers were combined and dried over anhydrous
Na2SO4, filtered, and evaporated under reduced pressure. For mPEG < 2.0 kDa, the oily
residue was dried in vacuo. For mPEG > 2.0 kDa, the oily residue was precipitated into
cold diethyl ether (500-800-mL), filtered and dried in vacuo. TLC analysis was used to
verify conversion using bromocresol green stain. Yield: (89-94 %); TLC: Rf= 0.26 (3:17
MeOH:DCM) for mPEG350; 1H NMR for mPEG350 (400 MHz, CDCl3): δ 3.35 (s 3H),
3.4-3.8 (m 30H), 4.01 (s 2H), 10.1-12.2 (br 1H).

mPEG-aldehyde (6a-e). Albright-Goldman oxidation was used to oxidize terminal
hydroxyl-moieties of mPEG to aldehyde groups. mPEG 1a-e was dissolved in a mixture
of dimethyl sulfoxide (DMSO) and acetic anhydride (Ac2O) (5 mL of 3:2 DMSO:Ac2O
for every 1 mmol of alcohol). This solution is prepared beforehand at least 24 hours
before reaction. The solution was stirred for 24 hours at ambient temperature. The
solution was concentrated in vacuo. For mPEG < 2.0 kDa the oily residue was further
dried in vacuo. For mPEG > 2.0 kDa, the oily residue was precipitated into cold diethyl
ether (500-800 mL) 2-3 times, filtered and dried in vacuo. Yield: (89-94 %).
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mPEG-amine (7a-e). An alternative synthesis of amine-terminal mPEG was developed
utilizing reductive amination. mPEG-aldehyde 6a-e (7.31 g), ammonium chloride (10.0
equiv.) and potassium hydroxide (3.3 equiv) were dissolved in anhydrous MeOH (25
mL). This solution was stirred for 30 min. A solution of sodium cyanoborohydride (10.0
equiv.) in anhydrous MeOH (10 mL) was added and the solution was stirred under argon
at ambient temperature for 24 hours. The solution was poured into 100 mL of deionized
water and extracted with DCM (100 mL) four times. The organic extracts were dried over
anhydrous sodium sulfate and concentrated in vacuo. For mPEG < 2.0 kDa the oily
residue was further dried in vacuo. For mPEG > 2.0 kDa, the oily residue was
precipitated into cold diethyl ether (500-800 mL), filtered and dried in vacuo. Yield: (9098 %); TLC: Rf= 0.04 (3:17 MeOH:DCM) for mPEG350.

mPEG350-NHS (8). Compound 5a (274 mg, 0.753 mmol), and NHS (217 mg, 1.885
mmol) were dissolved in 15 mL DCM and the resulting solution was cooled in an ice
bath. EDC (173 mg, 0.902 mmol) was then added followed by DIEA (393 µL, 2.259
mmol), and the solution was stirred while slowly warming from 4 to 20 °C over 18 hours.
Volatiles were removed under reduced pressure and the residue was dissolved in 50 mL
DCM. The organic filtrate was washed with 50 mL H2O twice before combining and
extracting the aqueous phase with DCM (2 x20 mL). The combined organic phases were
dried over anhydrous Na2SO4 before removing the solvent under reduced pressure and
purifying the residue by flash chromatography on silica (3:17 MeOH:DCM). Yield: 230
mg (84.4 %); TLC: Rf= 0.66 (3:17 MeOH:DCM); 1H NMR (400 MHz, CDCl3): δ 2.65 (s
4H), 3.35 (s 3H), 3.4-3.8 (m 30H), 4.01 (s 2H).
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mPEG350-DTPE (9a). Compound 3 (100 mg, 0.210 mmol) and DTPE (183 mg, 0.210
mmol) were dissolved in DMF (5 mL) in a 100 mL round bottom flask covered in
aluminum foil. DIEA (37 µL) was added and the solution was stirred at 20 C for 36
hours in the dark under N2. The volatiles were removed under reduced pressure and the
residue was purified by chromatography on silica (3:17 MeOH:DCM). Yield: 82 mg
(31.1%); TLC: Rf= 0.29 (3:17 MeOH:DCM). 1H NMR (400 MHz, CDCl3): δ 0.88 (t 6H),
1.25-1.35 (m 44H), 1.49 (m 8H), 2.22 (m 8H), 2.53 (br 2H), 2.61 (br 2H), 3.36 (s 3H),
3.54-4.32 (m, 40H), 512 (br 1H), 7.64 (br 1H).

mPEG350-DSPE (9b). Compound 3 (100 mg, 0.210 mmol) and DSPE (157 mg, 0.210
mmol) were dissolved in chloroform (10 mL) in a 100 mL round bottom flask. DIEA
(154 µL) was added and the solution was stirred at 20 °C for 36 hours under N2. The
volatiles were removed under reduced pressure and the residue was purified by
chromatography on silica (3:17 MeOH:DCM). Yield: 173.2 mg (81.6%); TLC: Rf= 0.24
(3:17 MeOH:DCM). 1H NMR (400 MHz, CDCl3) δ 4.48 – 4.33 (m, 1H), 4.33 – 4.05 (m,
4H), 3.91 – 3.69 (m, 5H), 3.64 (s, 52H), 3.37 (s, 6H), 3.07 (s, 2H), 2.95 (s, 2H), 2.71 (d, J
= 48.6 Hz, 7H), 2.33 (s, 1H), 1.24 (s, 22H), 0.87 (t, J = 15.3 Hz, 6H).

mPEG350-DPPE (9c). Compound 3 (61.0 mg, 0.13 mmol) and DPPE (100 mg, 0.14
mmol) were dissolved in chloroform (5 mL) in a 100 mL round bottom flask. DIEA (92
µL) was added and the solution was stirred at 20 °C for 36 hours under N2. The volatiles
were removed under reduced pressure and the residue was purified by chromatography
on silica (3:17 MeOH:DCM). Yield: 108.8 mg (72.3 %); TLC: Rf= 0.21 (3:17
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MeOH:DCM). 1H NMR (400 MHz, CDCl3) δ 5.20 (s, 1H), 4.36 (d, J = 13.7 Hz, 1H),
4.16 (s, 1H), 4.01 (s, 2H), 3.94 (s, 3H), 3.65 (d, J = 13.0 Hz, 18H), 3.54 (d, J = 5.8 Hz,
2H), 3.47 (s, 1H), 3.38 (d, J = 13.5 Hz, 3H), 2.86 (s, 1H), 2.27 (s, 3H), 1.56 (s, 4H), 1.23
(s, 40H), 0.86 (t, J = 6.5 Hz, 6H).

DTPE-PEG2K-biotin (11a). Biotin-PEG2K-NHS (10, 163 mg) and DTPE (52 mg) were
combined in an oven-dried 100 mL round bottom flask equipped with a rubber septum
and magnetic stir bar covered in aluminum foil. The solids were dissolve in 5 mL
chloroform and 26 µL DIEA was added. The solution was stirred under nitrogen for 36
hours. The volatiles were removed under reduced pressure and the residue was purified
by chromatography on silica (1:4 MeOH:DCM). Yield: 146 mg (75.3 %); TLC: Rf= 0.38
(1:4 MeOH:DCM). 1H NMR (400 MHz, CDCl3) δ 6.49 (s, 1H), 5.84 (s, 1H), 5.20 (s,
1H), 4.52 (s, 1H), 4.35 (s, 3H), 4.07 (d, J = 57.5 Hz, 11H), 3.63 (s, 343H), 3.10 (d, J =
32.1 Hz, 6H), 2.90 (d, J = 17.2 Hz, 3H), 2.82 – 2.55 (m, 4H), 2.52 – 2.03 (m, 19H), 1.68
(s, 12H), 1.57 – 1.08 (m, 91H), 0.87 (s, 6H).

DSPE-PEG2K-biotin (11b). Biotin-PEGK-NHS (10, 200 mg) and DSPE (66 mg) were
combined in an oven-dried 100 mL round bottom flask equipped with a rubber septum
and magnetic stir bar. The solids were dissolve in 10 mL chloroform and 34 µL DIEA
was added. The solution was stirred under nitrogen for 36 hours. The volatiles were
removed under reduced pressure and the residue was purified by chromatography on
silica (1:4 MeOH:DCM). Yield: 150 mg (56.4 %); TLC: Rf= 0.43 (1:4 MeOH:DCM).
1

H NMR (400 MHz, CDCl3) δ 6.59 (s, 1H), 6.13 (s, 1H), 5.46 (s, 1H), 5.28 (s, 4H), 5.16

(s, 1H), 4.56 – 4.43 (m, 1H), 4.41 – 4.24 (m, 2H), 4.11 (s, 2H), 3.97 (s, 5H), 3.62 (s,
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207H), 3.13 (s, 1H), 2.99 (s, 2H), 2.93 – 2.81 (m, 1H), 2.81 – 2.57 (m, 1H), 2.36 – 2.06
(m, 6H), 1.79 – 1.61 (m, 4H), 1.60 – 1.50 (m, 4H), 1.41 (d, J = 6.9 Hz, 8H), 1.35 (d, J =
6.5 Hz, 5H), 1.23 (s, 55H), 0.96 – 0.73 (m, 6H).

tert-Butyl N6-((benzyloxy)carbonyl)-L-lysinate (13). Nε-((benzyloxy)carbonyl)-Llysine (22.46 g, 80.11 mmol) was mixed with t-butyl acetate (270 mL) in a 500 mL round
bottom flask and concentrated HClO4 (10.0 mL) added to this mixture, producing a clear
solution. This solution was stirred for 24 hours before extracting with 120 mL 5% HCl
nine times. The aqueous extracts were combined and the pH was adjusted to about 12 via
addition of 33 % NaOH solution. The aqueous solution was extracted with diethyl ether
(4 x 240 mL). The ether extracts were combined and dried over anhydrous MgSO4. The
ether was then filtered and concentrated under reduced pressure and dried under a 50 m
vacuum overnight giving a colorless oil. Yield: 21.20 g (78.7 %). 1H NMR (400 MHz,
CDCl3): δ 1.30 (s 9H), 1.23-1.50 (m 8H), 2.99 (t 2H), 3.11 (t (1H), 4.91 (s 2H), 5.61 (br
1H), 7.14-7.16 (m 5H). 13C NMR (101 MHz, CDCl3): δ 175.18, 156.34, 142.38, 136.60,
128.31, 127.88, 108.60, 80.74, 77.46, 77.14, 76.82, 66.29, 54.66, 40.66, 34.36, 31.08,
29.53, 27.90, 22.64.

Di-t-Butyl 2,2'-((6-(((benzyloxy)carbonyl)amino)-1-(t-butoxy)-1-oxohexan-2yl)azanediyl)diacetate (14). Nε-Benzyloxycarbonyl-L-lysine-t-butyl ester (13, 13.921 g,
41.38 mmol) was dissolved in DMF (80 mL) prior to the addition of t-butyl bromoacetate
(18.34 mL, 24.21 g, 124.12 mmol) and DIEA (25.23 mL, 18.72 g, 144.85 mmol) by
syringe. The solution was stirred under N2 at 70 °C for 96 hours. The solvent was
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evaporated under reduced pressure and the residue was extracted with 200 mL of ethyl
acetate and filtered. The ethyl acetate extract was purified by flash chromatography on
silica (4:1 hexane:EtOAc) to give 14 as a slightly yellow oil. Yield: 27.37 g (84.4 %);
TLC: Rf = 0.18 (4:1 hexane:EtOAc); 1H NMR (CDCl3): δ 1.25-1.50 (m 6H), 1.30 (s
18H), 1.32 (s 9H), 3.04 (m 2H), 3.16 (t 1H), 3.33 (q 4H), 4.93 (s 2H), 5.39 (br 1H), 7.157.19 (m 5H). 13C NMR (101 MHz, CDCl3) δ 172.07, 170.41, 156.32, 136.69, 128.15,
127.79, 127.64, 80.70, 80.33, 77.54, 77.22, 76.90, 66.03, 64.91, 60.04, 53.62, 40.56,
29.93, 29.02, 27.97, 27.86, 27.73, 22.80, 20.71, 13.97.

Di-t-butyl 2,2'-((6-amino-1-(tert-butoxy)-1-oxohexan-2-yl)azanediyl)diacetate (15).
Compound 14 (9.84 g, 17.4 mmol) was dissolved in MeOH (90 mL) in a 500 mL round
bottom flask. To this solution was added 40 mg of 10% Pd/C. The flask was evacuated
and purged with H2 three times and then stirred for 12 hours under 1 atm H2. The
heterogeneous solution was then filtered through a pad of Celite, with further washing of
the Celite cake with 50 mL MeOH. The filtrate was concentrated under reduced pressure
to give 15 as a clear oil. Yield: 7.52 g (99.7 %); TLC: Rf = 0.02 (4:1 hexane:EtOAc); 1H
NMR (CDCl3): δ 1.29 (s 18H), 1.30 (s 9H) 1.1-1.5 (m 6H), 2.63 (t 2H), 3.16 (t 1H), 3.30
(q 4H), 3.96 (br 3H)13C NMR (101 MHz, CDCl3) δ 172.05, 170.46, 80.78, 80.42, 77.41,
77.09, 76.77, 64.94, 53.52, 49.54, 40.90, 31.09, 30.09, 27.95, 27.87, 22.91.

4-((5-(Bis(2-(tert-butoxy)-2-oxoethyl)amino)-6-(tert-butoxy)-6-oxohexyl)amino)-4oxobutanoic acid (16). Compound 15 (1.00 g, 2.32 mmol) and succinic anhydride (0.418
g, 4.18 mmol) were combined in an oven-dried 250 mL round bottom flask equipped
with a rubber septum and magnetic stir bar. The solids were dissolved in DCM (20 mL)
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and TEA (1.62 mL, 11.61 mmol) was added. The reaction was stirred at ambient
temperature for 18 hours. The solution was concentrated and dissolved in 50 mL ethyl
acetate. This solution was washed with 5% HCl (30 mL) twice. The organic phase was
concentrated and purified by flash chromatography using a gradient of 1:1 hexane ethyl
acetate to 1:1 hexane ethyl acetate. The pure fractions were combined and dried in vacuo
to give 16 as a colorless oil. Yield: 1.15 g (93.6 %); TLC: Rf = 0.28 (1:1 hexane:EtOAc).
1

H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 114.3 Hz, 2H), 6.96 (s, 1H), 3.46 – 3.24 (m,

6H), 3.23 – 2.97 (m, 3H), 2.54 (t, J = 6.4 Hz, 2H), 2.44 (d, J = 6.1 Hz, 2H), 1.79 – 1.46
(m, 3H), 1.34 (d, J = 6.2 Hz, 29H), 1.28 (d, J = 6.3 Hz, 3H).

Di-tert-butyl 2,2'-((1-(tert-butoxy)-1-oxo-6-(4-oxo-4-(prop-2-yn-1ylamino)butanamido)hexan-2-yl)azanediyl)diacetate (17). Compound 16 (1.15 g, 2.17
mmol) and propargylamine (131 mg, 2.38 mmol) and HOBt (322 mg, 2.38 mmol) were
combined in an oven-dried 250 mL round bottom flash equipped with a rubber septum
and magnetic stir bar. The solids were dissolved in DMF (8 mL) and EDC (457 mg, 2.38
mmol) was added followed by DIEA (1.15 mL, 6.50 mmol). The reaction was stirred for
24 hours at ambient temperature. The solution was diluted with 90 mL DCM and washed
with 5 % HCl (50 mL) twice. The organic phase was dried over anhydrous sodium sulfate
and concentrated in vacuo. The residue was purified via flash chromatography using a
gradient of 4:1 hexane:EtOAc to 1:1 hexane:EtOAc. Pure fractions were combined and
dried in vacuo to give Compound 17 as a clear oil. Yield: 1.09 g (88.5 %); TLC: Rf =
0.35 (1:1 hexane:EtOAc). 1H NMR (400 MHz, CDCl3) δ 8.03 (s, 1H), 7.12 (d, J = 4.9
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Hz, 1H), 3.48 – 3.26 (m, 5H), 3.26 – 3.06 (m, 3H), 2.94 (s, 1H), 2.52 (dd, J = 15.3, 10.9
Hz, 3H), 1.91 – 1.66 (m, 1H), 1.66 – 1.48 (m, 4H), 1.36 (d, J = 6.1 Hz, 34H).

2,2'-((5-(((Benzyloxy)carbonyl)amino)-1-carboxypentyl)azanediyl)diacetic acid (18).
Compound 12 (10.00 g, 35.67 mmol) was dissolved in 1.5 M NaOH and cooled to 0 °C
in an ice bath. Bromoacetic acid was also dissolved in 67 mL of 1.5 M NaOH and cooled
to 0 °C in an ice bath. The bromoacetic acid solution was added to the solution of
Compound 12 and the solution was allowed to warm to ambient temperature and stirred
for an additional 24 hours. The solution was heated to 50 ᵒC and stirred for 2 hours. The
solution was cooled back to 0 °C and the pH was adjusted to 2-3 using conc. HCl. The
precipitate was filtered and dried in vacuo to give Compound 18 as a white crystalline
solid. Yield: 11.67 g (82.6 %). 1H NMR (400 MHz, DMSO-d6) δ 12.51 (s, 0H), 7.68 –
7.06 (m, 6H), 4.98 (s, 2H), 3.55 – 3.38 (m, 4H), 3.31 (t, J = 7.4 Hz, 1H), 2.94 (s, 2H),
2.53 – 2.40 (m, 0H), 1.58 (s, 1H), 1.52 (s, 1H), 1.46 – 1.30 (m, 3H), 1.25 (s, 1H). 13C
NMR (101 MHz, DMSO) δ 190.15, 174.86, 174.14, 156.95, 138.18, 129.22, 128.60,
76.17, 65.99, 65.20, 54.27, 40.56, 40.35, 40.14, 30.20, 23.88.

2,2'-((5-Amino-1-carboxypentyl)azanediyl)diacetic acid (19). Compound 18 (2.90 g,
2.27 mmol) was dissolved in deionized water (50 mL) and 10 mL 1.5 M NaOH was
added to dissolve the material in an oven-dried 250 mL round bottom flask. Palladium on
carbon was added and the flask was equipped with a three-way adapter and a hydrogen
balloon. The flask was evacuated and purged with hydrogen. The reaction was stirred
vigorously under 1 atm hydrogen for 12 hours. The heterogeneous solution was filtered
through Celite to remove catalyst and the pH was adjusted to 2 via addition of conc. HCl
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and the white precipitate was concentrated using a rotary evaporator and isolated via
filtration. Compound 19 was obtained as a white crystalline solid. Yield: 1.92 g (96.9 %).
1

H NMR (400 MHz, D2O) δ 3.21 – 2.91 (m, 1H), 2.85 (t, J = 6.9 Hz, 0H), 2.45 (t, J = 7.0

Hz, 0H), 1.43 (q, J = 7.4 Hz, 0H), 1.39 – 1.23 (m, 0H), 1.23 – 0.97 (m, 0H).

Z-Lys-tris-NTA-OtBu (20). Compounds 15 (15.531 g, 36.07 mmol), 18 (2.67 g, 7.23
mmol) and HOBt (4.38 g, 32.46 mmol) were added to an oven-dried 250 mL round
bottom flask equipped with a rubber septum and a magnetic stir bar. The contents were
dissolved in DMF (240 mL) and cooled down to 0 °C in an ice bath. EDC (8.30 g, 43.29
mmol) was added followed by DIEA (12.57 mL, 72.14 mmol) and the solution was
allowed to warm to ambient temperature and stirred for 72 hours. The solution was
diluted with EtOAc and filtered then concentrated and purified via flash chromatography
using 5:95 MeOH:DCM giving Compound 20 as a yellow oil. Yield: 2.57 g (88.4 %);
TLC: Rf = 0.40 (5:95 MeOH:DCM). 1H NMR (500 MHz, CDCl3) δ 7.47 (d, J = 18.4 Hz,
3H), 7.32 – 7.15 (m, 5H), 5.24 (s, 1H), 4.98 (s, 2H), 3.44 – 3.32 (m, 11H), 3.30 (d, J =
5.0 Hz, 2H), 3.27 (d, J = 4.5 Hz, 2H), 3.23 – 3.01 (m, 13H), 2.97 (d, J = 6.9 Hz, 1H),
1.73 (s, 1H), 1.63 – 1.50 (m, 7H), 1.50 – 1.40 (m, 13H), 1.40 – 1.11 (m, 99H). 13C NMR
(126 MHz, CDCl3) δ 172.20, 172.15, 171.42, 170.65, 170.62, 170.10, 156.44, 136.70,
128.36, 127.89, 81.00, 80.64, 77.43, 76.92, 66.29, 64.94, 57.97, 56.19, 53.70, 41.86,
40.49, 39.16, 30.13, 29.87, 29.48, 29.18, 28.62, 28.06, 24.34, 24.13, 23.28, 23.00.

H2N-Lys-tris-NTA-OtBu (21). Compound 20 (0.420 g, 0.26 mmol) was dissolved in
MeOH (50 mL) in a 250 mL round bottom flask. To this solution was added 10% Pd/C.
The flask was evacuated and purged with H2 three times and then stirred for 12 hours
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under 1 atm H2. The heterogeneous solution was then filtered through a pad of Celite,
with further washing of the Celite cake with 50 mL MeOH. The filtrate was concentrated
under reduced pressure to give 21 as a clear yellow oil. Yield: 0.380 g (97.6 %); TLC: Rf
= 0.03 (EtOAc).

HO2C-Lys-tris-NTA-OtBu (22). Compound 21 and succinic anhydride were combined
in an oven dried 50mL round bottom flask equipped with a rubber septum and a magnetic
stir bar. DCM (5 mL) was added and TEA (37 µL) was added via syringe. The solution
was stirred for 18 hours at ambient temperature. The contents were concentrated and
purified via flash chromatography using 5:95 MeOH:DCM as eluent to give Compound
22 as a slightly yellow oil. Yield: 0.146 g (87.4 %); TLC: Rf = 0.39 (5:95 MeOH:DCM).
1

H NMR (400 MHz, CDCl3) δ 3.42 (s, 1H), 3.24 (d, J = 15.3 Hz, 1H), 1.51 (d, J = 10.5

Hz, 4H), 1.44 (d, J = 6.4 Hz, 21H).

Alkyne-Lys-tris-NTA-OtBu (23). Compound 22 (139 mg, 0.09 mmol), HOBt (58.6 mg,
0.43 mmol), and propargylamine (56 µL, 0.87 mmol) were combined in an oven dried 50
mL round bottom flask equipped with a magnetic stir bar and rubber septum. DCM
(5mL) was added and the solution was cooled to 0 °C in an ice bath. EDC (83 mg, 0.43
mmol) was added followed by DIEA (77µL, 0.43 mmol) and the solution was allowed to
warm to ambient temperature and stirred for 24 hours. The contents were concentrated
and purified via flash chromatography using 5:95 MeOH:DCM as eluent to give
Compound 22 as a slightly yellow oil. Yield: 0. g (76.4 %); TLC: Rf = 0.32 (5:95
MeOH:DCM). 1H NMR (400 MHz, CDCl3) δ 8.13 (d, J = 12.8 Hz, 1H), 7.65 (s, 1H),
7.56 (s, 1H), 7.36 – 7.04 (m, 3H), 4.14 – 3.86 (m, 2H), 3.60 (d, J = 3.5 Hz, 2H), 3.60 –
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3.33 (m, 17H), 3.33 – 2.98 (m, 18H), 2.84 (s, 4H), 2.49 (s, 2H), 2.37 – 2.09 (m, 3H), 1.96
(s, 2H), 1.87 – 0.98 (m, 150H), 0.96 – 0.60 (m, 6H).

Di-tert-butyl-2,2'-((1-(tert-butoxy)-6-(((4-nitrophenoxy)carbonyl)amino)-1oxohexan-2-yl)azanediyl)diacetate (24). p-Nitrophenyl chloroformate (PNP-Cl, 0.552 g,
2.74 mmol) was dissolved into 20 mL DCM in a 100 mL round bottom flask equipped
with a stir bar and addition funnel and was cooled to 4 °C in an ice bath. Compound 15
(0.983 g, 2.28 mmol) in 20 mL DCM was added to the addition funnel. The system was
evacuated and flashed with nitrogen gas. The solution of 15 was added over a one hour
period at 4 °C and stirred for an additional 12 hours warming to room temperature. The
solution was concentrated in vacuo and purified by flash chromatography using 4:1
hexane:EtOAc as eluent. Yield: 0.609 g (44.8 %).; TLC: Rf= 0.24 (4:1 hexanes:EtOAc);
1

H NMR (CDCl3): δ 1.38 (s 18H), 1.40 (s 9H), 1.18-1.59 (m 6H), 3.18-3.29 (m 3H), 3.40

(q 4H), 6.09 (br 1H), 7.24 (d 2H, J = 9 Hz), 8.14 (d 2H, J = 9 Hz); MS (ESI+). Expected:
596.68 [M+H]; Found 596.59 ([M+H], 618.54 [M+Na].

PNP-tris-NTA-OtBu (25). PNP-Cl (0.060 g, 0.30 mmol) was dissolved into 15 mL
DCM in a 100 mL round bottom flask equipped with a stir bar and addition funnel and
was cooled to 4 °C in an ice bath. Compound 21 (0.372 g, 0.25 mmol) in 10 mL DCM
was added to the addition funnel. The system was evacuated and flashed with nitrogen
gas. The solution of 21 was added over a one-hour period at 4 °C and stirred for an
additional 12 hours warming to room temperature. The solution was concentrated in
vacuo and purified by flash chromatography using EtOAc as eluent. Yield: 0.302 g (73.1
%).; TLC: Rf= 0.31 (EtOAc); 1H NMR (CDCl3): δ 1.35 (s 54H), 1.38 (s 27H), 110-1.68
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(m 18H), 3.09-3.37 (m 9H), 3.42 (q 12H), 6.14 (br 3H), 7.24 (d 2H, J = 9 Hz), 8.13 (d
2H, J = 9 Hz); MS (ESI+). Expected: 1665.01 [M+H]; Found 1666.45 ([M+2H], 1667.44
([M+3H]), 1689.39 [M+Na].

NHBoc-PEG2000-DTPE (27). NHS-PEG2K-NHBoc (26, 190 mg, 0.095 mmol) and
DTPE (82.8 mg, 0.095 mmol) were dissolved in DCM (10 mL) in a 25 mL round bottom
flask with stir bar. DIEA (83 µL, 0.474 mmol) was added and the flask was evacuated,
flushed with nitrogen and covered with aluminum foil. The solution was stirred at
ambient temperature for 48 hours in the dark. Volatiles were evaporated and purified by
flash chromatography on silica using an eluting system of DCM and MeOH starting with
95:5 then 90:10 then 85:15. Fractions containing product were combined and dried in
vacuo to give 27. Yield: 0.209 g (87.8 %).; TLC: Rf= 0.72 (80:20 DCM:MeOH); 1H
NMR (CDCl3): δ 0.88 (m 6H), 1.23-1.49 (m 50H), 1.42 (s 9H), 2.21 (m 8H), 2.66 (t 4H),
3.26-3.96 (m 180 H), 4.11-4.12 (m 2H), 4.33-4.36 (m 2H), 5.17 (br 1H).

NH2-PEG2000-DTPE (28). Compound 27 (209 mg, 0.076 mmol) and triethylsilane (200
µL, 1.25 mmol) was dissolved in 30 % TFA in DCM solution (20 mL) and stirred for 1.5
hours under ambient temperature and atmosphere. Volatiles were removed in vacuo and
the residue was evaporated with 15 mL DCM twice more. The product was dried in
vacuo and used without further purification. Yield: 0.191 g (91.3 %).; TLC: Rf= 0.56 (
80:20 DCM:MeOH).

NTA-(OtBu)3-PEG2000-DTPE (29). Compound 28 (95.5 mg, 0.034 mmol) and
Compound 24 (205 mg, 0.344 mmol) were dissolved in DCM (5 mL) in a 25 mL round
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bottom flask with stir bar covered in aluminum foil. The flask was evacuated and flushed
with nitrogen. DIEA (60 µL, 0.348 mmol) was added and the solution stirred for 48 hours
at ambient temperature under a nitrogen atmosphere in the dark. Volatiles were
evaporated under reduced pressure and the product was purified by flash chromatography
on silica using a gradient of DCM:MeOH as eluent starting with 90:10 moving to 85:15
then finally 80:20. Fractions containing product were pooled, concentrated and dried in
vacuo to give Compound 29. Yield: 29.0 mg (26.9 %).; TLC: Rf= 0.65 (80:20
DCM:MeOH).

NTA-PEG2000-DTPE (30). Compound 29 (29 mg, 0.009 mmol) and triethylsilane (100
µL, 0.625 mmol) were dissolved in 30% TFA in DCM solution (10 mL) in a 25 mL
round bottom flask with stir bar covered in aluminum foil. The solution was stirred under
ambient temperature and atmosphere for 1.5 hours in the dark. Volatiles were evaporated
and the residue was dissolved in 5mL PBS buffer (pH = 7.2) plus 5 mL MeOH. The
solution was extracted with CHCl3 (3x8 mL). The organic extracts were dried over
anhydrous Na2SO4, filtered, concentrated and dried in vacuo to give Compound 30.
Yield: 18.0 mg (62.1 %).; TLC: Rf= 0.01 (80:20 DCM:MeOH).

S-Trityl-3-mercaptopropionic acid (32). 3-Mercaptopropionic acid (31, 6.00 g, 56.5
mmol) was dissolved in DCM (50 mL) in a 250 mL round bottom flask. Trityl chloride
(17.34 g, 62.2 mmol) in DCM (30 mL) was added dropwise to this solution over 1 hour
before stirring for an additional 12 h. The white precipitate was filtered and washed with
diethyl ether (2 x 50 mL) and dried under a 50 m vacuum to give a fine white powder.
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Yield: 18.25 g (93%); 1H NMR (400 MHz, CDCl3): δ 2.25 (t, 2H, J = 8 Hz), 2.47 (t, 2H,
J = 8 Hz), 7.2-7.3 (m, 9H), 7.43 (d, 6H).

Di-t-butyl 2,2'-((1-(t-butoxy)-1-oxo-6-(3-(tritylthio)propanamido)hexan-2yl)azanediyl)diacetate (33). Compound 32 (1.46 g, 4.19 mmol) and Compound 15 (1.80
g, 4.19 mmol) were dissolved in DMF (100 mL) in a 250 mL round bottom flask. This
solution was cooled on an ice bath before addition of EDC (0.962 g, 5.02 mmol), HOBt
(0.678 g, 5.02 mmol), and 1.86 mL of DIEA (1.35 g, 10.4 mmol). The solution was
stirred under Ar for 48 hours while allowing the mixture to gradually warm from 4  20
C. The DMF was evaporated under reduced pressure and the residue was dissolved in
EtOAc (80 mL). This solution was washed with H2O (2 x 100 mL) before combining the
aqueous phases and back extracting with EtOAc (100 mL). The EtOAc layers were
combined and dried over anhydrous Na2SO4. The solvent was evaporated and the residue
purified by flash chromatography on silica using 1:1 hexane:EtOAc as eluent yielding 33
as a colorless oil. Yield: 1.70 g (53.4 %).; TLC: Rf= 0.54 (1:1 hexane:EtOAc); 1H NMR
(CDCl3): δ 1.22-1.61 (m 6H), 1.39 (s 18H), 1.43 (s 9H), 2.09 (t 2H), 2.46 (t 2H), 3.11 (m
2H), 3.25 (t 1H), 3.43 (m 4H), 5.98 (br 1H), 7.14-7.4 (m 15H). 13C NMR (126 MHz,
CDCl3) δ 172.39, 170.92, 170.73, 144.77, 129.59, 127.88, 126.61, 81.10, 80.73, 77.39,
77.14, 76.88, 66.66, 64.92, 53.91, 39.19, 35.36, 29.83, 28.41, 28.23, 28.16, 27.77, 22.89.;
MS (ESI+). Expected: 762.02 [M+H]; Found 762.71.
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2,2'-((1-Carboxy-5-(3-mercaptopropanamido)pentyl)azanediyl)diacetic acid (34).
Compound 33 (0.800 g, 1.05 mmol) was dissolved in DCM (10 mL), followed by
addition of Et3SiH (0.367 g, 3.16 mmol) and 2-mercaptoethanol (.246 g, 3.15 mmol).
This solution was cooled on an ice bath before addition of TFA (15 mL) dropwise over
10 min. The solution was stirred for 1 h at 4 C before removal of the volatiles under
reduced pressure. Diethyl ether (20 mL) and 4 drops of concentrated HCl were added to
the residue before decanting the organic phase and repeating the process two more times.
Toluene (30 mL) was then added to the residue and evaporated under reduced pressure
three times to give Compound 34 as a white powder. Yield: 0.327 g (92.7 %); 1H NMR
(500 MHz, DMSO-d6) δ 3.50 (q, J = 16.6, 15.4 Hz, 4H), 3.34 (d, J = 7.3 Hz, 1H), 2.99 (s,
2H), 2.92 – 2.76 (m, 1H), 2.70 – 2.55 (m, 2H), 2.47 (d, J = 13.4 Hz, 2H), 2.33 (d, J = 7.1
Hz, 1H), 2.27 – 2.06 (m, 1H), 1.70 – 1.45 (m, 2H), 1.36 (s, 3H), 1.23 (d, J = 15.3 Hz,
3H), 1.13 (t, J = 17.8 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 174.15, 173.35, 170.40,
64.75, 53.73, 40.28, 39.95, 39.61, 38.74, 31.17, 29.56, 29.25, 23.54, 20.44.

2,2'-((1-Carboxy-2-(tritylthio)ethyl)azanediyl)diacetic acid (36). H-Cys(Trt)-OH (1.00
g, 4.73 mmol) was dissolved in 30 mL 1.5 KOH in MeOH in a 100 mL round bottom
flask. Bromoacetic acid (2.760 g, 19.86 mmol) was dissolved in 10 mL 1.5 M KOH in
MeOH and 10 mL deionized water. The two separate solutions were cooled to 0 °C in an
ice bath and the bromoacetic acid solution wat added to the solution of H-Cys(Trt)-OH
and the solution was stirred at ambient temperature for 48 hours under argon. The
solution was stirred at 50 °C for 3 hours. The solution was concentrated in vacuo and
precipitated via the addition of conc. HCl. The precipitate was filtered and recrystallized
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from acidic water. Yield:2.27 g (82.0 %); 1H NMR (500 MHz, DMSO-d6) δ 7.30 (d, J =
3.7 Hz, 12H), 7.28 – 7.00 (m, 4H), 3.32 – 3.09 (m, 4H), 2.87 (t, J = 7.5 Hz, 1H), 2.82 (s,
0H), 2.55 (dd, J = 13.0, 6.9 Hz, 1H), 2.51 – 2.45 (m, 1H), 2.32 (dd, J = 13.0, 8.1 Hz, 1H).
13C NMR (126 MHz, DMSO) δ 173.88, 173.15, 144.96, 129.63, 128.47, 127.14, 66.61,
65.93, 54.40, 40.46, 40.13, 39.96, 39.46, 32.73.

Trt-Cys-tris-NTA-OtBu (37). Compound 36 (0.511 g, 1.07 mmol), Compound 15
(2.295 g, 5.33 mmol) and HOBt (0.735 g, 4.80 mmol) were combined in an oven-dried
100 mL round bottom flask equipped with a magnetic stir bar and rubber septum. The
contents were dissolved in 25 mL DMF and cooled to 0 °C in an ice bath. EDC (1.226 g,
6.40 mmol) followed by DIEA (1.857 mL, 10.66 mmol) were added and the solution was
allowed to warm to room temperature and stir for 36 hours at ambient temperature. The
solution was concentrated in vacuo and the residue was purified by flash chromatography
using a gradient of 1:1 hexane:EtOAc to 3:7 hexane:EtOAc to give Compound 37 as a
slightly yellow oil. Yield: 1.392 g (76.1 %).; TLC: Rf= 0.42 (1:1 hexane:EtOAc); 1H
NMR (500 MHz, CDCl3) δ 7.32 (d, J = 8.1 Hz, 6H), 7.19 (t, J = 7.6 Hz, 7H), 7.13 (t, J =
7.3 Hz, 3H), 3.45 – 3.29 (m, 13H), 3.25 – 3.15 (m, 6H), 1.55 (d, J = 6.8 Hz, 8H), 1.48 –
1.26 (m, 96H). 13C NMR (126 MHz, CDCl3) δ 172.22, 171.14, 170.62, 170.55, 144.47,
127.90, 126.71, 81.03, 80.66, 80.48, 77.42, 77.17, 76.91, 67.24, 65.85, 65.30, 64.95,
55.69, 53.67, 53.56, 39.36, 39.19, 34.62, 31.57, 31.45, 30.35, 29.88, 29.43, 28.17, 28.08,
23.49, 23.06.
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11-(2-((5-(Bis(carboxymethyl)amino)-5-carboxypentyl)amino)-2-oxoethyl)-2,20bis(carboxymethyl)-10-(mercaptomethyl)-9,13-dioxo-2,8,11,14,20pentaazahenicosane-1,3,19,21-tetracarboxylic acid (38). Compound 37 (1.392 g, 0.81
mmol) was dissolved in DCM (20 mL) and triethylsilane (1.94 mL, 12.16 mmol) was
added. TFA (20 mL) was added and the solution was stirred at ambient temperature for
1.5 hours under a stream of nitrogen. Volatiles were removed in vacuo. DCM (80 mL)
was added and evaporated in vacuo to remove excess TFA. The residue was trititurated
with diethyl ether to remove triphenylmethyl by-products. The residue was suspended in
deionized water and lyophilized to give Compound 38 as a white powder. Yield: 0.725 g
(92.2 %).; 1H NMR (500 MHz, DMSO-d6) δ 3.63 – 3.41 (m, 12H), 3.36 (dt, J = 13.0, 6.5
Hz, 5H), 3.29 – 3.15 (m, 3H), 3.15 – 2.94 (m, 6H), 2.77 – 2.61 (m, 1H), 1.71 – 1.57 (m,
3H), 1.52 (d, J = 8.4 Hz, 4H), 1.47 – 1.31 (m, 11H), 1.30 – 1.16 (m, 4H). 13C NMR (126
MHz, DMSO) δ 174.14, 173.38, 65.37, 64.81, 55.83, 53.76, 40.47, 40.30, 40.13, 39.97,
39.80, 39.63, 39.46, 38.87, 29.58, 29.26, 28.20, 23.59, 15.63.

Maleimide-PEG-DSPE (40a). DSPE (0.072 g, 0.096 mmol) and NHS-PEG2Kmaleimide (39a, 0.200 g, 0.095 mmol) were dissolved in CHCl3 (15 mL) in a 50 mL
round bottom flask with stir bar and DIEA (0.062g, 0.480) mmol was added via syringe.
The flask was evacuated and flushed with nitrogen and stirred for 72 hours at ambient
temperature. The volatiles were evaporated under reduced pressure and the residue
purified by flash chromatography on silica using a gradient starting with 85:15
DCM:MeOH and increasing in polarity to 80:20 DCM:MeOH. Yield: 0.118 g (43.4 %).;
TLC: Rf= 0.48 (4:1 DCM:MeOH); 1H NMR (CDCl3): δ 0.84 (t 6H), 1.15-1.40 (m 64H),
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2.24 (m 4H), 2.48 (t 2H) 2.99 (m 2H), 3.37-4.10 (m 180 H), 3.80-3.96 (m 4H), 4.12 (m
2H), 4.34 (d 2H), 5.17 (m 1H), 6.27 (br 1H), 6.67 (s 1H), 7.38 (br 1H).

Maleimide-PEG-DSPE (40b). DSPE (0.094 g, 0.13 mmol) and NHS-PEG3.4Kmaleimide (39b, 0.400 g, 0.12 mmol) were dissolved in CHCl3 (10 mL) in a 50 mL round
bottom flask with stir bar and DIEA (0.074 g, 0.57 mmol) was added via syringe. The
flask was evacuated and flushed with nitrogen and stirred for 72 hours at ambient
temperature. The volatiles were evaporated under reduced pressure and the residue
purified by flash chromatography on silica using a gradient starting with 85:15
DCM:MeOH and increasing in polarity to 80:20 DCM:MeOH. Yield: 0.146 g (30.1 %).;
TLC: Rf= 0.49 (4:1 DCM:MeOH); 1H NMR (400 MHz, CDCl3) δ 4.00 – 3.87 (m, 1H),
3.61 (s, 25H), 3.52 – 3.45 (m, 1H), 2.34 – 2.16 (m, 1H), 1.61 – 1.48 (m, 1H), 1.39 (d, J =
6.9 Hz, 1H), 1.33 (d, J = 6.6 Hz, 1H), 1.21 (s, 9H), 0.84 (t, J = 6.8 Hz, 1H).

NTA-PEG2K-DSPE (41a). Compounds 40a (20.0 mg, 0.007 mmol) and 34 (18.0 mg,
0.051 mmol) were dissolved in DMF (4 mL) in a 25 mL round bottom flask with stir bar.
TEA (15.0 µL, 0.119 mmol) was added and the flask was evacuated and flushed with
nitrogen. The solution was stirred at 40 °C for 24 hours monitoring the consumption of
starting material by TLC. Volatiles were removed in vacuo at 45 °C and the residue was
dissolved in 6 mL PBS buffer (pH = 7.2) plus 4 mL MeOH. This solution was extracted
with CHCl3 (3x15 mL). The organic extracts were combined and dried over anhydrous
Na2SO4, filtered and concentrated in vacuo to give 41a. Yield: 21.2 mg (a: 89.8 %; b:
53.3 %).; TLC: Rf= 0.0 (4:1 DCM:MeOH); 1H NMR (CDCl3): δ 0.84 (t 6H), 1.15-1.40
(m 64H), 2.25 (s 4H), 2.28-2.32 (m 2H), 2.48-2.53 (m 2H), 2.75-2.78 (m 4H), 2.48-3.7
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(m 180H), 3.70 (s 4H), 3.88 (br 2H), 4.00 (br 2H), 4.16 (br 2H), 4.37-4.40 (br 1H), 5.30
(s 1H), 6.96 (s 1H).

NTA-PEG3.4K-DSPE (41b). Compounds 40b (49.0 mg, 0.01 mmol) and 34 (21.0 mg,
0.05 mmol) were dissolved in DMF (5 mL) in a 25 mL round bottom flask with a stir bar.
TEA (16.4 µL, 0.09 mmol) was added and the flask was evacuated and flushed with
nitrogen. The solution was stirred at 40 °C for 24 hours monitoring the consumption of
starting material by TLC. Volatiles were removed in vacuo at 45 °C. the residue was
dissolved in 6 mL PBS buffer (pH = 7.2) plus 4 mL MeOH. This solution was extracted
with CHCl3 (3x15 mL). The organic extracts were combined and dried over anhydrous
Na2SO4, filtered and concentrated in vacuo to give 41b. Yield: 28.6 mg (53.3 %); 1H
NMR (500 MHz, CDCl3) δ 7.26 (s, 1H), 4.02 (d, J = 12.0 Hz, 1H), 3.82 – 3.74 (m, 1H),
3.63 (s, 55H), 3.54 – 3.46 (m, 1H), 2.50 (d, J = 29.9 Hz, 1H), 2.30 (d, J = 7.9 Hz, 1H),
2.24 (s, 1H), 1.70 – 1.65 (m, 1H), 1.59 (s, 3H), 1.43 (s, 2H), 1.37 (s, 3H), 1.24 (s, 18H),
0.87 (s, 6H).

NHS-PEG2K-MAL-2/5-dimethylfuran adduct (42). NHS-PEG2K-maleimide (0.200 g,
0.10 mmol) was added to an oven-dried 50 mL round bottom flask equipped with a
magnetic stir bar and rubber septum. The solid material was dissolved in toluene (10 mL)
and 2.5 dimethylfuran (2.50 mL g, 23.14 mmol) was added. The solution was heated to
40 °C and stirred under nitrogen for 12 hours. The solution was concentrated, precipitated
into 200 mL diethyl ether and filtered to give Compound 42 as a white powder. Yield:
151.7 mg (98.2 %); 1H NMR (400 MHz, CDCl3) δ 6.23 (s, 1H), 6.10 (s, 1H), 4.43 (s,
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2H), 3.55 (s, 182H), 3.37 (s, 2H), 3.30 (s, 1H), 3.12 (s, 1H), 2.78 (s, 4H), 2.73 (s, 4H),
2.29 (s, 2H), 2.20 (d, J = 8.2 Hz, 1H), 2.10 (s, 1H), 1.68 (s, 3H), 1.59 (s, 2H).

DSPE-PEG2K-MAL-2/5-dimethylfuran adduct (43). Compound 42 (0.200 g, 0.10
mmol) and DSPE (0.079 g, 0.11 mmol) were dissolved in chloroform (5 mL) in an ovendried 50 mL round bottom flask equipped with magnetic stir bar and rubber septum.
DIEA (95 µL, 0.53 mmol) was added and the solution was stirred for 72 hours at ambient
temperature. The volatiles were evaporated under reduced pressure and the residue
purified by flash chromatography on silica using a gradient starting with 85:15
DCM:MeOH and increasing in polarity to 80:20 DCM:MeOH. Yield: 0.182 g (75.8 %).;
TLC: Rf= 0.17 (95:5 DCM:MeOH); 1H NMR (400 MHz, CDCl3) δ 4.12 (dd, J = 11.9, 6.7
Hz, 1H), 3.98 – 3.87 (m, 5H), 3.79 (dd, J = 8.5, 5.0 Hz, 1H), 3.61 (s, 182H), 3.46 – 3.42
(m, 2H), 3.38 (q, J = 5.8 Hz, 3H), 3.18 (s, 1H), 3.00 (s, 2H), 2.78 (s, 1H), 2.62 (s, 1H),
2.29 – 2.16 (m, 4H), 1.74 (s, 1H), 1.65 (s, 1H), 1.54 (q, J = 9.3, 8.0 Hz, 4H), 1.39 (d, J =
7.3 Hz, 7H), 1.33 (d, J = 6.7 Hz, 7H), 1.21 (s, 61H), 0.84 (t, J = 6.8 Hz, 6H).

DSPE-PEG2K-MAL (44). Compound 43 was dissolved in toluene (20 mL) and heated
at 80 °C for 12 hours under argon. The solution was concentrated in vacuo and
redissolved in DCM (40 mL). This solution was filtered through a pad a Celite and
activated carbon. The product 44 was precipitated into diethyl ether (200 mL), filtered
and dried in vacuo. Yield: 0.112 g (61.5 %).; TLC: Rf= 0.69 (4:1 DCM:MeOH); 1H NMR
(400 MHz, CDCl3) δ 7.40 (s, 1H), 7.26 (s, 2H), 6.68 (s, 1H), 6.33 (s, 1H), 5.20 (s, 1H),
4.35 (d, J = 10.8 Hz, 1H), 4.18 – 4.09 (m, 1H), 3.97 (s, 4H), 3.80 (d, J = 7.5 Hz, 2H), 3.61
(s, 182H), 3.44 (s, 2H), 3.38 (s, 3H), 3.00 (s, 2H), 2.58 – 2.43 (m, 2H), 2.24 (s, 3H), 1.55
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(s, 4H), 1.42 (t, J = 7.8 Hz, 7H), 1.35 (d, J = 6.6 Hz, 7H), 1.22 (s, 48H), 0.85 (t, J = 6.6
Hz, 6H).

Tris-NTA-PEG2000-DSPE (45a). Compounds 40a (20.0 mg, 0.01 mmol) and 38 (48.0
mg, 0.05 mmol) were dissolved in DMF (5 mL) in a 25 mL round bottom flask with a stir
bar. TEA (35 µL, 0.22 mmol) was added and the flask was evacuated and flushed with
nitrogen. The solution was stirred at 40 °C for 24 hours monitoring the consumption of
starting material by TLC. Volatiles were removed in vacuo at 45 °C. the residue was
dissolved in 6 mL PBS buffer (pH = 7.2) plus 4 mL MeOH. This solution was extracted
with CHCl3 (3x15 mL). The organic extracts were combined and dried over anhydrous
Na2SO4, filtered and concentrated in vacuo to give 45a. Yield: 23.6 mg (87.8 %); 1H
NMR (400 MHz, CDCl3) δ 6.95 (s, 2H), 5.30 (s, 1H), 5.22 (t, J = 5.6 Hz, 1H), 4.12 (s,
1H), 4.00 (s, 3H), 3.87 (s, 2H), 3.82 (d, J = 6.8 Hz, 3H), 3.64 (s, 182H), 3.49 – 3.43 (m,
4H), 3.40 (s, 3H), 3.08 (s, 7H), 2.98 – 2.87 (m, 6H), 2.81 – 2.72 (m, 8H), 2.52 (d, J = 6.8
Hz, 4H), 2.36 – 2.26 (m, 6H), 2.24 (s, 5H), 1.88 (s, 2H), 1.65 – 1.48 (m, 11H), 1.46 –
1.40 (m, 3H), 1.29 (d, J = 32.8 Hz, 81H), 0.86 (d, J = 7.1 Hz, 16H).

Tris-NTA-PEG3.4K-DSPE (45b). Compounds 40b (49.0 mg, 0.01 mmol) and 38 (57.0
mg, 0.06 mmol) were dissolved in DMF (5 mL) in a 25 mL round bottom flask with stir
bar. DIEA (16.4 µL, 0.09 mmol) was added and the flask was evacuated and flushed with
nitrogen. The solution was stirred at 40 °C for 24 hours monitoring the consumption of
starting material by TLC. Volatiles were removed in vacuo at 45 °C and the residue was
dissolved in 6 mL PBS buffer (pH = 7.2) plus 4 mL MeOH. This solution was extracted
with CHCl3 (3x15 mL). The organic extracts were combined and dried over anhydrous
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Na2SO4, filtered and concentrated in vacuo to give 45b. Yield: 24.3 mg (40.2 %); 1H
NMR (500 MHz, CDCl3) δ 6.93 (s, 4H), 5.36 (dt, J = 10.7, 5.2 Hz, 1H), 5.21 (t, J = 5.2
Hz, 1H), 4.35 (d, J = 11.8 Hz, 1H), 4.15 (dd, J = 11.3, 7.0 Hz, 2H), 4.09 – 3.94 (m, 6H),
3.87 (s, 3H), 3.83 – 3.77 (m, 3H), 3.64 (s, 309H), 2.71 (s, 1H), 2.49 (s, 4H), 2.29 (d, J =
7.5 Hz, 9H), 2.24 (s, 7H), 1.88 (s, 3H), 1.59 (s, 20H), 1.51 – 1.43 (m, 13H), 1.37 (s, 35H),
1.25 (s, 146H), 0.90 – 0.80 (m, 50H).

Glutathione-NTA-PEG2K-DSPE (46). Compound 40b (20.0 mg, 0.01 mmol) and Lglutathione (15.4 mg, 0.05 mmol) were dissolved in DMF (5 mL) in a 25 mL round
bottom flask with a stir bar. DIEA (16.4 µL, 0.09 mmol) was added and the flask was
evacuated and flushed with nitrogen. The solution was stirred at 40 °C for 24 hours
monitoring the consumption of starting material by TLC. Volatiles were removed in
vacuo at 45 °C and the residue was dissolved in 6 mL PBS buffer (pH = 7.2) plus 4 mL
MeOH. This solution was extracted with CHCl3 (3x15 mL). The organic extracts were
combined and dried over anhydrous Na2SO4, filtered and concentrated in vacuo to give
Compound 46. Yield: 20.3 mg (93.1 %); 1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 8.8
Hz, 2H), 7.19 (d, J = 6.9 Hz, 1H), 6.95 (s, 1H), 5.20 (s, 1H), 4.20 – 4.08 (m, 1H), 4.00 (d,
J = 5.7 Hz, 5H), 3.64 (s, 182H), 3.05 (s, 1H), 2.50 (s, 3H), 2.36 – 2.16 (m, 6H), 1.71 –
1.50 (m, 9H), 1.31 (d, J = 50.7 Hz, 81H), 1.02 – 0.63 (m, 31H).
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2.7.2 Cell Lysate Preparation
The ASKA library, a complete E. coli K-12 ORF archive in which over 4000
bacterial proteins have been cloned into pCA24N expression vectors, was used. Each
protein coding ORF has an N-terminal His6 and a C-terminal green fluorescence protein
(GFP); each protein coding ORF is also available without the GFP fusion (which are the
strains used in these studies). Cells containing the RplL gene overexpression vector were
grown to OD = 0.6 in 100 mL of LB broth using a 37 °C shaker/incubator and induced
with a final concentration of 1.0 mM IPTG before allowing to grow for an additional 4 h.
After centrifugation, the supernatant was discarded before resuspending the cell pellet in
lysis buffer (20 mM Tris, 10 mM MgCl2, 100 mM KCl, pH=7.4, 100 µg aprotinin, 174
µg PMSF, 500 µg lysozyme) and incubation for 20 min. The cell membranes were
disrupted by sonication (35 pulses, 1 sec/pulse at 75 W) before centrifugation of the
suspension at 11,000 g for 10 min. The supernatant containing His6-RplL was diluted 10fold before application to the TEM grid for analysis.
Purified C-terminal His6-tag gp10 (capsid protein) of T7 bacteriophage was
typically produced at a concentration of ~1 x 1012 particles/mL. BL21 bacteria cells in 1
mL of LB media were grown to OD = 0.8 before addition of T7 bacteriophage (1.0 µL,
1.0X1012 particles/mL) to the culture and shaking at 37 °C for 1 h. After centrifugation of
the cells, the supernatant was used directly for TEM grid analysis.
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2.7.3 His8-GFP Purification
A glycerol stock of E. coli cells, transformed with the His8-GFPuv pT7-7 plasmid,
was shaken at 37 C overnight before addition to 250 mL of LB media with shaking at 37
C until an OD600 of 0.7 was reached. Then, a 1.0 M stock solution of isopropyl-β-Dthiogalactopyranoside (IPTG) was added, bringing the final concentration to 1.0 mM,
before shaking continually at 37 C for an additional 5 h. The cells were then centrifuged
at 11,000 g for 10 min, the supernatant discarded, and the pellet re-suspended in 10 mL
of lysis buffer (50 mM NaH2PO4, 100 mM NaCl, pH = 8.0, 100 µg aprotinin, 174 µg
phenylmethanesulfonyl fluoride (PMSF), and 500 µg of lysozyme). The suspension was
allowed to stand for 20 min before the cell membranes were disrupted using 3 rounds of
sonication (35 pulses of probe sonication, 1 sec/pulse at 75 W with 1 sec rest/pulse) and
the debris pelleted by centrifugation at 11,000 g for 30 min. The supernatant was
incubated with 100 µL of Ni-NTA agarose beads and gently rotated for 4 h. The beads
were pelleted using a bench top centrifuge operating at 5,000 g for 2 min. The
supernatant was discarded and the pellet was washed with PBS buffer containing
imidazole (50 mM NaH2PO4, 100 mM NaCl, 10 mM imidazole, pH = 8.0). The same
spin and wash sequence was repeated with 15 mM, 20 mM, and 30 mM imidazole in
PBS. The protein was eluted from the resin after a final spin, discarding of supernatant,
and incubation with 500 mM imidazole in PBS for 4 h. The removal of imidazole was
achieved by dialyzing the eluted protein against PBS (50 mM NaH2PO4, 100 mM NaCl,
10 mM imidazole, pH = 8.0) overnight using a 10,000 MWCO Slide-A-Lyzer. The
protein was characterized using 12.5% acrylamide SDS-PAGE gel electrophoresis.
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2.7.4 Purified Maltose Transporter Solubilized in Lipid Nanodisc
The methods used to purify and insert His6-MalFGK2 maltose transporter in lipid
nanodiscs derived from membrane scaffolding proteins (MSP) followed those described
in a previously reported protocol.42

2.7.5 TEM Grid Carbon Coating Procedure
A Formvar solution was prepared by dissolving 100 mg Formvar powder in 50
mL DCM. Copper grids (400 mesh) were purchased from Ted Pella and sonicated in
acetone for 30 min before drying overnight in a dust free environment. Glass microscope
slides were freshly cleaned with detergent, rinsed exhaustively with distilled water, dried
overnight in a vacuum oven, and stored in a dust free environment until coated with
Formvar solution for 30 seconds by partial immersion before drying for 5 min. The edges
of the glass slides then were scrapped with a razor before floating the Formvar film on
water by submersion of the glass slide into a darkly tinted Pyrex glass dish. The precleaned copper grids were placed atop the floating Formvar film (15 - 20 grids, shiny side
down) and picked up with a pre-cleaned glass slide before transfer to a Petri dish to dry
overnight. Then, a carbon film was evaporated onto the glass slide with the TEM grids
facing up before removal of the Formvar film by placement of the grids on top of filter
paper soaked with CHCl3 in a glass Petri dish for 30 min. Finally, the filter paper was
removed and the grids dried overnight in a dust free environment before transfer to a
standard TEM grid storage box.
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2.7.6 Langmuir-Schaefer Film Deposition onto TEM Grids
Stock solutions of two lipid mixtures (1:99 Ni2+:NTA-PEG2000DTPE:mPEG350-DTPE and 5:95 Ni2+:NTA-PEG2000-DTPE:mPEG350-DTPE) were
prepared in CHCl3 at 2.0 mg/mL and stored at -80 °C. Each of these were spread via 10
L microsyringe at the air-water interface of a KibronTrough S and compressed to a
final surface pressure of 30 mN/m (i.e., ~59 Å2/molecule for 1:99 Ni2+:NTA-PEG2000DTPE:mPEG350-DTPE monolayers and ~66 Å2/molecule for 5:95 Ni2+:NTA-PEG2000DTPE:mPEG350-DTPE monolayers). The compressed lipid monolayers were deposited
onto TEM grids by Langmuir-Schaefer transfer using tabbed TEM grids (Ted Pella) to
enable grid approach at 180 (and the transfer forceps at 90) relative to the air-water
interface and the LS film immediately blotted with filter paper. (n.b.: Standard TEM grids
and forceps produced extensive disruption of the interface during the LS transfer step,
making it impossible to determine accurate grid transfer ratios under these conditions.)
The supported monolayer films were then polymerized for 10 min using a handheld
8W/m2 254 nm lamp that was placed 6-8 cm above the grid surface before transfer to a
standard TEM grid box for later use.

2.7.7 Fluorescence Microscopy
Sessile drops of His8-GFPuv solution (3.5 µL, 2.0 mg GFP/mL in PBS) were
deposited onto 1:99 Ni2+:NTA-PEG2000-DTPE:mPEG350-DTPE, 5:95 Ni2+:NTAPEG2000-DTPE:mPEG350-DTPE, 100% mPEG350-DTPE, or bare carbon coated grid
surfaces for 2 min, followed by removal of excess sample using a microsyringe. Grids
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were then washed 3 times with 20 µL drops of Tris buffer before removal of the excess
solution via microsyringe. For elution of Ni2+:NTA-bound T7 bacteriophage from the
surface of the grid, 500 mM imidazole was deposited on the grid surface for 5 min before
washing twice with 20.0 µL of PBS. After preparation, the TEM grid was sandwiched
between a microscope slide and coverslip and sealed with nail polish before recording the
fluorescence images.

2.7.8 Negative Staining Procedure
T7 bacteriophage and RplL cell lysate samples were prepared by incubating a 5.0
µL drop of cell lysate on the grid surface for 2.0 min before gentle removal by
microsyringe. The grids were then washed 6 times with 20 µL drops of Tris buffer
followed by a final wash with 20 µL of distilled water. A 5 µL drop of 2% uranyl acetate
was placed on the grid for 1 min before removal of the excess solution with a wedge of
filter paper. Ni2+:NTA-immobilized samples were eluted from the grids by adding 5 µL
of 500 mM imidazole in Tris buffer immediately after sample deposition (i.e., instead of
6 Tris buffer washes). Nanodisc solubilized His6-MalFGK2 and purified his6-T7
bacteriophage samples were prepared in the same manner as the cell lysate samples,
except that the incubation time of the samples on DLPC and mPEG350-DTPE modified
grids was increased to 3 min. Negatively stained samples were imaged using a Tecnai
TF20 transmission electron microscope operating at 200 kV.
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2.7.9 Preparation of Frozen Hydrated Samples for Cryo-EM
TEM grids modified with stabilized 5:95 Ni2+:NTA-PEG2000-DTPE:mPEG350DTPE monolayers were treated with His-tag protein samples as described above for
negative-staining. After application of the protein solution, the excess sample was
removed by blotting the grids twice for 3 secoonds with an offset of -1 at 80 % humidity
using a Vitrobot (FEI Company). The grids were then cryo-fixed by plunging into liquid
ethane and imaged at 200 kV on an FEI CM200 transmission electron microscope using
low-dose techniques. Images were recorded using a Gatan Ultrascan CCD.
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CHAPTER THREE:
DEVELOPMENT OF GRAPHENE-OXIDE-BASED AFFINITY GRIDS FOR SINGLEPARTICLE CRYO-EM

3.1 Introduction
Single particle cryo-EM analysis (SPA) is a rapidly growing method for elucidating
structure of biological materials at near atomic resolution1 due to recent advances in
instrumentation and computational algorithms2. One aspect of the SPA process that is not
well optimized, however, is sample preparation. Furthermore, materials approaches to
modification of traditional TEM grid surfaces can dramatically increase the relative scope
of the technique3. Traditionally, proteins targeted for structural analysis must be
overexpressed and subjected to time-consuming purification and concentration steps,
sometimes under harsh conditions that disrupt protein-protein interactions of interest.
Recently, there have been efforts reported that seek to address these limitations, either by
improving grid rigidity to reduce beam-induced motion4 or by effecting on-grid
purification with ‘affinity grids’3c, 5 that employ metal chelating lipids that were
originally developed for two-dimensional protein crystallization at the lipid-water
interface6. The latter approach seeks to selectively capture biological target molecules
from complex mixtures such as cell lysates as an integral part of the TEM sample
preparation process3c, 7.
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Although lipid monolayer affinity grids have shown some success in producing
samples for cryo-EM reconstruction at 20 Å resolution5a, robust performance of the
reported grid coatings may be limited by film instability and non-uniformity under the
evaporative casting methods that have been reported. Additionally, these lipid films
require a thin polymer layer or a holey carbon substrate layer to provide mechanical
support of the deposited film. The electrical conductivity of monolayer graphene is six
orders of magnitude higher than amorphous carbon, and although the level of
conductivity in graphene decreases with the extent of oxidation, it has been shown to
recover much of this conductivity upon reduction with H2 plasma9. Additionally, unlike
unsupported lipid monolayers, the elasticity of graphene makes it ideal to resist
permanent deformation due to mechanical transfer techniques from the material-water
interface. Our interest in utilizing graphene-based affinity substrates is focused on
exploiting the superior mechanical strength and conductivity it offers. By conferring
better target specificity to this substrate, affinity graphenic substrates have the potential to
offer both improved stability and resistance to non-specific adsorption such that direct
capture from cell lysates may be feasible.

3.2 Design of Graphene-Oxide-NTA-Based Affinity Grids
We sought to address the limitations of lipid monolayer coated affinity grids by
employing a GO derivative that minimizes background signal due to the single atom
thickness and improved conductivity as a way to combat sample charging and instability
during image capture8. Here we demonstrate the utility of affinity grids using LangmuirSchaefer (LS) transfer of GO monolayer sheets that have been functionalized with
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covalently linked N, N-dicarboxymethyllysine (GO-NTA). Using these affinity grids,
we were able to selectively capture both His6-T7 bacteriophage and His6-GroEL. When
the prepared grids were further modified with bovine serum albumin (BSA), a common
antifouling agent that limits non-specific adsorption of non-targeted cellular debris, we
were able to selectively capture these proteins directly from bacterial lysate while
avoiding deposition of non-target proteins (Figure 3.1).

Figure 3.1 Conceptual Diagram of Sample Preparation Using a GO-NTA-Modified TEM
Grid. (i) GO-NTA monolayer deposition onto TEM grid via L-S transfer; (ii) activation
of NTA with Ni2+; (iii) blocking of non-specific reaction and/or adsorption sites with 4aminobenzoic acid (PABA) and bovine serum albumin (BSA); (iv) incubation of clarified
lysate with blocked grid; (v) washing of non-target molecules from grid, followed by
cryo-fixation or staining.
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3.3 Synthesis and Characterization of GO-NTA
GO was produced from graphene using Hummer’s method8. Activation of the GO
carboxylic acid groups with SOCl2 prior to reaction with the tris-t-butyl ester of lysine
NTA (15) gave GO-NTA-(O-t-Bu)3. TFA deprotection of this intermediate gave GONTA (51) (Scheme 3.1). Fourier transfer infrared spectroscopy was used to monitor these
reactions as shown in Figure 3.29. The spectra of GO displayed a broad absorption at
3236 cm-1 (O-H stretch) and a sharper absorption at 1648 cm-1 (C=O stretch)16. The
NTA-GO tris-t-butyl ester displayed an additional absorption at 2933 cm-1 (C-H stretch)
due to the incorporation of the lysine and t-butyl moieties. Following treatment of NTAGO tris-t-butyl ester with TFA, the presence of the aliphatic C-H stretching was greatly
reduced, indicating successful deprotection of the NTA chelator substituents10.

3.3.1 Synthesis of Graphene-Oxide-NTA
GO was synthesized using an improved Hummers’ method8 that is easier to
execute, is higher yielding, and does not evolve toxic gases (Scheme 3.1). This method
involves oxidation of bulk graphite powder by potassium permanganate in the presence
of sulfuric acid and phosphoric acid. It has been reported that there is no decrease in
conductivity in the final product between the original and improved method, making it an
attractive route for large scale production of GO.
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Scheme 3.1 Synthesis of GO-NTA.

Activation of the GO carboxylic acid groups with SOCl2 prior to reaction with the
tris-t-butyl ester of lysine NTA (15) gave GO-NTA-(O-t-Bu)3. TFA deprotection of this
intermediate gave GO-NTA (Scheme 3.1).

3.3.2

FT-IR Analysis of GO Derivatives

Fourier transfer infrared spectroscopy was used to monitor these reactions as
shown in Figure 3.29. The spectra of GO displayed a broad absorption at 3236 cm-1 (O-H
stretch) and a sharper absorption at 1648 cm-1 (C=O stretch)8. The NTA-GO tris-t-butyl
ester displayed an additional absorption at 2933 cm-1 (C-H stretch) due to the
incorporation of the lysine and t-butyl moieties.
Previous work has shown that the typical GO sheet absorption band at ~240 nm is
shifted to ~270 nm when the GO sheets are dispersed in aqueous solution. The origin of
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this hypsochromic shift is due to n-π* electronic transitions arising from the C=O bonds
introduced by oxidation11. GO-NTA samples prepared in this manner exhibited a major
absorption peak at ~280 nm, in good agreement with these reports.

Figure 3.2 FTIR Analysis of GO, GO-NTA-tris-t-butyl Ester and GO-NTA

Following treatment of NTA-GO tris-t-butyl ester with TFA, the presence of the
aliphatic C-H stretching was greatly reduced, indicating successful deprotection of the
NTA chelator substituents10.

126
3.3.3 Synthesis of Pyrene-NTA
In a similar approach, we sought to use hydrophobic interactions between pyreneNTA conjugate and graphene-coated TEM grids to generate a novel affinity grid surface.
We were interested in taking advantage of existing commercial graphene-functionalized
TEM grid technologies, as well as novel exfoliated graphene-coated grids, to utilize
affinity interactions for monolayer purification. To this end, a pyrene-functionalized NTA
derivative 53 was synthesized via two step sequence (Scheme 3.2).

Scheme 3.2 Synthesis of Pyrene-NTA.

Pyrene-NTA was synthesized via EDC-mediated coupling reaction between 15
and 4-pyrenebutyric acid (51) to yield 52 in 90.5 % yield after chromatographic
purification. Deprotection using TFA was used to give Compound 53 in 93.2 % yield.
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3.3.4 Synthesis of Triethoxysilyl-NTA
To enable affinity modification of glass surfaces with NTA ligand for affinity
purification, a triethoxysilyl-NTA derivative was designed and synthesized. This material
is designed to be used for modification of glass surfaces followed by treatment of the
modified surface with TFA to deprotect the t-butyl ester protecting groups.

Scheme 3.3 Synthesis of Triethoxysilyl-NTA.

To this end, Compound 15 was coupled to 3-(triethyxysilyl)propyl isocyanate (54) in
THF to give the target Compound 55 in 77.3 % yield after chromatographic purification
(Scheme 3.3).
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3.4 Fabrication and Evaluation of GO-NTA-Based Affinity Grids
Most reports of Langmuir dispersions of GO at the air-water interface focus on
surfactant-assisted dispersion methods to stabilize GO sheets dispersed in water12.
Treatment of GO with surfactants in these cases; however, biases the interfacial activity
towards water-surfactant activity rather than GO-NTA activity due to their high relative
abundance. The planar structure and functional group distribution on GO-NTA confers
edge amphiphilicity due to the distribution of hydrophilic carboxyl, ketone, aldehyde,
amide, and alcohol groups around the periphery of the hydrophobic aryl GO-NTA core
(Figure 3.2)13. Since GO-NTA becomes increasingly hydrophobic as displacement
toward the core from the GO-NTA edge increases, larger sheets will tend to be more
hydrophobic and migrate to the air-water interface, whereas smaller more hydrophilic
GO-NTA sheets are displaced into the aqueous subphase by the larger GO-NTA sheets14.

3.4.1 GO-NTA Monolayer Formation
Previously, it was thought that the use of surface-active agents was needed to disperse
GO sheets. More recent work; however, has shown that GO layers form at the air-water
interface in the absence of surfactant molecules15. Brewster angle microscopy studies
have shown that the interfacial refractive index of GO solutions change after a few hours
of stirring pure GO dispersions in water16. This suggests a time-dependent mechanism for
GO absorption at the air-water interface, with slower interfacial adsorption rates
attributable to slower diffusion rates of large graphene sheets relative to typical surfactant
molecules used for studies of the air-water interfaces. To increase the amount of surface-
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active graphene sheets present at the air-water interface while circumventing hours of
stirring, studies using rising gas bubbles of CO2 and N2 as a way of transporting these
sheets to the surface have proven successful14. These studies show that GO can migrate to
the air-water interface, while other work suggests that the surface activity of GO sheets in
water can be increased using volatile, polar protic solvents to enable their manipulation
using Langmuir compression15.

3.4.2 Characterization of GO-NTA Affinity Monolayers
Compression of the GO-NTA material at the interface gave a characteristic surface
pressure-area isotherm (Figure 3.3), suggesting a progression from isolated GO-NTA
sheets to close edge-to-edge packing of GO-NTA sheets, followed by folding, wrinkling,
and sliding of the nearest neighbor GO-NTA sheets atop one another upon further
compression17, in a manner analogous to pressure-induced collapse of Langmuir
phospholipid monolayer films15. Repulsive electrostatic interactions and attractive van
der Waals forces compete as GO-NTA sheets come into close contact.
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Figure 3.3 Spreading Behavior of GO-NTA Using a Langmuir Trough. A) Cartoon
depicting LS-transfer of GO-NTA surfaces onto TEM grids. B) Typical surface pressurearea isotherm for GO-NTA. C) GO-NTA monolayer subjected to several compressiondecompression cycles on the Langmuir trough.

Previous work with GO monolayers has suggested that over-compression of GO
causes irreversible coagulation above ~15 mN/m15 due to the increasing participation of
attractive van der Waals interactions once the repulsive electrostatic interactions between
sheet edges has been overcome by lateral compression. Transfer of these films onto
silicon substrates at multiple surface pressures enabled the transfer of single layer GO
sheets at surface pressures above 15 mN/m.
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3.4.2.1 Fluorescence Microscopy Analysis of GO-NTA
Epifluorescence microscopy, AFM, and SEM was employed to determine the
thickness and lateral distribution of GO-NTA sheets deposited onto solid substrates by LS transfer from the air-water interface18. In particular, epifluorescence microscopy of
Fluorescein-modified-PABA-GO-NTA (F-PABA-GO-NTA) monolayers proved useful
because opacity of the graphene-based sheet is directly related to its thickness as revealed
by analysis of monolayer-coated grid and negative control bare Cu TEM grid samples
that showed significantly greater fluorescence intensity for grids coated with F-PABAGO-NTA (Figure 3.4).

Figure 3.4 Analysis of F-PABA-GO-NTA Films by (A) Fluorescence Spectroscopy and
(B) Epifluorescence Microscopy. Fluorescence spectra were measured for the supernatant
(A, red spectrum) and the pellet (A, blue spectrum) after reaction of PABA-GO with
aminofluorescein. (B) Epifluorescence image of F-PABA-GO-NTA film on TEM grid
across the region indicated by the line in the epifluorescence image.

We then evaluated drop casting and L-S transfer deposition methods for the
production of the thinnest films possible, while yielding films with the highest density of
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NTA capture ligands. Drop casting18-19, followed by slow evaporation of solvent, resulted
in a fluorescence signal that completely spanned the holes of Formvar-coated 400 mesh
Cu grids (data not shown). Slow solvent evaporation enables GO sheets to settle on top of
one another to form a multi-layered film covering the TEM grid holes. Although
successful, our findings suggest that drop casting typically yields sheets that are too thick
and heterogeneous for protein structure elucidation applications by cryoEM. L-S transfer
in the presence of 2-propanol (IPA) proved successful for depositions onto 1500 mesh
grids, both with and without Formvar coating; however, L-S transfers with pure water
resulted in thicker heterogeneous coatings over a limited area of the holes. L-S transfer
onto Si wafers under identical conditions confirmed the presence of multilayered films
(Figure 3B & D). We were not able to fabricate functional coatings with 400 mesh grids
using L-S transfer, a finding we attribute to the mismatch between the average GO-NTA
sheet size of ~16 μm x 16 μm and the 37 μm x 37 μm grid holes of these grids. It is worth
noting that the GO-NTA sheet size can vary as a function of oxidation reaction duration
and sonication time employed during GO synthesis20.

3.4.2.2 AFM Analysis of GO-NTA
To gain further insight into the structure of these GO-NTA films, SEM and AFM
analyses were performed after compression to 15 mN/m and L-S transfer of GO-NTA
monolayer sheets onto Si wafers. To prepare Si wafers for L-S transfer, ~2.25 cm2 wafers
were cut and glued (bottom side) onto a transfer tube. The surface pressure was
maintained until the Si wafer contacted the monolayer; the film was then recompressed to
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15 mN/m after the L-S transfer step. The area difference before and after L-S transfer
indicated transfer efficiencies of 75 – 85%.

Figure 3.5 Characterization of GO-NTA Surfaces. (A) Pressure-area isotherm for GONTA sheets at the air:water interface, dispersed at 67 ng/mL in water at 20 °C. GO-NTA
sheets compressed at a rate of 500 mm2/min. (B) SEM images taken 1.0 keV, with 5 μm
scale bar and (C) AFM images of GO-NTA after LS-transfer onto Si wafers from a
subphase of pure H2O (5 μm scale bar). (D) SEM images taken at 0.5 keV (5 μm scale
bar) and (E) AFM of GO-NTA after LS-transfer onto Si wafers from a subphase of
IPA/H2O (5 μm scale bar). (F) TEM image of GO-NTA monolayers after LS transfer
from a subphase of IPA/H2O onto TEM grids; Inset: Selected area electron diffraction
analysis of GO-NTA monolayer.

Image analysis of the coated Si wafers revealed the presence of GO-NTA
monolayer sheets transferred from IPA-containing subphases with ~1.3 nm thicknesses
that were relatively uniform (Figure 3D & E), in good agreement with previously
reported values for single layer GO21. In the absence of IPA; however, data from SEM
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and AFM experiments revealed GO-NTA films comprised of overlapping sheets and
undesirable layer thickness variations (Figure 3.5 B & C).

3.4.2.3 SEM and SAED Analysis of GO-NTA
Selected area electron diffraction analysis of GO-NTA L-S films deposited onto
bare 2000 mesh grids from the air-IPA/H2O interface revealed a hexagonal diffraction
pattern, indicative of a single layer of graphenic material (Figure 3.5 F). The measured
intensity of the inner and outer peaks confirms the presence of a single GO-NTA layer
(Figure 3.6)19.

Figure 3.6 SAED of GO-NTA L-S Films on Bare 2000 Mesh TEM Grids.
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3.4.3 Affinity Capture of His6-T7 Phage Using BSA and PABA as Antifouling Agents
The capacity of GO-NTA coated grids to capture his6-T7 bacteriophage (his6-T7)
by affinity interaction was examined first by negative-stain TEM. After a 2 min exposure
of purified his6-T7 on GO-NTA modified 1500 mesh grids, dense clusters of phage
particles were found on the GO-NTA surface in the absence of Ni2+ (Figure 3.7 A).
Paradoxically, we observed fewer phage particles after charging the GO-NTA grids with
Ni2+ (Figure 3.7 B). We attribute these findings to non-specific and random covalent
coupling of lysine residues with epoxide and aldehyde residues on the GO sheets that are
inactivated upon exposure to the metal ion22. To obviate this problem, we chemically
deactivated these functional groups by treatment of GO-NTA with 4-aminobenzoic acid
(PABA) after L-S transfer. The resulting PABA-GO-NTA grids showed a reduction in,
but incomplete abrogation of, non-specific His6-T7 binding under the same incubation
conditions (Figure 3.7 C). When activated with Ni2+, PABA-GO-NTA grids revealed a
higher density of phage particles due to engagement of the NTA:Ni2+:his6 affinity
interaction (Figure 3.7 D).
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Figure 3.7 Micrographs of Negatively Stained His6-T7 Bacteriophage Using Various
TEM Grid Coatings: (A, B) GO-NTA; (C, D) PABA-GO-NTA; and (E–H) BSA-PABAGO-NTA. Negative controls (A, C, E) demonstrate no capture of purified phage when
Ni2+ is absent, whereas coatings treated with Ni2+ (B, D, F) show capture of purified
phage. Affinity capture of phage from lysate (G) can be reversed by incubation of (G)
with 500 mM imidazole (H) that removes the Ni2+ from the coating and abrogates the
affinity interaction between the phage and the grid surface.
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To further enhance the anti-fouling properties of this material, we incubated the
PABA-GO-NTA grids with BSA immediately before the affinity capture step. Under
these conditions, BSA appears to complete the blockade of non-specific viral particle
adsorption (Figure 3.7 E), suggesting that BSA inhibits non-specific binding more
effectively than PABA modification. After Ni2+ activation of the BSA-blocked PABAGO-NTA surfaces, we observed a recovery in his6-T7 binding to the grids (Figure 3.7 F).
To further demonstrate the Ni2+ dependence of this interaction, we treated the grid with
500 mM imidazole, leading to the elution of his6-T7 from the grid (data not shown).
Taken together, these findings demonstrate the importance of deactivating highly reactive
chemical functionalities on the surface of GO prior to use in affinity capture experiments.
Next, we sought to capture his6-T7 directly from clarified E. coli lysate. The
engineered His-tag does not interfere with his6-T7 infectivity, thereby enabling the
infection of BL21 cells and viral replication in vitro. A negative control experiment
demonstrated that Ni2+-free BSA-PABA-GO-NTA grids resulted in little or no capture of
phage and minimal background adsorption from non-targeted cellular material (Figure
S4); however, Ni2+ activation prompted selective his6-mediated binding of bacteriophage
to the grid surface (Figure 3.7 G). As an additional control, the grid was washed with 500
mM imidazole after Ni2+, but prior to incubation with lysate, to demonstrate that
imidazole stripping of the metal ion results in the abrogation of his6-T7 binding (Figure
3.6 H). These results indicate that BSA-PABA-GO-NTA coated grids are able to
effectively purify his6-T7 directly from clarified lysate on the grid using the reversible
NTA:Ni2+:his6 affinity interaction.
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3.4.4 Affinity Capture of His6-GroEL from Lysate Using BSA-PABA-GO-NTA Affinity
Grids
The performance of antifouling BSA-PABA-GO-NTA coatings for highresolution single particle reconstruction analysis was then evaluated by performing ongrid affinity capture of his6-GroEL from E. coli lysates. As observed for His6-T7 capture,
specific binding of his6-GroEL occurred only with Ni2+-activated (Figure 3.8 B), but not
Ni2+-free (Figure 3.8 A) or 500 mM imidazole treated grids (Figure 3.8 C).

Figure 3.8 Micrographs of His6-GroEL Lysate Affinity Capture Using BSA-PABA-GONTA TEM Grid Coating. Micrographs (A–C) are negatively stained. (A) Negative
control showing no capture of his6-GroEL when Ni2+ is absent. (B) Affinity coating
activated with Ni2+ displays specific capture of his6-GroEL from lysate. Treatment of the
grid in (B) with 500 mM imidazole (C) leads to Ni2+ stripping from the coating and
abrogation of his6-GroEL capture. (D) Representative cryo-EM image of affinity
captured his6-GroEL from lysate.
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Next, we obtained cryo-EM images of his6-GroEL deposited onto BSA-PABAGO-NTA coated grids (Figure 3.8 D). Initial attempts at his6-GroEL capture and
cryofixation on 1500 mesh grids coated with BSA-PABA-GO-NTA generated
unacceptably thick sample vitrification; however, high quality samples of his6-GroEL
captured from lysate were afforded by BSA-PABA-GO-NTA films deposited by L-S
transfer onto lacey carbon-supported 400 mesh copper grids.

3.4.5 Single-Particle Analysis of His6-GroEL
EMAN 2.123 was used for single particle analysis of his6-GroEL deposited onto BSAPABA-GO-NTA coated grids since this protein target is often used for gauging workflow
performance and data processing robustness24. The reconstruction effort followed the
usual steps from within the application, except that the particles were manually picked.
Background signal contributions by the BSA blocking layer may also have contributed to
the difficulties encountered during attempts at automated particle picking. Nonetheless,
5363 particles were hand-picked from 217 micrographs and the particles rapidly
converged into coherent classes displaying high contrast (Figure 3.9 A).
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Figure 3.9 Single-Particle Analysis of his6-GroEL Captured from Lysate. (A) Class
averages of his6-GroEL images captured from BSA-PABA-GO-NTA coated grids that
were used to build the initial model; (B) Top and (C) side views of refined his6-GroEL
EM map at 8.1 Å resolution (gold standard, 0.143 criteria); (D) Fourier Shell
Correlations: gold standard using conservative masking (black), and cross-validation
between published GroEL map EMD-5001 and our map (red); (E) Top and (F) side views
of overlay with our his6-GroEL EM map (blue) and EMD-5001 (yellow).

Of 50 total class averages, 12 were chosen to produce an initial model with imposed D7
symmetry (Figure 3.9 A). After 12 refinement iterations with an angular sampling of 1.76
degrees, we were able to produce a gold standard (0.143 criteria) density map having 8.1
Å resolution using conservative masking (Figures 3.9 B-D). There were visible nodes in
the FSC curve at regular intervals that resulted from an uneven distribution of micrograph
defocuses.
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To verify the accuracy of our model, we performed a comparison with published 4.2 Å
resolution cryo-EM map EMD-500124c that was also produced by EMAN using D7
symmetry. Chimera25 was used to fit the volumes before calculating the FSC, yielding a 9
Å resolution using 0.5 criteria (Figure 3.9 D-F).
A substantial difference between our map and the published structure was
observed, wherein additional electron density within the inner pore of the protein was
found in the case of our his6-GroEL map. We attribute this finding to the extended amino
acid sequences at the N- and C-termini (i.e., MRGSHHHHHHTDPALRA and GLCGR,
respectively) of our his6-GroEL construct derived from the ASKA Library.
Wild type N- and C-termini of the protomers are located at the surface of the inner
pore lining the assembled tetradecameric complex. Thus, the 14 engineered subunits
comprising our His6-GroEL complex yield an additional 308 residues that occupy the
pore, of which 84 are histidines. Given the large number of potential metal chelation
regioisomers and topoisomers, as well as the high potential for conformational flexibility
in the N- and C-terminal sequences, we believe that this density is unlikely to adopt a
defined structure and instead appears as a filled “droplet” within each ring. Also, there is
a noticeable decrease in density in the flexible apical region that suggests less structural
coherency. We infer from these findings that the additional pore residues, along with
NTA chelation, may create dynamic distortions to the structure of GroEL that could vary
for each particle, reducing coherency and map density at the apical ends. Further
experiments that vary the length and number of his-tag linkers per particle may allow for
a better model convergence with improved resolution, and potentially improved
resemblance to wild type GroEL.
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3.5 Conclusions
Our findings show that a new functionalized GO-NTA monolayer sheet can be
used as a coating to facilitate on-grid affinity purification from clarified cell lysates for
negative stain TEM and cryo-EM single particle reconstruction analysis. GO sheets were
successfully functionalized with lysine-NTA affinity ligands and compressed monolayer
films at the air-water interface were prepared by employing an IPA/H2O mixture to lower
surface tension before L-S transfer onto EM grids. SEM, AFM, fluorescence
spectroscopy, and TEM analysis of these films suggests that single monolayer sheets of
GO-NTA can be transferred onto Si wafers, bare copper grids, and holey carbon grids
using this method. Since GO films are thinner than amorphous carbon substrates and
offer better electron dissipation than lipid-based affinity grids, we believe these two
benefits will yield improved contrast for cryo-EM image acquisition of biological
molecules.
Two blocking techniques, PABA coupling and BSA adsorption, were needed to
deactivate the reactive GO surface towards non-specific adsorption of occult impurities
present in complex samples such as cell lysates. Our data shows that further
investigations into blocking agents that minimize background noise and improve
cryofixation reliability are needed. Nonetheless, this grid coating approach showed good
specificity for capture of His-tagged T7 bacteriophage and GroEL from highly complex
cell lysates, while limiting background adsorption of non-targeted cellular material.
The utility of these grids for on-grid purification from cell lysates and single
particle reconstruction was demonstrated using His6-GroEL. Capture of this target onto
the surface of GO-NTA affinity grids from clarified cell lysates was then used as the key
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step to enable selection of 5363 particles for reconstruction analysis, yielding a map with
a gold standard resolution of 8.1 Å. The presence of additional His-tag and linker amino
acids in our engineered GroEL was distinctly visible in our density map, but our final
map could still be fit to a published high-resolution EM map to 9 Å resolution using 0.5
criteria. We conclude based on these findings that affinity capture-based graphenic
materials offer great potential for simplified and accelerated cryo-EM sample preparation
for high-resolution structure elucidation. These coatings possess many advantages over
NTA-lipid-modified grids5a, 5b or other grid coatings that lack protection from nonspecific binding4, thereby offering substantial improvements in sample preparation time
and reduced sample volumes needed to acquire high resolution structural information of a
given protein target and, potentially, its interaction partners.

3.6 Experimental Methods
All reactions were carried out under a blanket of N2 gas. Reaction progress was
monitored by thin-layer chromatography (TLC) analysis. TLC spots were visualized
either by UV light (254nm), exposure by ninhydrin staining (100 mL n-BuOH, 3 mL
Accor, 0.3 g ninhydrin), or by staining with I2. Flash column chromatography was carried
out using 230-400 mesh silica gel and analytical grade solvents. 1H and 13C nuclear
magnetic resonance (NMR) spectra were recorded on either a Bruker AV500HD
(500MHz) or a Bruker ARX400 spectrometer (400 MHz). Chemical shifts are reported in
ppm relative to the residual solvent peaks as internal standard. Flake graphite (F516, 200300 mesh) was obtained from Asbury Carbons Inc. EDC, HOBt, and DIEA were
purchased from Advanced Chemtech. DCM, toluene, and acetonitrile (ACN) were
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distilled from CaH2. Tetrahydrofuran (THF) was distilled from sodium benzophenone
ketyl. All other reagents were purchased from Sigma Aldrich and used without further
purification.

3.6.1 GO-NTA Synthesis
GO (49). A 9:1 mixture of H2SO4 and H3PO4 (130 mL total volume) was stirred
with 1 g of graphite flakes (48, F516 flake graphite, 200-300 mesh, Asbury Carbons,
Inc.) and KMnO4 (6.0 g, 6.0 wt. equiv.). The reaction began with heating to ~40 °C and
proceeded with further heating and stirring at 50 °C for 12 hours before cooling to 20 °C
and pouring the reaction mixture into 120 mL of ice cold-water with 1 mL 30% H2O2.
Next, this suspension was passed through a metal U.S. Standard testing sieve (W.S.
Tyler, 300 μm) and then passed through a glass wool plug to filter larger particulates. The
filtrate was then centrifuged at 4,000 rpm for 4 h, the supernatant discarded, and the
pellet washed twice with a 1:1:1 volumetric ratio of H2O, 30% HCl, and EtOH before
passing the material through the testing sieve and centrifuging the filtrate at 4,000 rpm
for 4 h to pellet the aggregated material. The supernatant was precipitated with Et2O (200
mL) and filtered through a 0.45 μm PTFE membrane to gather the solid. The final
material was dried under a 15 m vacuum for 12 h, yielding 49 (1.8 g).
GO-NTA (50). GO (49, 335 mg) was stirred in a mixture of SOCl2 (60 mL) and
DMF (1.5 mL) at 70 °C for 72 hours before evaporating the SOCl2 and DMF and
washing the residue with dry DCM (3 x 50 mL). Toluene (50 mL) and Et3N (3 mL) were
then added and the mixture stirred for 30 min. Tris(O-t-butyl)-N,N-
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dicarboxymethyllysine ester (15, 533 mg) was then added and the mixture stirred at 70 ˚C
for 72 hours before washing with THF and H2O (9,000 rpm for 15 min, 3 times for each
solvent), then vacuum drying at 60 ˚C for 24 h. TFA (10 mL) in DCM (30 mL) was
added to the dried t-butyl-NTA ester intermediate (180 mg) and stirred at 60 ˚C for 5 h
before washing with THF and H2O (11,000 rpm x 15 min, 3 times for each solvent)11, 26.

3.6.2 Synthesis of Pyrene-NTA
Di-tert-butyl 2,2'-((1-(tert-butoxy)-1-oxo-6-(4-(pyren-1-yl)butanamido)hexan-2yl)azanediyl)diacetate (52). 1-Pyrenebutyric acid (51, 0.198 g, 0.69 mmol) Compound
15 (0.296 g, 0.69 mmol) and HOBt were combined in an oven-dried 50 mL round bottom
flask equipped with a magnetic stir bar. DMF (5 mL) was added followed by EDC (0.145
g, 0.76 mmol). The contents were swirled to dissolve the solids and the flask sealed with
a rubber septum and filled with argon gas. The reaction was stirred at ambient
temperature for 30 minutes. DIEA (0.444 g, 3.43 mmol) was added via syringe and the
reaction was stirred for an additional 36 hours at ambient temperature. Volatiles were
evaporated and the residue was purified by flash chromatography using 2:3
EtOAc:hexane as eluent. Compound 52 was obtained as a slightly yellow oil. (0.447 g,
90.5 %). Rf 2:3 EtOAc:hexane 0.29. 1H-NMR (500 MHz, CDCl3) δ 8.25 (d, J = 9.2 Hz,
1H), 8.15 – 8.06 (m, 2H), 8.06 – 7.99 (m, 2H), 7.99 – 7.86 (m, 3H), 7.80 (d, J = 7.8 Hz,
1H), 6.19 (s, 1H), 3.56 – 3.39 (m, 4H), 3.37 – 3.23 (m, 4H), 3.18 (s, 1H), 2.28 (t, J = 7.3
Hz, 2H), 2.23 – 2.10 (m, 2H), 1.63 (s, 2H), 1.53 (s, 3H), 1.43 (s, 11H), 1.40 (s, 17H). 13C
NMR (126 MHz, CDCl3) δ 172.84, 172.43, 170.78, 136.15, 131.36, 130.89, 129.82,
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128.73, 127.46, 127.28, 126.57, 125.76, 125.02, 124.76, 123.47, 81.12, 80.73, 77.48,
77.23, 76.97, 64.90, 53.98, 39.19, 35.98, 32.92, 29.81, 28.42, 27.57, 22.90.

2,2'-((1-Carboxy-5-(4-(pyren-1-yl)butanamido)pentyl)azanediyl)diacetic acid (53).
Compound 52 (0.447 g, 0.638 mmol) was dissolved in DCM (20 mL) and triethylsilane
(0.371 g, 3.191 mmol) was added. TFA (20 mL) was added and the solution turned a
slight clear black color. The solution was stirred at ambient temperature for 1.5 hours
under a slight argon flow. After about 40 minutes, the reaction turned a slight
beige/yellow color. After 1.5 hours, the solution was concentrated in vacuo. The residue
was combined with DCM (80 mL) and evaporated twice to remove left over TFA. The
residue was dissolved in deionized water and lyophilized to give Compound 53 as a
yellow powder. (0.317 g, 93.2 %). 1H NMR (500 MHz, DMSO-d6) δ 12.54 (s, 2H), 8.36
(d, J = 8.9 Hz, 1H), 8.26 (d, J = 7.1 Hz, 2H), 8.20 (d, J = 6.1 Hz, 2H), 8.10 (d, J = 9.2 Hz,
2H), 8.04 (t, J = 7.1 Hz, 1H), 7.92 (d, J = 7.4 Hz, 1H), 7.78 (s, 1H), 3.60 (s, 4H), 3.48 (d,
J = 13.4 Hz, 5H), 3.29 (s, 4H), 3.02 (s, 2H), 2.48 (s, 4H), 2.20 (s, 2H), 1.99 (s, 2H), 1.56
(d, J = 49.6 Hz, 2H), 1.36 (d, J = 23.3 Hz, 6H), 1.12 (d, J = 26.8 Hz, 1H), 0.88 (s, 1H).
13

C NMR (126 MHz, DMSO) δ 174.32, 173.53, 172.10, 137.06, 131.34, 130.89, 129.75,

128.61, 128.00, 127.91, 127.66, 126.94, 126.58, 125.38, 125.24, 124.69, 124.61, 123.98,
64.70, 53.72, 40.31, 39.97, 39.64, 38.80, 35.44, 32.74, 29.73, 29.38, 28.15, 23.62.
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3.6.3 Synthesis of Triethpxysilyl-NTA
tert-Butyl 16-(2-(tert-butoxy)-2-oxoethyl)-15-(tert-butoxycarbonyl)-4,4-diethoxy-9oxo-3-oxa-8,10,16-triaza-4-silaoctadecan-18-oate (55). Compound 15 (0.102 g, 0.237
mmol) was dissolved in THF (2 mL) in an oven-dried 25 mL round bottom flask
equipped with a rubber septum and magnetic stir bar. The solution was evacuated and
purged with argon before cooling to 0 °C in an ice bath and addition of 3(triethoxysilyl)propyl isocyanate (54) via syringe dropwise over 3 minutes. The solution
was allowed to warm to ambient temperature and stirred for an additional 18 hours. The
volatiles were evaporated in vacuo and the residue was purified by flash chromatography
using 95:5 DCM:MeOH as eluent to give Compound 55 as a colorless oil. (0.142 g, 77.3
%). 1H NMR (500 MHz, Chloroform-d) δ 3.74 (q, J = 7.0 Hz, 6H), 3.47 – 3.32 (m, 4H),
3.29 – 3.21 (m, 1H), 3.21 – 3.13 (m, 1H), 3.09 (d, J = 3.7 Hz, 3H), 1.59 (d, J = 6.4 Hz,
3H), 1.55 – 1.47 (m, 3H), 1.39 (d, J = 4.3 Hz, 27H), 1.15 (t, J = 7.0 Hz, 10H). 13C NMR
(126 MHz, CDCl3) δ 172.48, 170.85, 158.61, 81.08, 80.83, 76.83, 64.89, 58.29, 54.00,
42.88, 39.68, 29.57, 28.58, 28.16, 23.79, 22.51, 18.26, 7.63.

3.6.4 GO-NTA Exfoliation
The GO-NTA 50 sheets were ultrasonically exfoliated at 1 mg/mL by suspension
of the powder in 5:1 MeOH:H2O using probe sonication at 150 watts for five cycles (45 s
sonication followed by 45 s of rest in each cycle). The product was centrifuged at 1200 g
for 10 min, after which the supernatant of exfoliated GO-NTA sheets was removed from
the sediment of aggregated sheets and subjected to another 5 rounds of sonication. A final
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centrifugation at 1200 g for 10 min was performed prior to removal of the supernatant to
yield a GO-NTA solution that was stored for subsequent grid coating experiments.

3.6.5 Langmuir Trough Setup
Exfoliated GO-NTA was deposited at the air-water interface of a Kibron Trough
via a syringe pump fitted with a 20 mL syringe. The GO-NTA dispersion was loaded into
the syringe and slowly introduced at the air-water interface at a rate of 100 L/min until
the surface pressure reached 15 mN/m. The film was then allowed to relax for 5 min,
followed by slow compression of the film to 15 mN/m. IPA was then added to the
subphase and the film transferred to either Si wafers, bare 1500 mesh TEM grids, or
holey carbon grids by Langmuir-Schaefer (L-S) transfer.

3.6.6 4-Aminobenzoic Acid (PABA) Modification of GO-NTA
GO-NTA (1 mg/mL) was partially deactivated by adding PABA (30 mg) to a 10
mL GO-NTA dispersion. This mixture was probe sonicated at 150 W for 30 sec of
continuous sonication, followed by shaking for 24 h on a rotary mixer. The PABA-GONTA was then exfoliated and washed as described above for GO-NTA exfoliation.

3.6.7 Fluorescein Modification of GO-NTA
Fluorescein modification of GO-NTA was performed by adding 2 mg of
aminofluorescein to an aqueous solution of PABA-GO-NTA (10 mL at 1 mg/mL). This
mixture was probe sonicated for 30 s at 150 W of continuous sonication and then placed
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on a rotary mixer in the dark for another 24 h. The material was then centrifuged to pellet
the GO species before re-suspending in water, addition of 5:1 MeOH:H2O, re-pelleted,
and decanted a total of 10 times before exfoliation of the Fluorescein-PABA-GO-NTA
(F-PABA-GO-NTA) product as described above for GO-NTA.

3.6.8 Bovine Serum Albumin (BSA) Modification of GO-NTA
Following L-S transfer of GO-NTA or PABA-GO-NTA onto EM grids and
overnight drying in a desiccator, the grids were placed on a strip of Teflon before
addition of BSA (10 μL of 0.1 mg/mL) and incubation for 5 min, followed by 3 x 20 μL
double deionized H2O washes. The modified grids were then stored in a desiccator until
use.

3.6.9 Fluorescence Microscopy Sample Preparation
F-PABA-GO-NTA was deposited onto 1500 mesh grids in the dark by L-S
transfer as described above. After transfer, the grids were allowed to dry in the dark for 1
d before sandwiching them between a glass and cover slip with 5 μL of double deionized
H2O and the sandwich sealed with nail polish. The glass slide was then mounted on a
light microscope for epifluorescence imaging.
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3.6.10 GO Concentration Measurements
The concentrations of the GO-NTA dispersions were measured at different steps
of the synthesis by monitoring the UV-vis spectra of the products. The extinction
coefficient data used for one batch of GO-NTA is shown (Figure S1A). Since each batch
of GO-NTA has minor differences in concentration, each preparation was evaluated for
its own experimentally determined extinction coefficient for subsequent concentration
measurements. Standard solutions used to determine the extinction coefficients were
prepared by dispersing a weighed amount of dry GO-NTA into known volumes of 5:1
MeOH:H2O and measuring the absorbance at 280 nm across a series of dilutions with 5:1
MeOH:H2O. The extinction coefficient was derived from the slope of these
concentration-dependent absorption plots.

3.6.11 GO-NTA Grid Treatment with Purified His6-T7 Phage
Purified C-terminal gp10 His6-T7 bacteriophage was initially prepared at a
concentration of 1012 particles/mL, with dilution to 1010 particles/mL in HEPES buffer
(pH = 7.4) before application to the affinity grid surface. GO-NTA modified grids were
placed on a Teflon strip, 1 mM NiSO4 (10 μL) added and the grids incubated for 5 min
before washing with double deionized H2O (2 x 20 μL) and HEPES buffer (1 x 20 μL).
Purified phage (3.5 μL) was then applied to the surface and incubated for 2 min before
washing with HEPES (2 x 20 μL), double deionized H2O (1 x 20 μL), and staining with
2% uranyl acetate (5 μL).
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3.6.12 GO-NTA Grid Treatment with His6-T7 Phage Lysate
BL21 bacterial cells in 1 mL of LB media were grown to an OD of 0.8 before
adding 1.0 µL of His6-T7 bacteriophage (1 x 1012 particles/mL) to the media and shaking
the culture for 1 h. After bench top centrifugation of the cells, the supernatant was
withdrawn for use in His6-T7 bacteriophage particle capture studies. The grids were Ni2+activated as described above, except that His6-T7 lysate (5 μL) was applied to the surface
before incubation for 2 min. The grids were then washed with HEPES (2 x 20 μL),
double deionized H2O (1 x 20 μL), and then stained with 2% uranyl acetate (5 μL).

3.6.13 GO-NTA Grid Treatment with His6-GroEL Lysate
The ASKA Library was used to express N-terminal His6-GroEL. Cells containing
N-His6-GroEL gene overexpression vector were grown to OD = 0.6 (in 100 mL of LB
broth using a 37 ˚C shaker/incubator) and induced with a final concentration of 1.0 mM
IPTG, before allowing the cells to grow for an additional 4 h. After centrifugation and
removal of the supernatant, the cell pellet was re-suspended in lysis buffer (20 mM
HEPES, 100 mM NaCl, pH = 7.4, 100 µg aprotinin, 174 µg phenylmethanesulfonyl
fluoride (PMSF), and 500 µg of lysozyme) and allowed to sit for 20 min. Further
disruption of the cell membranes was effected by 110 W probe sonication (35 pulses at 1
second/pulse), followed by centrifugation at 11,000 g for 10 min. The supernatant
containing His6-GroEL was diluted 10-fold and assayed for affinity binding using the
Ni2+-activation procedure described above, except that N-His6-GroEL lysate (5 μL) was
applied to the surface and incubated for 2 min. The grids were then washed and stained
with 2% uranyl acetate as described above.
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3.6.14 Affinity Capture of His6-GroEL from Lysate onto BSA-PABA-GO-NTA Affinity
Grids for Cryo-EM Imaging
Samples were prepared as described above for negative stain TEM imaging,
except that BSA-PABA-GO-NTA modified grids were exposed to His6-GroEL lysate,
after which the excess solution was removed by blotting twice for 6 s per blot using an
offset setting of -1 at 80% humidity using a Vitrobot device (FEI Company). The grids
were then plunged into liquid ethane for cryofixation and imaged at 300 kV on an FEI
Titan Krios equipped with a Gatan K2 Summit direct electron detection camera using
low-dose techniques. Integrated microscope automation software Leginon27 was used to
acquire a large set of micrographs at 11,000x magnification with an exposure time of 7.6
sec.

3.6.15 Single-Particle Analysis of His6-GroEL
Direct electron detector movie frames were processed in Appion28 to produce a
set of averaged, motion-compensated micrographs to be used in subsequent steps. The
micrographs had a 1.32 Å2/pixel resolution across a 4096 Å x 4096 Å array. EMAN 2.1
software31 was used for reconstruction of 5363 particles that were manually picked from
217 micrographs using a box size of 256. Automatic contrast transfer function (CTF)
estimation and structure factor were determined from the incoherent sum of particles
using e2ctf and phase-flipped to generate high-pass CTF-corrected particle stacks.
Defocus was estimated to range between 0.4 μm – 4 μm, but 55% of the particles were
defocused between 2 μm – 3 μm which resulted in a somewhat jagged CTF slope.
Particles were binned 2X for class averaging and 12 classes were chosen to create an

153
initial model with imposed D7 symmetry. The classes contained a mix of top and side
views. In the refinement steps, the input set of particles was divided into even/odd halves,
each containing 2682 particles. Two independent refinements were generated, producing
a gold standard of 8.1 Å (using 0.143 criteria) after 12 iterations over two refinements
with an angular sampling of 1.76 degrees. Additionally, we performed Fourier shell
correlation against an existing high-resolution cryo-EM map, EMD-500134. The maps
were rotated and translated using Chimera35 to fit the volumes together. The correlation
of our model against EMD-5001 (4.2 Å) gave an approximate resolution of 9 Å.
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CHAPTER FOUR:
DEVELOPMENT OF AFFINITY POLYROTAXANE CONSTRUCTS FOR SINGLE
PARTICLE CRYO-EM

4.1 Introduction
There are great opportunities for the design of new organic materials as tools for
the elucidation of protein structure1, particularly in cases where traditional structure
determination methods are ineffective or impractical. A host of different materials and
approaches for interfacial templating have been developed including affinity lipids2,
facial amphiphiles3, conformationally-restricted amphiphiles4, nanodiscs5, lysolipidguided cubic phase formation6, symmetry-guided chelation7, and polymer nucleants8.
Some of these agents are directed toward the accelerated production of protein crystals
for x-ray diffraction (XRD) analysis, while others are intended to facilitate single particle
analysis (SPA) by cryoelectron microscopy (cryo-EM).
XRD and NMR based methods account for the vast majority of high-resolution
protein structures to date9, however, these methods are exceptionally challenging for the
analysis of integral membrane protein (IMP), multiprotein complex structures, and other
biomacromolecular assemblies, such as viral particles. Cryo-EM has become an
increasingly powerful method for determining the three-dimensional structures of
proteins and their assemblies via SPA10. Recently, the technique has been used to
determine protein structural information at 2.2 Å resolution11. Cryo-EM, unlike other
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electron microscopy techniques, does not require staining or embedding in nonphysiological media. A key challenge for structure determination via cryo-EM is that the
method requires the collection of more than 30,000 images of the target structure to
enable image reconstruction at near atomic resolution. Since protein concentrations used
for SPA are typically in the μg-mg/mL range, data collection is a laborious and timeconsuming process under these conditions because there are typically a limited number of
particles in the field of view at the magnification (18,000-24,000x) required to image the
nano-scale targets. Thus, accelerated SPA by cryo-EM requires the development of
materials and methods that increase the probability of finding the target particles in the
vitrified sample.
One method of overcoming this challenge is through the use of automated
methods12. Alternative strategies seek to concentrate proteins at material interfaces for
structural analysis. The first effort of this type was reported by Kornberg13 and coworkers
who used antibody-based affinity interactions to concentrate protein targets on affinity
lipid monolayer surfaces.
The desire for more general methods to promote specific monolayer-protein
interactions eventually led to the development of NTA-modified lipids that are capable of
binding recombinant proteins bearing six or more repeating histidine residues (i.e. histag). Thompson and coworkers first demonstrated the ability of NTA-lipids to facilitate
the two-dimensional crystallization and structural determination of his-tagged Moloney
leukemia virus capsid (his6-MoCA) at the air-water interface14. Negative-stain TEM was
used to determine the his6-MoCA structure at 9.5 Å resolution. More recently, this
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method has been adapted and used by Walz15 and coworkers for the elucidation of thetransferrin receptor complex and the human rp13 ribosomal complex.
A disadvantage of the lipid-monolayer approach, however, is that twodimensional crystals or adsorbates can only be used to produce projection maps of the
target structure unless a tilt series of images is collected to produce a three-dimensional
structure with a “missing cone” due to sample tilting limitations beyond ~60˚. The lipidtubule method16 was developed to overcome these difficulties by using liquid-phase
galactosylceramide lipid tubule templates that have been doped with low molar ratios of
affinity lipids to promote specific interactions with the lipid template surface. These
materials enable specific adsorption of proteins such that a single TEM image reveals all
orientations of the adsorbed molecules, thereby eliminating the need for tilt-series
imaging or multiple constructs of the protein with the affinity tag placed at different
protein loci. This approach enabled the rapid elucidation of perfringolysin 0 at ~25 Å
resolution17. The major limitation of this approach is that a highly consistent tubule
diameter is required for high-resolution re-construction.

4.2 Design of Novel NTA-Modified Polyrotaxanes for Cryo-EM
These challenges led us to develop a family of polyrotaxane (PR) materials, a
class of supramolecular structures where one or more macrocycles are threaded onto a
linear polymer that has been subsequently end-capped with bulky substituents to prevent
dethreading of the macrocycle(s)18. The term rotaxane is derived from Latin for wheel
and axle. The supramolecular materials consist of three main components: the
macrocycle or “wheel” which is usually a cyclic molecule (e.g. cyclodextrin, crown-
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ether, etc.), the axle, which is usually a linear polymer bearing an affinity for the
macrocycle interior, and the endcap which is a bulky molecule (larger than the diameter
of the macrocycle) which can be conjugated to the axle termini. If the endcap is smaller
than the diameter of the macrocycle, the material is referred to as a pseudorotaxane or
pseudopolyrotaxane. The kinetic and thermodynamic properties of the rotaxanation
process are determined by the non-covalent interactions between the macrocycle and
linear polymer and interactions between macrocycles of adjacent rotaxanes19.

Table 4.1 Physical Properties of Cyclodextrins.

Cyclodextrins are commercially-available, water-soluble20, well-defined,
biocompatible, easily-modified and available in different cavity diameters (Table 4.1).
CD’s also may protect their threaded axle from degradation after threading21.
Cyclodextrins (CD) have been utilized for polyrotaxanes synthesis and applications
extensively22. Cyclodextrins (Figure 4.1) are cyclic oligosaccharides of glucose referred
to as α-cyclodextrin (α-CD, 6 units), β-cyclodextrin (β-CD, 7 units) and γ-cyclodextrin
(γ-CD, 8 units). α-CD and γ-CD exhibit very high water solubility with β-CD only having
moderate solubility. CD-based polyrotaxanes are capable of producing a wide variety of
molecular architectures.
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Figure 4.1 Molecular Structures of Cyclodextrins.

Similarly, many different axle components have been utilized for rotaxane
synthesis. These materials are generally polymeric in nature with linear polymers being
the most heavily utilized. The axle may be any component with a cross-section smaller
than the macrocycle cavity and a length greater than that of the macrocycle.
Polyrotaxanes are generally synthesized by either threading, followed by
endcapping, clipping, or slippage. Of these, threading, followed by endcapping is the
most common (Figure 4.2). The endcapping process is formally referred to as
rotaxanation. Cyclodextrin-based polyrotaxanes are the most widely-studied PR
derivatives for biomedical and life science applications. They have been used as
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transfection reagents22c, 23, as therapeutic agents22a, for modulation of ligand-protein
interactions24, etc.21, 25.

Figure 4.2 Summary of Polyrotaxane Architectures and Syntheses19. (A) Different CDbased polyrotaxane architectures (B) Methods of forming main-chain type polyrotaxanes.

These structures possess several uniquely advantageous properties resulting from
the non-covalent interactions between polymer axle and macrocycle, such as free lateral
and rotational mobility of the threaded macrocycles so that they can adapt to the steric
demands of the adsorbate, facile preparation from inexpensive precursors, and uniform
diameters that are defined by the macrocycle. The great structural diversity possible with
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these materials26 has led to a number of proposed applications, including their use as
carriers for drug and gene delivery27. There are few reports in the literature, however, of
polyrotaxanes that have been used specifically for studying protein-binding or proteinprotein interactions28.

Figure 4.3 Conceptual Diagram of His-Tagged Protein Adsorption onto NTA-ModifiedPolyrotaxane Scaffolds. Polyrotaxanes bearing multiple laterally-and rotationally-mobileLys-NTA-α-CD’s facilitate adsorption of his-tagged proteins. The relatively small
protein, his6-GFP, (31 kD) yields a complex with a high degree of α-CD mobility,
enabling favorable CD-CD and GFP-GFP interactions. Comparatively large protein
assemblies (e.g. his6-gp10 connector polypeptide, 440 kD) lead to complexes with more
constrained α-CD mobility due to molecular crowding of the bound proteins. In both
cases, adsorbed proteins are presented in all possible orientations due to the dynamic
mobility of the threaded Lys-NTA-α-CD to which they are chelated.
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In the present study, the development of an approach that is conceptually similar
to the NTA-lipid tubule template method that would retain the specific recognition and
lateral diffusion properties of the lipid-tubule approach in a more chemically robust
format is described. This strategy utilizes the principle of NTA:Ni2+:polyhistidine
recognition on a polyrotaxane template that bears multiple laterally- and rotationallymobile lysine-N,N-di(carboxylmethyl)-α-cyclodextrins (LysNTA-α-CD) to concentrate
his-tagged proteins on a spatially well-defined scaffold for single particle analysis by
cryo-EM.
These materials are designed to have good solubility in biological buffers and
facilitate SPA of his-tagged proteins since: (1) like the lipid tubule approach, each TEM
image reveals all 3D orientations of the adsorbed protein; (2) data collection is expedited
by protein concentration at the polyrotaxane surface rather than being randomly
distributed in solution; (3) polyrotaxanes offer a constant diameter template at the
threaded cyclodextrin core; and (4) the rod-like polyrotaxane morphology should
suppress information loss due to protein-protein overlap and secondary scattering events
in projection EM images that is much more likely using a conventional polymer
modification approach (Figure 4.3).
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4.3 Synthesis and Characterization of NTA-Modified Polyrotaxanes

4.3.1 Synthesis of Homobifunctional PEG Derivatives
In a similar fashion described in Chapter 1 for mPEG derivatives, a small library
of homobifunctional PEG derivatives was synthesized (Scheme 4.1) following modified
protocols previously reported for end group modification of PEG29. PEG of various
molecular weight (~2000-35,000 Da) 56a-e was converted to the mesylate (57a-e) via
treatment with methansulfonyl chloride in dichloromethane (DCM) in the presence of
triethylamine with average yield of 89-95 %. The mesylates were converted to bis-azideterminal-PEG (58a-e) via SN2 displacement by sodium azide in N,N-dimethylformamide
(DMF) in 90-98 % average yield. Reduction using hydrogen gas (1 atm) and 10 mol %
palladium on carbon (Pd/C) support in ethyl acetate (EtOAc) gave the terminal amine
(59a-e) in 88-96 % average yield.

Scheme 4.1 Synthesis of Homobifunctional PEG Derivatives.
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Carboxyl-terminal PEG were obtained via Jones oxidation of 56a-e giving 60a-e
in 88-94 % average yield. Conversion was determined via TLC analysis combined with
staining with bromocresol green to verify oxidation. An alternative route to amine
terminal PEG through an aldehyde-terminal intermediate was also utilized. The aldehydeterminal PEG derivatives were obtained via Albright-Goldman oxidation of 56a-e to give
61a-e in 89-94 % average yield. The aldehyde-terminal PEG were then converted to the
amine 62a-e via reductive amination mediated by sodium cyanoborohydride and
ammonia in methanol in 91-97 % overall yield. Reported yields are given as percent
recovery. Polymers were purified via extractions and precipitation into diethyl ether. The
efficiency of conversion for Jones oxidation is near complete29b. Conversions reported for
the Albright-Goldman and reductive amination protocols are 78-86 %29b.

Scheme 4.2 Synthesis of Amine-Terminal PEG via CDI-Coupling.
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Additionally, in order to generate a third PEG-bis-amine with a different synthetic
methodology, Compounds 63a-e were synthesized via coupling of ethylenediamine to the
terminal hydroxyl groups of PEG via CDI-mediated coupling, in the presence of
triethylamine, forming an N’-2-aminoethylcarbamate terminus. Compounds 63a-e were
obtained in 91-97 % average yield). Similarly, in order to generate a tetrafunctional PEGamine capable of accommodating two endcaps per terminus, tris(2-aminoethyl)amine was
coupled to terminal hydroxyl groups of PEG via CDI-coupling in the presence of
triethylamine. Compounds 64a-e were obtained in 89-95 % average yield.

Scheme 4.3 Synthesis PEG-bis-MBPA.

Additionally, bis-tertiary bromide terminal PEG was synthesized by direct
esterification of PEG (56a-e) with 2-methyl-2-bromopropionic acid (Scheme 4 .3)
mediated by EDC and DMAP in a solution of DCM and pyridine. Compounds 65a-e
were obtained in 92-98 % yield.
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4.3.2 Synthesis of TNB-Capped Polyrotaxanes
A small library of TNBS-capped polyrotaxanes composed of PEG and α-CD as
the axle and macrocycle, respectively, was synthesized by threading α-CD and PEG in
aqueous solution followed by rotaxanation via reaction of 2,4,6-trinitrobenzenesulfonic
acid (TNBS) with PEG-bis-amine (59a-d). The polyrotaxanes (66a-d) were isolated by
exploiting the poor aqueous solubility of the polyrotaxanes compared to the high
solubility of both PEG and α-CD by a centrifugal purification process followed by
dialysis (Scheme 4.4).

Scheme 4.4 Synthesis of TNB-Capped Polyrotaxanes from 59.

The polyrotaxanes were characterized via 1H-NMR to determine the number of
CD’s, threading efficiency and estimated molecular weight (Table 4.2). The yields were
highest for the PEG of low molecular weight. Threading efficiency was also generally
higher for polyrotaxanes synthesized from lower molecular weight PEG.
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Table 4.2 Characterization of TNB-Capped Polyrotaxanes from 59.

Similarly, polyrotaxanes were synthesized from Compounds 63a, 63c, 63e via
threading of the PEG and α-CD in water followed by rotaxanation via substitution
reaction of TNBS with terminal amino functionalities of PEG. The compounds were
purified by centrifugal washing and dialysis.

Scheme 4.5 Synthesis of TNB-Capped Polyrotaxanes from 63.
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The polyrotaxanes were characterized via 1H-NMR to determine the number of
CD’s, threading efficiency and estimated molecular weight (Table 4.3). Yields were
generally high and relatively consisted for the different molecular weights of PEG. This
suggests that rotaxanation efficiency may be better for Compounds 67a, 67c, and 67e
relative to Compounds 66a-d due to greater end group fidelity in Compound 63 relative
to Compound 59. This further suggests that generating PEG-bis-amine by direct coupling
mediated by CDI with ethylenediamine is a better strategy relative to the three step
synthesis used to generate 59.

Table 4.3 Characterization of TNB-Capped Polyrotaxanes from 63.

In order to generate test if a larger endcap may lead to less dethreading from
slipping Compounds 64b and 64c were similarly threaded with α-CD in aqueous solution
followed by endcapping via reaction of the terminal amines with TNBS. In this case,
since two TNBS molecules may be present on each of the two polyrotaxane termini, it
should be less likely to dethread during post-modification in organic solution (Scheme
4.6).
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Scheme 4.6 Synthesis of TNB-capped polyrotaxanes from 64.

The polyrotaxanes were characterized via 1H-NMR to determine the number of
CD’s, threading efficiency and estimated molecular weight (Table 4.2). Yields were
relatively low. It was also observed that during threading of PEG and α-CD precipitation
of pseudopolyrotaxanes usually happens relatively quickly (less than 30 min) and
generally happens quicker for lower PEG molecular weight. This suggests that lower
weight PEG effectively presents more polymer termini present in solution on which a CD
may become threaded. During threading of Compounds 63 and 64 pseudorotaxane
formation was slow and the overall viscosity of the solution remained relatively low
indicating that termini of Compounds 63 may be too bulky to be suitable for threading of
α-CD. Threading efficiency for Compound 63b was extremely high while Compound 63c
was comparable to other polyrotaxanes based on PEG of molecular weight of 10.0 kDa
(Table 4.4).
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Table 4.4 Characterization of TNB-Capped Polyrotaxanes from 63.

Overall, TNBS-capped polyrotaxanes were synthesized from three different PEGbis-amine constructs accessed through different synthetic methodologies. All three
strategies successfully generated polyrotaxanes with PEG-bis-ethylenediamine showing
the best yield likely due to greater overall amine-conversion in the PEG starting material.

4.3.3 Modification of TNB-Capped Polyrotaxanes with NTA

Scheme 4.7 Modification of TNB-Capped Polyrotaxane with NTA.
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Compound 66c was randomly conjugated modified with NTA via CDI-mediated
coupling between the hydroxyl moieties of α-CD and Compound 15. This methodology
yields a carbamate linkage which is expected to exhibit high stability for TFA-mediated
deprotection and aqueous applications of the material (Scheme 4.7). Compound 69 was
deprotected to yield the free acid groups of NT via treatment with TFA. Compound 70
was purified via dialysis and size exclusion chromatography to remove small molecular
contaminants and occult impurities. NMR and GPC revealed that Compound 70 was
composed of approximately 17 CD’s with an average of 1.1 NTA/CD after the two step
post-modification approach. One downside of this approach is that even after successive
treatments with TFA, some t-butyl moieties were present in the NMR spectra. This
observation is proposed to be due to O-alkylation by the reactive species (t-butyl cation)
generated during deprotection. This side reaction could not be effectively avoided even
via addition of scavengers commonly used in peptide synthesis (triethylsilane, phenol,
etc.).
In an effort to avoid the associated side-reactions of deprotection of t-butylprotected-NTA-modified polyrotaxanes, a small library of NTA and tris-NTA derivatives
was synthesized with (2-trimethylsilyl)ethyl ester protecting groups. These esters employ
mild fluoride-mediated ester deprotection, generating the carboxylic acid, ethene, and
trimethylsilyl fluoride. Any O-silylation of hydroxyl groups of polyrotaxanes modified
with these derivatives during deprotection should be hydrolysable during the subsequent
aqueous dialytic purification.
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Scheme 4.8 Synthesis of (2-trimethylsilyl)ethyl-Protected NTA.

Starting from Compound 18, EDC and DMAP were utilized to esterify the free
carboxyl groups of Compound 18 with (2-trimethylsilyl)ethanol in a mixture of pyridine
and DCM to give Compound 71 in 63.4 % yield. Hydrogenation on 10 Pd/C in isopropyl
alcohol under 1 atm. hydrogen gave Compound 72 in 93.4 % yield. Compound 72 was
further succinylated to give carboxylate derivative 73 in 92.0 % yield. Methyl ester NTAderivative 74 was also synthesized via acid-catalyzed esterification in MeOH. Sulfuric
acid was found to be superior to p-toluenesulfonic acid (PTSA) for this purpose as the
PTSA salt was difficult to remove.
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Scheme 4.9 Synthesis of (2-trimethylsilyl)ethyl-Protected tris-NTA.

A (2-trimethylsilyl)ethyl derivative of tris-NTA was also synthesized.
Compounds 18 and 72 were coupled to give Compound 75 in 47.2 % yield. Compound
75 was hydrogenated to remove the Z-protecting group to give Compound 76 in 98.8 %
yield. Compound 76 was further succinylated to give carboxylic acid derivative 77 in
98.2 % yield (Scheme 4.9).
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Scheme 4.10 Synthesis of NTA-Modified Polyrotaxanes Using (2-trimethylsilyl)ethyl
Ester-Protected NTA.

Next, an attempt to synthesize NTA-modified polyrotaxanes using the postmodification and fluoride-mediated deprotection was made. Polyrotaxane 67e was postmodified with Compound 72 mediated by CDI in DMSO. The NTA-modified
polyrotaxane 78 was isolated via dialysis. 1H-NMR indicated the presence of 29 CD’s,
with approximately 6.2 NTA/CD and an associated estimated molecular weight of 110.0
kDa. Compound 78 was then subjected to treatment with tetrabutylammonium fluoride
(TBAF) in DMSO to effect deprotection of the (2-trimethylsilyl)ethyl ester groups of
NTA. This strategy proved successful. After purification by dialysis and size-exclusion
chromatography, 1H-NMR indicated the presence of NTA-modified polyrotaxane with
approximately 24 CD’s and 2.8 NTA/CD after the two step post-modification sequence.
The NMR spectra also indicated the presence of butyl groups, which could be from
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tetrabutylammonium cation or possibly due to N-alkylation by TBAF, which has been
reported.

4.3.4 Screening of Aqueous Endcapping Methods
Due to the moderate success using the post-modification-deprotection strategy for
synthesis of NTA-modified polyrotaxanes, a small screening study was performed to
identify possible aqueous endcapping methodologies, which might be used to install
bulkier endcaps than TNBS due to the observation of loss of CD (possibly from slippage)
during previous strategies.

Scheme 4.11 Synthesis of Z-Phenylalanine-Capped Polyrotaxanes.

179
Compound 80 was synthesized from the pseudopolyrotaxane composed of PEGbis-amine (59c) and α-CD via amide-coupling between the terminal amino groups of the
lyophilized pseudopolyrotaxane and free carboxylate of Z-phenylalanine mediated by
EDC, HOBt, and N-methylmorpholine (NMM) in MeOH. The reaction was unsuccessful
when the same process was repeated using ethanol in place of methanol. The
polyrotaxane was purified via centrifugation and dialysis 1H-NMR indicated the presence
of 16 CD’s.

Scheme 4.12 Synthesis of POEGMA-Capped Polyrotaxanes.
An ATRP strategy30 was also utilized to grow a short poly(oligoethylene glycol)
methacrylate (POEGMA) from tertiary-bromide terminal PEG 65c. This polyrotaxane
was synthesized via threading of Compound 65c by α-CD in water followed by aqueous
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ATRP as the rotaxanation reaction. The polyrotaxanes were isolated via centrifugation
and dialysis. 1H-NMR revealed that the POEGMA polymer did not undergo a high
degree of polymerization with only about 2.6 monomers incorporated on each terminus
and approximately 22 CD’s threaded. In fact, the process was completely unsuccessful
several times, which is attributed to no polymerization in those cases.

4.3.5 Synthesis of Fluorescein-Capped Polyrotaxanes via CuAAC
Next, we sought to design a small library of polyrotaxanes incorporating a larger
endcap that could also impart fluorescence properties for imaging studies. Fluorescein is
a water soluble heterocyclic compound commonly used as a dye31. Many derivatives
have previously been synthesized.

Figure 4.4 Design of Fluorescein-Capped Polyrotaxanes.
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The copper-catalyzed azide-alkyne cycloaddition32 (CuAAC) was chosen as an
endcapping method since it is a very high efficiency reaction that is compatible with
aqueous conditions and conjugation of large macromolecules. During the previous
screening study, this strategy had been identified as a high-yielding strategy for aqueous
polyrotaxane synthesis (data not shown). We sought to use bis-alkynyl-terminal PEG and
an azido-derivative of fluorescein to synthesize these materials
To utilize this strategy, a small library of bis-alkynyl-PEG derivatives was
synthesized (Scheme 4.13) via direct coupling of propargylamine with Compounds 68ae. Since the Jones oxidation effectively oxidizes PEG termini in high efficiency, this twostep protocol (also utilizing EDC coupling, another high-yielding reaction) is expected to
yield polymers with high end group fidelity.

Scheme 4.13 Synthesis of PEG-bis-alkyne.

Next, we sought to synthesize an azide derivative of fluorescein. Compound 84
has previously been reported33 in 66.5 % yield via diazotization followed by substitution
using sodium nitrite and sodium azide in methanol. However, this protocol suffers from
poor yield and lack of purity. The product was also never characterized.
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Scheme 4.14 Synthesis of 5-Azidofluorescein.

An alternative synthetic protocol was designed (Scheme 4.14) utilizing organic
nitrite and azide derivatives whose by-product could be easily removed. The reaction was
carried out with t-butyl nitrite and trimethylsilyl azide in a mixture of acetonitrile (ACN),
methanol, and water. The product was purified chromatographically and isolated in 95.8
% yield.

Scheme 4.15 Synthesis of Isothiocyanate-NTA Derivative.

Since previous experiences with post modification usually resulted in loss of
CD’s, which leads to a less rigid polyrotaxane, and harsh deprotection methodologies
tended to lead to complications, a post modification strategy based around a two-step
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protocol involving amine-functionalization of the polyrotaxane followed by direct
conjugation of an isothiocyanate derivative of NTA was designed (Scheme 4.15).
4-Aminobenzoic acid (PABA, 85) was Boc-protected in 69.3 % yield and coupled
with Compound 15 via EDC-coupling in the presence of HOBt and DIEA in DMF to
give Compound 87 in 44.5 % yield. A global TFA-mediated deprotection was used to
give NTA-derivative 88 in 71.1 % yield. Compound 88 was converted to an
isothiocyanate derivative via thiophosgene in a biphasic mixture of DCM and water to
give Compound 89 in 65.1 % yield.

Scheme 4.16 Synthesis of Fluorescein-Capped Polyrotaxanes.

A small library of fluorescein-capped polyrotaxanes was synthesized from
Compounds 82b-d, α-CD and Compound 84 under aqueous conditions. Pseudorotaxane
formation was carried out followed by aqueous CuAAC via addition of a DMSO solution
of 84, CuSO4 and sodium-l-ascorbate. The heterogeneous rotaxanation reaction was
allowed to proceed for 48 hours The polyrotaxanes were purified via centrifugation
process utilizing water and aqueous solutions of EDTA to remove Cu(II) followed by
dialysis against water to remove CD and unthreaded polymer.
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Table 4.5 Characterization of Fluorescein-Capped Polyrotaxanes.

Yields for Compounds 90a-c were generally good, being superior in average yield
and reproducibility than previous methods. Also, since fluorescein is a larger molecule
than TNBS, it is anticipated that dethreading via slippage should be reduced in these
materials. 1H-NMR (Figure 4.5 C) indicated the threading were relatively high in
comparison to previous methods.
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Figure 4.5 Characterization of Fluorescein-Capped Polyrotaxanes via NMR and GPC.
(A) Physical appearance of 90a. (B) GPC Chromatogram of 90a. (C) 1H-NMR spectral
characterization of fluorescein-capped polyrotaxane 90a. (D) 2D NOESY spectra of
fluorescein-capped polyrotaxane 90a.

Since the pseudorotaxane is kept under equilibrium conditions during the
rotaxanation reaction, even though the rotaxanation reaction is slow, high yields and
threading are still possible. 2D NMR showed the presence of proximal interactions
between PEG and CD protons. GPC analysis (Figure 4.5B) of Compounds 90a-c in
DMSO yielded number average molecular weight data in relative agreement with NMR
observation, but consistently lower, having greater difference with the higher weight PEG
derivatives. This may be due to presence of dethreaded α-CD, which would not be
differentiated from polyrotaxane-associated CD in NMR.
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4.3.6 Modification of Fluorescein-Capped Polyrotaxanes with NTA

Scheme 4.17 Modification of Fluorescein-Capped Polyrotaxanes with IsothiocyanateNTA Derivative.

Fluorescein-capped polyrotaxanes (90a-c) were modified with NTA via a twostep post-modification sequence. First, Compounds 9a-c were modified with 2,2(ethylenedioxy)bis(ethylamine) (EBE) via CDI-coupling in DMSO in the presence of
triethylamine. Compounds 91a-c were then conjugated with Compound 89 via thiourea
formation in the presence of triethylamine in aqueous DMSO. The NTA-modified
polyrotaxanes were purified between each step via dialysis against DMSO and water to
remove unreacted starting materials, dethreaded CD’s, etc.
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Table 4.6 Characterization of NTA-Modified Fluorescein-Capped Polyrotaxanes.

The NTA-modified polyrotaxanes 92a-c were characterized via 1H-NMR and
GPC (Table 4.6). NMR revealed that the apparent number of threaded CD’s and
molecular weight had decreased considerable relative to the unmodified polyrotaxanes.
This observation could be attributable to slippage, or hydrolysis of threaded CD’s or
removal of unthreaded CD’s during purification. GPC showed good agreement with
NMR for calculated molecular weight, although it was slightly higher than the calculated
molecular weights from NMR. Mw/Mn was also observed to increase after post
modification.

4.4 Evaluation of NTA-Modified Polyrotaxanes
To quantify the Ni2+ chelation capacity of 70, the total Ni2+ content bound to NTA
was analyzed by ICP-MS. A solution of 20 mM NiSO4 was added to 70 and the metal
bound PRTx isolated and purified by size exclusion chromatography using Sephadex G25M. ICP-MS analysis of the purified material revealed a Ni2+ content corresponding to
approximately 19 NTA units per polyrotaxane (assuming a 1:1 Ni2+:NTA stoichiometry),
a finding that is consistent with the 1H-NMR data for this compound.
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Figure 4.6. Fluorescence Microscopy Analysis of His6-GFP Complexation with Ni2+Activated 70 (Olympus BX51, 10 X objective, DP71 CCD camera). (a) His6-GFP (3.0
μM) in 10 mM HEPES buffer at pH 8.0. (b) Ni2+:70 complex (176 nM), (control). (c)
Mixture of 3.0 µM his6-GFP and 176 nM Ni2+:70 complex at a 1:1 his6-GFP:α-CD
stoichiometry. (d) Same as (c), except that 500 mM imidazole solution was added to (c)
to strip the unbound Ni2+ from the 70:Ni complex. (e) Fluorescence intensities of samples
(a)-(d), with the average intensity (black bar), minimum intensity (striped bar) and
maximum intensity (dotted bar) reported for the CCD counts collected over randomly
selected 50 μm X 50 μm areas of the corresponding image.

Fluorescence microscopy was used to evaluate the protein adsorption properties
of Ni2+-activated 70 using his6-green fluorescent protein (his6-GFP). Figure 4.6A shows a
3.0 µM solution of his6-GFP mounted between two glass slides and viewed by
fluorescence microscopy. The appearance of a uniform fluorescence emission across the
field of view indicates that GFP does not aggregate under these conditions. Figure 4.6B
confirms that Ni2+-activated 70 has no appreciable fluorescence emission under these
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conditions. When 10 µL of a 176 nM Ni2+-activated 70 solution was added to 3.0 µM
his6-GFP to produce a 1:1 GFP:α-CD ratio and imaged under identical conditions, many
intensely fluorescent spots surrounded by zones of depleted fluorescence intensity were
observed (Figure 4.6C). We infer from these observations that the regions of high
emission intensity are due to locally high GFP concentrations that have been facilitated
by the Ni2+:70 complex since GFP does not aggregate under the same conditions in the
absence of the polyrotaxane additive. When a 500 mM imidazole solution was added to
disrupt the Ni2+:his6-GFP complexation interaction, a rehomogenization of the
fluorescence intensity was observed. This observation is consistent with the expectation
that excess imidazole should outcompete the his-tags for Ni2+ binding, thereby disrupting
the his6-GFP:Ni2+:70 complex and re-dispersing his6-GFP as a dilute solution of GFP
monomer.
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Figure 4.7 Tapping Mode AFM Analysis of His6-GFP on NTA-Modified Polyrotaxane
Scaffolds. Tapping mode AFM analysis of: (A, B) 176 nM Ni2+:70 complex; (C, D) his6GFP:Ni2+:70 complex, prepared by mixing 176 nM Ni2+:70 complex solution with a 3.0
µM his6-GFP solution in 10 mM HEPES buffer at pH 8.0 to attain a 1:1 his6-GFP:α-CD
stoichiometry. (E, F) Sample C after addition of 500 mM imidazole solution. Samples
were visualized on a Veeco Multimode AFM with a Nanoscope IIIa controller in air at
22 °C. The line scans in B, D & F correspond to the image areas shown in the insets of A,
C, & E, respectively.
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AFM studies were then performed to provide greater insight into the his6-GFP
aggregation phenomena in the presence of Ni2+:70 complex. AFM images of Ni2+:70
complexes deposited onto mica (Figure 4.7A) reveal the presence of features with an
average long dimension of 60 nm and an average height of 1.2 nm. After addition of 3.0
µM his6-GFP at a 1:1 GFP:α-CD molar ratio, these objects were transformed into rodshaped structures with an average length of ~100 nm (Figure 4.7B) and an average height
of 3.7 nm, consistent with the adsorption of his6-GFP (GFP is a -barrel structure that is
approximately 4.2 nm high x 2.4 nm in diameter) onto the 1.4 nm diameter polyrotaxane
scaffold. Addition of 500 mM imidazole to this solution, followed by incubation for 1 h
prior to AFM imaging (Figure 4.7C), produced samples that had reverted back to the
original morphology with an average diameter of ~40 nm and average height of 1.1 nm.
These observations are consistent with our fluorescence microscopy observations and the
expected reversible complexation of his6-GFP with the Ni2+:70 complex.
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Figure 4.8 Cryo-EM Imaging of His6-GFP adsorbed to NTA-Modified Polyrotaxane
Scaffolds. Cryo-EM imaging of: (A) 1 mM Ni2+:70 complex; (B) 1 mM his6-GFP:Ni2+:70
complex at a 1:1 his6-GFP:α-CD stoichiometry. A gallery of Ni2+:70 complex features
observed at higher magnification appear to the right for samples in the absence (A) and
presence (B) of his6-GFP. Samples were spread onto C-FlatTM grids and plunge-frozen in
liquid ethane. Images were recorded using a Gatan 4k × 4k CCD camera on a Philips
CM200 transmission electron microscope operating at 40 kV accelerating voltage.

In order to evaluate the potential of Ni2+:70 complexes for SPA applications,
cryo-EM imaging was performed using a small protein target (his6-GFP) that would
otherwise be difficult to visualize with this technique due to the combined effects of low
EM contrast and extensive protein dispersion. Cryo-EM imaging of his6-GFP:Ni2+:70
complexes showed the presence of similar rod-like structures, however, these structures
were noticeably larger in diameter and exhibited greater electron density than the protein-
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free control. These observations are in agreement with our fluorescence microscopy and
AFM data, providing further support for the hypothesis that his6-GFP chelation to Ni2+activated 70 leads to protein concentration onto the polyrotaxane scaffold. Taking the
AFM and cryo-EM imaging data together, our results suggest that a thin protein layer
surrounding the polyrotaxane is formed, although the lateral and rotational organization
of this adsorbate is still unclear.

Figure 4.9. TEM Analysis of His6-gp10 Adsorbed to NTA-Modified Polyrotaxane
Scaffolds. (A) 3Dstructure of gp10 from the top and side. (B) Negative-stain TEM
imaging of his6-gp10:Ni2+:70 complexes. Images were taken with FEI/Philips CM-10
Bio-Twin instrument using glow discharged carbon-coated formvar copper 400 mesh
grids (80 kV accelerating voltage) stained with a 2% UO2(OAc)2 solution.
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In order to evaluate the ability of large protein assemblies to specifically adsorb to
Ni2+-activated NTA-polyrotaxanes, we performed negative stain TEM imaging of Ni2+:70
complexes treated with his-tagged bacteriophage phi29 connector protein assemblies
(his6-gp10) at a 1:1 his6-gp10:-CD ratio. This 440 kD protein dodecamer of gp10
connects the phage head to the ATP-driven motor that is responsible for DNA
translocation and packaging during the formation of mature virion particles34. TEM
images (Figure 4.9B) revealed the presence of many round pore-containing objects whose
dimensions are consistent with phi29 connector protein assemblies; these features were
presented in the same roughly linear arrangement seen for the Ni2+-activated NTApolyrotaxane control. We infer from these observations that his6-gp10 is binding to the
Ni2+:70 scaffold in a manner similar to his6-GFP, except that the protein is not as densely
packed along the polyrotaxane scaffold due to the spatial demands of the much larger
phi29 connector array.

Figure 4.10. UV-Vis Analysis of Azidofluorescein (84) and Compounds 92a-c in PBS.
(Inset) Appearance of 92a-c Solutions.
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Ni2+ complexes of Compounds 92a-c were prepared in a similar fashion to
Compound 70, Ni2+ complexes of 92a-c were dialyzed to remove excess Ni2+ followed by
lyophilization. Complexes were then analyzed by ICP-MS to determine the relative
number of NTA’s per polyrotaxane. UV-Vis spectra (Figure 4.10) were recorded for
Compounds 92a-c and Compound 84, which is the endcap for the polyrotaxanes. All four
solutions exhibited strong absorptions at 494 nm, which is characteristic of fluorescein35.
All three polyrotaxanes 92a-c exhibited absorption maxima characteristic of fluorescein
and their color was also very similar to that of solutions of Compound 84. This spectral
evidence further illustrates the successful endcapping of polyrotaxanes by fluorescein and
shows that the spectral properties of fluorescein can be utilized in experimentation with
the fluorescein-capped polyrotaxane derivatives 92a-c.

Figure 4.11. UV-Vis Spectra of (A) His6-GroEL Lysate and (B) His6-GFPuv Lysate.
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Figure 4.11 shows the UV-Vis spectra of his6-GroEL lysate and purified his6GFPuv. The GroEL lysate exhibits broad absorption from 200-400 nm characteristic of a
crude lysate. The his6-GFPuv exhibited spectral properties consistent with other GFP
variants.

Figure 4.12. Centrifugal Isolation of 92a-c Complexes with His6-GFPuv and His6-GroEL
Lysate. (A) solutions of Compounds 92a-c. (B) Appearance of his6-GFP-uv and his6GroELlysate. (C) Appearance of sediments generated from 92a-c and his6-GFPuv. (D)
Appearance of sediments generated from 92a-c and his6-GroEL.

From our previous fluorescence microscopy results, there was good evidence that
the NTA-modified polyrotaxanes were forming complexes of very high molecular weight
which were large enough to be visible by fluorescence microscopy. We developed a
method to isolate these complexes via centrifugation of mixtures of 92a-c with his-tagged

197
proteins. These complexes were isolated after 30 minute incubation via centrifugation at
12,000 g for 30 minutes. These pellets could then be resuspended and dispersed via
sonication to generate samples suitable for imaging. This process is a variation on the
monolayer purification approach15, 36 that may be useful for cryo-EM sample preparation.
Figure 4.12 visually shows the appearance of solutions of 92a-c, his6-Gro-EL, his6GFPuv and sediments generated via incubation of each PR and his-tagged protein,
respectively.

Figure 4.13. Centrifugal Isolation of His6-GFPuv Complexed with 92a-c.

In order to further demonstrate the capacity for isolation of his-tagged proteins
from purified solution and crude cell lysate using NTA-modified polyrotaxanes, UV-Vis

198
spectra were recorded of various solutions subjected to the centrifugal isolation protocol
used for isolation of his-tagged proteins (Figure 4.13). The controls where either protein
only or polyrotaxane only showed relatively low fluorescence intensity because no
sedimentation was observed. Residual spectra properties are attributed to some solution
being left in the tube. However, UV-Vis spectra of the resuspended lysates all exhibited
spectra similar to his6-GFPuv with trace characteristics of 92a-c.

Figure 4.14. Centrifugal Isolation of His6-GroEL Complexed with 92a-c.

Similarly, UV-Vis spectra were recorded of various solutions subjected to the
centrifugal isolation protocol used for isolation of his-tagged proteins (Figure 4.14) with
his6-GroEL lysate. The results are similar to those with his6-GFP, the controls showed
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low absorption and no visible sedimentation was observed. Residual absorption is
attributed to solution left in the tube after decantation. All the Compounds 92a-c with
his6-GroEL visible formed sediments and after resuspension, the UV-Vis spectra were
similar to spectra of his6-GroEL.

Figure 4.15. SDS-PAGE Analysis of Isolation of His6-GroEL from Cell Lysate. Lane 1:
Molecular weight ladder (BLUEStain). Lanes 2-4: his6-GroEL lysate. Lanes 5-7:
Compound 92c + his6-GroEL lysate. Lanes 8-10: Ni:NTA beads (Talon resin) + his6GroEL isolated via centrifugation protocol.

SDS-PAGE was used to evaluate the purity of pellets isolated via centrifugation
and using a commercial Ni:NTA resin using the centrifugation protocol used to isolate
his-tagged proteins with NTA-modified polyrotaxanes (Figure 4.15). Results indicate that
the protein composition of the sediments resembles the lysate with a possible modest
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degree of purification. The centrifugation process was modified slightly to use
commercial Ni:NTA resin in place of Compounds 92a-c. The protein composition of the
material isolated also resembles the lysate. This shows that it may be possible to further
modify the protocol to generate higher quality protein solutions via addition of washing
steps or flow-based methods.

Figure 4.16. TEM Analysis of His6-GroEL Isolated via Centrifugal Purification. (A)
representative negatively-stained TEM image. (B) 4.2 Å reconstruction of native GroEL
with D7 symmetry with a single subunit highlighted in red reported by Ludtke et al.37 (C)
4.7 Å reconstruction of native GroEL with C7 symmetry reported by Ludtke et al.37 A
single subunit in the A ring is colored blue while a single subunit in the B ring is colored
yellow.

In order to further evaluate the ability of Compounds 92a-c for isolation and cryoEM of his-tagged protein from cell lysate, GroEL cell lysate was subjected to the
centrifugal isolation protocol detailed above and resuspended sediment was qualitatively
evaluated by TEM. Figure 4.16 depicts a representative image from this dataset. The
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image appears to show his6-GroEL adsorbed to the tubular polyrotaxane scaffold. These
particles are confirmed to be his6-GroEL as reported in cryo-EM efforts previously by
Ludtke37. The appearance of the adsorbed particles is concurrent with results from UVVis and SD-PAGE that his6-GroEL is present in complex with Compounds 92a-c via
affinity interaction. Efforts are currently directed toward generation of 3D reconstruction
from cryo-EM datasets generated using this isolation method.

4.5 Conclusions
A library of polyrotaxanes based on PEG, α-CD and various endcaps and
rotaxanation methods was synthesized. Several of these compounds were further
modified with NTA moieties to impart affinity interactions on the tubular polyrotaxane
templates which might be used for isolation of proteins and assisted cryo-EM via
homogenization of orientational distribution from lateral and rotational mobility of the
CD’s upon which the protein is adsorbed. The laterally- and rotationally-mobile NTA-CD
ligating groups enabled the capture of two his-tagged proteins of substantially different
size and facilitated their imaging via AFM, cryo-TEM, and TEM. This material may
greatly facilitate the cryo-EM analysis of his-tagged proteins by concentrating them into
large and readily detectable clusters that enables projection images of the protein
structure in all possible 3D orientations. It is anticipated that these NTA-modified
polyrotaxane materials may be an important new tool for facilitating SPA by reducing
both the amount of purified protein necessary for SPA and the time required for
acquisition of the large particle counts needed for high-resolution analysis.
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4.6 Experimental Methods
All reactions were carried out under a blanket of N2 or argon gas. Reaction
progress was monitored by thin-layer chromatography (TLC) analysis. TLC spots were
visualized either by UV light (254nm), exposure by ninhydrin staining, staining with
phosphomolybdic acid (PMA), staining by bromocresol green, or by staining with I2.
Flash column chromatography was carried out using 230-400 mesh silica gel and
analytical grade solvents. Solvents were purchased from Mallinckrodt/Baker and used
without further purification unless noted. Toluene was purchased from Fisher. PEG
polymers were from Sigma-Aldrich and were purified before use via precipitation from a
solution in DCM into diethyl ether. 2,4,6-trinitrobenzenesulfonic acid (1.0 M in H2O)
was purchased from Aldrich. Sodium 2,4,6-Trinitrobenzenesulfonate (TNBS) was
obtained by neutralization of 2,4,6-trinitrobenzenesulfonic acid solution with NaHCO3.
α-Cyclodextrin (α-CD) was purchased from Tokyo Kasei Inc. Dichloromethane (DCM),
and toluene were distilled from CaH2. Triethylamine (TEA) was distilled from CaH2 and
stored over BaO. Tetrahydrofuran (THF) was distilled from sodium-benzophenone ketyl.
Dimethyl sulfoxide (DMSO) was distilled from CaH2. N-(3-dimethylaminopropyl)-N’ethylcarbodiimide hydrochloride (EDC) was purchased from Advanced Chemtech. All
other chemicals were purchased from Sigma Aldrich and used without further
purification.
1

H and 13C nuclear magnetic resonance (NMR) spectra were recorded on either a

Bruker AV500HD (500MHz) or a Bruker ARX400 spectrometer (400 MHz). Chemical
shifts are reported in ppm relative to the residual solvent peaks as internal standard
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4.6.1 Synthesis of Homobifunctional PEG Derivatives
PEG-bis-mesylate (57a-e). PEG was dried azeotropically with toluene several times and
dried in vacuo for 18 hours. As a representative reaction, PEG (3.00 g) was dissolved in
DCM (85 mL) and triethylamine (3.00 equiv.) was added. The solution was cooled to 0
°C in an ice bath and methansulfonyl chloride (MsCl, 2.2 equiv.) was added dropwise
over 10 minutes. The reaction was stirred for an additional 30 minutes at 0 °C. The
solution was transferred to a separatory funnel with an additional 50 mL DCM. The
solution was washed with 100 mL ice water followed by 100 mL 5 % HCl solution. The
organic solution was dried with anhydrous sodium sulfate and concentrated in vacuo. The
oily residue was precipitated into cold diethyl ether (500-800 mL), filtered and dried in
vacuo to give 57a-e as white powders. Yield: (89-95 %).

PPEG-bis-azide (58a-e). PEG-bis-mesylate 57a-e (3.00 g) was dissolved in DMF (150
mL) and sodium azide (20.0 equiv.) was added. The solution was stirred for 90 °C for 48
hours. DMF was evaporated in vacuo. The residue was dissolved in DCM (200 mL),
filtered and washed with deionized water (150 mL) twice. The aqueous washes were
extracted with DCM (100 mL) twice each and the organic extracts were combined with
the original organic solution and concentrated in vacuo. The oily residue was precipitated
into cold diethyl ether (500-800 mL), filtered and dried in vacuo to give 58a-e as white
powders. Yield: (90-98 %).

PEG-bis-amine (59a-e). PEG-bis-azide 58a-e (3.00 g) was dissolved in ethyl acetate (50
mL) and 10% palladium on carbon (wet type) was added via spatula. The flask was
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equipped with a three-way adapter and a hydrogen balloon. The flask was evacuated and
purged with hydrogen three times and stirred vigorously under 1 atm hydrogen
atmosphere for 24 hours at ambient temperature. The solution was gravity filtered
through Celite and concentrated in vacuo. The oily residue was precipitated into cold
diethyl ether (500-800 mL), filtered and dried in vacuo to give 59a-e as white powders.
Yield: (88-96 %).

PEG-bis-carboxylic acid (60a-e). Jones oxidation was used to produce carboxylic acidterminal PEG. As a representative reaction, PEG (2.50 g) was dissolved in 280 mL
acetone. Jones’ Reagent (2.2 equiv) was added to a 500 mL round bottom flask and the
mPEG solution was added to this flask dropwise over 1 hour via addition funnel. The
resulting solution was stirred at 20 C for 1 hour before quenching the excess Jones
reagent with a few mL of iPrOH. The resulting green precipitate was removed by
decantation of the liquid solution. The volatiles were removed under reduced pressure
and the residue dissolved in 150 mL H2O. The aqueous phase was extracted with DCM (4
x 120 mL). Depending of PEG molecular weight, it may be necessary to add MeOH
(100-200 mL) to effect phase separation. The organic layers were combined and dried
over anhydrous Na2SO4, filtered, and evaporated under reduced pressure. The oily
residue was precipitated into cold diethyl ether (500-800-mL), filtered and dried in vacuo
to give 60a-e as white powders. TLC analysis was used to verify conversion using
bromocresol green stain. Yield: (88-94 %).
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PEG-bis-aldehyde (61a-e). Albright-Goldman oxidation was used to oxidize terminal
hydroxyl-moieties of PEG to aldehyde groups. PEG 56a-e was dissolved in a mixture of
dimethyl sulfoxide (DMSO) and acetic anhydride (Ac2O) (5 mL of 3:2 DMSO:Ac2O for
every 1 mmol of alcohol). This solution is prepared beforehand at least 24 hours before
reaction. The solution was stirred for 24 hours at ambient temperature. The solution was
concentrated in vacuo. The oily residue was precipitated into cold diethyl ether (500-800
mL) 2-3 times, filtered and dried in vacuo to give 61a-e as white powders. Yield: (89-94
%).

PEG-bis-amine (62a-e). An alternative synthesis of amine-terminal PEG was developed
utilizing reductive amination. PEG-aldehyde 61a-e (3.00 g), ammonium chloride (10.0
equiv) and potassium hydroxide (3.3 equiv) were dissolved in anhydrous MeOH (25 mL).
This solution was stirred for 30 min. A solution of sodium cyanoborohydride (10.0 equiv)
in anhydrous MeOH (10 mL) was added. And the solution was stirred under argon at
ambient temperature for 24 hours. The solution was poured into 100 mL of deionized
water and extracted with DCM (100 mL) four times. The organic extracts were dried over
anhydrous sodium sulfate and concentrated in vacuo. The oily residue was precipitated
into cold diethyl ether (500-800 mL), filtered and dried in vacuo to give 62a-e as white
powders. Yield: (91-97 %).

PEG-bis-ethylenediamine (63a-e). An alternative synthesis of amine-terminal PEG was
developed direct CDI coupling of ethylenediamine to PEG. PEG 56a-e (2.00 g) was
dissolved in DCM (100 mL), cooled down to 0 °C in an ice bath and triethylamine (10.00
equiv) was added followed by CDI (5.00 equiv). The solution was stirred for 2 hours
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warming to room temperature and ethylenediamine (20.0 equiv) was added via syringe.
The solution was stirred for an additional 24 hours at ambient temperature. The solution
was transferred to a separatory funnel and washed with 100 mL 5 % HCl twice followed
by deionized water. The organic phase was dried over sodium sulfate, concentrated and
precipitated into diethyl ether (600-800 mL), filtered and dried in vacuo to give 63a-e as
a white powders. Yield: (91-97 %).

PEG-bis-(tris-2-aminoethyl)amine) (64a-e). An alternative synthesis of amine-terminal
PEG was developed direct CDI coupling of tris-(2-aminoethyl)amine to PEG. PEG 56a-e
(2.00 g) was dissolved in DCM (100 mL), cooled down to 0 °C in an ice bath and
triethylamine (10.00 equiv) was added followed by CDI (5.00 equiv). The solution was
stirred for 2 hours warming to room temperature and tris-(2-aminoethyl)amine (20.0
equiv) was added via syringe. The solution was stirred for an additional 24 hours at
ambient temperature. The solution was transferred to a separatory funnel and washed
with 100 mL 5 % HCl twice followed by deionized water. The organic phase was dried
over sodium sulfate, concentrated and precipitated into diethyl ether (600-800 mL),
filtered and dried in vacuo to give 63a-e as a white powders. Yield: (89-95 %).

PEG-bis-(2-methyl-2-bromopropionamide) (65a-e). PEG-bis-amine (59a-e) (2.00 g),
2-methyl-2-bromopropionic acid (20.0 equiv), and HOBt (16.0 equiv) were dissolved in
20 mL DCM. DIEA (30.0 equiv) was added via syringe and the solution was cooled to 0
°C in an ice bath. EDC was added and the solution was stirred for 48 hours warming to
room temperature. The solution was diluted with 50 mL DCM and washed with % % HCl
(50 mL) twice then deionized water (50 mL). The organic solution was dried over
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anhydrous sodium sulfate, filtered and precipitated into diethyl ether (600-800 mL),
filtered and dried in vacuo to give 65a-e as white solids. Yield: (92-88 %).

4.6.2 Synthesis of TNBS-Capped Polyrotaxanes
TNBS-capped-PEG-bis-amine-α-CD polyrotaxanes (66a-d). α-CD (10.0 g, 10.28
mmol) was fully dissolved in 120 mL of deionized H2O before addition of PEG-bisamine (1.50 g). The mixture was sonicated for 30 min at 20 °C and the resulting white
gel-like substance stored at 20 °C for 12 h. TNBS was neutralized to pH of 9.0 via
addition of solid NaHCO3 to generate sodium 2,4,6-trinitrobenznesulfonate. Sodium
2,4,6-trinitrobenznesulfonate (4.00 equiv per mol polymer) was then added as an aqueous
slurry and stirred at 20 °C for 12 hours. The reaction mixture was washed via
centrifugation sequentially with water 8 times before dialyzing the product (molecular
weight cut-off 6,000-8,000) against DMSO for 3 d, then water for 3 d. The retained
dialysate was then lyophilized to give polyrotaxane 66a-d as yellow powders. Yield: (9288 %). Yield: a: 5.068 g, b: 1.605 g, c: 1.029 g, d: 0.653 g; 1H NMR (400 MHz, DMSOd6) δ 8.73-8.97 (s, TNB-C-H), δ 5.51 (d, α-CD-OH), 5.43 (s, α-CD-OH), 4.79 (s, α-CDOH), 4.47 (t, α-CD-C1-H), 3.87 – 3.06 (m, α-CD and PEG).

TNBS-capped-PEG-bis-ethylenediamine α-CD polyrotaxanes (67a,c,e). α-CD (10.0 g,
10.28 mmol) was fully dissolved in 120 mL of deionized H2O before addition of PEGbis-ethylenediamine (1.50 g). The mixture was sonicated for 30 min at 20 °C and the
resulting white gel-like substance stored at 20 °C for 12 h. TNBS was neutralized to pH
of 9.0 via addition of solid NaHCO3 to generate sodium 2,4,6-trinitrobenznesulfonate.
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Sodium 2,4,6-trinitrobenzenesulfonate (4.00 equiv per mol polymer) was then added as
an aqueous slurry and stirred at 20 °C for 12 hours. The reaction mixture was washed via
centrifugation sequentially with water 8 times before dialyzing the product (molecular
weight cut-off 6,000-8,000) against DMSO for 3 d, then water for 3 d. The retained
dialysate was then lyophilized to give polyrotaxanes 67a,c,e as yellow powders. Yield:
(92-88 %). Yield: a: 3.017 g, c: 4.434 g, e: 4.687 g. 1H NMR (400 MHz, DMSO-d6) δ
8.73-8.97 (s, TNB-C-H), δ 5.51 (d, α-CD-OH), 5.43 (s, α-CD-OH), 4.79 (s, α-CD-OH),
4.47 (t, α-CD-C1-H), 3.87 – 3.06 (m, α-CD and PEG).

TNBS-capped PEG- bis-(tris-2-aminoethyl)amine) α-CD polyrotaxanes (68b,c). αCD (10.0 g, 10.28 mmol) was fully dissolved in 120 mL of deionized H2O before
addition of PEG- bis-(tris-2-aminoethyl)amine) (1.50 g). The mixture was sonicated for
30 min at 20 °C and the resulting white gel-like substance stored at 20 °C for 12 h. TNBS
was neutralized to pH of 9.0 via addition of solid NaHCO3 to generate sodium 2,4,6trinitrobenzenesulfonate. Sodium 2,4,6-trinitrobenzenesulfonate (8.00 equiv per mol
polymer) was then added as an aqueous slurry and stirred at 20 °C for 12 hours. The
reaction mixture was washed via centrifugation sequentially with water 8 times before
dialyzing the product (molecular weight cut-off 6,000-8,000) against DMSO for 3 d, then
water for 3 d. The retained dialysate was then lyophilized to give polyrotaxanes 68b,c as
yellow powders. Yield: (92-88 %). Yield: b: 0.266 g, c: 0.170; 1H NMR (400 MHz,
DMSO-d6) δ 8.73-8.97 (s, TNB-C-H), δ 5.51 (d, α-CD-OH), 5.43 (s, α-CD-OH), 4.79 (s,
α-CD-OH), 4.47 (t, α-CD-C1-H), 3.87 – 3.06 (m, α-CD and PEG).
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4.6.3 NTA-Modification of TNBS-Capped Polyrotaxanes
t-Butyl-NTA-Modified-TNBS-capped-PEG-bis-amine-α-CD polyrotaxane (69).
Polyrotaxane 66c (200 mg, 7.42 µmol) was dried in a 100 mL round bottom flask at 40
°C under vacuum for 48 h before adding dry DMSO (20 mL) and stirring until the
material dissolved. N,N'-Carbonyldiimidazole (CDI, 1.328 g, 8.19 mmol) was added to
the polyrotaxane solution and the reaction allowed to proceed for 24 h at 20 °C under a
N2 atmosphere. The reaction mixture was precipitated using a mixed ethereal solution
(160 mL dry Et2O and 50 mL dry THF). The precipitate was added to NTA intermediate
15 (0.485 g, 1.13 mmol) in 10 mL dry DMSO and triethylamine (0.181 mL, 1.30 mmol)
and the reaction stirred for 24 h at 20 °C under N2. The product was dialyzed (molecular
weight cut-off 6.0-8.0 kDa) against DMSO for 48 hours then deionized water for 48
hours. The retained material was lyophilized to give t-butyl-NTA-modified polyrotaxane
69 as a yellow powder. Yield: 0.150 g.

NTA-Modified-TNBS-capped-PEG-bis-amine-α-CD polyrotaxane (70). Compound
69 (0.276 g) was dissolved in DMSO (20 mL). TFA (20 mL) was added with stirring for
6 hours to deprotect the NTA t-butyl esters. The solution was concentrated in vacuo to
remove TFA. The residue was dialyzed (molecular weight cut-off 6.0-8.0 kDa) against
DMSO for 72 hours followed by deionized water for 72 hours. The material was further
purified by Sephadex G-25 gel filtration chromatography using water as eluent.
Polyrotaxane 70 was recovered by lyophilization. Yield: 0.103 g.
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Bis(2-(trimethylsilyl)ethyl) 2,2'-((14,14-dimethyl-3,10-dioxo-1-phenyl-2,11-dioxa-4aza-14-silapentadecan-9-yl)azanediyl)diacetate (71). Compound 18 (10.62 g, 26.8
mmol), 2-(trimethylsilyl)ethanol (19.01 g, 160.8 mmol) and DMAP (2.45 g, 20.1 mmol)
were added to an oven dried 250 mL round bottom flask equipped with a magnetic stir
bar and a rubber septum. The contents were dissolved in a 3:1 DMF: pyridine solution
(250 mL) and cooled down to 0 °C in an ice bath. EDC (16.22 g, 84.6 mmol) was added.
The solution was stirred for 18 hours warming to room temperature. The solution was
concentrated and redissolved in Et2O (300 mL) and filtered. The filtrate was transferred
to a separatory funnel and washed with 5 % HCl (100 mL) twice then deionized water
(100 mL). The organic phase was dried over anhydrous sodium sulfate, concentrated and
purified by flask chromatography using 4:1 hexane: EtOAc as eluent. The pure fractions
were combined, concentrated and dried in vacuo to give 71 as a clear oil. Yield: 11.726 g
(62.8 %).; TLC: Rf= 0.33 (4:1 Hex: EtOAc); 1H NMR (400 MHz, CDCl3) δ 7.47 – 7.29
(m, 4H), 5.08 (s, 2H), 4.93 (s, 1H), 4.33 – 3.96 (m, 6H), 3.60 (s, 4H), 3.39 (t, J = 7.5 Hz,
1H), 3.26 – 2.99 (m, 2H), 1.80 – 1.60 (m, 2H), 1.60 – 1.43 (m, 4H), 1.43 – 1.33 (m, 1H),
1.33 – 1.04 (m, 1H), 0.98 (q, J = 8.4 Hz, 6H), 0.03 (d, J = 6.1 Hz, 28H).

Bis(2-(trimethylsilyl)ethyl) 2,2'-((6-amino-1-oxo-1-(2-(trimethylsilyl)ethoxy)hexan-2yl)azanediyl)diacetate (72). Compound 71 (12.136 g, 17.4 mmol) was dissolved in
MeOH (80 mL) in a 250 mL round bottom flask equipped with a stir bar and a three-way
adapter with 90 ͦ stopcock equipped with a balloon. A spatula tip of 10 % palladium on
carbon (wet type) was added and the flask was evacuated and purged with hydrogen 5
times. The heterogeneous mixture was stirred for 12 hours at ambient temperature. The
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solution was gravity filtered through a pad of Celite and activated carbon and the filtrate
was concentrated in vacuo to give Compound 72 as a clear oil. Yield: 9.156 g (93.4 %).;
TLC: Rf= 0.01 (4:1 Hex: EtOAc); 1H NMR (400 MHz, CDCl3) δ 4.47 (s, 3H), 4.21 –
3.99 (m, 6H), 3.53 (s, 4H), 3.33 (t, J = 7.5 Hz, 1H), 2.74 (t, J = 7.0 Hz, 2H), 1.63 (dd, J =
14.6, 7.9 Hz, 2H), 1.52 (tt, J = 17.2, 9.3 Hz, 3H), 1.37 – 1.27 (m, 1H), 1.06 – 0.70 (m,
5H), -0.03 (d, J = 4.2 Hz, 25H).

2,2-Dimethyl-6,15-dioxo-8-(2-oxo-2-(2-(trimethylsilyl)ethoxy)ethyl)-9-((2(trimethylsilyl)ethoxy)carbonyl)-5-oxa-8,14-diaza-2-silaoctadecan-18-oic acid (73).
Compound 72 (0.743 g, 1.31 mmol) was dissolved in DCM (30 mL). DIEA was added
via syringe (0.171 g, 1.32 mmol) followed by succinic anhydride (0.198 g, 1.98 mmol).
The solution as stirred for 18 hours under nitrogen at ambient temperature. The solution
was concentrated and redissolved in Et2O (150 mL). The solution was transferred to a
separatory funnel and washed with 0.1 M HCl (50 mL) twice. The organic phase was
dried over anhydrous sodium sulfate, concentrated and purified using a gradient of 10 %
MeOH/DCM to 15 % MeOH/DCM. The pure fractions were combined, concentrated and
dried in vacuo to give Compound 73 as a clear oil. Yield: 0.805 g (92.0 %).; TLC: Rf=
0.58 (15 % MeOH/DCM); 1H NMR (400 MHz, CDCl3) δ 9.22 (s, 1H), 6.70 (s, 1H), 4.13
(dd, J = 11.1, 5.6 Hz, 6H), 3.73 – 3.62 (m, 1H), 3.56 (d, J = 12.5 Hz, 3H), 3.38 (t, J = 7.5
Hz, 1H), 3.21 (dd, J = 12.0, 5.5 Hz, 2H), 2.61 (dd, J = 13.9, 7.0 Hz, 3H), 2.52 (d, J = 6.3
Hz, 2H), 1.79 – 1.60 (m, 2H), 1.58 – 1.34 (m, 4H), 1.32 – 1.10 (m, 1H), 0.95 (q, J = 8.1
Hz, 6H), -0.00 (d, J = 4.7 Hz, 25H).
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Dimethyl 2,2'-((6-(((benzyloxy)carbonyl)amino)-1-methoxy-1-oxohexan-2yl)azanediyl)diacetate (74). Compound 18 (8.353 g, 21.1 mmol) was dissolved in
anhydrous MeOH in an oven-dried 500 mL round bottom flask equipped with a magnetic
stir bar and rubber septum. The solution was cooled to 0 °C in an ice bath and sulfuric
acid (4.28 mL) was added dropwise via Pasteur pipette. A reflux condenser was attached
and the solution was heated to reflux and stirred for 60 hours. The solution was
concentrated in vacuo and redissolved in Et2O (250 mL). The solution was washed with 5
% NaHCO3 solution (80 mL) twice followed by deionized water (80 mL) and brine (80
mL). The organic phase was dried over anhydrous sodium sulfate, concentrated and
purified via flash chromatography using a gradient of 4:1 hexane: EtOAc to 1:1 hexane:
EtOAc. The pure fractions were combined, concentrated and dried in vacuo to give
Compound 74 as a clear oil. Yield: 6.711 g (72.6 %).; TLC: Rf= 0.37 (1:1 hexane:
EtOAc); 1H NMR (400 MHz, CDCl3) δ 7.09 (s, 5H), 5.52 (s, 1H), 4.85 (s, 2H), 3.42 (s,
13H), 3.19 (s, 1H), 2.93 (s, 2H), 1.45 (s, 2H), 1.27 (s, 3H), 1.14 (s, 1H). 13C NMR (101
MHz, CDCl3) δ 172.64, 171.42, 156.28, 136.73, 128.11, 127.66, 77.81, 77.49, 77.17,
65.89, 64.19, 52.01, 51.16, 50.97, 40.44, 32.72, 29.60, 29.05, 22.64.

Z-Lys-tris-NTA-(Otmse) (75). Compound 18 (1.61 g, 4.06 mmol) and Compound 72
(9.156 g, 16.3 mmol) and HOBt (1.98 g, 14.7 mmol) were added to an oven-dried 500
mL round bottom flask equipped with a magnetic stir bar and rubber septum. The
contents were dissolved in DMF (90 mL) and cooled to 0 °C in an ice bath. EDC (3.00 g,
14.7 mmol) was added and the solution was stirred for 48 hours warming to room
temperature. The solution was concentrated in vacuo and redissolved into EtOAc (200
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mL). the solution was washed with 5% HCl (80 mL) three times. The organic solution
was dried over anhydrous sodium sulfate, concentrated and purified via flash
chromatography using a gradient of 1:1 hexane:EtOAc to 100 % EtOAc. The pure
fractions were combined, concentrated and dried in vacuo to give Compound 75 as a
clear viscous oil. Yield: 3.894 g (47.2 %).; TLC: Rf= 0.77 (100 % EtOAc); 1H NMR (400
MHz, CDCl3) δ 7.45 (s, 1H), 7.33 (s, 4H), 5.13 (s, 1H), 5.07 (s, 2H), 4.37 – 3.90 (m,
19H), 3.58 (s, 11H), 3.37 (q, J = 10.2, 7.2 Hz, 6H), 3.28 – 2.89 (m, 10H), 1.84 – 1.61 (m,
7H), 1.50 (s, 12H), 1.35 (dp, J = 21.8, 6.9 Hz, 5H), 0.98 (q, J = 8.8 Hz, 18H), 0.03 (d, J =
5.1 Hz, 76H).

H2N-Lys-tris-NTA-(Otmse) (76). Compound 75 (1.00 g, 0.49 mmol) was dissolved in
MeOH (50 mL) in a 250 mL round bottom flask equipped with a magnetic stir bar and a
three-way adapter equipped with a balloon and a 90°stopcock. A spatula tip of 10 %
palladium on carbon was added and the flask was evacuated and purged with hydrogen
three times and the heterogeneous mixture was stirred at ambient temperature under 1
atm hydrogen for 18 hours. The mixture was gravity filtered through a pad of Celite and
activated carbon. The filtrate was concentrated and dried in vacuo to give Compound 76
as a clear oil. Yield: 0.922 g (98.8 %).; TLC: Rf= 0.02 (100 % EtOAc); 1H NMR (400
MHz, CDCl3) δ 7.90 (s, 1H), 6.28 (s, 1H), 4.37 – 3.88 (m, 18H), 3.67 – 3.43 (m, 12H),
3.39 (s, 3H), 3.32 (s, 3H), 3.26 – 3.02 (m, 9H), 2.95 (s, 1H), 1.62 (s, 9H), 1.37 – 1.13 (m,
4H), 0.94 (q, J = 8.4 Hz, 17H), -0.02 (d, J = 4.7 Hz, 74H).
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HO2C-Lys-tris-NTA-(Otmse) (77). Compound 76 (0.488 g, 0.26 mmol) was dissolved
in DCM (50 mL) in an oven-dried 250 mL round bottom flask equipped with a stir bar
and rubber septum. DIEA (183 µL, 1.03 mmol mmol) was added followed by succinic
anhydride (0.155 g, 1.55 mmol). The solution was stirred for 18 hours at ambient
temperature. The solution was concentrated in vacuo and redissolved in 120 mL Et2O.
The solution was transferred to a separatory funnel and washed with 0.1 M HCl (50 mL)
twice then deionized water (50 mL). The organic phase was dried over anhydrous sodium
sulfate, concentrated and purified via flash chromatography using 10 % MeOH/DCM as
eluent. The pure fractions were combined, concentrated and dried in vacuo to give
Compound 77 as a clear viscous soil. Yield: 0.492 g (97.4 %).; TLC: Rf= 0.29 (10 %
MeOH/DCM); 1H NMR (400 MHz, CDCl3) δ 7.65 (s, 1H), 4.26 – 3.94 (m, 18H), 3.61 (d,
J = 30.5 Hz, 11H), 3.50 – 3.40 (m, 3H), 3.34 (s, 4H), 3.23 (d, J = 22.1 Hz, 10H), 2.98 (s,
1H), 2.62 (d, J = 10.1 Hz, 6H), 1.83 (d, J = 11.7 Hz, 1H), 1.75 – 1.58 (m, 6H), 1.58 – 1.36
(m, 12H), 1.36 – 1.27 (m, 4H), 1.25 – 1.14 (m, 5H), 1.11 (d, J = 6.4 Hz, 1H), 0.96 (q, J =
8.0 Hz, 17H), 0.00 (d, J = 4.9 Hz, 72H).

Tmse-NTA-Modified-TNBS-capped-PEG-bis-ethylenediamine-α-CD polyrotaxane
(78). Polyrotaxane 67e (400 mg) was dried in a 100 mL round bottom flask at 40 °C
under vacuum for 48 h before adding dry DMSO (25 mL) and stirring until the material
dissolved. N,N'-Carbonyldiimidazole (CDI, 1.909 g) was added to the polyrotaxane
solution and the reaction allowed to proceed for 24 h at 20 °C under a N2 atmosphere.
The reaction mixture was precipitated using a mixed ether solution (160 mL dry Et2O and
50 mL dry THF). The precipitate was added to NTA intermediate 72 (0.633 g, 1.12
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mmol) in 10 mL dry DMSO and triethylamine (0.476 µL) and the reaction stirred for 24
h at 20 °C under N2. The product was dialyzed (molecular weight cut-off 6.0-8.0 kDa)
against DMSO for 48 hours then deionized water for 48 hours. The retained material was
lyophilized to give t-butyl-NTA-modified polyrotaxane 69 as a yellow powder. Yield:
0.600 g.

NTA-Modified-TNBS-capped-PEG-bis-ethylenediamine-α-CD polyrotaxane (79).
1.0 M TBAF in THF (6.6. mL) was added to 15 mL DMSO and THF was stripped in
vacuo. Compound 78 (0.400 g) was dissolved in this solution. The solution was stirred at
ambient temperature for 3 hours. The solution was dialyzed (molecular weight cut-off
6.0-8.0 kDa) against DMSO for 72 hours followed by deionized water for 72 hours.
Polyrotaxane 79 was recovered by lyophilization. Yield: 0.267 g.

4.6.4 Screening of Aqueous Endcapping Methods
Nα-Cbz-l-Phenylalanine-capped-PEG-bis-carboxylate-α-CD polyrotaxane (80). αCD (8.0 g, 10.28 mmol) was fully dissolved in 60 mL of deionized H2O before addition
of PEG-bis-carboxylate 52c (0.750 g). The mixture was sonicated for 30 min at 20 °C
and the resulting white gel-like substance stored at 20 °C for 12 h. The slurry was
transferred to two 50 mL centrifuge tubes and pelleted. The water supernatant was
decanted and the pseudorotaxane was lyophilized. A solution of Nα-Z-l-phenylalanine
(0.434 g, 1.50 mmol), NMM (0.379 g, 3.75 mmol) and HOBt (36.5 mg, 0.27 mmol) in
MeOH (30 mL). This solution was added to the lyophilized pseudorotaxane and EDC
(0.288 g, 1.50 mmol) was added. The heterogeneous slurry was stirred for 48 hours at
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ambient temperature. The reaction mixture was washed via centrifugation sequentially
with water 8 times before dialyzing the product (molecular weight cut-off 6,000-8,000)
against DMSO for 3 d, then water for 3 d. The retained dialysate was then lyophilized to
give polyrotaxane 80 as a white powder. Yield: 0.285 g.

Poly(oligoethyene glycol) methacrylate-capped-PEG-bis-(2-methyl-2bromopropionamide)-α-CD polyrotaxane (81). All deionized water was degassed via
sonication followed by bubbling nitrogen for 30 min. α-CD (8.00 g) was dissolved in
deionized water (60 mL). PEG-bis-(2-methyl-2-bromopropionamide) 65c (0.750 g) was
dissolved in 10 mL deionized water. The two aqueous solutions were combined in a 125
mL flask. The mixture was sonicated for 30 min at 20 °C and the resulting white gel-like
substance stored at 20 °C for 12 hours under nitrogen. mPEG-methacrylate (avg. Mn =
500 Da, 7.652 mL, 16.5 mmol) was added via syringe. Copper(II) bromide solution (1.45
mL, 1.0 M in deionized water, 1.46 mmol) and 2,2-bypyridine solution (bpy, 2.0 mL, 125
mg/mL in DMSO, 1.60 mmol) were combined and added to the pseudorotaxane solution
via syringe. Sodium-l-ascorbate solution (145.6 µL, 0.1 M in deionized water, 14.6 µmol)
was added via syringe and the slurry was stirred for 48 hours at ambient temperature. The
reaction mixture was washed via centrifugation sequentially with water 8 times before
dialyzing the product (molecular weight cut-off 6,000-8,000) against DMSO for 3 d, then
water for 3 d. The retained dialysate was then lyophilized to give polyrotaxane 81 as a
white powder. Yield: 0.878 g.
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4.6.5 Synthesis of Fluorescein-Capped Polyrotaxanes
PEG-bis-alkyne (82a-e). mPEG-bis-carboxylate 60a-e (2.50 g) were dissolved in DCM
(20 mL) in an oven dried 100 mL round bottom flask equipped with a magnetic stir bar
and rubber septum. HOBt (5.00 equiv), DIEA (10.00 equiv) and propargylamine (20.0
equiv) were added. The solution was cooled to 0 °C in an ice bath. EDC (10.0 equiv) was
added and the solution was stirred warming to ambient temperature for 48 hours. The
solution was diluted with 60 mL DCM. The solution was transferred to a separatory
funnel and washed with 5 % HCl (70 mL) twice then deionized water (70 mL) twice. The
aqueous washes were combined and extracted with DCM (50 mL) three times. The
organic extract was combined with the original DCM solution and dried over anhydrous
sodium sulfate. The solution was filtered, concentrated and precipitated into 400 mL
diethyl ether twice, filtered and dried in vacuo to give Compounds 82a-e as white
powders. Yield: (86-90 %).

5-Azido-3',6'-dihydroxy-3H-spiro[isobenzofuran-1,9'-xanthen]-3-one (84). 5aminofluorescein (.100 g, 0.29 mmol) was dissolved in a mixture of 1:1:2 (water:MeOH:
acetonitrile) (8 mL) in a 50 mL round bottom flask. The flask was filled with nitrogen
and stirred at 0 °C for 10 min. tert-Butyl nitrite (51.3 µL, 0.40 mmol) was added by
syringe, followed by trimethylsilyl azide (47.8 µL, 0.36 mmol) over 5 min. The flask was
covered with foil and stirred for 3 hours at ambient temperature. The solution was
concentrated in vacuo and purified by flash chromatography on silica with 85:15
(DCM:MeOH). Yield: 0.206 g (95.8 %).; TLC: Rf= 0.53 (15 % MeOH/DCM); 1H NMR
(400 MHz, Methanol-d4) δ 7.79 – 7.57 (m, 1H), 7.44 – 7.26 (m, 1H), 7.26 – 7.04 (m, 1H),
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6.95 – 6.73 (m, 2H), 6.72 – 6.62 (m, 2H), 6.59 (dd, J = 12.1, 2.3 Hz, 1H), 6.56 – 6.50 (m,
1H). 13C NMR (101 MHz, DMSO) δ 171.40, 167.83, 156.22, 143.49, 131.14, 129.19,
124.88, 117.83, 117.15, 113.30, 103.75, 49.64, 49.43, 49.22, 49.00, 48.79, 48.58, 48.37.
ESI+: expected 373.32, found 374.2 (M+H).

4-((tert-Butoxycarbonyl)amino)benzoic acid (86). 4-Aminobenzoic acid (4.00 g, 29.17
mmol) was dissolved in dioxane (100 mL) and deionized water (50 mL) in an oven-dried
250 mL round bottom flask equipped with a magnetic stir bar and rubber septum. Di-tertbutyl-dicarbonate (12.720 g, 58.28 mmol) was added followed by triethylamine (8.16
mL, 58.28 mmol). The solution was stirred for 24 hours at ambient temperature. The
solution was concentrated in vacuo and the crude product was precipitated via addition of
3.0 M HCl (15 mL). The crude product was filtered and recrystallized from
MeOH/deionized water to give Compound 86 as an off white crystalline solid. Yield:
4.799 g (69.3 %); 1H NMR (400 MHz, DMSO-d6) δ 12.59 (s, 1H), 9.72 (s, 1H), 7.82 (d, J
= 8.6 Hz, 2H), 7.54 (d, J = 8.5 Hz, 2H), 1.46 (s, 9H). 13C NMR (101 MHz, DMSO) δ
189.46, 167.90, 153.41, 144.66, 131.91, 124.82, 121.23, 118.80, 117.71, 117.37, 117.34,
80.53, 76.15, 41.00, 40.80, 40.59, 40.38, 40.17, 39.96, 39.75.

Di-tert-butyl 2,2'-((1-(tert-butoxy)-6-(4-((tert-butoxycarbonyl)amino)benzamido)-1oxohexan-2-yl)azanediyl)diacetate (87). Compound 86 (0.896 g, 3.78 mmol),
Compound 15 (1.626 g, 3.78 mmol) and HOBt (0.567 g, 4.34mmol) were combined in an
oven dried 250 mL round bottom flask equipped with a stir bar and rubber septum. The
contents were dissolved in DMF (38 mL). The solution was cooled to 0 °C in an ice bath
and EDC (0.833 g, 4.34 mmol) was added. The solution was stirred for 48 hours warming
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to ambient temperature. The solution was concentrated in vacuo and the residue was
dissolved in DCM (120 mL). The solution was transferred to a separatory funnel and
washed with 0.1 M HCl (80 mL) twice and deionized water (80mL). The organic solution
was dried over anhydrous sodium sulfate, filtered, concentrated and purified via flash
chromatography using 5 % MeOH/DCM as eluent. The pure fractions were combined,
concentrated and dried in vacuo to give Compound 87 as a clear oil. Yield: 1.090 g (44.5
%).; TLC: Rf= 0.35 (5 % MeOH/DCM); 1H NMR (500 MHz, CDCl3) δ 7.74 (d, J = 8.7
Hz, 2H), 7.39 (d, J = 8.6 Hz, 2H), 7.18 (s, 1H), 6.74 (t, J = 5.2 Hz, 1H), 3.69 (t, J = 6.6
Hz, 2H), 3.53 – 3.32 (m, 7H), 3.32 – 3.17 (m, 1H), 1.90 – 1.52 (m, 11H), 1.43 (d, J =
26.5 Hz, 25H), 1.37 (s, 15H). 13C NMR (126 MHz, CDCl3) δ 172.41, 170.75, 167.11,
152.50, 141.41, 128.78, 128.12, 117.57, 81.10, 80.71, 77.35, 77.10, 76.84, 67.89, 64.97,
53.95, 39.68, 29.94, 28.57, 28.28, 28.18, 28.07, 25.57, 23.03.

2,2'-((5-(4-Aminobenzamido)-1-carboxypentyl)azanediyl)diacetic acid (88).
Compound 87 (1.090 g, 1.68 mmol) was dissolved in DCM (15 mL) in an oven-dried 100
mL round bottom flask equipped with a magnetic stir bar and rubber septum.
Triethylsilane (0.195 g, 1.68 mmol) was added via syringe and the solution was cooled to
0 °C in an ice bath. TFA (15 mL) was added slowly and the solution was stirred for 2
hours warming to room temperature. The solution was concentrated and rotovapped
together with DCM (60 mL) three times. The residue was recrystallized twice from
Et2O/MeOH, filtered and dried in vacuo to give Compound 88 as a white crystalline
solid. Yield: 1.090 g (44.5 %); 1H NMR (500 MHz, Methanol-d4) δ 7.72 (d, J = 8.0 Hz,
2H), 6.93 (d, J = 7.9 Hz, 2H), 3.82 – 3.59 (m, 5H), 3.55 – 3.44 (m, 2H), 3.36 (t, J = 6.5
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Hz, 2H), 3.30 (s, 2H), 1.83 (d, J = 13.5 Hz, 1H), 1.64 (d, J = 13.2 Hz, 3H), 1.57 – 1.38
(m, 4H). 13C NMR (126 MHz, MeOD) δ 174.04, 168.46, 145.48, 128.63, 126.51, 116.58,
65.35, 53.87, 48.11, 47.94, 47.77, 47.60, 47.43, 47.26, 47.09, 39.22, 29.18, 28.73, 26.96,
23.45, 14.04.

2,2'-((1-carboxy-5-(4-isothiocyanatobenzamido)pentyl)azanediyl)diacetic acid (89).
Compound 88 (0.786 g, 2.06 mmol) was dissolved in deionized water (46.2 mL). The
slightly cloudy solution was cooled to 0 °C in an ice bath. Thiophosgene (355 mg, 3.09
mmol) was dissolved in DCM (12.73 mL) in an oven-dried 20 mL scintillation vial. The
thiophosgene solution was added to the aqueous solution of Compound 88 slowly. The
biphasic solution was stirred vigorously for 2 hours warming to ambient temperature. The
solution was stirred for an additional 30 min at 45 °C. The solution was concentrated to
remove DCM and the remaining aqueous solution was lyophilized to give Compound 89
as a white solid. Yield: 0.568 g (65.1 %); 1H NMR (500 MHz, DMSO-d6) δ 8.52 (t, J =
5.4 Hz, 1H), 7.87 (d, J = 8.7 Hz, 2H), 7.48 (d, J = 8.6 Hz, 2H), 3.62 – 3.42 (m, 5H), 3.38
(t, J = 7.3 Hz, 1H), 3.21 (q, J = 6.8 Hz, 2H), 1.70 – 1.59 (m, 1H), 1.56 (d, J = 10.2 Hz,
1H), 1.53 – 1.44 (m, 2H), 1.45 – 1.20 (m, 5H). 13C NMR (126 MHz, DMSO) δ 174.14,
173.32, 165.26, 135.20, 134.12, 132.74, 129.23, 126.29, 64.78, 53.74, 40.47, 40.31,
40.14, 39.97, 39.80, 39.64, 39.47, 29.62, 29.19, 28.18, 23.64.

Fluorescein-capped-PEG-bis-alkyne α-CD polyrotaxanes (90a-c). Alpha-cyclodextrin
(α-CD) (5.33 g) was dissolved in 35 mL water. PEG-bis alkyne (82b-d, a = 0.500 g, 0.15
mmol; b = 0.500 g, 0.05 mmol; c = 0.500 g, 0.025 mmol) was dissolved in 11.66 mL
water. The solutions were combined flushed with nitrogen and sonicated for 1 hour. After
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several minutes the materials formed a white gel. The solutions were stirred at ambient
temperature for 12 hours. 5-Azidofluorescein 84 (a = 219 mg, 0.587 mmol; b = 75 mg,
0.200 mmol; c = 38 mg, 0.102 mmol) was added as a solution in 2 mL DMSO and the
solutions were stirred for 10 min. 1.0 M CuSO4 solution (a = 148 μL, 0.148 mmol; b = 50
μL, 0.052 mmol; c = 25 μL, 0.025 mmol) and 1.0 M sodium-l-ascorbate solution (a = 294
μL, 0.293 mmol; b = 100 μL, 0.010 mmol 0.100 mmol, c = 50 μL, 0.050 mmol) were
added via syringe and the heterogeneous solution was stirred for 48 hours at ambient
temperature. The material was centrifuged, the supernatant was decanted, and the
centrifugate resuspended in 5% EDTA solution and centrifuged. This process was
repeated twice more to remove the remaining copper(II) and copper(I). The material was
dialyzed against DMSO (MWCO = 6-8 kDa, Fisher) to remove unreacted materials for 3
days and deionized water for 3 days with regeneration of the dialysate 2-3 times/day. The
material remaining was lyophilized to obtain the unmodified Fluorescein-capped
polyrotaxanes 90a-c as yellow powders. Yield: a = 2.408 g, b = 2.939 g, c = 1.691 g.

4.6.6 NTA-Modification of Fluorescein-Capped Polyrotaxanes
EBE-modified-fluorescein-capped-PEG-bis-alkyne α-CD polyrotaxanes (91a-c).
Compounds 90a,b,c (0.500 g) were dissolved in DMSO (15 mL). The solutions were
sonicated to obtain complete dissolution. TEA (a,b,c = 414 μL, 0.003 mmol) was added
followed by CDI (a = 0.196 g, 1.21 mmol; b = 0.204 g, 1.26 mmol, c = 0.192 g, 1.18
mmol). The solutions were flushed with nitrogen and stirred for 24 hours at ambient
temperature. 2,2’-(Ethylenedioxy)bis(ethylamine) (EBE, a = 4.33 mL, 29.70 mmol, b =
4.58 g, 30.23 mmol; c = 4.38 g, 29.55 mmol) was added by syringe and the solutions
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were stirred for an additional 24 hours. The material was dialyzed against DMSO
(MWCO = 6-8 kDa, Fisher) to remove unreacted materials for 3 days and deionized
water for 3 days with regeneration of the dialysate 2-3 times/day. The material remaining
was lyophilized to obtain the EBE-modified-fluorescein-capped polyrotaxanes 91a-c as
yellow powders. Yield: a = 0.259 g, b = 0.215 g, c = 0.302 g.

NTA-modified-fluorescein-capped-PEG-bis-alkyne α-CD polyrotaxanes (92a-c).
EBE-modified-fluorescein-capped-PEG-bis-alkyne α-CD polyrotaxanes (91a-c: a: 0.125
g, b: 0.103 g, c; 0.156 g) were dissolved in DMSO (4 mL) and deionized water (3 mL) in
oven-dried 100 mL round bottom flasks equipped with magnetic stir bars and rubber
septa. Compound 89 (a-c: 70 mg) was added followed by DIEA (a-c: 100 µL). The
solutions were stirred for 18 hours at ambient temperature. The material was dialyzed
against deionized water (MWCO = 6-8 kDa, Fisher) to remove unreacted materials for 8
days with regeneration of the dialysate 2-3 times/day. The material remaining was
lyophilized to obtain the EBE-modified-fluorescein-capped polyrotaxanes 91a-c as
yellow powders. Yield: a = 0.095 g, b = 0.092 g, c = 0.132 g.

4.6.7 Ni-Activation of NTA-Modified Polyrotaxanes
NTA-modified polyrotaxane 70 (100 mg) was dissolved in 1 mL of 20 mM Ni2+
solution and the excess Ni2+ removed by gel filtration using Sephadex G-25M. After
lyophilization, the Ni2+:70 complex was obtained as a solid (60 mg).
NTA-modified polyrotaxanes 92a-c (50 mg) were dissolved in 1mL of 20 mM
Ni2+ solution and the excess Ni2+ was removed via dialysis against deionized water
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(MWCO = 2.0 kDa) to remove free Ni2+. After the dialysate contained to Ni2+, the
solutions were flash frozen and lyophilized.

4.6.8 Gel-Permeation Chromatography (GPC)
GPC was performed using an Agilent 1200 Series GPC equipped with a Wyatt
Dawn Heleos-II multi-angle light scattering (MALS) detector, Wyatt Optilab rEX
refractive index (RI) detector and Wyatt quasi-elastic light scattering (QELS) detector
using a single Shodex OHpakSB-803 HQ (8.0x3000 mm, 6 µm) column preceded by a
Shodex OHpak SB807G (8.0x50.0 mm, 35 µm) guard column using DMSO as eluent.
dn/dc was determined for each sample using a five-point calibration curve (0.5-2.5
mg/mL) generated using Optilab rEX detector in flow mode in combination with ASTRA
software. Samples were dissolved at 1.8 mg/mL in DMSO and run at 0.2 mL/min. Mn
and Mw/Mn were calculated using ASTRA software.

4.6.9 Preparation of ICP-MS Samples
Ni2+:70 or Ni2+:92a-c complex (2.6 mg) was digested in 1 mL 70% HNO3 (Aristar
Ultra, VWR, West Chester, PA) solution for 3 days. The solution was diluted with double
deionized water until reaching a concentration of 2% HNO3 (35 mL, 2.25 µM) and then
further diluted 103-fold with 2% HNO3 solution. Standard solutions of Ni2+ were
prepared by diluting a NiSO4 standard solution (Exaxol, Clearwater, FL) with 2% HNO3
solution until reaching a final concentration of 10 ppb. Blank 2% HNO3 solutions were
prepared by diluting 70% HNO3 (Aristar Ultra) with double deionized water.
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4.6.10 Fluorescence Microscopy
A 3.0 µM his6-GFP solution in 10 mM HEPES buffer at pH 8.0 was prepared and
a 10 µL aliquot transferred to a glass slide, covered with a cover slip and examined by
fluorescence microscopy (Figure 2A). In order to visualize the Ni2+:70 complex, a
solution of Ni2+:70 complex without protein (control) was prepared by mixing a 20 mM
NiSO4 solution and NTA-polyrotaxane in a 1:1 Ni2+:NTA ratio to yield a 176 nM
solution which was then transferred to a glass slide, covered with a cover slip and
examined by fluorescence microscopy (Figure 2B). In order to visualize the his6GFP:Ni2+:70 complex, a his6-GFP:Ni2+:70 solution was prepared by adding an aliquot of
3.0 µM his6-GFP in 10 mM HEPES buffer at pH 8.0 to a 176 nM Ni2+:70 solution to
attain 1:1 his6-GFP:α-CD stoichiometry. A 10 µL sample of this solution was transferred
to a glass slide, covered with a cover slip and examined by fluorescence microscopy
(Figure 2C). A 10 µL aliquot of 500 mM imidazole was added to the solution in Figure
2C and a 10 µL sample of this mixture sealed with a cover slip and evaluated by
fluorescence microscopy (Figure 2D). All measurements were made using a Olympus
BX51 microscope with a 10 X objective and a DP71 CCD camera; the raw data were
analyzed using Metavue Processing Software. Final images were converted to grayscale
and the brightness and contrast adjusted equally in all images to enhance visualization.

4.6.11 Atomic Force Microscopy
AFM samples were prepared to further visualize the adsorption properties of the
his6-GFP: Ni2+:70 complex (Figure 3A). A 176 nM solution of Ni2+:70 complex without
protein (control) was prepared by mixing a 20 mM NiSO4 solution and NTA-
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polyrotaxane in a 1:1 Ni2+:NTA ratio to yield a 176 nM solution (Figure 3B). A 176 nM
Ni2+:4 complex solution and a 3.0 µM his6-GFP solution in 10 mM HEPES buffer at pH
8.0 were mixed to attain a 1:1 his6-GFP:α-CD stoichiometry on the mica surface (Figure
3C). A third sample was prepared as described for Figure 3B, except that a 10µL aliquot
of a 500 mM imidazole solution was added to a 10µL sample of the solution in Figure 3B
to strip GFP from the polyrotaxane scaffold. The samples were visualized by tappingmode AFM using a Multimode AFM with a Nanoscope IIIa controller (Veeco) in air at
22 °C. The AFM tips (NSC15/AlBS, MikroMasch, USA) used had a typical uncoated
probe tip radius of 10 nm or less; the cantilevers had a spring constant of 40 N/m.

4.6.12 Transmission Electron Microscopy
TEM was performed using a FEI/Philips CM-10 Bio-Twin instrument and
captured on Kodak electron image film (type so-163). Copper 400 mesh grids stabilized
with formvar and carbon (Ted Pella INC. product No. 01814-F) were glow discharged
under a plasma for 30 seconds prior to specimen loading. The imaging conditions were:
spot size 3, accelerating voltage = 80kV, and apertures of 50 µm (AuF objective) and 200
µm (condenser). All specimens were stained with an aqueous 2% uranyl acetate solution
as described below.
A 7.0 µL drop of the specimen was loaded onto the grid and left for 10 sec. Filter
paper was used to wick away most of the 7.0 µL drop (leaving just enough to cover the
surface of the grid) followed by 3 washing steps with 7.0 µL of double de-ionized water
(wicking with filter paper after each wash). After the last washing step with water, 7.0 µL
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of staining solution was applied to the grid, wicked away with filter paper, and repeated a
second time. The specimen was then allowed to dry before imaging.

4.6.13 Cryogenic Electron Microscopy
For cryo-EM imaging using Compound 70. A 176 nM Ni2+:70 solution (Figures
4A & S2A) and a mixed solution of 176 nM Ni2+:70 complex + 3.0 µM his6-GFP (1:1
his6-GFP:α-CD stoichiometry) in 10 mM HEPES buffer, pH 8.0 (Figures 4B & S2B)
were concentrated to ∼1 mM, spread onto C-FlatTM grids then plunge-frozen in liquid
ethane. Images were recorded using a Gatan 4k × 4k charge-coupled device camera on a
Philips CM-200 TEM.
For cryo-EM imaging using Compound 92c. Samples were prepared as detailed in
SDS-PAGE and resuspended into 50 µL PBS, spread onto C-flatTM grids then plungefrozen in liquid ethane. Images were recorded using a Gatan 4k × 4k charge-coupled
device camera on a Philips CM-200 TEM.

4.6.14 Expression of His6-GroEL and His6-GFP
The ASKA Library was used to express N-terminal His6-GroEL. Cells containing
N-His6-GroEL gene overexpression vector were grown to OD = 0.6 (in 100 mL of LB
broth using a 37 ˚C shaker/incubator) and induced with a final concentration of 1.0 mM
IPTG, before allowing the cells to grow for an additional 4 h. After centrifugation and
removal of the supernatant, the cell pellets were stored at -80 °C and split among 5
different 50 mL tubes (200 mL broth equivalent). Each cell pellet was re-suspended in
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lysis buffer (6.0 mL 50 mM PBS, 500 mM NaCl, pH = 7.4, 100 µg aprotinin, 174 µg
phenylmethanesulfonyl fluoride (PMSF), and 500 µg of lysozyme) and allowed to sit for
1.5 h (stirring every 30 min). Further disruption of the cell membranes was effected by
110 W probe sonication (35 pulses at 1 second/pulse), followed by centrifugation at
11,000 g for 30 min. The supernatant was removed and filtered through a 0.1 µm PVDF
membrane and used for experiments immediately.
His6-GFP was expressed from BL21 (DE3, MW 27.950.3 g/mol, ε280 = 22015,
pI= 6.30)) E. coli containing the his6-GFPuv pT7-7plasmid with C-terminal his-tag. His6GFP gene overexpression vector were grown to OD = 0.6 (in 100 mL of LB broth using a
37 °C shaker/incubator) and induced with a final concentration of 1.0 mM IPTG, before
allowing the cells to grow for an additional 3 h. Cells were centrifuged at 4,000 g for 10
minutes at 4 °C. The cell pellets were stored at -80 ᵒC. The pellet was resuspended in
25.0 mL PBS containing 1mM PMSF. The cell suspension was vortexed and sonicated
and a spatula tip of lysozyme was added. The suspension was incubated for 1.5 h (mixing
every 30 min.). The suspension was probe sonicated and for 15 minutes using microtip
(pulsed, 30 % duty cycle) and centrifuged at 11,000 rpm for 30 min at 4 °C. The
supernatant was removed and filtered through a 0.1 µm PVDF membrane and further
purified by FPLC.

4.6.15 SDS-PAGE
A solution of 92 (450 µg/mL) in PBS 20 mM, 500 mM NaCl) was made and any
undissolved material was removed by centrifugation followed by filtration of the
supernatant through a 0.1 µm PVDF membrane. 92:his6-GroEL solution was made by
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mixing different volumes of GroEL lysate with 92 solution. The solution was allowed to
sit for 30 min at 4 °C and was centrifuged at 12,000 g for 30 min. The supernatant was
decanted and the pellet was resuspended in 50 µL PBS.

4.6.16 UV-Vis Analysis of PR-NTA Interaction with His6-GroEL and His6-GFP
A solution of Compound 84 was made at 15 µg/mL in PBS (20 mM, 500 mM
NaCl). Solutions of 92a-c were made at 350 µg/mL in PBS (20 mM, 500 mM NaCl).
Any undissolved material was removed via centrifugation and filtration of the
supernatant through a 0.1 µm PVDF membrane. Mixtures of 92 and his6-Gro-EL lysate
and his6-GFP were made by mixing 1.0 mL of the protein solution with 100 µL of 92
solution. Samples were centrifuged at 12,000 g for 30 min at 4 °C and samples were
resuspended in 50 µL PBS (20mM, 500 mM NaCl) and analyzed via UV Vis
spectroscopy. This process was scaled up to generate larger samples for UV-Vis analysis
and visual analysis (e.g. the photos of the complex pellets).
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CHAPTER FIVE:
DEVELOPMENT OF NOVEL BLOCK COPOLYMERS FROM
ORGANOCATALYTIC RING-OPENING POLYMERIZATION FOR DRUG AND
GENE DELIVERY

5.1 Introduction
There has been considerably increased interest in the use of nanoparticle-based
drug delivery systems in recent decades1. Nanoparticles2 are defined as colloidal-sized
particles having diameters between 1 and 1000 nm. These materials may have drugs or
other therapeutic agents dispersed passively or via chemical ligation to alter the
pharmacokinetic and pharmacodynamics properties of the therapeutic agent3.
A wide variety of nanoparticles composed of a vast array of materials including
lipids, polymers, biomolecules and inorganic materials have been investigated, resulting
in diverse delivery systems that vary in their physicochemical properties and are suited to
address a variety of challenges. Thus far, many different nanoparticle-based drug delivery
systems have been developed including, but not limited to, liposomes4, micelles5,
nanospheres6, niosomes7, nanocapsules8, solid lipid nanoparticles9, microemulsions,
polymersomes10 and carbon nanotubes11 (Figure 5.1).

235

Figure 5.1 Classification of Nanoparticulate-Based Drug-Delivery Systems8b.

5.1.1 Diblock Copolymers in Drug and Gene Delivery
Amphiphilic block copolymers have been one of the most extensively studied
delivery platforms owing to their synthetic accessibility, modular properties, and the
variety of nanoparticle types which may be formulated using these materials. The interest
in amphiphilic polymer-based nanoparticles owes in part to several advantages they
provide for delivering their payload. The nano-scale size of these materials allows for
direct administration of the therapeutic agent to the bloodstream via intravenous
injection. Nanoparticles under ~200 nm show increased circulation times, which may be
attributed to increased radius of curvature, which smaller particles possess compared to
larger particles and may prevent efficient binding of opsinins12. They also show
decreased renal excretion if the particles are sufficiently large enough to avoid glomerular
filtration. Furthermore, the extended circulation times of nanoparticle-based drug
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delivery systems has also been shown to lead to increased accumulation of nanoparticleassociated therapeutic agents in tissues with increased vascular permeability and impaired
lymphatic drainage13. This principle, known as the enhanced permeability and retention
(EPR) effect1b, has been proposed to allow for passive targeting of the therapeutic agent
to its site of action while reducing accumulation in healthy tissue. This may allow for
enhanced therapeutic efficacy in comparison to the therapeutic agent in the absence of the
drug delivery system. Nanoparticles have also been used to increase the aqueous
solubility of hydrophobic drugs via solubilization within the hydrophobic cores of the
delivery system14.

Figure 5.2 Amphiphilic Copolymer-Based Drug Delivery Platforms and Their General
Characteristics8b.
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Amphiphilic block copolymers have attracted a great deal of attention in terms of
their ability to form many different types of nanoparticles (Figure 5.2). These compounds
are typically prepared via polymerization of multiple monomers or the macroinitiation of
a polymerization by an existing polymer. Amphiphilic copolymers typically consist of a
hydrophilic block and a hydrophobic block. The amphiphilic detergent-like nature of the
resulting copolymer enables access to many different nanoparticle structures.

Figure 5.3 Architectures of Various Therapeutic Strategies Utilizing Amphiphilic Block
Copolymers.

Amphiphilic copolymers often consist of biocompatible, biodegradable
hydrophobic blocks like polyesters15, poly(amino acids)16, polycarbonates17,
polyphosphoesters18 and polysiloxanes19 conjugated to biocompatible hydrophilic blocks.
Common hydrophobic blocks include poly(lactic acid) (PLA)20, polycaprolactone
(PCL)15a, 21, polyvalerolactone (PVL), poly(lactide-co-glycolide) (PLGA)6, 15b, 22 among
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many others. Amphiphilic copolymer-based systems often incorporate poly(ethylene
glycol) (PEG) to act as a hydrophilic component and barrier to adhesion12a, 23. However,
other hydrophilic polymers blocks like poly(N-vinyl-2-pyrrolidone), poly(2-ethyl-2oxazoline)19a and poly(acrylic acid)24 have also been used. Amphiphilic copolymers
enable the design of complex multifunctional drug delivery platforms via the facile
incorporation of targeting ligands, imaging agents, therapeutic agents and other cargo
(Figure 5.3). These constructs may also be designed to undergo stimuli-sensitive
degradation to achieve controlled release of their cargo.
To date, many different block copolymers have been synthesized composed of
varying block compositions and relative block lengths. By precisely controlling the
composition and relative molecular weights of block copolymers, various nanoparticle
structures such as micelles, nanospheres, core-shell nanoparticles, nanocapsules, and
polymersomes may be obtained. Many different methods of formulation have been
utilized for production of these materials including, but not limited to, emulsification25,
nanoprecipitation, emulsion polymerization, or microfluidic strategies26.

5.1.2 Organocatalytic ROP
In recent years, organic catalysis has become an increasingly attractive method for
the synthesis of functional amphiphilic copolymers and has become a powerful
alternative to traditional metal-based catalysis27. Since the first report of living
polymerization of lactide using 4-dimethylamino-pyridine (DMAP) reported by
Nederberg et al28, organocatalysis has progressed to the point that organic catalysts can
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now offer many tangible advantages in comparison with their organometallic
counterparts. Most organic catalysts are relatively inexpensive commercially-available
chemicals, which are generally easily purified, have long shelf lives, and are well-suited
for a range of reaction conditions, solvents and monomers. Generally, they are organic
acids or bases, which simply require drying to allow for good control of molecular weight
and end group fidelity. This is because water can typically act as an initiator, leading to
altered end groups and decreased polymer molecular weight relative to the targeted
molecular weight.

Figure 5.4 Coordination-Insertion Mechanism for Metal-Catalyzed ROP.

Ring-opening polymerization (ROP) is the most common method for synthesis of
well-defined biodegradable block copolymers. ROP may be used to generate many
different polymers including polyesters, polycarbonates, etc., which are attractive for
therapeutic applications. Traditional metal-based catalysts generally function via the
coordination-insertion mechanism (Figure 5.4) as in the case of the polymerization of llactide by tin(II) 2-ethylhexanoate. These catalysts have generated concerns related to
trace contamination of the polymer with catalyst, which may lead to significant toxicity.
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Figure 5.5 Dual Activation Mechanism of Monomer and Initiator in ROP of δValerolactone by TBD.

Common orgnanocatalysts for ROP include N-heterocyclic carbenes, organic
“super base” catalysts29 and bifunctional catalysts. (-)-Sparteine has been used as an
organocatalyst, but due to its low availability as a natural product, it has not been
extensively studied. Tris[2-(dimethylamino)ethyl]amine (Me6TREN) has been shown to
exhibit similar activity to (-)-sparteine. Bifunctional thiourea-amine catalysts were first
applied to the polymerization of lactide30. These systems involve simultaneous activation
of monomer by the thiourea (a Lewis acid) and the initiator (an alcohol) by the aminecomponent. This strategy was applied to two-component systems of thiourea and organic
base and bifunctional thiourea-amine (TU/A) catalysts30. However, these systems show
relative sluggish polymerization kinetics for other monomers (caprolactones, carbonates,
etc.).
The most common super-base catalysts include 1,8-diazabicyclo[5.4.0]undec-7ene (DBU), 1,4,5-triazabicyclo[4.4.0]dec-5-ene (TBD), 7-methyl-3,5,7triazabicyclo[4.4.0]dec-5-ene (MTBD), and other phosphazene-based compounds27.
These catalysts are more active than the TU/A system, display different activities (TBD >
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MTBD > DBU) and have been applied for the polymerization of many different cyclic
monomers31. TBD, in particular has been shown to exhibit very high reactivity for
monomers with low ring strain or which exhibit low conversion with other catalysts.
TBD functions via dual activation of the monomer and initiator in an analogous fashion
to the TU/A-based catalysts (Figure 5.5). Alternatively, TBD has been shown to
polymerize L-lactide via an H-bonding mechanism which does not involve acyl
transfer32.

5.1.3 Pendant Polymer-Based Gene Delivery
Gene delivery involves the treatment of human disease via the transfer of genetic
material into specific cells of the patient33. Advances in biotechnology, along with the
completion of the human genome project, have led to the identification of numerous
disease-causing genes. Gene therapy may offer potential therapeutic benefit for genetic
diseases that are currently untreatable or involve challenging treatment regimens.
Various approaches to gene delivery have been proposed, but gene delivery
vectors are classified as being either viral or non-viral. Viruses like retrovirus,
adenovirus, lentivirus, herpes simplex virus and pox virus may all be transformed into
gene delivery vehicles by replacement of part of the viral genome with the therapeutic
gene of interest. Viral vectors account for the majority of gene delivery studies in the
literature and ongoing clinical trials. However, safety concerns associated with
immunogenicity of viral vectors have been the primary bottleneck to progress on viral
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gene delivery. There are also concerns associated with large scale production of viralbased gene therapies.
Non-viral gene therapy34 offers the potential for improved safety, greater
flexibility, and more facile and robust design and production strategies. Non-viral gene
delivery vectors function to electrostatically bind the nucleic acid cargo, condense the
cargo into particles, protect the cargo from degradation and mediate cellular entry. Many
different material strategies have been proposed as non-viral gene-delivery vectors11, 35.

Figure 5.6 Pendant Polymer-Based Gene Delivery Strategies. (A) Fabrication of CholPVA-PEG pendant polymer-based transfection complexes and transfection. (B) Chemical
structures of Chol-PVA-PEG and cationic β-CD derivatives36. (C) Structures of
hyaluronic acid (HA)-based pendant polymers and β-CD -PEI.

Kulkarni et al.36-37 first introduced the concept of pendant-polymer-based gene
delivery with the system composed of poly(vinyl alcohol) (PVA) grafted with PEG and
also grafted with cholesterol via acid-sensitive benzylidene acetal linkages, amine-
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modified-β-cyclodextrin and siRNA as a therapeutic agent (Figure 5.6A,B). These
materials effectively formed transfection complexes in the 120-170 nm range via
electrostatic interaction of siRNA and the cationic cyclodextrins, which are further held
together via non-covalent interactions of cholesterol with the CD-cavities. β-CD has been
shown to possess host-guest interactions with a wide variety of compounds with binding
constants in the 100.5-105 M-1 in aqueous media38. Another approach, based on
cyclodextrin-containing oligomers, has also been introduced by Davis3, 35b, 39. The
pendant polymer concept was further applied to microfluidic assembly of transfection
complexes composed of hyaluronic acid (HA)-modified with adamantine, β-CD-PEI
conjugate and siRNA26a.
Although these materials showed good performance, several issues related to the
reproducibility of the PVA and HA-based material synthesis, and the limitations
associated with working from pre-formed commercial materials, prompted the design of a
second generation of pendant polymers. We sought to improve on the pendant polymer
concept by utilizing organocatalytic ROP to synthesize a library of well-defined blockcopolymers, which could allow for tunable synthesis, the incorporation of targeting
moieties and biodegradability.

5.2 Organocatalytic ROP Synthesis of PEG-b-Polycarbonate Pendant Polymers
The oligocarbonate-based non-viral gene delivery introduced by Cooley et al31b
prompted the design of pendant polymers based on PEG-polycarbonate diblock
copolymers (Figure 5.7). These materials are designed for tunable synthesis via
organocatalytic ROP mediated by various organic catalysts. Specifically, TBD and the
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DBU/thiourea-based system30 were utilized due to their respective activities and abilities
to generate well-defined copolymers with low polydispersity29a. Polycarbonate diblocks
are also expected to show controlled and sustained degradation rates and degrade into
non-acidic and non-toxic by-products, which are suitable for biomedical applications. In
addition to homopolymerization of cyclic carbonate monomers initiated by mPEG
(Figure 5.7A), copolymers where the cyclic carbonate monomer is blended with
trimethylene carbonate (TMC) are also included in the library to evaluate the effect of
pendant group density on nanoparticle formation and efficacy of transfection complexes
derived from mPEG-b-polycarbonate materials (Figure 5.7B).

Figure 5.7 Chemical Structures of Targeted mPEG-b-Polycarbonate Pendant Polymer
Library. (A) Homopolymerization of carbonate monomers. (B) Copolymerization of
carbonate monomers blended with trimethylene carbonate (TMC).

We sought to synthesize a library of mPEG-b-polycarbonate diblock copolymers
bearing various moieties, which exhibit affinity for the β-CD cavity, various overall
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molecular weight and relative block length, and various densities of pendant group along
the linear polycarbonate backbone. These materials were designed to form transfection
complexes together with the β-CD-PEI conjugate introduced previously26a and the
nucleic acid cargo to effect gene delivery (Figure 5.8).

Figure 5.8 Schematic of Gene Delivery Using the mPEG-b-Polycarbonate:β-CD-PEIBased Gene Delivery Strategy.

5.2.1 Synthesis of Cyclic Carbonate Monomers
In order to generate a library of mPEG-b-polycarbonate pendant polymers, a
small library of cyclic carbonate monomers bearing ethyl, benzyl, cholesteryl, and
adamantyl esters were synthesized following a modified method previously reported for
synthesis of cyclic carbonates with various functionalities40. These pendant groups were
chosen due to their known host:guest interaction with β-CD.
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Scheme 5.1 Synthesis of Cyclic Carbonate Monomers.

2,2-Bis(hydroxymethyl)propionic acid (BHMPA, 93) was chosen as the
commercial feedstock for synthesis of cyclic carbonate pendant monomers. BHMPA is a
cheap, commercially available common building block for synthesis of six-membered
cyclic carbonates. Treatment of BHMPA with benzyl bromide in DMF after formation of
the potassium salt of BHMPA gave Compound 94 in 83.2 % yield after recrystallization.
Compound 94 was treated with triphosgene in a solution of DCM and pyridine at -78 °C
to yield the benzyl carbonate monomer 95 in 82.6 % yield after chromatographic
purification. Carboxylate derivative 96 was obtained via benzyl ester hydrogenolysis with

247
10 % palladium on carbon to give 96 in 95.8% yield. Cholesteryl ester derivative 97 was
synthesized via esterification of Compound 96 and cholesterol mediated by EDC and
DMAP in a solution of DCM and THF in 68.1% yield after chromatographic purification
and recrystallization. Adamantyl ester derivative 98 was synthesized via esterification of
Compound 96 and 1-adamantanemethanol mediated by EDC and DMAP in THF in
47.9% yield after chromatographic purification and recrystallization.

Scheme 5.2 Syntheses of Trimethylene Carbonate.

Trimethylene carbonate (TMC) was synthesized as a spacing monomer in order to
vary pendant group density along the linear polycarbonate backbone. TMC was initially
synthesized using di-tert-butyl dicarbonate (Boc2O) and DMAP in acetonitrile to give
102 in 74.2% yield after chromatographic purification and recrystallization. This method
is very fast, but suffers from the use of large quantities of reagents and necessitates
chromatographic purification. An alternative synthesis of TMC utilizing 3-bromo-1propanol under 1 atm of carbon dioxide in the presence of cesium carbonate in DMF was
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used to give 104 in 89.0% yield after recrystallization. This method gives TMC in overall
higher yield and only requires crystallization to yield monomer suitable for
polymerization. However, this method requires extended reaction times to generate TMC
in respectable yield.

5.2.2 Homopolymerization of Carbonate Monomers by TBD

Scheme 5.3 Synthesis of mPEG-b-PTMC Diblock Copolymers.

Initial polymerization studies focused on synthesis of mPEG-b-PTMC via
organocatalytic ROP of TMC initiated by mPEG of various molecular weights catalyzed
by TBD (Scheme 5.3). PEG and TMC were purified by precipitation and
recrystallization, respectively, before polymerization. A molecular weight of 12.0 kDa
was targeted for the PTMC blocks of the three diblock copolymers 105a-c.
Polymerizations were carried out under nitrogen at 1.0 M initial TMC concentration in
DCM with 5 mol % TBD as catalyst. Polymerizations were quenched after 12 hours with
benzoic acid and purified via precipitation into diethyl ether.
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Table 5.1 Characterization of mPEG-b-PTMC.

Compounds 105a-c were characterized via 1H-NMR and GPC. The results are
summarized in Table 5.1. Mn was determined based on 1H-NMR and GPC. % Conversion
was calculated based off of Mn from 1H-NMR. Overall, % conversions were high ranging
from 94.8 % - 97.5 %, suggesting near complete conversion of monomer. Mn calculated
from 1H-NMR all fall just below 12.0 kDa, while the average Mn calculated from GPC of
the diblock copolymers in THF were consistently higher. Mw/Mn determined from GPC
all fall around 1.2, suggesting that the diblock copolymers are relatively monodisperse.

Figure 5.9 1H-NMR Spectra of mPEG-b-PTMC Diblock Copolymers.
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1

H-NMR-spectra were used to determine Mn by integrating the PEG methylene

regions according to the number of protons present for a monodisperse polymer of the
reported average molecular weight of the commercial mPEG 1a-e. The sum of integrals
of the TMC protons were used to calculate Mn and % conversion. NMR spectra also
reveal that the isolated materials show no evidence of unreacted monomer or catalyst.

Scheme 5.4 Homopolymerization of Carbonate Monomers by TBD.

Next, efforts were made to generate a small library of mPEG-b-polycarbonate
homopolymers using ROP of Compounds 95, 97, 98, 100 and 104. Polymerizations were
carried out under nitrogen for 12 hours in DCM solution. Monomers and PEG were
purified immediately beforehand via recrystallization and precipitation into diethyl ether,
respectively. Polymerizations were carried out at [M] of 1.0 M using either 5 or 10 mol %
TBD as catalyst. A molecular weight of 10.0 kDa was targeted for the polycarbonate
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block when 1e (mPEG5K) was used as an initiator and a molecular weight of 5.0 kDa
was targeted for the polycarbonate block when 1d (mPEG2K) was used an initiator.
Polymerizations were quenched via addition of benzoic acid and purified via
precipitation into diethyl ether.

Table 5.2 Characterization of TBD-catalyzed mPEG-b-Polycarbonate Homopolymers.

1

H-NMR and GPC in THF were used to characterize the mPEG-b-polycarbonate

homopolymers synthesized via TBD-catalyzed ROP of cyclic carbonate monomers. %
Conversion and Mn calculated from 1H-NMR showed that there was a high degree of
variability for homopolymers generated using TBD. % Conversions varied from very low
(24.1%) to high (95.2%). Mn calculated from NMR roughly agreed with Mn calculated
from GPC after taking into account the additional molecular weight due to mPEG.
Mw/Mn varied greatly from 1.08-1.86 with most centered from 1.2-1.4. This indicates a
relatively high degree of polydispersity which could be due to transesterification at
extended reaction times, although no evidence was obtained from 13C-NMR.
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5.2.3 Copolymerization of Carbonate Monomers by TBD
Next, a small library of copolymers was synthesized where carbonate monomers
95, 97, or 98 were copolymerized with Compound 100 (Figure 5.5). Molecular weights
of 12.0 kDa and n:m of 1:3 were targeted. Polymerizations were carried out in DCM
solution at [M] = 1.0 M using 10 mol % TBD relative to [M]. Monomers and PEG were
purified beforehand and polymerizations were run for 12 hours at ambient temperature.
Polymerizations were quenched via addition of benzoic acid and purified via
precipitation into diethyl ether.

Scheme 5.5 Copolymerization of Carbonate Monomers by TDB.

1

H-NMR and GPC in THF were used to characterize the copolymers generated

via TBD catalyzed ROP. Total % conversions were moderate, indicating that the
polymerizations only proceeded moderately efficiently. Calculated values for relative
number of monomers incorporated into the polycarbonate polymers agreed with the
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targeted ratio of 1:3, indicating that the different monomers did not likely differ greatly in
their activities toward ROP. Mn from 1H-NMR agreed relatively well with GPC values,
with a slightly higher value from GPC consistent with previous data. Mw/Mn ranged from
1.35-1.42, which is comparable to values obtained from homopolymerizations (table 5.3).

Table 5.3 Characterization of TBD-catalyzed mPEG-b-Polycarbonate Copolymers.

5.2.4 Homopolymerization of Carbonate Monomers by DBU/TU
Having obtained modest results for homopolymerizations and copolymerizations
of carbonate monomers using TBD as catalyst, we sought to move to a milder ROP
catalyst. We chose to go with the combination of DBU and thiourea Compound 110. This
co-catalyst combination has been previously used to generate oligomers of similar
monomers using various alcohols as catalysts31b, 41. This catalyst functions via activation
of the monomer by the thiourea and activation of the initiator or propagating polymer
terminus by the base (DBU). Interestingly, other thioureas have shown little or no
activity. This observation has been attributed to the specific N-H acidity imparted on the
thiourea by the 3,3-ditrifluoromethyl substituents30.
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Scheme 5.6 Synthesis of Thiourea (TU) Co-Catalyst.

Compound 110 was synthesized via reaction between cyclohexylamine (108) and
3,5-ditrifluoromethyl-phenyl isothiocyanate (109) in THF. A yield of 95.3 % was
obtained after chromatographic purification.

Scheme 5.7 Homopolymerization of Carbonate Monomers by DBU/TU.
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With Compound 110 in hand, a small library of mPEG-b-polycarbonate
homopolymers was synthesized via organocatalytic ROP of cyclic carbonate monomers
95, 97, 98, 100 and 104. All monomers and PEG were purified immediately beforehand
by recrystallization and precipitation, respectively. Polymerizations were carried out
under nitrogen at ambient temperature using 5 mol % each of DBU and TU (110) in
DCM at a concentration where initial [M] = 1.0 M. Polymerizations were run for 24 or 48
hours and quenched with benzoic acid before precipitation into diethyl ether to remove
catalysts and unreacted monomers.

Table 5.4 Characterization of DBU/TU-Catalyzed mPEG-b-Polycarbonate
Homopolymers.

1

H-NMR and GPC in THF were used to characterize mPEG-b-polycarbonate

homopolymers (111a-o). % Conversion indicated that the DBU/TU co-catalyst system
allowed for synthesis of higher molecular weight polycarbonate polymers and provided
much better control and subsequent polydispersity. Interestingly, little difference between
24- and 48-hour reaction times was observed, indicating that all monomers were
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consumer by 24 hours. Mn as measured by NMR and GPC were in relative agreement
with a slight bias for increased molecular weight for GPC measurements similar to the
trend observed for previous compounds. Mw/Mn were significantly improved for
DBU/TU relative to TBD ranging from 1.11-1.23. These observations are consistent with
other materials synthesized using this co-catalyst system.

Figure 5.10 Monitoring of 95 Polymerization using DBU/TU by 1H-NMR.

A brief kinetic experiment was used to monitor monomer consumption via 1HNMR in order to determine optimal reaction times for polymerization of the carbonate
monomers using DBU/TU and the conditions outlined above for homopolymerization of
carbonate monomers (Figure 5.10). Conditions used for synthesis of 111c were used and
aliquots were removed at pre-determined time points, quench with benzoic acid and
analyzed via 1H-NMR after drying. During polymerization, the carbonate monomers
become decyclized, leading to a homogenization of the methylene protons on either side
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of the carbonate functional group. In the monomer, these protons give two distinct
doublets at 4.2 and 4.7 ppm. This is due to interaction of these methylene protons with
the carbonyl of the ester moiety through space. Upon polymerization, these proton signals
become homogenized in NMR due to the flexibility of the carbonate backbone. The ratios
of integrals of these two sets of protons were used to determine the relative % monomer
consumption at various time points. Results indicated that polymerizations reached a
maximum of ~94 % monomer conversion by approximately 1 hour after initiation of
polymerization. These results indicate that extended reaction times are not necessary for
polymerization of cyclic carbonate monomers using the DBU/TU system. This also
suggests that low % conversion, and high polydispersity of diblock copolymers generated
using TBD as catalyst, may be due to side reactions associated with extended reaction
times and possible transesterification of the pendant ester moieties, although no evidence
of this was observed via 13C-NMR.

5.2.5 Copolymerization of Carbonate Monomers by DBU/TU
Having obtained positive results for homopolymerization of carbonate monomers
using the DBU/TU system, we synthesized a small library of diblock copolymers where
the polycarbonate block consisted of the pendant carbonate monomers blended with
TMC. The purpose of these materials was to evaluate the effect of pendant group density
along the linear polycarbonate backbone on material performance. Since the monomers
are expected to show similar activities for ROP using DBU/TU, we can expect relatively
homogenous distributions of pendant moieties in the resultant polymer. If one monomer

258
has increased reactivity, it will be present in greater proportion towards beginning of the
polycarbonate block.

Scheme 5.8 Copolymerization of Carbonate Monomers by DBU/TU.

Copolymerizations were carried out under nitrogen using 10 mol % DBU/TU in
DCM such that the total [M] was 1.0 M, initially. Reactions were allowed to proceed for
24 hours before quenching with benzoic acid followed by precipitation into diethyl ether
to remove catalysts and unreacted monomers. Total polycarbonate molecular weights of
10.0 kDa were targeted with various ratios of 95 to TMC (2:1, 1:1, 1:2, 1:4).

Table 5.5 Characterization of DBU/TU-Catalyzed mPEG-b-Polycarbonate Copolymers.
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1

H-NMR and GPC were used to characterize copolymers generated via DBU/TU-

catalyzed ROP of cyclic monomers, 95 and TMC initiated by 1e. 1H-NMR indicated high
% conversion of monomers and good control of monomer incorporation ratios via control
of monomer feed ratios. Mn calculated from 1H-NMR and GPC were in good agreement.
Mw/Mn as determined from GPC measurements ranged from 1.14-1.22, indicating
relatively monodisperse copolymer formation.

5.3 Performance of mPEG-b-Polycarbonate Pendant Polymers
Next, some of the homopolymers generated via TBD-catalyzed ROP were tested
for their abilities to effectively form nanoparticles in combination with β-cyclodextrinpoly(ethyleneimine) (β-CD-PEI) conjugate (as described by Kulkarni, et al.26a) and
pDNA.

5.3.1 Formulation of mPEG-b-Polycarbonate Pendant Polymer-Based Transfection
Complexes
Transfection complexes composed of various mPEG-b-polycarbonate diblock
copolymers, β-CD-PEI and pDNA were prepared via precomplexation of β-CD-PEI and
the pDNA before addition of the diblock copolymer, which acts as a polymeric coating
via host:guest interaction of the pendant groups with cyclodextrin cavities and
hydrophobic interactions. This method was first referred to as “Method B” by Kulkarni et
al42.
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Figure 5.11 Size Analysis of Transfection Complexes at Various N/P Ratios by DLS.

Dynamic light scattering (DLS) was used to determine size and polydispersity of
transfection complexes generated using Compounds 106e-g and 106j-l (Figure 5.11).
Transfection complexes ranged in size from approximately 100-250 nm in size. This size
regime is highly amenable to gene delivery applications. Transfection complexes formed
from lower weight diblock copolymers showed relatively larger sizes compared to those
of higher weight polymers. Particle sizes generally decreased with increasing N/P and
little correlation in particle size and pendant group was observed. Polydispersity indices
ranged from 0.25-0.4.

261

Figure 5.12 Surface Zeta (ζ) Potential Analysis of Transfection Complexes at Various
N/P Ratios.

Zeta potential analysis revealed slightly positive zeta potentials in the range of 510 mV. This slightly positive surface charge is generally preferred in order to promote
internalization via electrostatic interaction of the positively-charged nanoparticle surface
and the negatively-charged cellular surface. N/P of 10, 20, and 30 resulted in similar
surface charges. β-CD-PEI alone exhibited an elevated positive surface charge.
Copolymers 106e and 106j both exhibited neutral charge in solution while mixtures of
the copolymer with β-CD-PEI resulted in positive surface charges that were lower in
magnitude than β-CD-PEI alone, indicating that the diblock copolymers effectively
screen the positive surface charge of β-CD-PEI. Furthermore, β-CD-PEI in combination
with the diblock copolymers showed similar zeta potential to the transfection complexes.
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This suggests that siRNA is likely not surface exposed and, thus, protected from
degradation.

Figure 5.13 Gel Retardation Analysis of Transfection Complexes at Various N/P Ratios.

Next, a gel retardation assay was performed to determine the ability of the mPEGb-polycarbonate:β-CD-PEI-based materials to condense pDNA at various N/P ratios.
Higher molecular weight diblock copolymers resulted in the need for high N/P ratios (e.g.
>20) to effectively condense pDNA, while lower molecular weight diblock copolymers
effectively condensed pDNA at N/P =5 in two of three cases with the other effectively
condensing pDNA at N/P = 10.
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5.3.2 Transfection Efficiency in HeLa Cells

Figure 5.14 % GFP Positive HeLa Cells Treated with Transfection Complexes
Containing AcGFP pDNA.

Transfection complexes prepared from mPEG-b-polycarbonates 106e, 106f, 106j,
or 106l in combination with β-CD-PEI and AcGFP pDNA were evaluated for their
transfection efficiencies in HeLa cells (Figure 5.14). Transfection complexes showed
similar efficiency in terms of positive cells to Lipofectamine (L2K). Overall, transfection
complexes prepared from mPEG-b-polycarbonates with different pendant groups showed
similar transfection efficiencies. Polymer molecular weight also seemed to have little
correlation to transfection efficiency. Higher N/P tended to give higher transfection
efficiency. This observation may be due to higher overall surface charge for particles at
N/P = 60, for instance.
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Figure 5.15 % Mean Fluorescence of HeLa Cells Treated with Transfection Complexes
Containing AcGFP pDNA.

When transfection efficiency is evaluated in terms of % mean fluorescence
(Figure 5.15), similar trends are revealed. All the transfection complexes performed with
similar efficiency to L2K. Transfection efficiencies were consistent for different
transfection complexes with no clear correlation between transfection efficiency and
polymer molecular weight, or pendant group. N/P ratios of 20-30 tended to show highest
transfection efficiency.

5.4 Organocatalytic ROP Synthesis of mPEG-b-PCL and SILY-PEG-b-PCL
In an effort to design and evaluate a novel microparticle-based drug delivery
system for delivery of hydrophobic anti-inflammatory compounds to the GI tract, and
utilizing a novel collagen-binding peptide (SILY) pioneered by Paderi and Panitch43 for
specific targeting of exposed collagen, a small library of mPEG-b-PCL diblock
copolymers were synthesized via organocatalytic ROP mediated by TBD (Scheme 5.9).
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Scheme 5.9 ROP of ε-Caprolactone by TBD Using mPEG as Macroinitiator.

Polymerizations were performed under nitrogen in DCM, yielding [M] of 2.0 M
and 5 mol % TBD relative to [M]. Molecular weights of 15.0 kDa were targeted for each
polymer so as to yield diblock copolymers possessing similar PCL blocks (~15.0 kDa)
and PEG blocks of various molecular weight (550 Da, 2.0 kDa, 5.0 kDa). Polymerization
reactions were allowed to run for 72 hours before quenching with benzoic acid to yield
the catalyst inactive and precipitation into ether to remove catalyst and unreacted
monomer.

Table 5.6 Characterization of mPEG-b-PCL Copolymers.

1

H-NMR and GPC in THF were used to characterize the small family of mPEG-

b-PCL diblock copolymers synthesized via organocatalytic ROP mediated by TBD in
DCM. Relative % conversion and Mn calculated from 1H-NMR indicated that nearly all
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of the monomer was incorporated into polymer for all three cases with % conversions
upwards of 95 %. Mn calculated by 1H-NMR was just below 15.0 kDa for all three
polymers, while Mn calculated from GPC was very consistent with the expected
molecular weights after taking into account the molecular weight of the macroinitiator in
addition to the PCL block. Mw/Mn calculated from GPC were surprisingly low, indicating
well-controlled living polymerization of ε-caprolactone under these conditions.

Figure 5.16 1H-NMR Spectra of mPEG-b-PCL Diblock Copolymers.

1

H-NMR spectra of Compounds 113a-c revealed that the compounds were

isolated in high purity with no traces of catalyst, unreacted monomers or other occult
impurities (Figure 5.16).
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Scheme 5.10 Synthesis of Collagen-Binding SILY-PEG-b-PCL Conjugate.

A novel strategy for synthesis of conjugates between thiol-containing peptides
and PEG-b-PCL diblock copolymers was used to generate the SILY-PEG-b-PCL
conjugate 117 via a two-step post-modification process after organocatalytic ROP of εcaprolactone by heterobifunctional PEG derivative 114 (Scheme 5.10).
SILY peptide (H2N-RRANAALKAGELYKSILYGC-CO2H) was first developed
as a synthetic peptide used to synthesize a dermatan sulfate-containing peptidoglycan
based on decorin, a natural collagen-binding peptideglycan. The SILY peptide functions
as a collagen binding motif. This synthetic peptidoglycan was shown to specifically bind
collagen, delay fibrillogenesis and increase collagen gel stiffness in the same way decorin
does.
Polymerization of ε-caprolactone catalyzed by TBD using heterobifunctional αcarboxyl-ω-hydroxyl-PEG derivative 114 was performed using 5 mol % TBD relative to
[M] with an additional 1.0 equivalent to account for deprotonation of the terminal
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carboxyl group in DCM at ambient temperature. PCL block molecular weight of 15.0
kDa was targeted. The reaction was allowed to proceed for 72 hours, then quenched with
benzoic acid before precipitation into diethyl ether to remove catalysts and unreacted
monomer to give Compound 115. Compound 115 was then coupled to N-(2aminoethyl)maleimide via EDC-mediated coupling in the presence of HOBt and DIEA in
DCM to give maleimide-PEG-b-PCL (116). Compound 116 was then conjugated to SILY
via Michael addition of the thiol group of the lone cysteine residue of SILY and the
maleimide terminus of Compound 116 to give peptide-polymer conjugate 117.

Table 5.7 Characterization of SILY-PEG-b-PCL and Precursors.

SILY-PEG-b-PCL and precursors were characterized via 1H-NMR and GPC in
THF (Table 5.7). Compound 115 showed high monomer conversion and Mn from 1HNMR and GPC were consistent and suggested (note that n from NMR represents
molecular weight of the PCL block, while Mn from GPC represents the molecular weight
of the entire construct). Mw/Mn for Compound 115 was 1.14, suggesting a relatively
monodisperse diblock copolymer. After coupling to N-(2-aminoethyl)maleimide,
Compound 116 showed consistent Mn in comparison to Compound 115 indicating that
the PCL block was retained with minimal degradation. After coupling to SILY,
Compound 117 showed consisted Mn for the PCL block from and NMR and GPC
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reflected the additional molecular weight of the peptide. Mw/Mn increased slightly after
each post-modification reaction. This may be due to some hydrolysis of PCL during the
reaction sequence.

Figure 5.17 1H-NMR Analysis of SILY-PEG-b-PCL and Precursors.

1

H-NMR analysis of SILY-PEG-b-PCL in combination with GPC was used to

verify successful reaction efficiency for each step in the sequence (Figure 5.17). The
terminal carboxyl group of Compound 115 is apparent as a broad singlet at
approximately 10.2 ppm. Peaks consistent with maleimide protons were observed in the
1

H-NMR of Compound 116. SILY-PEG-b-PCL (117) displayed numerous alkyl and

aromatic signals corresponding to various moieties of the peptide. This data, along with
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the increased Mn observed from GPC verify that SILY-PEG-b-PCL conjugate was
synthesized successfully.

5.5 Organocatalytic ROP Synthesis of mPEG-b-PLGA
A small library of mPEG-b-PLGA diblock copolymers was synthesized via
organocatalytic ROP mediated by DBU using a method pioneered by Qian et al.44
involves controlled addition of glycolide, the more reactive monomer, to generate
random copolymers of PLGA grown from macroinitiators via organocatalytic ROP.
PLGA is a biodegradable hydrophobic polyester commonly used in a wide variety of
biomedical applications, which is typically synthesized in bulk using tin-based
organometallic catalysts. However, this method results in high polydispersities. The
method of Qian et al allows for fast and efficient synthesis of random well-defined PLGA
polymers.
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Scheme 5.11 Organocatalytic ROP Synthesis of mPEG-b-PLGA Catalyzed by DBU.

Lactide and glycolide were each recrystallized immediately beforehand allowed
to dry until constant mass was observed and used for polymerization. Polymerizations
were run in DCM using 1.0 equivalent of DBU relative to the macroinitiator.
Polymerizations were carried out by constant addition of glycolide solution to the
polymerization vessel containing PEG, lactide, and the catalyst. Polymerizations were
run for 10 min before quenching with benzoic acid to cease catalyst activity. This
strategy functions to effectively maintain a low concentration of glycolide relative to
lactide to maintain random incorporation of either monomer into the growing polyester.
This is necessary because glycolide is much more active toward ROP than lactide. This
method allows for control of the relative ratios of lactide to glycolide (LA:GA) in the
product copolymer. In this study, LA:GA of 1:1 were targeted.
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Table 5.8 Characterization of mPEG-b-PLGA Diblock Copolymers.

1

H-NMR was used to determine the molecular weight of mPEG-b-PLGA diblock

copolymers and relative lactide:glycolide ratios of monomer conversion (Table 5.8).
Overall, obtained PLGA Mn from 1H-NMR was variable. Mn of 10.0 kDa was targeted
for polymerizations using 1e as macroinitiator and 5.0 kDa was targeted when 1d was
used. Variability between targeted and obtained molecular weights is attributable to slight
differences in polymerization kinetics over the very short reaction period, which makes
optimal quenching times difficult to predict in the absence of real-time monitoring of the
polymerization. However, ratios of lactide to glycolide calculated from 1H-NMR
suggested nearly 1:1 stoichiometry with some variability for the polymers, which also
showed decreased control of molecular weight.

5.6 Synthesis of Cyclic Amino-Acid N-Carboxyanhydride Monomers
There has been significant interest in the chemical synthesis of polypeptides. Most
polypeptides are synthesized via solid-phase peptide synthesis (SPPS) protocols 45. Solidphase peptide synthesis methodologies allow fast, efficient synthesis of short peptides of
an exact determinable sequence. However, this method has several weaknesses including,
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cost per amino acid, limitation of the maximum attainable molecular weight, and
scalability. Today, medium sized peptides (30-50 residues) can be routinely synthesized
via SPPS protocols using uronium-based coupling reagents and the standard orthogonal
Fmoc-Boc methodology45a. The advantages of SPPS lie in its sequence specificity and
relative standardization. Recently, the drug glatarimer acetate (Copaxone), which is a
random synthetic copolymer of glutamic acid, lysine, alanine, and tyrosine with average
Mn of 6.4 kDa, was approved for the treatment of multiple sclerosis. The drug is a
myelin-basic protein biomimetic. Thus, glatarimer acetate may act as a decoy, averting an
autoimmune response against myelin.

Figure 5.18 Polymerization of Amino Acid N-Carboxyanhydride Monomers. (A) The
“amine” mechanism of NCA polymerization. (B) “Active Monomer” mechanism of NCA
polymerization. (C) NCA polymerization using ammonium salts.
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An alternative strategy for the synthesis of polypeptides involves the ring opening
polymerization of amino acid N-carboxyanhydrides (NCA). The NCA approach is the
most commonly used approach for producing high molecular weight peptide homo- and
copolymers on a gram or greater scale. NCA polymerization is the method of choice for
synthesizing peptides like glatarimer acetate, where the exact sequence specificity is not
required. By employing amine-terminal macroinitiators one can obtain block copolymers
with a synthetic block and a polypeptide block or blocks. These so called “hybrid block
copolymers” or “molecular chimeras” may be of particular utility in the fields of drug and
gene delivery due to their inherent biocompatibility and programmable properties.
NCA polymerization should preferentially proceed via the amine mechanism
(Figure 5.18A). That is, nucleophillic attach of the NCA by an initiating primary amino
group. This reaction is commonly run in dimethylformamide (DMF) at room
temperature. However, using the amine mechanism, broad polydispersity indices in
excess of 1.4-1.6 are commonly observed. This is due to side reactions involving
deprotonation of weakly acidic N-H protons from an NCA monomer or an amide of the
growing polypeptide chain (Figure 5.18B). This can lead to branching and contributes to
an overall broadening of the polydispersity of the polymer46.
Alternative strategies have sought to avoid the amine mechanism and thereby the
active monomer side reaction by using catalytic systems. Deming, et al. used transition
metal catalysts based on nickel (II) complexes47. Since amines can act as effective
nucleophiles and bases, an effective switching between the amine mechanism and active
monomer mechanism will always occur in NCA polymerization. There is also evidence
that these side reactions may depend heavily on the purity of the NCA monomers.. High
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vacuum technique has also been utilized to speed the amine mechanism by fast
degradation of the carbamic acid byproduct.
Dimitrov and Schlaad48 found that by simply adding protons or using a
hydrochloride salt to initiate the polymerization, polymers were obtained with PDIs near
unity (Figure 5.18C). They used amine-hydrochloride-terminal polystyrene to initiate a
polymerization of an NCA derivative of Nε-benzyloxycarbonyl-l-lysine (Z-L-Lys). The
underlying hypothesis assumes that by keeping the propagating amine protonated when
the active monomer is formed, it will be much more likely to be reprotonated rather than
initiating acyl transfer. Polymer growth proceeds via the “amine” mechanism. These
reactions were slow, taking several hours to complete due to decreased effective
concentration of the propagating amine. The desirability of this mode of NCA
polymerization comes from the accessibility of primary amine hydrochlorides and the
simplicity of the reaction conditions.
Several different amino acid-based N-carboxyanhydride monomer synthesis
methods have been previously described. Initially NCA’s were synthesized via
suspension of the amino acid in a dry solvent (dioxane, EtOAc) at elevated temperature
before passing phosgene through the mixture until a homogeneous solution is obtained49.
The resulting solution must then be evaporated or purged for extended periods to remove
excess phosgene before purification by recrystallization. This procedure is potentially
unsafe due to the use of phosgene. Nα-Cbz-protected amino acids may also be converted
to the corresponding NCA via treatment with phosphorus pentachloride.
Later, the Fuchs-Farthing method50 was developed utilizing triphosgene as
carbonylation reagent in place of phosgene using ethyl acetate (EtOAc) as solvent. This
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method generally involved sequential crystallization to remove impurities. A method
employing flash chromatographic purification of NCA’s was also introduced. Numerous
NCA’s have been reported via this method including NCA’s derived from γ-benzyl-Lglutamate, L-alanine, Nε-benzyloxycarbonyl-L-lysine, O-benzyl-L-threonine, O-benzylL-serine, β-benzyl-L-aspartate, L-leucine, L-tyrosine, and glycine.
During the course of experimentation into applying the pendant polymer concept
to peptide copolymers derived from NCA’s, we attempted to use the Fuchs-Farthing
method to numerous amino-acid NCA’s but found that it was not applicable to many
amino acids due to their inability to become dissolved in ethyl acetate as solvent even at
elevated temperatures in excess of 80 °C. In particular, L-alanine proved non-amenable to
NCA synthesis. Thus, several solvents were screened to determine a solvent for
triphosgene-based NCA synthesis with broad applicability for a wide variety of amino
acid starting materials.
Tetrahydrofuran (THF) was found to be a suitable solvent for every amino acid
that we attempted to convert to the corresponding NCA at relatively mild temperatures.
Since THF is easily dried, readily evaporated after NCA synthesis and miscible with
water, it is especially amenable to previous purification strategies applied to NCA’s. In
order to test the utility of the modified Fuchs-Farthing method in THF, we synthesized a
small library of NCA monomers, including some previously reported NCA’s and some
novel NCA’s. The lowest temperature required to effect solubilization of the starting
materials was used to avoid side reactions. The results of this study are reported in
Scheme 5.12.
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Scheme 5.12 Synthesis of Amino Acid-NCA Monomers.

NCA’s were obtained in high yield (87.1% - 97.1%) and in high purity based on
NMR. Relatively hydrophilic amino acids (L-alanine, S-benzyl-L-cysteine) required the
highest temperature (70 °C) to effect conversion while L-phenylalanine was solubilized
at 60 °C. Nε-Cbz-L-lysine, and γ-methyl-L-glutamic acid were converted at 50 °C.
Relatively lipophilic amino acids (γ-benzyl-L-glutamate, L-isoleucine) were converted to
the corresponding NCA’s at ambient temperature in THF. This modified synthetic
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approach to NCA synthesis using THF as universal solvent for carbonylation of amino
acids using triphosgene is expected to be applicable to a wide range of natural and
synthetic amino acid derivatives. Since THF is a good solvent able to solubilize a wide
variety of compounds, is easily evaporated and miscible with water, this synthetic
procedure may extend the range of accessible NCA’s and the corresponding molecular
architectures of polypeptides derived from NCA polymerization.

5.7 Conclusions
The pendant polymer-based gene delivery concept has shown potential as a novel
non-viral gene delivery strategy. However, we sought to address material-specific
limitations of previously reported pendant polymer materials by using modern synthetic
strategies to design and synthesize a more well-defined new generation of pendant
polymers based on diblock copolymers derived from organocatalytic ROP. A family of
mPEG-b-polycarbonate diblock pendant polymers was successfully synthesized from
several novel and previously reported cyclic carbonate monomers via organocatalytic
ROP using TBD and the bifunctional DBU/TU system. Several copolymerizations of the
cyclic carbonate monomers were performed to generate materials having tunable pendant
group density alone the polymer backbone. These materials were characterized by NMR
and GPC. The diblock copolymers showed the ability to form nanoparticles, typically
100-250 nm in size, with slightly positive surface zeta-potentials, effectively condensed
pDNA at N/P ratios above 10, and showed comparable transfection efficiencies to
Lipofectamine-2000 (L2K) in HeLa Cells.

279
A small library of mPEG-b-PCL diblock copolymers was successfully
synthesized via organocatalytic ROP of ε-caprolactone catalyzed by TBD using mPEG as
a macroinitiator. A collagen binding peptide (SILY) conjugate (SILY-PEG-b-PCL) was
also synthesized via organocatalytic ROP of ε-caprolactone catalyzed by TBD using αcarboxyl-ω-hydroxyl-heterobifunctional PEG as a macroinitiator. DBU was used to
synthesize a small library of mPEG-b-PLGA diblock copolymers having controlled
random incorporation of lactide and glycolide into the PLGA backbone. These materials
were characterized via 1H-NMR and GPC.
A new synthetic method for preparation of amino acid N-carboxyanhydrides
(NCA’s) was developed based on a modified method which was previously reported
where THF was substituted as solvent for the reaction. This protocol showed broad
applicability for synthesis of several NCA’s from amino acids having highly varied
solubility properties, including L-alanine. This method may provide for synthesis of a
wide variety of novel NCA’s in the future.

5.8 Future Directions
Future efforts for the polycarbonate-based pendant polymers will focus on
evaluation of the complete library for performance and investigation of the pendant group
density on performance. Furthermore, a similar strategy to that used to synthesize SILYPEG-b-PCL may be applied to the polycarbonate system to generate targeted-PEG-bpolycarbonate pendant polymers. This strategy could prove to be a powerful modular
approach to actively-targeted gene delivery systems. The amino-acid-NCA’s may also be
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used to generate a similar library of polypeptide-based pendant polymers, which may
exhibit unique properties relative to other pendant polymer materials.

5.9 Experimental Methods
All reactions were carried out under a blanket of N2 or argon gas. Reaction
progress was monitored by thin-layer chromatography (TLC) analysis. TLC spots were
visualized either by UV light (254nm), exposure by ninhydrin staining, staining with
phosphomolybdic acid (PMA), staining with p-anisaldehyde or by staining with I2. Flash
column chromatography was carried out using 230-400 mesh silica gel and analytical
grade solvents. Solvents were purchased from Mallinckrodt/Baker and used without
further purification unless noted. Toluene was purchased from Fisher. α-Methoxypoly(ethylene glycol) (mPEG, 1a-e) having average molecular weights of 350 Da, 550
Da, 750 da, 2.0 kDa, and 5.0 kDa were purchased from Sigma Aldrich and purified prior
to polymerization by precipitation of a dichloromethane (DCM) solution into an excess of
diethyl ether (Et2O) three times each followed by vacuum filtration and drying in vacuo
for 24 hours. 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) was purchased from Sigma
Aldrich and stirred together with CaH2 for 48 hours, followed by distillation in vacuo.
1,5,7-Triazabicyclo [4.4.0]dec-5-ene (TBD) was purchased from Sigma Aldrich and
purified by stirring a DCM solution in the presence of CaH2 for 48 hours, followed by
filtration and recrystallization from DCM/pentane. ε-Caprolactone was purchased from
Sigma and purified via stirring with CaH2 for 48 hours, followed by vacuum distillation.
Lactide was purchased from Sigma Aldrich and purified via recrystallization from
toluene. Glycolide was purchased from Sigma Aldrich and purified via recrystallization
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from toluene/THF. 2-Maleimidoethylamine hydrochloride was purchased from Santa
Cruz Biotechnology and used without further purification. Benzoic acid was purchased
from Sigma Aldrich and purified by recrystallization from aqueous ethanol. N-(3Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC) and Nhydroxybenzotriazole hydrate (HOBt) were purchased from Advanced Chemtech and
used without purification. Dichloromethane (DCM) and toluene were purified by
distillation from CaH2. Tetrahydrofuran (THF) was purified by distillation from sodium
benzophenone ketyl. HPLC grade THF used for GPC was purchased from Fisher
Scientific and used without further purification. Dialysis tubing (regenerated cellulose)
was purchased from Spectrum Labs. NMR solvents were purchased from Cambridge
Isotope Laboratories and used without further purification. Other reagents were
purchased from Sigma Aldrich and used without further purification. Other solvents were
purchased from Fisher Scientific and used without further purification.
1

H-NMR and 13C-NMR samples were prepared by dissolving ~10 mg of sample

in CDCl3 and spectra were acquired using a Bruker AV-III-500-HD NMR spectrometer
at 500 mHz for 1H and 125 mHz for 13C or a Bruker ARX-400 NMR spectrometer at 400
mHz for 1H and 100 mHz for 13C using residual solvent as an internal standard. Monomer
% conversion and number average molecular weight (Mn) were calculated relative to the
theoretical number of protons associated with the initiator with respect to the average of
polymer-associated protons.
Gel permeation chromatography (GPC) was performed using an Agilent 1200
Series GPC equipped with a Wyatt Dawn Heleos-II multi-angle light scattering (MALS)
detector, Wyatt Optilab rEX refractive index (RI) detector and Wyatt quasi-elastic light
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scattering (QELS) detector using a single Waters Styragel HR-3 5 µm 7.8x300 mm
column preceded by a Waters Styragel 20 µm 4.6x30 mm guard column using THF as
eluent. Flow rates of 0.2-0.5 mL/min were used and 100 µL injections of 1.8 mg/mL
samples were used. dn/dc was determined for each sample using a five-point calibration
curve (samples from 0.5-2.5 mg/mL, 2.0 mL total) generated using Optilab rEX detector
in flow mode in combination with ASTRA software. Mn and Mw/Mn were calculated
using ASTRA software.
PEI (2.5kD) was purchased from Polysciences, Inc. Dialysis membranes
(MWCO: 6000-8000) were purchased from Fisher Scientific. AcGFP1 plasmid vector
and MTS reagent were purchased from Promega®. pDNA was amplified in E. coli and
purified according to the supplier’s protocol (Qiagen, Hilden, Germany). The
concentration and purity of the pDNA was determined by absorption at 260 and 280 nm
and by agarose gel electrophoresis, respectively. The purified pDNA was re-suspended in
TE bu er (10 mM Tris-Cl, pH 7.5, 1 mM EDTA) and kept frozen in aliquots at a
concentration of 0.5 mg/mL. Lipofectamine®2000 (L2K) transfection reagent was
purchased from Invitrogen. Cell culture reagents such as DMEM and RPMI media, FBS,
sodium pyruvate, trypsin, and PBS were obtained from Atlanta Biologicals.
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5.9.1 Synthesis of Cyclic Carbonate Monomers
Benzyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate (94). Benzyl bromide was
purified beforehand via shaking with conc. H2SO4, water, sat. NaHCO3, then water,
followed by drying over anhydrous sodium sulfate and vacuum distillation. 2,2Dihydroxymethylpropionic acid (36.00 g, 268.4 mmol) was added to an oven dried 1L
round bottom flask equipped with a magnetic stir bar and rubber septum. DMF (500 mL)
was added and the solid was dissolved with stirring. Anhydrous potassium carbonate
(55.64 g, 402.6 mmol) was added and the mixture was stirred for 30 min under ambient
conditions to generate the potassium carboxylate salt. Benzyl bromide (68.86 g, 402.6
mmol) was added via addition funnel dropwise over 30 min at ambient temperature. The
mixture was stirred for an additional 18 hours at ambient temperature under nitrogen. The
reaction mixture was poured into 1L deionized water and this solution was divided into
three equal parts. Each part was extracted with EtOAc (170 mL) four times each. The
combined extracts were dried over anhydrous sodium sulfate, concentrated in vacuo and
the residue was crystallized from benzene to give Compound 94 as a white crystalline
solid. Yield: 50.06 g (83.2 %); 1H NMR (500 MHz, CDCl3) δ 7.45 – 7.28 (m, 5H), 5.21
(s, 2H), 3.93 (dd, J = 11.2, 6.0 Hz, 2H), 3.73 (dd, J = 11.3, 5.6 Hz, 2H), 2.89 (t, J = 6.1
Hz, 2H), 1.08 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 175.74, 135.66, 128.65, 128.33,
127.87, 77.30, 77.05, 76.79, 68.34, 66.71, 49.26, 17.13.

Benzyl 5-methyl-2-oxo-1,3-dioxane-5-carboxylate (95). Compound 94 (16.51 g, 73.6
mmol) was dissolved in DCM (280 mL) and pyridine (45 mL) in an oven-dried 500 mL
round bottom flask equipped with a magnetic stir bar and an addition funnel. Triphosgene
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(11.36 g, 38.3 mmol) dissolved in DCM (45 mL) was added to the addition funnel. The
solution of 94 was cooled to -78 °C and the triphosgene solution was added dropwise
over 1 hour at -78 °C. The dry ice/acetone bath was removed and the solution was
allowed to stir for an additional 2 hours while warming to ambient temperature. The
reaction was quenched via addition of 75 mL sat. NH4Cl solution. The biphasic solution
was transferred to a separatory funnel and the aqueous phase was removed. The organic
phase was washed with 5% HCl (150 mL) three times, then deionized water (100 mL).
The organic solution was dried over anhydrous sodium sulfate, concentrated and purified
via flash chromatography using a gradient of 100 % DCM to 2.5 % MeOH/DCM. The
pure fractions were combined, concentrated and recrystallized from toluene/hexane to
give Compound 95 as a white crystalline solid. Yield: 15.22 g (82.6 %).; TLC: Rf= 0.47
(2.5 % MeOH/DCM); 1H NMR (500 MHz, CDCl3) δ 7.58 – 7.30 (m, 5H), 5.21 (s, 2H),
4.70 (d, J = 10.9 Hz, 2H), 4.20 (d, J = 10.9 Hz, 2H), 1.32 (s, 3H). 13C NMR (126 MHz,
CDCl3) δ 170.93, 147.40, 134.77, 128.78, 128.75, 128.22, 77.31, 77.06, 76.81, 72.95,
67.92, 40.25, 17.59.

5-Methyl-2-oxo-1,3-dioxane-5-carboxylic acid (96). Compound 95 (5.00 g, 20.0 mmol)
was added to an oven-dried 250 mL round bottom flask equipped with a magnetic stir bar
and a rubber septum. The solid was dissolved in EtOAc (50 mL) and THF (70 mL) and a
spatula tip of 10% palladium on carbon (wet type) was added. The flask was equipped
with a three-way adapter attached to a balloon. The flask and balloon were evacuated and
filled with hydrogen three times and stirred under 1 atm hydrogen for 16 hours. The
catalyst was removed via gravity filtration through Celite, concentrated and recrystallized
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from toluene/EtOAc to give Compound 96 as a white crystalline solid. The product is
positive for staining with bromocresol green. Yield: 3.07 g (95.8 %).; TLC: Rf= 0.06 (5
% MeOH/DCM); 1H NMR (400 MHz, DMSO-d6) δ 12.68 (s, 1H), 4.52 (d, J = 10.4 Hz,
2H), 4.29 (d, J = 10.4 Hz, 2H), 1.14 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 178.44,
152.46, 108.61, 77.79, 45.14, 44.93, 44.72, 44.51, 44.31, 44.10, 43.89, 21.50.

Cholesteryl 5-methyl-2-oxo-1,3-dioxane-5-carboxylate (97). Compound 96 (3.066 g,
19.1 mmol), cholesterol (8.144 g, 21.1 mmol) and DMAP (0.351 g, 2.9 mmol) were
combined in an oven-dried 500 mL round bottom flask equipped with a stir bar and
rubber septum. The contents were dissolved in DCM (50 mL), THF (50 mL) and pyridine
(25 mL). The solution was cooled to 0 °C in an ice bath and EDC (4.405 g, 22.8 mmol)
was added. The solution was stirred for 72 hours while warming to room temperature.
The solution was concentrated in vacuo and the residue was dissolved in DCM (150 mL).
The solution was washed with 5% HCl (150 mL) three times, saturated NaHCO3 (120
mL) and brine (100 mL). The organic solution was dried over anhydrous sodium sulfate
and purified via column chromatography using a gradient of 100 % DCM, 1.25 %
MeOH/DCM and 2.5 % MeOH/DCM. The pure fractions were combined and
recrystallized from toluene/MeOH to give Compound 97 as white crystalline flakes
similar to cholesterol. Yield: 6.892 g (68.1 %).; TLC: Rf= 0.26 (100 % DCM); 1H NMR
(400 MHz, CDCl3) δ 5.38 (d, J = 4.3 Hz, 1H), 4.70 (s, 1H), 4.67 (d, J = 10.6 Hz, 2H),
4.18 (d, J = 10.8 Hz, 2H), 2.32 (d, J = 6.9 Hz, 2H), 2.08 – 1.97 (m, 2H), 1.95 (s, 1H), 1.92
– 1.75 (m, 3H), 1.64 (s, 1H), 1.61 – 1.58 (m, 1H), 1.58 – 1.52 (m, 2H), 1.52 – 1.44 (m,
3H), 1.44 – 1.38 (m, 1H), 1.32 (d, J = 10.1 Hz, 6H), 1.25 (d, J = 11.8 Hz, 1H), 1.14 (dtd, J
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= 22.4, 12.9, 11.1, 6.5 Hz, 7H), 1.06 – 0.95 (m, 6H), 0.92 (dd, J = 14.6, 6.1 Hz, 4H), 0.85
(d, J = 6.6 Hz, 6H), 0.67 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 170.37, 147.47, 138.82,
123.18, 108.59, 77.25, 76.94, 76.62, 75.96, 72.97, 56.55, 56.02, 49.86, 42.20, 40.04,
39.59, 39.41, 37.65, 36.71, 36.43, 36.07, 35.68, 31.79, 31.71, 28.11, 27.90, 27.41, 24.17,
23.72, 22.72, 22.46, 20.93, 19.20, 18.62, 17.47, 11.75.

((1s,3s)-Adamantan-1-yl)methyl 5-methyl-2-oxo-1,3-dioxane-5-carboxylate (98).
Compound 96 (2.108 g, 13.2 mmol), 1-adamantanemethanol (2.19 g, 13.8 mmol) and
DMAP (322 mg, 2.6 mmol) were added to an oven-dried 250 mL round bottom flask
equipped with a magnetic stir bar and rubber septum. The contents were dissolved in
THF (15 mL) and pyridine (10 mL) and cooled to 0 °C in an ice bath. EDC (3.280 g, 17.1
mmol) was added. The solution was stirred for 72 hours while warming to ambient
temperature. The solution was concentrated in vacuo and poured into 100 mL deionized
water. The mixture was extracted with DCM (80 mL) four times. The DCM extracts were
combined, dried over anhydrous sodium sulfate and purified via column chromatography
using a gradient of 4:1, 7:3, 3:2, and 1:1 (v/v) mixtures of hexane:EtOAc. The pure
fractions were combined, concentrated and recrystallized from toluene/hexane to give
Compound 98 as a white crystalline solid. Yield: 1.943 g (47.9 %).; TLC: Rf= 0.43 (1:1
Hex: EtOAc); 1H NMR (400 MHz, CDCl3) δ 4.75 – 4.57 (m, 2H), 4.28 – 4.10 (m, 2H),
3.76 (s, 2H), 1.96 (s, 3H), 1.70 (d, J = 12.3 Hz, 3H), 1.61 (d, J = 12.4 Hz, 3H), 1.49 (d, J
= 2.5 Hz, 6H), 1.30 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 171.06, 147.35, 108.60,
77.33, 77.01, 76.69, 75.31, 72.94, 40.23, 39.01, 36.68, 33.28, 27.76, 17.57.
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Ethyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate (99). Compound 93 (15.00
g, 111.8 mmol) was dissolved in 125 mL 200 proof ethanol in an oven-dried 250 mL
round bottom flask equipped with a magnetic stir bar and a rubber septum. Conc. H2SO4
(5.00 mL) was added and the solution was stirred for 3 hours at reflux. Ethanol was
evaporated in vacuo and the residue was redissolved into 200 mL EtOAc. The solution
was washed with sat. NaHCO3 (100 mL), then deionized water (100 mL) twice. The
organic solution was dried over anhydrous sodium sulfate, and concentrated in vacuo to
give Compound 99 as a clear viscous oil. Yield: 15.729 g (86.7 %).; TLC: Rf= 0.64 (15
% MeOH/DCM); 1H NMR (400 MHz, CDCl3) δ 4.04 (q, J = 7.1 Hz, 2H), 3.72 (d, J = 5.6
Hz, 2H), 3.66 (d, J = 6.1 Hz, 2H), 3.54 (dd, J = 10.4, 5.3 Hz, 2H), 1.14 (t, J = 7.1 Hz,
3H), 0.96 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 175.63, 77.42, 77.10, 76.78, 65.88,
60.70, 49.09, 16.95, 13.84.

Ethyl 5-methyl-2-oxo-1,3-dioxane-5-carboxylate (100). Compound 99 (5.564 g, 34.3
mmol) was dissolved in DCM (75 mL) and pyridine (15 mL) in an oven-dried 250 mL
round bottom flask equipped with a magnetic stir bar and an addition funnel. In a separate
50 mL conical flask, triphosgene (5.294 g, 17.8 mmol) was dissolved in DCM (15 mL).
The triphosgene solution was transferred to the addition funnel and the solution of
Compound 99 was cooled to -78 °C in a dry ice/acetone bath. The triphosgene solution
was added dropwise over 1 hour. The -78 °C bath was removed and the solution was
stirred for an additional 3 hours while warming to ambient temperature. The reaction was
quenched via addition of 100 mL sat. NH4Cl solution. The biphasic solution was
transferred to a separatory funnel and the aqueous layer was removed. The organic
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solution was washed with 5% HCl (100 mL) twice, deionized water (100 mL) and brine
(80 mL). The organic phase was dried over anhydrous sodium sulfate, concentrated in
vacuo, and purified via flash chromatography using a gradient of 100 % DCM to 2.5 %
MeOH/DCM to give Compound 100 as a clear waxy solid. Yield: 3.509 g (54.4 %).;
TLC: Rf= 0.47 (2.5 % MeOH/DCM); 1H NMR (400 MHz, CDCl3) δ 4.54 (d, J = 10.8 Hz,
2H), 4.20 – 4.11 (m, 2H), 4.10 – 4.01 (m, 2H), 1.35 – 0.96 (m, 6H). 13C NMR (101 MHz,
CDCl3) δ 171.10, 147.51, 77.55, 77.23, 76.90, 72.82, 61.93, 39.91, 16.99, 13.75.

1,3-Dioxan-2-one (102). 1,3-Propanediol (0.930 g, 12.2 mmol) was added to an ovendried 500 mL round bottom flask equipped with a stir bar and rubber septum. Di-tertbutyl dicarbonate (Boc2O, 8.00 g, 36.7 mmol) was dissolved in 100 mL acetonitrile
(ACN) in a separate 125 mL flask. The Boc2O solution was added the 500 mL flask and
DMAP (1.493 g, 12.2 mmol) immediately after. The solution was stirred at ambient
temperature under nitrogen for 30 min. The solution was transferred to a separatory
funnel together with 420 mL chloroform. The organic solution was washed with 1.0 M
HCl (150 mL) twice, followed by deionized water (150 mL). The organic phase was
dried over anhydrous sodium sulfate, concentrated and purified via flash chromatography
using a gradient of 2.5 % MeOH/DCM to 5% MeOH/DCM. The pure fractions were
combined and recrystallized from diethyl ether (Et2O) to give Compound 102 as a white
crystalline solid. Yield: 0.926 g (74.2 %).; TLC: Rf= 0.35 (5 % MeOH/DCM); 1H NMR
(400 MHz, CDCl3) δ 4.76 – 3.98 (m, 4H), 2.12 (t, J = 8.4 Hz, 2H). 13C NMR (101 MHz,
CDCl3) δ 148.42, 77.32, 77.00, 76.69, 67.89, 21.61.

289
1,3-Dioxan-2-one (104). 3-Bromo-1-propanol (5.00 g, 36.0 mmol) was added to an ovendried 500 mL round bottom flask equipped with a magnetic stir bar. DMF was added
(108 mL) followed by Cs2CO3 (12.893 g, 39.6 mmol). Carbon dioxide was bubbled
through the solution vigorously for 5 min, then a three-way adapter equipped with a
balloon was attached to the flask. The flask was evacuated and purged with carbon
dioxide 5 times. The heterogeneous mixture was stirred vigorously under 1 atm carbon
dioxide for 4 days. The mixture was filtered to remove Cs2CO3 and the cake was washed
with DCM. The filtrate was concentrated in vacuo and redissolved in DCM (200 mL).
The solution was washed with deionized water (80 mL) and the organic phase was dried
over anhydrous sodium sulfate, concentrated and recrystallized from diethyl ether to give
Compound 104 as a white crystalline solid. Yield: 3.259 g (89.0 %).; TLC: Rf= 0.34 (5 %
MeOH/DCM; 1H NMR (500 MHz, CDCl3) δ 4.43 (d, J = 5.8 Hz, 4H), 2.13 (p, J = 5.8
Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 148.49, 77.33, 77.08, 76.82, 67.96, 21.74.

5.9.2 Polymerizations of Carbonate Monomers Using TBD
mPEG-b-PTMC (105a-c). mPEG (a: 32.1 mg, b: 117mg, c: 292mg; 58.4µmmol) was
added to an oven-dried 5.0 mL conical vial equipped with magnetic spin vane and PTFE
septum. Trimethylene carbonate (104, 0.700 g, 6.86 mmol) was added and contents were
dissolved in 5.5 mL DCM. TBD solution in DCM (35 mg/mL, 1.364 mL) was added via
pipette and the vial was capped and filled with nitrogen. The solutions were stirred for 12
hours at ambient temperature. The polymerization was quenched via addition of 80 mg
benzoic acid. The solution was precipitated twice into 250 mL diethyl ether from DCM,
filtered and dried in vacuo to give 105a-c as white powders. Yield: a: 723 mg, b: 808 mg,
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c: 850 mg; 1H NMR (500 MHz, CDCl3) δ 4.63 – 3.90 (m, PTMC -C(=O)-O-CH2-), 3.62
(PEG -CH2-), 2.15 – 1.76 (m, PTMC).

TBD-catalyzed mPEG-b-polycarbonate diblock pendant copolymers (106a-q). 1d
(mPEG2K) or 1e (mPEG5K) (100 mg) was added to an oven-dried 5.0 mL conical vial
equipped with magnetic spin vane and PTFE septum. Carbonate monomer (95, 97, 98,
100, or 104) (200 mg) was added and the contents were dissolved in DCM. TBD solution
(35 mg/mL in DCM) was added (5 mol % relative to monomer). The amount of initial
DCM used is equal to the volume required to give [M] = 1.0 M, taking into account the
volume of the TBD solution. The vials were flushed with nitrogen and stirred for 12
hours at ambient temperature. The polymers were isolated via precipitation into 40 mL
Et2O plus 5 mL iPrOH in 50 mL centrifuge tubes. The precipitate was isolated via
centrifugation and dried in vacuo to give Compounds 106a-q as white solids. Mn was
calculated by comparing PEG methylene proton integrals with characteristic integrals
from the respective monomers. Yield: a: 139 mg, b: 286 mg, c: 256 mg, d: 238 mg, e:
263 mg, f: 242 mg, g: 212 mg, h: 261 mg, i: 176 mg, j: 224 mg, k: 252 mg, l: 197 mg, m:
260 mg, n: 227 mg, o: 240 mg, p: 188 mg, q: 212 mg.

TBD-catalyzed mPEG-b-polycarbonate diblock pendant polymers (107a-c). 1e (100
mg, 0.02 mmol), Compound 100 and one of either Compound 95, 97, or 98 were added
to an oven-dried 5.0mL conical vial containing a magnetic spin vane and a PTFE septum.
The total mass of monomers is equal to 200 mg. The relative amounts of monomers were
determined by solving a system of equations targeting total polycarbonate molecular
weight of 12.0 kDa and a 3:1 ratio of 100 to either 95, 97, or 98. The DCM was added
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and the solutions were stirred to dissolve mPEG and monomers. TBD solution was added
next via syringe (35 mg/mL in DCM). The amounts of TBD solution and DCM were
determined by targeting 10 mol % TBD relative to total [M]. The initial volume of DCM
is equal to the total volume required to give [M] = 1.0 M minus the volume of the TBD
solution. The vials were flushed with nitrogen and stirred at ambient temperature for 12
hours. The polymers were isolated via precipitation into 40 mL Et2O plus 5 mL iPrOH in
50 mL centrifuge tubes. The precipitate was isolated via centrifugation and dried in vacuo
to give Compounds 107a-c as white solids. Mn was calculated by comparing PEG
methylene proton integrals with characteristic integrals from the respective monomers.
Yield: a: 232 mg, b: 216 mg, c: 208 mg.

5.9.3 Polymerization of Carbonate Monomers Using DBU/TU
1-(3,5-Bis(trifluoromethyl)phenyl)-3-cyclohexylthiourea (110). 3,5,-Bis(trifluoromethyl)phenyl isothiocyanate (1.01 g, 3.72 mmol) was added to an oven-dried
25 mL round bottom flask equipped with a magnetic stir bar and a rubber septum. THF (5
mL) was added followed by cyclohexylamine (427 µL, 3.72 mmol). The flask was
flushed with nitrogen and stirred for 3 hours at ambient temperature. The solution was
filtered through a pad of Celite with DCM (20 mL). The filtrate was concentrated and
purified via flash chromatography using a gradient of 2.5 % MeOH/DCM to 5 %
MeOH/DCM. The pure fractions were combined, concentrated and recrystallized from
DCM/pet. Ether to give Compound 110 as a white powder. Yield: 1.314 g (95.3 %).;
TLC: Rf= 0.75 (5 % MeOH/DCM); 1H NMR (500 MHz, CDCl3 δ 8.40 (s, 1H), 7.75 (s,
2H), 7.70 (s, 1H), 6.08 (s, 1H), 4.20 (s, 1H), 2.06 (dd, J = 12.5, 3.4 Hz, 2H), 1.71 (d, J =
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10.2 Hz, 2H), 1.63 (dd, J = 9.1, 4.1 Hz, 1H), 1.50 – 1.35 (m, 2H), 1.27 – 1.14 (m, 3H).
13

C NMR (126 MHz, CDCl3) δ 179.12, 138.86, 133.51, 133.24, 132.97, 132.68, 125.99,

123.82, 121.65, 119.34, 77.28, 77.03, 76.77, 54.04, 32.36, 25.26, 24.56. 19F NMR (471
MHz, DMSO-d6) δ -62.75.

DBU/TU-catalyzed-mPEG-b-polycarbonate diblock pendant polymers (111a-n). 1d
(mPEG2K) or 1e (mPEG5K) (100 mg) was added to an oven-dried 5.0 mL conical vial
equipped with magnetic spin vane and PTFE septum. Carbonate monomer (95, 97, 98,
100, or 104) (200 mg) was added and the contents were dissolved in DCM. TU (110)
solution (0.125 M in DCM) was added via syringe, followed by DBU solution (1.0 M in
DCM). The amounts of DBU and TU solution and DCM were determined by targeting 5
mol % DBU and TU relative to total [M]. The initial volume of DCM is equal to the total
volume required to give [M] = 1.0 M, minus the volume of the DBU and TU solution
volumes. The vials were flushed with nitrogen and stirred for 12 hours at ambient
temperature. The polymers were isolated via precipitation into 40 mL Et2O plus 5 mL
iPrOH in 50 mL centrifuge tubes. The precipitate was isolated via centrifugation and
dried in vacuo to give Compounds 111a-n as white solids. Mn was calculated by
comparing PEG methylene proton integrals with characteristic integrals from the
respective monomers. Yield: a: 251 mg, b: 256 mg, c: 263 mg, d: 277 mg, e: 214 mg, f:
278 mg, g: 240 mg, h: 271 mg, i: 267 mg, j: 244 mg, k: 261 mg, l: 284 mg, m: 243 mg,
n: 214 mg.

DBU/TU-catalyzed-mPEG-b-polycarbonate diblock pendant copolymers (112a-d).
1e (150 mg, 0.03 mmol), Compound 104 and Compound 95, were added to an oven-dried
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5.0mL conical vial containing a magnetic spin vane and a PTFE septum. The total mass
of monomers is equal to 300 mg. The relative amounts of monomers were determined by
solving a system of equations targeting total polycarbonate molecular weight of 10.0 kDa
and 1:2 (a), 1:1 (b), 2:1 (c), and 4:1 (d) ratios of 104:95. DCM was added and the
solutions were stirred to dissolve mPEG and monomers. TU (110) solution (0.125 M in
DCM) was added via syringe, followed by DBU solution (1.0 M in DCM). The amounts
of DBU and TU solution and DCM were determined by targeting 5 mol % DBU and TU
relative to total [M]. The initial volume of DCM is equal to the total volume required to
give [M] = 1.0 M, minus the volume of the DBU and TU solution volumes. The vials
were flushed with nitrogen and stirred at ambient temperature for 24 hours. The polymers
were isolated via precipitation into 40 mL Et2O plus 5 mL iPrOH in 50 mL centrifuge
tubes. The precipitate was isolated via centrifugation and dried in vacuo to give
Compounds 112a-d as white solids. Mn was calculated by comparing PEG methylene
proton integrals with characteristic integrals from the respective monomers. Yield: a: 418
mg, b: 417 mg, c: 411 mg, d: 373 mg.

5.9.4 pDNA-Pendant Polymer Transfection Complex Formation
mPEG-b-polycarbonate pendant polymers solutions (1 mM equivalent of pendant
groups) were vortex mixed with equal volumes of β-CD-PEI+ (1mM equivalent of PEI)
solution in water to form mPEG-b-polycarbonate:β-CD-PEI+ complexes. Transfection
complexes were formed by adding appropriate amount of mPEG-b-polycarbonate:β-CDPEI+ complexes to the 1 µg of pDNA (unmodified or FITC-labelled) dissolved in 30 µL
of TE buffer in 1.5 mL centrifuge tubes. The amount of mPEG-b-polycarbonate:β-CD-
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PEI+ added to DNA varied from 1-3 µL so as to achieve final N/P ratios of 5, 10, 20 & 30.
The above solution was incubated at 4 °C for 1 h before use in transfection experiments.

5.9.5 Particle Size and Zeta (ζ) Potential Measurements
The diameters, size distributions, and ζ-potentials of the materials were evaluated
by dynamic light scattering (DLS) using a Zetasizer Nano S (Malvern Instruments Ltd.)
at 20 °C with a scattering angle of 90°. At least 40 measurements were made and
averaged for each sample. The particles were diluted to 1 mL with HEPES buffer prior to
analysis.

5.9.6 Gel Retardation Assay
The complexation ability of mPEG-b-polycarbonate:CD-PEI+ with pDNA was
determined by low melting point 1% agarose gel electrophoresis. The agarose gels were
precast in TBE buffer with GelRed® dye at 1:10,000 dilution. mPEG-bpolycarbonate:CD-PEI+:pDNA complexes containing 0.2 μg of pDNA at different N/P
ratios were loaded onto the gel before addition of loading dye (1:5 dilution) to each well
and electrophoresis at a constant voltage of 55 V for 2 h in TBE buffer. The pDNA bands
were then visualized under a UV transilluminator at  = 365 nm.
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5.9.7 In Vitro Transfection Assay in HeLa Cells
HeLa cells were cultured in complete DMEM medium with 10% FBS. All cells
were incubated at 37 °C, 5% CO2, and 95% relative humidity, respectively, at a cell
density of 75,000 cells/well in 24-well plates. After 24 h, the culture media was replaced
with serum free media, with addition of mPEG-b-polycarbonate:CD-PEI+:pDNA
complexes containing 1 μg of AcGFP, at N/P ratios of 5, 10, 20 and 30. The cells were
incubated with the complexes for 4 h, after which the spent media was aspirated and fresh
serum-supplemented media was added. After a total of 36 h incubation, the media was
aspirated and the cells were washed with PBS, trypsinized, and analyzed by flow
cytometry using a FC500. The % GFP mean fluorescence intensity was calculated
relative to L2k controls, considered as 100%.

5.9.8 Synthesis of mPEG-b-PCL and SILY-PEG-b-PCL
mPEG-b-poly(ε-caprolactone) (113a-c). mPEG (a: 25.7 mg, b: 93.3 mg, c: 233.3 mg;
46.7 µmmol) was added to an oven-dried 5.0 mL conical vial equipped with magnetic
spin vane and PTFE septum. ε-Caprolactone (0.700 g, 6.13 mmol) was added and
contents were dissolved in 1.166 mL DCM. TBD solution in DCM (35 mg/mL, 1.22 mL)
was added ([M] = 2.0 M) via pipette and the vial was capped and filled with nitrogen.
The solutions were stirred for 72 hours at ambient temperature. The polymerization was
quenched via addition of 80 mg benzoic acid. The solution was precipitated twice into
250 mL diethyl ether from DCM, filtered and dried in vacuo to give Compounds 113a-c
as white powders. Yield: a: 670 mg, b: 716 mg, c: 867 mg; 1H NMR (500 MHz, CDCl3)
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δ 4.05 (t, PCL-CH2), 3.64 (s, PEG-CH2), 2.30 (t, PCL-CH2), 1.64 (h, PCL-CH2CH2), 1.37
(p, PCL-CH2). 13C NMR (126 MHz, CDCl3) δ 173.53, 77.29, 77.03, 76.78, 70.58, 64.15,
34.12, 28.35, 25.54, 24.58.

Carboxylate-PEG-b-poly(ε-caprolactone) (115). ε-Caprolactone (700 mg, 6.13 mmol)
and HO2C-PEG5K-OH (233.3 mg, 46.65 mmol) were added to an oven dried 5.0 mL
conical vial equipped with a magnetic spin vane and PTFE septum. The vial was then
evacuated and purged with argon three times. DCM (1.66 mL) was added via syringe and
solid components were allowed to dissolve followed by 1.41 mL TBD solution (35
mg/mL in DCM) to produce [M] = 2.0 M. The solution was stirred for 72 hours and
quenched with benzoic acid (1.2 equiv to TBD) at the end of the reaction period.
Compound 115) was purified by precipitation twice from DCM into 200 mL cold Et2O,
dried in vacuo for 24 hours and obtained as a white powder. Yield: 0.857 g (91.8 %).; 1H
NMR (500 MHz, CDCl3) δ 10.13-10.27 (br, PEG-CO2H), δ 4.05 (t, PCL-CH2), 3.63 (s,
PEG-CH2), 2.30 (t, PCL-CH2), 1.64 (dq, PCL-CH2CH2), 1.37 (p, PCL-CH2).

Maleimide-PEG-b-poly(ε-caprolactone) (116). Compound 115 (250 mg, 12.6 µmol), 2maleimidoethylamine hydrochloride (46.0 mg, 0.260 mmol) and HOBt (35.2 mg, 0.260
mmol) were added to an oven-dried 5.0 mL conical vial equipped with a magnetic spin
vane and PTFE septum. DCM (3.0 mL) was added and solids were dissolved by stirring
for 5 minutes and cooled to 4 °C in an ice bath. EDC (50.0 mg, 0.261 mmol) was added
followed by diisopropylethylamine (DIEA, 116 µL, 0.651 mmol). The vial was evacuated
and purged with argon three times and stirred for 48 hours warming to ambient
temperature. At the end of the reaction period, the reaction mixture was combined with
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50 mL DCM, 100 mL methanol (MeOH) and 50 mL deionized water in a 250 mL
separatory funnel. The contents were shaken and allowed to separate. The lower organic
phase was removed. The aqueous phase was extracted additionally with 50 mL DCM
four times. Organic extracts were combined and dried with anhydrous sodium sulfate.
The solution was concentrated to approximately 10 mL and the polymer was isolated via
precipitation into 200 mL cold Et2O followed by vacuum filtration. The precipitation
process was repeated once more and the product was dried in vacuo for 24 hours and
obtained as a white powder. Yield: 0.221 g (88.4 %).; 1H NMR (500 MHz, CDCl3) δ 6.79
(s, maleimide-CH2), δ 4.05 (t, PCL-CH2), 3.63 (s, PEG-CH2), 2.30 (t, PCL-CH2), 1.64
(dq, PCL-CH2CH2), 1.37 (p, PCL-CH2).

SILY-PEG-b-Poly(ε-caprolactone) (117). Compound 116 (100 mg, 0.0052 mmol) and
lyophilized SILY peptide (20.7 mg, 9.40 µmol) were added to an oven-dried 5.0 mL
conical vial equipped with a magnetic spin vane and PTFE septum. The vial was
evacuated and purged with argon three times. The contents were solubilized in 1.0 mL
dimethylformamide (DMF) and stirred at ambient temperature for 24 hours. At the end of
the reaction period, the reaction mixture was combined with 50 mL DCM, 100 mL
MeOH and 50 mL deionized water in a 250 mL separatory funnel. The contents were
shaken and allowed to separate. The lower organic phase was removed. The aqueous
phase was extracted additionally with 50 mL DCM four times. Organic extracts were
combined and dried with anhydrous sodium sulfate. The solution was concentrated and
dialyzed against 500 mL DMSO (MWCO 5,000 Da) for 8 hours four times, followed by
deionized water for 2 hours four times. After dialysis the aqueous turbid solution was
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transferred to a 50 mL centrifuge tube, frozen and lyophilized. The lyophilized powder
was dissolved in minimal DCM and precipitated into 50 mL cold Et2O in a centrifuge
tube, isolated via vacuum filtration and dried in vacuo for 24 hours to give Compound
117 as a white powder. Yield: 92.3 mg (76.5 %). 1H NMR (500 MHz, DMSO-d6) δ 9.08
(s, 9H), 8.12 (s, 9H), 8.04 (d, J = 23.1 Hz, 15H), 7.91 (d, J = 31.5 Hz, 30H), 7.85 – 7.62
(m, 58H), 7.58 (s, 8H), 7.28 (s, 12H), 7.16 (s, 11H), 7.05 (s, 5H), 6.98 (t, J = 8.8 Hz,
25H), 6.59 (s, 19H), 6.40 (s, 7H), 4.96 (d, J = 6.1 Hz, 3H), 4.47 (dd, J = 16.8, 9.8 Hz,
5H), 4.32 (s, 24H), 4.25 – 4.02 (m, 61H), 3.95 (d, J = 6.5 Hz, 225H), 3.80 – 3.58 (m,
41H), 3.50 (s, 454H), 3.39 (s, 14H), 3.30 (s, 126H), 3.08 (s, 36H), 2.92 (s, 15H), 2.74 (d,
J = 11.6 Hz, 56H), 2.56 – 2.44 (m, 161H), 2.24 (t, J = 7.3 Hz, 241H), 1.62 – 1.40 (m,
542H), 1.29 (q, J = 8.0 Hz, 303H), 0.99 (d, J = 7.2 Hz, 4H), 0.92 – 0.68 (m, 110H).

5.9.9 Synthesis of mPEG-b-PLGA
mPEG-b-poly(lactide-co-glycolide) (118a-h). Lactide and glycolide were recrystallized
from toluene and toluene/THF, respectively, before polymerizations. 1d or 1e (675 mg)
was added together with lactide (1.350 g, 9.37 mmol) to an oven-dried 100 mL round
bottom flask equipped with a magnetic stir bar and rubber septum. The contents were
dissolved in DCM (33 mL). In a separate round bottom flask, glycolide (0.675 g, 5.82
mmol) was dissolved in THF (9 mL). The glycolide solution was added to the
lactide/mPEG solution over 10 min via syringe pump. The polymerization was quenched
via addition of 150 mg benzoic acid. The solution was concentrated and precipitated into
500 mL diethyl twice, filtered and dried in vacuo to give Compounds 118a-h as white
granular solids. Yield: a: 1.116 g, b: 0.809 g, c: 1.489 g, d: 1.675 g, e: 1.755 g, f: 1.131

299
g, g: 1.298 g; 1H NMR (400 MHz, CDCl3) δ 5.20 (m, PLA methine), 4.78 (m, PGA
methylene), 4.43 – 4.22 (m, PEG), 3.62 (s, PEG methylene), 1.57 (m, PLA methyl). 13C
NMR (101 MHz, CDCl3) δ 169.22, 166.25, 77.25, 76.94, 76.62, 70.46, 68.90, 60.72,
16.54.

5.9.10 Synthesis of Cyclic Amino Acid N-Carboxyanhydride Monomers
(S)-4-Methyloxazolidine-2,5-dione (120). A mortar and pestle was used to grind
commercial L-alanine before drying in vacuo overnight at 50 °C in a vacuum oven. The
ground and dried L-alanine (2.033 g, 22.8 mmol) was added to an oven-dried 2-necked
round bottom flask equipped with a magnetic stir bar, rubber septum and inlet adapter
attached to a nitrogen line containing a 10 % NaOH scrubber. TFF (60 mL) was added
via syringe. The solution was heated to 70 °C and stirred for 5 min. In a separate 50 mL
conical flask, triphosgene (3.047 g, 10.3 mmol) was dissolved in THF (20 mL). The
trisphosgene solution was added to the heterogeneous suspension via syringe pump over
30 min. After the completion of the addition, the solution was nearly clear. The solution
was stirred for an additional 1 hour at 70 °C. The solution was concentrated in vacuo and
Compound 120 was recrystallized several times using THF/toluene/hexane, filtered and
dried in vacuo at ambient temperature to give Compound 120 as a white crystalline solid.
Yield: 2.288 g (87.1 %); 1H NMR (400 MHz, DMSO-d6) δ 9.00 (d, J = 20.1 Hz, 1H),
4.45 (hept, J = 7.2 Hz, 1H), 1.64 – 1.00 (m, 3H). 13C NMR (101 MHz, DMSO) δ 221.66,
173.28, 152.57, 76.17, 53.71, 41.03, 40.82, 40.61, 40.40, 40.20, 39.99, 39.78, 17.66.
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(S)-4-((S)-Sec-butyl)oxazolidine-2,5-dione (122). L-Isoleucine was dried beforehand in
a vacuum over at 50 °C for 24 hours. L-Isoleucine (2.00 g, 15.2 mmol) was added to an
oven-dried 2-necked round bottom flask equipped with a magnetic stir bar, rubber septum
and inlet adapter attached to a nitrogen line containing a 10 % NaOH scrubber. THF (40
mL) was added via syringe. Triphosgene (1.719 g, 5.8 mmol) was dissolved in THF (8
mL) in a separate 20 mL conical round bottom flask. The triphosgene solution was added
over 30 min via syringe pump. The solution was stirred for an additional 2 hours at
ambient temperature. The solution became clear during the 2 hour stir. The solution was
concentrated and purified via recrystallization from toluene/DCM/hexane to give 122 as a
white crystalline solid. Yield: 2.268 g (94.8 %); 1H NMR (400 MHz, CDCl3) δ 7.10 (s,
1H), 4.28 (s, 1H), 2.26 – 1.76 (m, 1H), 1.74 – 1.44 (m, 1H), 1.37 (d, J = 6.5 Hz, 1H), 1.05
(d, J = 6.0 Hz, 3H), 0.95 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 168.79,
153.48, 77.27, 76.95, 76.64, 62.40, 37.24, 24.16, 14.72, 11.27.

Benzyl (S)-3-(2,5-dioxooxazolidin-4-yl)propanoate (124). L-Glutamic acid benzyl ester
was dried beforehand in a vacuum over at 50 °C for 24 hours. L-glutamic acid benzyl
ester (3.50 g, 14.8 mmol) was added to an oven-dried 2-necked round bottom flask
equipped with a magnetic stir bar, rubber septum and inlet adapter attached to a nitrogen
line containing a 10 % NaOH scrubber. THF (36 mL) was added via syringe and the
solution became clear. Triphosgene (1.66 g, 5.6 mmol) was dissolved in THF (9 mL) in a
separate 20 mL conical round bottom flask. The triphosgene solution was added over 30
min via syringe pump. The solution was stirred for an additional 2 hours at ambient
temperature. The solution was concentrated and purified via recrystallization from
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toluene/DCM/hexane to give 124 as a white crystalline solid. Yield: 3.689 g (95.0 %); 1H
NMR (400 MHz, DMSO-d6) δ 12.37 (s, 2H), 7.59 (d, J = 8.1 Hz, 1H), 7.46 – 7.14 (m,
5H), 5.02 (s, 2H), 3.98 (td, J = 9.4, 4.9 Hz, 1H), 2.39 – 2.16 (m, 2H), 1.96 (tt, J = 13.0,
6.4 Hz, 1H), 1.83 – 1.60 (m, 1H). 13C NMR (101 MHz, DMSO) δ 174.61, 174.47,
157.06, 137.87, 129.24, 128.60, 76.16, 66.31, 53.93, 41.04, 40.62, 40.41, 40.21, 39.79,
30.98, 26.97.

Methyl (S)-3-(2,5-dioxooxazolidin-4-yl)propanoate (126). L-Glutamic acid methyl
ester was dried beforehand in a vacuum over at 50 °C for 24 hours. L-glutamic acid
benzyl ester (3.00 g, 18.6 mmol) was added to an oven-dried 2-necked round bottom
flask equipped with a magnetic stir bar, rubber septum and inlet adapter attached to a
nitrogen line containing a 10 % NaOH scrubber. THF (50 mL) was added via syringe and
the solution was heated to 50 °C and stirred for 5 min. Triphosgene (2.430 g, 8.2 mmol)
was dissolved in THF (10 mL) in a separate 20 mL conical round bottom flask. The
triphosgene solution was added over 30 min via syringe pump. The solution was stirred
for an additional 2 hours at 50 °C during which the solution became clear. The solution
was concentrated and purified via recrystallization from THF/hexane to give Compound
126 as a white crystalline solid. Yield: 3.312 g (95.1 %); 1H NMR (400 MHz, DMSO-d6)
δ 9.08 (s, 1H), 4.57 – 4.35 (m, 1H), 3.59 (s, 3H), 2.48 – 2.31 (m, 2H), 2.11 – 1.97 (m,
1H), 1.89 (dq, J = 14.9, 7.4 Hz, 1H). 13C NMR (101 MHz, DMSO) δ 173.15, 172.21,
152.74, 107.93, 57.07, 52.41, 41.05, 40.84, 40.63, 40.42, 40.21, 40.01, 39.80, 29.75,
27.29.
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Benzyl (S)-(4-(2,5-dioxooxazolidin-4-yl)butyl)carbamate (128). H-Lys(Z)-OH was
dried beforehand in a vacuum over at 50 °C for 24 hours. H-Lys(Z)-OH (4.00 g, 14.3
mmol) was added to an oven-dried 2-necked round bottom flask equipped with a
magnetic stir bar, rubber septum and inlet adapter attached to a nitrogen line containing a
10 % NaOH scrubber. THF (50 mL) was added via syringe and the solution was heated
to 50 °C and stirred for 5 min. Triphosgene (1.867 g, 6.3 mmol) was dissolved in THF
(10 mL) in a separate 20 mL conical round bottom flask. The triphosgene solution was
added over 30 min via syringe pump. The solution was stirred for an additional 2 hours at
50 °C during which the solution became clear. The solution was concentrated and
purified via recrystallization from THF/hexane to give 128 as a white crystalline solid.
Yield: 4.214 g (96.4 %); 1H NMR (400 MHz, CDCl3) δ 7.35 (d, J = 5.1 Hz, 5H), 7.15 (s,
1H), 5.09 (s, 2H), 5.01 (s, 1H), 4.25 (s, 1H), 3.18 (s, 2H), 2.05 – 1.87 (m, 1H), 1.86 –
1.71 (m, 1H), 1.53 (s, 3H), 1.34 (d, J = 63.9 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ
169.85, 156.81, 152.47, 152.43, 136.26, 128.49, 128.13, 127.92, 77.25, 76.94, 76.62,
66.82, 57.40, 40.06, 30.75, 29.03, 21.25.

(R)-4-((Benzylthio)methyl)oxazolidine-2,5-dione (130). S-Benzyl-L-cysteine was dried
beforehand in a vacuum over at 50 °C for 24 hours. S-benzyl-L-cysteine (3.00 g, 14.2
mmol) was added to an oven-dried 2-necked round bottom flask equipped with a
magnetic stir bar, rubber septum and inlet adapter attached to a nitrogen line containing a
10 % NaOH scrubber. THF (45 mL) was added via syringe and the solution was heated
to 70 °C and stirred for 5 min. Triphosgene (1.601 g, 5.4 mmol) was dissolved in THF
(11 mL) in a separate 20 mL conical round bottom flask. The triphosgene solution was
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added over 30 min via syringe pump. The solution was stirred for an additional 2 hours at
70 °C during which the solution became clear. The solution was concentrated and
purified via recrystallization from THF/hexane to give Compound 130 as a white
crystalline solid. Yield: 3.273 g (97.1 %); 1H NMR (400 MHz, DMSO-d6) δ 9.20 (s, 1H),
7.48 – 6.97 (m, 5H), 4.76 (t, J = 4.1 Hz, 1H), 3.93 – 3.62 (m, 2H), 3.05 – 2.63 (m, 2H).
13

C NMR (101 MHz, DMSO) δ 171.38, 152.90, 138.76, 129.83, 129.38, 127.98, 58.83,

41.04, 40.83, 40.62, 40.41, 40.21, 40.00, 39.79, 36.94, 32.58.

(S)-4-Benzyloxazolidine-2,5-dione (132). L-Phenylalanine was dried beforehand in a
vacuum over at 50 °C for 24 hours. L-phenylalanine (3.50 g, 21.2 mmol) was added to an
oven-dried 2-necked round bottom flask equipped with a magnetic stir bar, rubber septum
and inlet adapter attached to a nitrogen line containing a 10 % NaOH scrubber. THF (70
mL) was added via syringe and the solution was heated to 60 °C and stirred for 5 min.
Triphosgene (2.389 g, 8.1 mmol) was dissolved in THF (14 mL) in a separate 20 mL
conical round bottom flask. The triphosgene solution was added over 30 min via syringe
pump. The solution was stirred for an additional 2 hours at 60 °C during which the
solution became clear. The solution was concentrated and purified via recrystallization
from THF/hexane to give Compound 132 as a white crystalline solid. Yield: 3.809 g
(94.0 %); 1H NMR (400 MHz, DMSO-d6) δ 9.09 (s, 1H), 7.29 (tt, J = 12.8, 6.2 Hz, 3H),
7.22 – 7.00 (m, 2H), 4.91 – 4.62 (m, 1H), 3.17 – 2.90 (m, 2H). 13C NMR (101 MHz,
DMSO) δ 171.69, 152.52, 135.65, 130.55, 129.29, 128.02, 59.11, 41.03, 40.82, 40.62,
40.41, 40.20, 39.99, 39.78, 37.16.
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ABSTRACT: We report the preparation and performance of
TEM grids bearing stabilized nonfouling lipid monolayer
coatings. These ﬁlms contain NTA capture ligands of
controllable areal density at the distal end of a ﬂexible
poly(ethylene glycol) 2000 (PEG2000) spacer to avoid
preferred orientation of surface-bound histidine-tagged (Histag) protein targets. Langmuir−Schaefer deposition at 30 mN/m of mixed monolayers containing two novel synthetic lipids
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[(5-amido-1-carboxypentyl)iminodiacetic acid]polyethylene glycolamide
2000) (NTA-PEG2000-DSPE) and 1,2-(tricosa-10′,12′-diynoyl)-sn-glycero-3-phosphoethanolamine-N-(methoxypolyethylene
glycolamide 350) (mPEG350-DTPE)in 1:99 and 5:95 molar ratios prior to treatment with a 5 min, 254 nm light exposure was
used for grid fabrication. These conditions were designed to limit nonspeciﬁc protein adsorption onto the stabilized lipid coating
by favoring the formation of a mPEG350 brush layer below a ﬂexible, mushroom conformation of NTA-PEG2000 at low surface
density to enable speciﬁc immobilization and random orientation of the protein target on the EM grid. These grids were then
used to capture His6-T7 bacteriophage and RplL from cell lysates, as well as puriﬁed His8-green ﬂuorescent protein (GFP) and
nanodisc solubilized maltose transporter, His6-MalFGK2. Our ﬁndings indicate that TEM grid supported, polymerized NTA lipid
monolayers are capable of capturing His-tag protein targets in a manner that controls their areal densities, while eﬃciently
blocking nonspeciﬁc adsorption and limiting ﬁlm degradation, even upon prolonged detergent exposure.

■

INTRODUCTION

were extended to the realm of cryoEM single particle
reconstruction by Walz and co-workers, with the structures
for 50S ribosomal subunits,10 transferrin−transferrin receptor
complex,11,12 and human RNA polymerase II13 reported using a
commercially available NTA lipid conjugate, 1,2-dioleoyl-snglycero-3-[((N-(5-amino-1-carboxypentyl)iminodiacetic acid)succinyl] (DGS-NTA), in mixed monolayers with DLPC.
They also extended this technique to the retrieval of protein
targets from cell lysates;11,13 however, the potential of the
approach is currently limited by the low stability,10 nonspeciﬁc
fouling,11 and preferred orientation14 limitations of DGSNTA:DLPC monolayers.
We report our attempts to address these challenges by
depositing nonfouling PEG-lipid15−17 coatings containing
common aﬃnity ligands like NTA3,8,9,18,19 onto TEM grids.20
These coatings are prepared by compression of lipid ﬁlms
whose NTA surface density and PEG mushroom-brush
conformational state can be controlled by initial ﬁlm
composition and applied surface pressures prior to Langmuir−Schaefer (LS) deposition onto the EM grid. Brush
conformation methoxypoly(ethylene glycol) (mPEG) coatings
are highly nonfouling,21−23 thereby enabling the application of
cell lysates directly onto the grid and removal of the

Cryogenic electron microscopy (cryoEM) single particle
reconstruction is a rapidly advancing method of protein
structure elucidation that is now capable of producing
structures with resolutions approaching 2.2 Å, provided that
thousands of single particle images can be collected.1 At
present, this is achieved by collecting and class averaging images
from many diﬀerent carbon-coated grid preparations that
randomly adsorb and present the protein target in multiple
orientations for cryoEM imaging. Since many protein target
candidates exist in low copy number, may be highly labile, and/
or are derived from infectious agents that are in low supply,
there is signiﬁcant motivation for the development of new
sample preparation methods to improve the throughput and
predictability of this technique.
Lipid monolayers have been used to concentrate proteins at
interfaces for structure determination, as ﬁrst described by
Uzgiris and Kornberg.2 Subsequent aﬃnity monolayer developments explored a variety of aﬃnity lipid−ligand interactions
such as biotin−streptavidin, ATP lipid−ATP binding protein,
Ni2+:nitrilotriacetic acid (NTA)-hexahistidine-tagged (His6-tag)
protein, or Cu2+:iminodiacetic acid-His6-tag protein.3 Many of
these eﬀorts were focused on the development of twodimensional crystallization methods using nitrilotriacetic acid
(NTA)-modiﬁed lipid conjugates,4−9 with some cases showing
the potential of NTA lipids for structure elucidation with
resolutions in the 10−25 Å regime.5,8,9 NTA lipid monolayers
© 2016 American Chemical Society
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Figure 1. Conceptual diagram showing stabilized monolayer aﬃnity grid fabrication and utilization. (top left) A ﬂuid-phase mixed lipid monolayer
comprised of Ni2+:NTA-PEG2000-DSPE and mPEG350-DTPE (1:99 or 5:95 mol:mol) was compressed until the mPEG350-DTPE component
entered the brush regime and the diyne lipid chains were fully condensed; (top center) the condensed lipid monolayer ﬁlm was deposited onto
carbon-coated TEM grids via Langmuir−Schaefer (LS) transfer; (top right) photopolymerization of the LS ﬁlm, followed by Ni2+ activation,
produces a grid with a stable aﬃnity capture coating; (bottom right) solutions containing the His-tag protein of interest are deposited onto the
coated grids, either as a clariﬁed cell lysate or as a puriﬁed protein sample; (bottom center) blotting and rinsing of the sample removes nontarget
material prior to (bottom left) cryoﬁxation (or negative staining) and sample imaging.

Figure 2. Structures of (A) mPEG350-DTPE and (B) NTA-PEG2000-DSPE.

grids were then used to capture His6-T7 bacteriophage and
His6-RplL from cell lysates, as well as puriﬁed histidine-tagged
green ﬂuorescent protein (His8-GFP) and nanodisc embedded
His 6 -MalFGK 2 (Figure 1). Our ﬁndings indicate that
polymerized NTA lipid monolayers are capable of capturing
His6-protein targets in a manner that controls their areal
densities, while eﬃciently blocking nonspeciﬁc adsorption and
limiting ﬁlm degradation upon prolonged detergent exposure.

nonspeciﬁcally bound material in subsequent buﬀer washing
steps. In addition to the reduced sample quantity demands
required for cryoEM analysis, the shortened sample processing
times also limit the opportunities for proteolytic degradation
and/or protein unfolding of the His6-target that may occur
during standard sample processing protocols. LS deposition of
a mixed monolayer containing two synthetic polymerizable
lipids1,2-(tricosa-10′,12′-diynoyl)-sn-glycero-3-phosphoethanolamine-N-(methoxypolyethylene glycolamide 350)
(mPEG350-DTPE) and 1,2-(tricosa-10′,12′-diynoyl)-sn-glycero-3-phosphoethanolamine-N-[(5-amido-1-carboxypentyl)iminodiacetic acid]polyethylene glycolamide 2000) (NTAPEG2000-DTPE)prior to treatment with a 5 min, 254 nm
light exposure was used to prepare stabilized aﬃnity
monolayers supported on carbon coated EM grids. These

■

EXPERIMENTAL METHODS

Synthesis of mPEG350-DTPE, NTA-PEG2000-DSPE, and NTAPEG2000-DTPE. The detailed synthesis procedures for mPEG350DTPE, NTA-PEG2000-DSPE, and NTA-PEG2000-DTPE (Figure 2)
are reported in Supporting Information.
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Cell Lysate Preparations. The ASKA library, a complete E. coli K12 ORF archive in which over 4000 bacterial proteins have been
cloned into pCA24N expression vectors, was used. Each protein
coding ORF has an N-terminal His6 and a C-terminal green
ﬂuorescence protein (GFP); each protein coding ORF is also available
without the GFP fusion (which are the strains used in these studies).
Cells containing the RplL gene overexpression vector were grown to
OD = 0.6 in 100 mL of LB broth using a 37 °C shaker/incubator and
induced with a ﬁnal concentration of 1.0 mM IPTG before allowing to
grow for an additional 4 h. After centrifugation, the supernatant was
discarded before resuspending the cell pellet in lysis buﬀer (20 mM
Tris, 10 mM MgCl2, 100 mM KCl, pH = 7.4, 100 μg aprotinin, 174 μg
PMSF, 500 μg lysozyme) and incubation for 20 min. The cell
membranes were disrupted by sonication (35 pulses, 1 s/pulse at 75
W) before centrifugation of the suspension at 11 000 g for 10 min. The
supernatant containing His 6-RplL was diluted 10-fold before
application to the TEM grid for analysis.
Puriﬁed C-terminal His8-tag gp10 (capsid protein) of T7
bacteriophage was typically produced at concentrations of ∼1 × 1012
particles/mL. BL21 bacteria cells in 1 mL of LB media were grown to
OD = 0.8 before addition of T7 bacteriophage (1.0 μL, 1.0 × 1012
particles/mL) to the culture and shaking at 37 °C for 1 h. After
centrifugation of the cells, the supernatant was used directly for TEM
grid analysis.
His8-GFP Puriﬁcation. A glycerol stock of E. coli cells, transformed
with the His8-GFPuv pT7−7 plasmid, was shaken at 37 °C overnight
before addition to 250 mL of LB media with shaking at 37 °C until an
OD600 of 0.7 was reached. Then, a 1.0 M stock solution of isopropyl-βD-thiogalactopyranoside (IPTG) was added, bringing the ﬁnal
concentration to 1.0 mM, before shaking continually at 37 °C for an
additional 5 h. The cells were then centrifuged at 11 000 g for 10 min,
the supernatant discarded, and the pellet resuspended in 10 mL of lysis
buﬀer (50 mM NaH2PO4, 100 mM NaCl, pH = 8.0, 100 μg aprotinin,
174 μg phenylmethanesulfonyl ﬂuoride (PMSF), and 500 μg of
lysozyme). The suspension was allowed to stand for 20 min before the
cell membranes were disrupted using 3 rounds of sonication (35 pulses
of probe sonication, 1 s/pulse at 75 W with 1 s rest/pulse) and the
debris pelleted by centrifugation at 11 000 g for 30 min. The
supernatant was incubated with 100 μL of Ni-NTA agarose beads and
gently rotated for 4 h. The beads were pelleted using a benchtop
centrifuge operating at 5000 g for 2 min. The supernatant was
discarded and the pellet was washed with PBS buﬀer containing
imidazole (50 mM NaH2PO4, 100 mM NaCl, 10 mM imidazole, pH =
8.0). The same spin and wash sequence was repeated with 15 mM, 20
mM, and 30 mM imidazole in PBS. The protein was eluted from the
resin after removal of the supernatant and incubation of the beads with
500 mM imidazole in PBS for 4 h. The removal of imidazole from the
eluted protein was achieved by dialysis against PBS (50 mM
NaH2PO4, 100 mM NaCl, 10 mM imidazole, pH = 8.0) overnight
using a 10 000 MWCO Slide-A-Lyzer. The protein was characterized
using 12.5% acrylamide SDS-PAGE gel electrophoresis.
Puriﬁed Maltose Transporter Solubilized in Lipid Nanodisc.
The methods used to purify and insert His6-MalFGK2 maltose
transporter in lipid nanodiscs derived from membrane scaﬀolding
proteins (MSP) followed those described in a previously reported
protocol.24
Langmuir−Schaefer Film Deposition onto TEM Grids. Stock
solutions of two lipid mixtures (1:99 Ni2+:NTA-PEG2000-DTPE:mPEG350-DTPE and 5:95 Ni2+:NTA-PEG2000-DTPE:mPEG350DTPE) were prepared in CHCl3 at 2.0 mg/mL and stored at −80
°C. Each of these were spread via 10 μL microsyringe at the air−water
interface of a Kibron μTrough and compressed to a ﬁnal surface
pressure of 30 mN/m (i.e., ∼59 Å2/molecule for 1:99 Ni2+:NTAPEG2000-DTPE:mPEG350-DTPE monolayers and ∼66 Å2/molecule
for 5:95 Ni2+:NTA-PEG2000-DTPE:mPEG350-DTPE monolayers).
The compressed lipid monolayers were deposited onto TEM grids by
Langmuir−Schaefer transfer using tabbed TEM grids (Ted Pella) to
enable grid approach at 180° (and the transfer forceps at 90°) relative
to the air−water interface. The LS ﬁlm was immediately blotted with
ﬁlter paper. (n.b.: Standard TEM grids and forceps produced extensive

disruption of the interface during the LS transfer step, making it
impossible to determine accurate grid transfer ratios under these
conditions.) The supported monolayer ﬁlms were then polymerized
for 10 min using a hand-held 8 W/m2 254 nm lamp that was placed
6−8 cm above the grid surface before transfer to a standard TEM grid
box for later use.
Fluorescence Microscopy. Sessile drops of His8-GFPuv solution
(3.5 μL, 2.0 mg GFP/mL in PBS) were deposited onto 1:99
Ni 2+ :NTA-PEG2000-DTPE:mPEG350-DTPE, 5:95 Ni2+ :NTAPEG2000-DTPE:mPEG350-DTPE, 100% mPEG350-DTPE, or bare
carbon coated grid surfaces for 2 min, followed by removal of excess
sample using a microsyringe. Grids were then washed 3 times with 20
μL drops of Tris buﬀer before removal of the excess solution via
microsyringe. For elution of Ni2+:NTA-bound T7 bacteriophage from
the surface of the grid, 500 mM imidazole was deposited on the grid
surface for 5 min before washing twice with 20.0 μL of PBS. After
preparation, the TEM grid was sandwiched between a microscope
slide and coverslip and sealed with nail polish before recording the
ﬂuorescence images.
Negative-Staining Procedure. T7 bacteriophage and RplL cell
lysate samples were prepared by incubating a 5.0 μL drop of cell lysate
on the grid surface for 2.0 min before gentle removal by microsyringe.
The grids were then washed 6 times with 20 μL drops of Tris buﬀer
followed by a ﬁnal wash with 20 μL of distilled water. A 5 μL drop of
2% uranyl acetate was placed on the grid for 1 min before removal of
the excess solution with a wedge of ﬁlter paper. Ni2+:NTAimmobilized samples were eluted from the grids by adding 5 μL of
500 mM imidazole in Tris buﬀer immediately after sample deposition
(i.e., instead of 6 Tris buﬀer washes). Nanodisc solubilized MalFGK2
and puriﬁed T7 bacteriophage samples were prepared in the same
manner as the cell lysate samples, except that the incubation time of
the samples on DLPC and mPEG350-DTPE modiﬁed grids was
increased to 3 min. Negatively stained samples were imaged using a
Tecnai TF20 transmission electron microscope operating at 200 kV.
Preparation of Frozen Hydrated Samples for Cryo-TEM.
TEM grids modiﬁed with stabilized 5:95 Ni2+:NTA-PEG2000DTPE:mPEG350-DTPE monolayers were treated with His-tag protein
samples as described above for negative-staining. After application of
the protein solution, the excess sample was removed by blotting the
grids twice for 3 s with an oﬀset of −1 at 80% humidity using a
Vitrobot (FEI Company). The grids were then cryo-ﬁxed by plunging
into liquid ethane and imaged at 200 kV on an FEI CM200
transmission electron microscope using low-dose techniques. Images
were recorded using a Gatan Ultrascan CCD.

■

RESULTS AND DISCUSSION

mPEG350-DTPE was prepared in 24% yield by treatment of
commercially available 1,2-(tricosa-10′,12′-diynoyl)-sn-glycero3-phosphoethanolamine (DTPE) with the N-hydroxysuccinimidyl (NHS) active ester form of mPEG350 (Supporting
Information, Scheme S1). NTA-PEG2000-DSPE was prepared
in 40% yield by sequential modiﬁcation of doubly activated
NHS-PEG2000-maleimide with 1,2-distearoyl-sn-glycero-3phosphoethanolamine (DSPE) and a thiol-modiﬁed lysineNTA derivative (Figure 2; Supporting Information, Schemes
S2−S4). NTA-PEG2000-DTPE was prepared in 13% yield in a
similar manner as NTA-PEG2000-DSPE, except that DTPE
was used for NHS displacement instead of DSPE.
CHCl3 stock solutions of the lipid mixtures were prepared,
spread at the air−water interface at 20 °C, a 5 min incubation
period allowed for evaporation of the solvent, and the ﬁlms
compressed at a rate of 10 Å2/molecule until collapse at 30−35
mN/m for the mixed monolayers and 40 mN/m for pure
mPEG350-DTPE monolayers. The pressure−area isotherms
shown in Figure S1 for 1:99 and 5:95 NTA-PEG2000DTPE:mPEG350-DTPE lipid mixtures displayed gradually
increasing surface pressures upon ﬁlm compression, except
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variations in ﬂuorescence observed. In those cases, we attribute
the areas of decreased ﬂuorescence to grid regions with an
incomplete carbon coating, whereas zones of substantially
increased ﬂuorescence were ascribed to incomplete LS transfer
of the brush layer mPEG350-DTPE. We infer from these
ﬁndings that nonspeciﬁc binding of protein on the brush
regime mPEG350-DTPE coated grids is much lower than that
of glow discharged bare carbon ﬁlms due to the combined
eﬀects of molecular weight, polymer hydration, excluded
volume, elastic restoration, and grafting density on the surface
that enhance the antifouling properties of the mPEG
coating.22,26,27 In some cases, low molecular weight PEG
polymers such as mPEG350 display greater antifouling
properties than their higher molecular weight counterparts
since the shorter PEG chains are better able to form a more
densely packed layer.28,29 Based on these ﬁndings, we
concluded that brush regime mPEG350-DTPE monolayers,
deposited onto a carbon coated surface by LS transfer, would
be a good candidate for blocking nonspeciﬁc adsorption of
macromolecules onto EM grid surfaces. To test this
assumption, we conducted a comparative study between
DLPC monolayers and mPEG350-DTPE stabilized monolayers, both deposited via LS transfer, using bare carbon grids as
a control.
His8-GFPuv capture on grids bearing stabilized 1:99 and 5:95
Ni2+:NTA-PEG2000-DTPE:mPEG350-DTPE monolayers was
ﬁrst demonstrated by ﬂuorescence microscopy. Wide-ﬁeld
ﬂuorescence images (Figure S4) of Ni2+:NTA-PEG2000DTPE:mPEG350-DTPE modiﬁed grids reveal a nonuniform,
concentration-dependent GFP ﬂuorescence. Some spots of
bright ﬂuorescence, suggestive of GFP aggregation, were also
observed. The observed pixel intensities in the ﬂuorescence line
scan analyses were higher for the grids bearing a 5:95
Ni2+:NTA-PEG2000-DTPE:mPEG350-DTPE coating than
the grids coated with a 1:99 monolayer. In both cases, the
bound His8-GFPuv could be removed from the grid surface
after a brief 5 min exposure to either 500 mM imidazole or 150
mM EDTA to remove Ni2+ from the His8:Ni2+:NTA complex
to enable elution of the immobilized protein target from
stabilized, Ni2+ activated 1:99 and 5:95 Ni2+:NTA-PEG2000DTPE:mPEG350-DTPE monolayers. These ﬁndings indicate
that His-tag targets can be captured in an NTA concentrationdependent manner, with higher NTA loadings producing
greater target protein concentrations on TEM grids coated with
stabilized, Ni2+-activated NTA-PEG2000-DTPE:mPEG350DTPE monolayers.
Puriﬁed His6-T7 bacteriophage (1011−1012 particles/mL)
was used to probe the nonspeciﬁc adsorption properties of
DLPC and mPEG350-DTPE stabilized monolayer-coated grids
at higher resolution, with carbon coated, glow-discharged grids
serving as a control. The sample aggregated on grids lacking
modiﬁed DLPC or mPEG350 monolayers (Figure 3A). We
identiﬁed virus-like particles on these grids, as shown in Figure
3A (inset); however, the poor sample quality produced on
unmodiﬁed, glow-discharged grids made accurate quantiﬁcation
of adsorbed virus particles impossible. Therefore, we only
quantiﬁed virus adsorption onto DLPC and mPEG350
modiﬁed grids, as discrete particles could be discerned in
both cases. DLPC coated grids were found to decrease the
amount of T7 that was adsorbed to the grid relative to bare
carbon grids (Figure 3B), indicating that interactions between
T7 bacteriophage and the DLPC monolayer are not as
favorable. Nonetheless, a signiﬁcant amount of occult debris

that the onset of surface pressure occurred at larger molecular
areas as the NTA-PEG2000-DTPE composition in the ﬁlm
increased. We attribute this observation to the displacement of
surface-adsorbed NTA-PEG2000 from the air−water interface
as previously described25 for mixed mPEG2000-lipid monolayers. As this desorption process progresses, the majority
component, mPEG350, undergoes a mushroom−brush regime
transition upon compression to 30 mN/m while the NTAPEG2000 fraction remains in the mushroom conﬁguration. The
extension of the PEG2000 polymer mushroom conformation
from the surface of the ﬁlm can be calculated by Lo = αN(α/
D)2/3, where Lo = the length of PEG graft, α = length of PEG
monomer (3.5 Å), N = number of ethylene glycol units in the
PEG chain (i.e., 45), and D = the distance between grafting
sites. For a lipid ﬁlm containing 1% NTA-PEG2000-DTPE, the
grafting site separation is estimated to be 47 Å and the Lo = 2.8
nm. Fully compressed 5:95 NTA-PEG2000-DTPE:mPEG350DTPE monolayers are estimated to have a grafting site
separation of 9.4 Å and a NTA-PEG2000 graft extension of
8.2 nm. As the lipid ﬁlm is compressed below 113 Å2/molecule,
the mPEG350 fraction enters the brush regime, while the NTAPEG2000 polymer chain accommodates further compression
by extending farther away from the air−water interface in a
concentration-dependent manner. Consequently, a longer
NTA-PEG was prepared for these studies since it would confer
greater conformational freedom to the immobilized histidinetagged target and present it in a greater diversity of possible
orientations for cryoEM single particle analysis.
Since the lipid ﬁlms typically collapsed at surface pressures
above 30 mN/m, the monolayers were compressed to 30 mN/
m prior to Langmuir−Schaefer (LS) transfer onto carboncoated grids that were not subjected to glow discharge before
LS deposition. This method produced transfer ratios between
0.89 and 0.97 for the LS deposition step. Photopolymerization
of the lipid monolayer was initiated by placing the grids ∼6−8
cm from a hand-held UV lamp and irradiating for 10 min. Grid
performance as a function of varied irradiation time suggested
that a 10 min exposure was most favorable.
After monolayer ﬁlm transfer onto 400 mesh grids and
staining with freshly prepared 1% UO2(OAc)2, TEM images
revealed the presence of large continuous areas exceeding 900
μm2 in size that were punctuated by much smaller zones of
higher contrast (Figure S2). We infer from these ﬁndings that
the large area regions were monolayer ﬁlms with occasional,
interspersed domains of bilayer and trilayer ﬁlms arising from
partial monolayer collapse during compression that were
preserved by the photopolymerization process. Suﬃciently
large areas of the grid were coated by stabilized monolayer ﬁlm
structures to make them suitable for negative stain and cryoEM
studies; however, the multilayer sections of the ﬁlm were
helpful for monitoring the stability of the ﬁlm in the presence of
detergents as described below.
The antifouling properties of the mPEG350 brush layer
within the stabilized monolayer coating was probed qualitatively using ﬂuorescence microscopy analysis of His8-GFPuv
adsorption onto these modiﬁed surfaces. Wide ﬁeld and line
scan ﬂuorescence microscopy analysis revealed that glow
discharged bare amorphous carbon surfaces possessed nearly
20-fold greater ﬂuorescence intensities after exposure to His8GFPuv than grids bearing mPEG350 brush regime coatings
(>8000 RFU and ∼400 RFU, respectively; Figure S3). Our data
shows that the ﬂuorescence distribution was uniform over both
types of surfaces; however, in rare instances there were small
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GFPuv capture on grids bearing stabilized 1:99 and 5:95
Ni 2+:NTA-PEG2000-DTPE:mPEG350-DTPE monolayers.
Wide-ﬁeld ﬂuorescence images (Figure S4) of Ni2+:NTAPEG2000-DTPE:mPEG350-DTPE modiﬁed grids reveal a
nonuniform, concentration-dependent GFP ﬂuorescence. Occasional spots of bright ﬂuorescence, suggestive of GFP
aggregation, were also observed. The observed average pixel
intensities in the ﬂuorescence line scan analyses were higher for
the grids bearing a 5:95 Ni2+:NTA-PEG2000-DTPE:mPEG350-DTPE coating than the grids coated with a 1:99
monolayer. In both cases, the bound His8-GFPuv could be
removed from the grid surface after a brief 5 min exposure to
either 500 mM imidazole or 150 mM EDTA to remove Ni2+
from the His8:Ni2+:NTA complex to enable elution of the
immobilized protein target from stabilized, Ni2+ activated 1:99
and 5:95 Ni2+:NTA-PEG2000-DTPE:mPEG350-DTPE monolayers. These ﬁndings indicate that histidine-tagged targets can
be captured in an NTA concentration-dependent manner, with
higher NTA loadings producing greater target protein
concentrations on TEM grids coated with stabilized, Ni2+activated NTA-PEG2000-DTPE:mPEG350-DTPE monolayers.
Aﬃnity capture of His6-T7 bacteriophage from cell lysates
was then tested by negative stain and cryoelectron microscopy
using grids modiﬁed with mPEG350-DTPE stabilized monolayers, Ni2+:NTA-PEG2000-DTPE:mPEG350-DTPE stabilized
monolayers, and Ni2+:NTA-PEG2000-DTPE:mPEG350-DTPE
stabilized monolayers rinsed with 500 mM imidazole after
lysate exposure (Figure 4). In the presence of mPEG350-DTPE
stabilized monolayers, we observed minimal binding of His6-T7
bacteriophage and very low levels of debris from the lysate onto
the grid (Figure 4A). In some cases, T7 particles were not
observed on the brush polymer surface even at low

Figure 3. Comparative performance of uncoated (bare carbon, glowdischarge), DLPC, and mPEG350-DTPE coated grids toward
nonspeciﬁc protein adsorption (i.e., lacking NTA groups to promote
speciﬁc binding). The capacity of these grids to reject nonspeciﬁc
protein adsorption was tested by negative stain TEM analysis using
His6-T7 bacteriophage in puriﬁed form or within cell lysates. (A)
Puriﬁed His6-T7 bacteriophage on glow-discharged bare carbon grid;
(B) puriﬁed His6-T7 bacteriophage on 100% DLPC monolayer coated
grid; (C) His6-T7 bacteriophage on stabilized 100% mPEG350-DTPE
monolayer coated grid; (D) number of nonspeciﬁc contaminants
adsorbed from puriﬁed His6-T7 bacteriophage solution onto bare
carbon grids (blue), DLPC coated grids (red), and mPEG350-DTPE
coated grids (green) as determined by counting 60 randomly selected
ﬁelds across 3 diﬀerent grids for each grid type; (E) His6-T7
bacteriophage in cell lysate applied to 100% DLPC coated grid; and
(F) His6-T7 bacteriophage in cell lysate applied to stabilized 100%
mPEG350-DTPE coated grid.

remained on the DLPC monolayer coated grids. Grids coated
with mPEG350-DTPE stabilized monolayers, however, displayed a greatly reduced accumulation of both T7 and debris
(Figure 3C). The appearance of the virus particles in these
samples included round-like objects as well as more familiar
hexagonal projection of the mature icosahedral form of the
virus. The T7 phage particles in these images represent the
immature form where an absence of mature capsid shell protein
gives results in the rounded appearance of these particles.30 The
low abundance of T7 phage particles highlights the antifouling
opportunities of these PEGylated surfaces. Quantitative
comparisons of the T7 particle densities on DLPC and
mPEG350 monolayers revealed an accumulation of ∼110
particle/1 μm2, and 5 particle/1 μm2, respectively. We infer
from these ﬁndings that mPEG350-DTPE stabilized monolayers are the most eﬀective toward blocking nonspeciﬁc
adsorption of T7 bacteriophage (Figure 3D). Low magniﬁcation images of puriﬁed T7 deposited onto both DLPC and
mPEG-DTPE stabilized monolayer coated grids reveal a
substantially lower background in the case of mPEG350DTPE coated grids (Figure 3E,F).
After evaluating the capacity of these grids to inhibit
nonspeciﬁc adsorption, we next turned our attention to their
ability to direct aﬃnity-guided interactions with NTA-modiﬁed
grids. First, we used ﬂuorescence microscopy to monitor His8-

Figure 4. Eﬀect of NTA surface density on His-T7 bacteriophage
captured from cell lysates using negative stain and cryoEM analysis.
(A) Negative stain TEM appearance of grid coated with stabilized
100% mPEG350-DTPE monolayer after 2 min exposure to cell lysate
containing His-T7 bacteriophage; (B) same as in (A), except that the
grid was coated with stabilized 1:99 Ni2+:NTA-PEG2000-DSPE:mPEG350-DTPE monolayer; (C) same as in (B), except that the grid
was rinsed with 500 mM imidazole, pH = 7.4, after the 2 min lysate
exposure step; and (D) cryoEM appearance of grid coated with
stabilized 5:95 Ni2+:NTA-PEG2000-DSPE:mPEG-350-DTPE monolayer after 2 min exposure to cell lysate containing His-T7
bacteriophage.
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magniﬁcation, suggesting a complete blockage of nonspeciﬁc
adsorption. Grids bearing Ni2+-charged 1:99 NTA-PEG2000DTPE:mPEG350-DTPE stabilized monolayers were capable of
capturing His6-T7 bacteriophage from cell lysate while limiting
the background adsorption of undesired nontarget cellular
components (Figure 4B). It is worth noting that T7 viral
particles often give mixed results of negative-stain and positivestained particles since UO22+ salts may positively stain packaged
nucleic acid within the capsid structure.31 Exposure of these
samples to 500 mM imidazole led to greatly decreased surface
adsorption of His6-T7 bacteriophage, suggesting that the
interaction of phage particles with the supported NTA-lipid
monolayer is Ni2+ speciﬁc (Figure 4C). We attribute the
occurrence of the few remaining particles to either nonspeciﬁc
adsorption to uncoated grid regions or particles that are avidly
bound due to multivalent interactions between the phage
particles and the NTA-PEG grafted surface. To compensate for
particle capture eﬃciency limitations in samples prepared for
cryogenic imaging10 due to unfavorable kinetics and/or modest
ligand−receptor aﬃnities,32 we examined 1:99 and 5:95
Ni2+:NTA-PEG2000-DTPE:mPEG350-DTPE stabilized monolayer coated grids to determine whether the areal density of
NTA ligands had a detectable inﬂuence on His 6 -T7
bacteriophage capture eﬃciency. Using identical sample
processing methods and incubation times, we qualitatively
observed an increase in particle surface density with increasing
Ni2+:NTA-PEG2000-DTPE composition (unpublished data).
Since this comparison was not performed in a side-by-side
manner between 1:99 and 5:95 Ni2+:NTA-PEG2000-DTPE:mPEG350-DTPE stabilized monolayers with the same lysate, it is
conceivable that these ﬁndings may be the result of diﬀerent
virus titers in the His6-T7 bacteriophage preparations. Nonetheless, these ﬁndings are consistent with the His8-GFPuv
experiments described above (Figure S4) showing that higher
surface concentrations of aﬃnity capture lipid produces greater
areal densities of immobilized target on the NTA-modiﬁed
surface, with the 5:95 Ni2+:NTA-PEG2000-DTPE:mPEG350DTPE stabilized monolayer coated grids being more suitable
for cryoEM sample preparation (Figure 4D). The immobilization of both mature and immature T7 phage from lysate
samples (Figure S8) highlights the potential of rapid
puriﬁcation using aﬃnity grids toward studying dynamic
processes, which may not be possible when visualizing puriﬁed
samples generated using standard TEM sample preparations.
We next demonstrated the capture of the 50S E. coli
ribosomal subunit,10 His6-RplL, directly from cell lysates onto
grids coated with Ni2+:NTA-PEG2000-DTPE:mPEG350DTPE stabilized monolayers. Negative stain EM images of
His6-RplL lysate deposited onto grids coated with mPEG350DTPE stabilized monolayers showed no appreciable targetspeciﬁc adsorption onto the grid (Figure 5A). After LS
deposition of 20:80 Ni2+:NTA-PEG2000-DTPE:mPEG350DTPE stabilized monolayers onto the grids, particles consistent
with the size and various shapes of the 50S subunit were
observed on the grid surface (Figure 5B). When 500 mM
imidazole was added to samples containing the captured
ribosomal particles on 20:80 Ni2+:NTA-PEG2000-DTPE:mPEG350-DTPE stabilized monolayers, the previously adsorbed
particles were eluted from the surface of the TEM grid (Figure
5C), consistent with the expectation that the interaction of
His6-RplL with the surface of the grid is Ni2+ speciﬁc. Using the
same sample preparation procedure, cryoEM analysis revealed
the capture of His6-RplL from E. coli lysates (Figure 5D) as

Figure 5. Aﬃnity capture of His-RplL from cell lysates onto stabilized
Ni2+:NTA-PEG2000-DTPE:mPEG-350-DTPE monolayer coated
grids. (A) Negative stain TEM of grid coated with stabilized 100%
mPEG350-DTPE after 2 min exposure to cell lysate containing HisRplL; (B) negative stain TEM of grid coated with 20:80 Ni2+:NTAPEG2000-DSPE:mPEG350-DTPE after 2 min exposure to cell lysate
containing His-RplL; (C) same as in (B), except that the grid was
rinsed with 500 imidazole, pH = 7.4, after the 2 min exposure to cell
lysate containing His-RplL; and (D) cryoEM image of grid coated with
stabilized 5:95 Ni2+:NTA-PEG2000-DSPE:mPEG-350-DTPE monolayer after 2 min exposure to cell lysate containing His-RplL.

crown-like projections in some images (Figure 5D). These have
frequently been reported and are attributed to the 50S
ribosomal subunit. The earliest reported TEM images of
ribosomes were small, featureless bumps on the grid surface;33
however, more powerful tools eventually led to the revelation
of several features in the ribosomal units such as “crown-like”
and “duck-like” projections for the 50S and 30S subunits,
respectively.34,35 Since the RplL protein carries the hexahistidine tag on the 50S subunit in our construct, we identiﬁed
many more of these particles bound to the grid than the 30S
subunit. Crown-like projections are clearly seen from the side
view of the 50S particle with a central protuberance, a ridge, a
stalk, and two groove-like features.
A key design feature of these stabilized aﬃnity coatings is
their utilization of two diﬀerent types of poly(ethylene glycol)modiﬁed lipids, one high molar ratio brush layer short segment
to block nonspeciﬁc adsorption and facilitate stabilization via
photopolymerization (i.e., mPEG350-DTPE) and a second low
molar ratio component to enable multiple orientations of the
captured protein target to avoid preferred orientations at the
monolayer interface and provide a more representative single
particle reconstruction analysis data set. We tested this
hypothesis by preparing dozens of TEM grids bearing stabilized
Ni2+:NTA-PEG2000-DSPE:mPEG350-DTPE coatings that had
been treated with His6-RplL containing lysates. CryoEM
evaluation of these grids conﬁrmed that the NTA-PEG2000
tether is capable of both capturing and presenting multiple
orientations of the bound His6-RplL target as demonstrated by
the overlay of the known 50S subunit and 70S complex
structures in diﬀerent rotational conﬁgurations (data not
shown).
MSP have become an increasingly popular tool for stabilizing
membrane protein dispersions since it provides a platform in
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which the local environment of solubilized membrane proteins
resemble the natural environment of the lipid bilayer in cells.36
MSP are used to corral lipids and membrane proteins within
disk-like structures containing a lipid bilayer interior that can
host reconstituted membrane proteins for structure analysis by
electron microscopy,37,38 protein modiﬁcation studies,39 and
protein activation analysis.40 We used the puriﬁed hexahistidine-tagged maltose transporter, His6-MalFGK2, solubilized in
MSP lipid nanodisc, for evaluating their aﬃnity capture
properties on NTA-modiﬁed stabilized aﬃnity grids. Although
His-tag MSP can be used for aﬃnity puriﬁcation,41 we used a
His6-MalFGK2 construct for nanodisc reconstitution to ensure
that only nanodisc containing His6-MalFGK2 are surface
immobilized. We found that mPEG350-DTPE stabilized
monolayer coated grids treated with His6-MalFGK2 nanodisc
appeared to have fewer particles bound to the grid surface
(Figure 6A) than the grids coated with 1:99 Ni2+:NTA-

predominantly top/bottom views of the particles, i.e., a disklike appearance in TEM micrographs (Figure 6D), suggesting
that a longer PEG spacer is needed to collect a greater number
of side views for this solubilized target.
In order to test the durability of the stabilized monolayers
toward detergent exposure, the modiﬁed grids were treated
with either 0.03% Triton X-100 (CAC = 0.015%), 0.014%
Tween 20 (CAC = 0.0072%), and 0.5% CHAPS (CMC =
0.49%) solutions for varying periods of time before TEM
observation. Lipid monolayers adsorbed to solid substrates
display better detergent resistance than lipid bilayers that are
prone to disruption via lipid ﬂip-ﬂop.43,44 Initial encounter of
detergents with the outer bilayer leaﬂet results in ﬂuidization
and lipid ﬂip-ﬂop from the inner leaﬂet to the outer leaﬂet,
eventually leading to complete solubilization of the bilayer
structure.44 Inhibition of ﬂip-ﬂop due to adsorption of a highly
compressed monolayer onto the solid carbon substrate inhibits
ﬂip-ﬂop processes, leading to improved detergent resistance.
Despite some evidence of enhanced detergent resistant of
supported DLPC monolayers, prior attempts to produce TEM
grids coated with mixed Ni2+:NTA-DSG:DPLC monolayers
showed that their exposure to harsher detergents such as Triton
X-100, Tween-20, and CHAPS led to monolayer solubilization.10 We tested the detergent resistance of our stabilized
Ni2+:NTA-PEG2000-DTPE:mPEG350-DTPE monolayer coatings under conditions where DLPC monolayers failed by using
0.03% Triton X-100, 0.014% Tween 20, and 0.5% CHAPS at 5,
15, and 30 min exposures to the detergent solutions. Negative
stain TEM observation of the coatings after detergent exposure
indicated that stabilized Ni 2+ :NTA-PEG2000-DTPE:mPEG350-DTPE monolayer coatings remain intact after 30
min of incubation with Triton X-100, Tween-20, and CHAPS
(Figure S6). In the case of Triton X-100, some holes in the
monolayer were occasionally observed, but none were apparent
in grids treated with Tween 20 or CHAPS. The capacity of
these coatings to immobilize puriﬁed His6-T7 bacteriophage
after detergent exposure for 20 min indicated that a modest
reduction in phage binding to the grid occurred; however, the
immobilized His6-T7 bacteriophage particles were bound
speciﬁcally as indicated by their ability to be removed by
elution with 500 mM imidazole (unpublished data).
Fluorescence microscopy analysis of detergent-treated
Ni2+:NTA-PEG2000-DTPE:mPEG350-DTPE monolayers revealed that the stabilized Ni2+ lipid monolayer coatings retained
their ability to capture His8-GFPuv. Pixel intensity data was
collected over the entire ﬂuorescence image (Figure 7) to best
represent the overall speciﬁc capture capacity of the coating,
regardless of whether it had been detergent compromised or
not. In the case of Triton X-100 exposed samples, the
ﬂuorescence was occasionally enhanced near the grid edges,
possibly as a result of solubilized or damaged monolayer near
the center of the grid holes that were unable to capture His8GFPuv in those regions. We did not see this phenomenon with
either CHAPS- or Tween 20-treated surfaces. These grids
exhibited a uniform distribution of His8-GFPuv ﬂuorescence
over the grid holes until the surfaces were treated with 500 mM
imidazole to displace the immobilized protein. Despite the
limitations of these stabilized Ni2+:NTA-PEG2000-DTPE:mPEG350-DTPE monolayer coatings toward prolonged Triton
X-100 exposure, our data indicates that histidine-tagged
proteins can be reversibly immobilized even after detergent
exposure. We infer from these ﬁndings that both the integrity of
the stabilized lipid monolayer and the speciﬁc aﬃnity capture of

Figure 6. Aﬃnity capture of MSP nanodisc containing puriﬁed HisMalFGK2. (A) Negative stain TEM of stabilized 100% mPEG350DTPE monolayer-coated grid after treatment with His-MalFGK2 in
nanodiscs; (B) negative stain TEM of His-MalFKG2 in nanodisc
captured on stabilized 1:99 Ni2+:NTA-PEG2000-DSPE:mPEG350DTPE monolayer-coated grid; (C) same as in (B), except that the grid
was rinsed with 500 mM imidazole, pH = 7.4, after the His-MalFGK2
in nanodisc exposure step; and (D) cryoEM of His-MalFGK2 in
nanodisc captured on stabilized 5:95 Ni2+:NTA-PEG2000-DSPE:mPEG-350-DTPE monolayer-coated grid.

PEG2000-DTPE:mPEG350-DTPE stabilized monolayers (Figure 6B). Treatment of the His6-MalFGK2-immobilized grids
with 500 mM imidazole produced a decrease in MSP nanodisc
binding to the surface (Figure 6C), further suggesting that the
interaction between nanodisc solubilized His6-MalFGK2 and
the NTA-modiﬁed surface is Ni2+ speciﬁc. High magniﬁcation
images of nanodisc solubilized His6-MalFGK2 immobilized
onto 5:95 Ni2+:NTA-PEG2000-DTPE:mPEG350-DTPE stabilized monolayers (Figure 6D) reveal a set of disc-like features in
the size range of other lipid nanodisc dispersions (7−13 nm in
diameter).42 Although the His6-MalFGK2 within the MSP
nanodiscs is not directly observed due to its small size relative
to the nanodiscs, the fact that these features elute with 500 mM
imidazole strongly corroborates the assumption that they
contain His6 -MalFGK2 . In addition, our images show
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Figure 7. Eﬀect of detergent exposure on 1:99 Ni2+:NTA-PEG2000DSPE:mPEG350-DTPE stabilized monolayer aﬃnity grids as
determined by ﬂuorescence microscopy using His-GFP as a probe
for NTA monolayer retention.

the grids remains intact after exposure to detergents that has
proven detrimental to previously reported mixed Ni2+:NTADGS:DLPC monolayers.10
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Langmuir−Schaefer transfer of compressed, mixed lipid
monolayers containing Ni2+:NTA-PEG2000:mPEG350 headgroups in 1:99 and 5:95 molar ratios are capable of capturing
His-tag protein targets from cell lysates with controllable areal
densities and low degrees of nonspeciﬁc protein adsorption.
Photopolymerization of the mPEG350-DTPE component in
these monolayers by irradiating for 5 min at 254 nm produced
EM grids with stabilized lipid coatings that were used to then
used to capture His6-T7 bacteriophage and His6-RplL from cell
lysates, puriﬁed His8-GFPuv, and nanodisc embedded His6MalFGK2. Our data indicate that the cross-linked lipid coating
maintains the nonfouling properties of the monolayer and
provides multiple orientations of the captured target on the
surface, while also aﬀording greater mechanical and detergent
resistance than previously reported for EM grid-supported
DLPC monolayers.
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Single particle cryo-EM analysis (SPA) is a rapidly growing method for elucidating structure of biological materials at near atomic resolution1,2 due to recent advances in instrumentation and computational algorithms3. One
aspect of the SPA process that is not well optimized, however, is sample preparation. Traditionally, proteins targeted for structural analysis must be overexpressed and subjected to time-consuming purification and concentration steps, sometimes under harsh conditions that disrupt protein-protein interactions of interest. Recently,
there have been efforts reported that seek to address these limitations, either by improving grid rigidity to reduce
beam-induced motion4–6 or by effecting on-grid purification with ‘affinity grids’7–10 that employ metal chelating
lipids that were originally developed for two-dimensional protein crystallization at the lipid-water interface11–14.
The latter approach seeks to selectively capture biological target molecules from complex mixtures such as cell
lysates as an integral part of the TEM sample preparation process10,15.
Although lipid monolayer affinity grids have shown some success in producing samples for cryo-EM reconstruction at 20 Å resolution7, robust performance of the reported grid coatings may be limited by film instability
and non-uniformity under the evaporative casting methods that are often employed. Additionally, these lipid
films require a thin polymer layer or a holey carbon substrate layer to provide mechanical support of the deposited film. The electrical conductivity of monolayer graphene is six orders of magnitude higher than amorphous
carbon, and although the level of conductivity in graphene decreases with the extent of oxidation, it has been
shown to recover much of this conductivity upon reduction with H2 plasma9. Additionally, unlike unsupported
lipid monolayers, the elasticity of graphene makes it ideal to resist permanent deformation due to mechanical
transfer techniques from the material-water interface. Our interest in utilizing graphene-based affinity substrates
is focused on exploiting the superior mechanical strength and conductivity it offers. By conferring better target
specificity to this substrate, affinity graphenic substrates have the potential to offer both improved stability and
resistance to non-specific adsorption such that direct capture from cell lysates may be feasible.
ͷ
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Figure 1. Conceptual diagram of sample preparation using a GO-NTA modified TEM grid. (i) GO-NTA
monolayer deposition onto TEM grid via L-S transfer; (ii) activation of NTA with Ni2+; (iii) blocking of nonspecific reaction and/or adsorption sites with 4-aminobenzoic acid (PABA) and bovine serum albumin (BSA);
(iv) incubation of clarified lysate with blocked grid; (v) washing of non-target molecules from grid, followed by
cryo-fixation or staining.

We sought to address the limitations of lipid monolayer coated affinity grids by employing a GO derivative
that minimizes background signal due to the single atom thickness and improved conductivity as a way to combat
sample charging and instability during image capture16. Here we demonstrate the utility of affinity grids using
Langmuir-Schaefer (L-S) transfer of GO monolayer sheets that have been functionalized with covalently linked
Nα, Nα-dicarboxymethyllysine (GO-NTA). Using these affinity grids, we were able to selectively capture both
His6-T7 bacteriophage and His6-GroEL. When the prepared grids were further modified with bovine serum
albumin (BSA), a common antifouling agent that limits non-specific adsorption of non-targeted cellular debris,
we were able to selectively capture these proteins directly from bacterial lysate while avoiding deposition of
non-target proteins (Fig. 1).

Results and Discussion

   Ǥ GO was produced from graphene using Hummer’s
method16. Activation of the GO carboxylic acid groups with SOCl2 prior to reaction with the tris-t-butyl ester of
lysine NTA gave GO-NTA-(O-t-Bu)3. TFA deprotection of this intermediate gave GO-NTA (Fig. 2A). Fourier
transfer infrared spectroscopy was used to monitor these reactions as shown in Fig. 2B 17. The spectra of GO
displayed a broad absorption at 3236 cm−1 (O-H stretch) and a sharper absorption at 1648 cm−1 (C=O stretch)16.
The NTA-GO tris-t-butyl ester displayed an additional absorption at 2933 cm−1 (C-H stretch) due to the incorporation of the lysine and t-butyl moieties. Following treatment of NTA-GO tris-t-butyl ester with TFA, the presence of the aliphatic C-H stretching was greatly reduced, indicating successful deprotection of the NTA chelator
substituents18.
Previous work has shown that the typical GO sheet absorption band at ~240 nm is shifted to ~270 nm when
the GO sheets are dispersed in aqueous solution. The origin of this hypsochromic shift is due to n-π* electronic
transitions arising from the C=O bonds introduced by oxidation19. GO-NTA samples prepared in this manner
exhibited a major absorption peak at ~280 nm (Figure S1), in good agreement with these reports.

Ǧ Ǥ Most reports of Langmuir dispersions of GO at the air-water interface
focus on surfactant-assisted dispersion methods to stabilize GO sheets dispersed in water20. Treatment of GO
with surfactants in these cases; however, biases the interfacial activity towards water-surfactant activity rather
than GO-NTA activity due to their high relative abundance. The planar structure and functional group distribution on GO-NTA confers edge amphiphilicity due to the distribution of hydrophilic carboxyl, ketone, aldehyde, amide, and alcohol groups around the periphery of the hydrophobic aryl GO-NTA core (Fig. 2A)21. Since
GO-NTA becomes increasingly hydrophobic as displacement toward the core from the GO-NTA edge increases,
larger sheets will tend to be more hydrophobic and migrate to the air-water interface, whereas smaller more
hydrophilic GO-NTA sheets are displaced into the aqueous subphase by the larger GO-NTA sheets22.
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Figure 2. Synthesis and characterization of GO-NTA. (A) Reaction sequence for preparation of GO-NTA from
GO. (B) FTIR spectra of (i) GO, (ii) GO-NTA (O-t-Bu)3, and (iii) GO-NTA.

Previously, it was thought that the use of surface-active agents was needed to disperse GO sheets. More recent
work; however, has shown that GO layers form at the air-water interface in the absence of surfactant molecules23.
Brewster angle microscopy studies have shown that the interfacial refractive index of GO solutions change after a
few hours of stirring pure GO dispersions in water24. This suggests a time-dependent mechanism for GO absorption at the air-water interface, with slower interfacial adsorption rates attributable to slower diffusion rates of large
graphene sheets relative to typical surfactant molecules used for studies of the air-water interfaces. To increase
the amount of surface-active graphene sheets present at the air-water interface while circumventing hours of
stirring, studies using rising gas bubbles of CO2 and N2 as a way of transporting these sheets to the surface have
proven successful22. These studies show that GO can migrate to the air-water interface, while other work suggests
that the surface activity of GO sheets in water can be increased using volatile, polar protic solvents to enable their
manipulation using Langmuir compression23.
Compression of the GO-NTA material at the interface gave a characteristic surface pressure-area isotherm
(Fig. 3A), suggesting a progression from isolated GO-NTA sheets to close edge-to-edge packing of GO-NTA
sheets, followed by folding, wrinkling, and sliding of the nearest neighbor GO-NTA sheets atop one another upon
further compression25, in a manner analogous to pressure-induced collapse of Langmuir phospholipid monolayer
films23. Repulsive electrostatic interactions and attractive van der Waals forces compete as GO-NTA sheets come
into close contact. Previous work with GO monolayers has suggested that over-compression of GO causes irreversible coagulation above ~15 mN/m23 due to the increasing participation of attractive van der Waals interactions once the repulsive electrostatic interactions between sheet edges has been overcome by lateral compression.
Transfer of these films onto silicon substrates at multiple surface pressures enabled the transfer of single layer GO
sheets at surface pressures above 15 mN/m.
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Figure 3. Characterization of GO-NTA surfaces. (A) Pressure-area isotherm for GO-NTA sheets at the airwater interface, dispersed at 67 ng/mL in water at 20 °C. GO-NTA sheets compressed at a rate of 500 mm2/min.
(B) SEM images taken 1.0 keV, with 5 μm scale bar and (C) AFM images of GO-NTA after LS-transfer onto Si
wafers from a subphase of pure H2O (5 μm scale bar). (D) SEM images taken at 0.5 keV (5 μm scale bar) and (E)
AFM of GO-NTA after LS-transfer onto Si wafers from a subphase of IPA/H2O (5 μm scale bar). (F) TEM image
of GO-NTA monolayers after L-S transfer from a subphase of IPA/H2O onto TEM grids; Inset: Selected area
electron diffraction analysis of GO-NTA monolayer.

  ǦǤ Epifluorescence microscopy, AFM, and SEM was employed
to determine the thickness and lateral distribution of GO-NTA sheets deposited onto solid substrates by L-S
transfer from the air-water interface26. In particular, epifluorescence microscopy of F-PABA-GO-NTA monolayers proved useful because opacity of the graphene-based sheet is directly related to its thickness as revealed by
analysis of monolayer-coated grid and negative control bare Cu TEM grid samples that showed significantly
greater fluorescence intensity for grids coated with F-PABA-GO-NTA (Figure S2).
We then evaluated drop casting and L-S transfer deposition methods for the production of the thinnest films
possible, while yielding films with the highest density of NTA capture ligands. Drop casting26,27, followed by slow
evaporation of solvent, resulted in a fluorescence signal that completely spanned the holes of Formvar-coated 400
mesh Cu grids (data not shown). Slow solvent evaporation enables GO sheets to settle on top of one another to
form a multi-layered film covering the TEM grid holes. Although successful, our findings suggest that drop casting typically yields sheets that are too thick and heterogeneous for protein structure elucidation applications by
cryoEM. L-S transfer in the presence of 2-propanol (IPA) proved successful for depositions onto 1500 mesh grids,
both with and without Formvar coating; however, L-S transfers with pure water resulted in thicker heterogeneous
coatings over a limited area of the holes. L-S transfer onto Si wafers under identical conditions confirmed the presence of multilayered films (Fig. 3B,D). We were not able to fabricate functional coatings with 400 mesh grids using
L-S transfer, a finding we attribute to the mismatch between the average GO-NTA sheet size of ~16 μm × 16 μm
and the 37 μm × 37 μm grid holes of these grids. It is worth noting that the GO-NTA sheet size can vary as a function of oxidation reaction duration and sonication time employed during GO synthesis28.
To gain further insight into the structure of these GO-NTA films, SEM and AFM analyses were performed
after compression to 15 mN/m and L-S transfer of GO-NTA monolayer sheets onto Si wafers. To prepare Si wafers
for L-S transfer, ~2.25 cm2 wafers were cut and glued (bottom side) onto a transfer tube. The surface pressure was
maintained until the Si wafer contacted the monolayer; the film was then recompressed to 15 mN/m after the L-S
transfer step. The area difference before and after L-S transfer indicated transfer efficiencies of 75–85%. Image analysis of the coated Si wafers revealed the presence of GO-NTA monolayer sheets transferred from IPA-containing
subphases with ~1.3 nm thicknesses that were relatively uniform (Fig. 3D,E), in good agreement with previously
reported values for single layer GO29. In the absence of IPA; however, data from SEM and AFM experiments
revealed GO-NTA films comprised of overlapping sheets and undesirable layer thickness variations (Fig. 3B,C).
Selected area electron diffraction analysis of GO-NTA L-S films, deposited onto bare 2000 mesh grids from
the air-IPA/H2O interface, revealed a hexagonal diffraction pattern, indicative of a single layer of graphenic material (Fig. 3F). The measured intensity of the inner and outer peaks confirms the presence of a single GO-NTA
layer (Figure S3)27.
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ƥ ͼǦͽ E. coli ǦƤ 
and PABA +Ǥ The capacity of GO-NTA coated grids to capture His6-T7 bacteriophage (His6-T7) by affinity interaction was examined first by negative-stain TEM. After a 2 min exposure
of purified His6-T7 on GO-NTA modified 1500 mesh grids, dense clusters of phage particles were found on the
GO-NTA surface in the absence of Ni2+ (Fig. 4A). Paradoxically, we observed fewer phage particles after charging
the GO-NTA grids with Ni2+ (Fig. 4B). We attribute these findings to non-specific and random covalent coupling
of lysine residues with epoxide and aldehyde residues on the GO sheets that are inactivated upon exposure to the
metal ion30. To obviate this problem, we chemically deactivated these functional groups by treatment of GO-NTA
with 4-aminobenzoic acid (PABA) after L-S transfer. The resulting PABA-GO-NTA grids showed a reduction in,
but incomplete abrogation of, non-specific His6-T7 binding under the same incubation conditions (Fig. 4C). When
activated with Ni2+, PABA-GO-NTA grids revealed a higher density of phage particles due to engagement of the
NTA:Ni2+:His6 affinity interaction (Fig. 4D). To further enhance the anti-fouling properties of this material, we
incubated the PABA-GO-NTA grids with BSA immediately before the affinity capture step. Under these conditions, BSA appears to complete the blockade of non-specific viral particle adsorption (Fig. 4E), suggesting that BSA
inhibits non-specific binding more effectively than PABA modification. After Ni2+ activation of the BSA-blocked
PABA-GO-NTA surfaces, we observed a recovery in His6-T7 binding to the grids (Fig. 4F). To further demonstrate
the Ni2+ dependence of this interaction, we treated the grid with 500 mM imidazole, leading to the elution of
His6-T7 from the grid (data not shown). Taken together, these findings demonstrate the importance of deactivating
highly reactive chemical functionalities on the surface of GO prior to use in affinity capture experiments.
Next, we sought to capture His6-T7 directly from clarified E. coli lysate. The engineered His-tag does not
interfere with His6-T7 infectivity, thereby enabling the infection of BL21 cells and viral replication in vitro. A
negative control experiment demonstrated that Ni2+-free BSA-PABA-GO-NTA grids resulted in little or no capture of phage and minimal background adsorption from non-targeted cellular material (Figure S4); however,
Ni2+ activation prompted selective His6-mediated binding of bacteriophage to the grid surface (Fig. 4G). As an
additional control, the grid was washed with 500 mM imidazole after Ni2+, but prior to incubation with lysate,
to demonstrate that imidazole stripping of the metal ion results in the abrogation of His6-T7 binding (Fig. 4H).
These results indicate that BSA-PABA-GO-NTA coated grids are able to effectively purify His6-T7 directly from
clarified lysate on the grid using the reversible NTA:Ni2+:His6 affinity interaction.

ƥ  E. coliǦǦ ǦƤ Ǥ
The performance of antifouling BSA-PABA-GO-NTA coatings for high-resolution single particle reconstruction
analysis was then evaluated by performing on-grid affinity capture of His6-GroEL from E. coli lysates. As observed
for His6-T7 capture, specific binding of His6-GroEL occurred only with Ni2+-activated (Fig. 5B), but not Ni2+-free
(Fig. 5A) or 500 mM imidazole treated grids (Fig. 5C). Next, we obtained cryo-EM images of His6-GroEL deposited onto BSA-PABA-GO-NTA coated grids (Fig. 5D). Initial attempts at His6-GroEL capture and cryofixation on
1500 mesh grids coated with BSA-PABA-GO-NTA generated unacceptably thick sample vitrification; however,
high quality samples of His6-GroEL captured from lysate were afforded by BSA-PABA-GO-NTA films deposited
by L-S transfer onto lacey carbon-supported 400 mesh copper grids.

Single Particle Analysis of HisͼǦ Ǥ EMAN 2.131 was used for single particle analysis of His6-GroEL

deposited onto BSA-PABA-GO-NTA coated grids since this protein target is often used for gauging workflow
performance and data processing robustness32–34. The reconstruction effort followed the usual steps from within
the application, except that the particles were manually picked. Background signal contributions by the BSA
blocking layer may have contributed to the difficulties encountered during attempts at automated particle picking.
Nonetheless, 5363 particles were hand-picked from 217 micrographs and the particles rapidly converged into
coherent classes displaying high contrast (Fig. 6A).
Of 50 total class averages, 12 were chosen to produce an initial model with imposed D7 symmetry (Fig. 6A).
After 12 refinement iterations with an angular sampling of 1.76 degrees, we were able to produce a gold standard
(0.143 criteria) density map having 8.1 Å resolution using conservative masking (Fig. 6B–D). There were visible
nodes in the FSC curve at regular intervals that resulted from an uneven distribution of micrograph defocuses.
To probe the accuracy of our model, we performed a comparison with published 4.2 Å resolution cryo-EM
map EMD-500134 that was also produced by EMAN using D7 symmetry. Chimera35 was used to fit the volumes
before calculating the FSC, yielding a 9 Å resolution using 0.5 criteria (Fig. 6D–F).
A substantial difference between our map and the published structure was observed, wherein additional electron density within the inner pore of the protein was found in the case of our His6-GroEL map. We attribute this
finding to the extended amino acid sequences at the N- and C-termini (i.e., MRGSHHHHHHTDPALRA and
GLCGR, respectively) of our His6-GroEL construct derived from the ASKA Library.
Wild type N- and C-termini of the protomers are located at the surface of the inner pore lining the assembled
tetradecameric complex. Thus, the 14 engineered subunits comprising our His6-GroEL complex yield an additional 308 residues that occupy the pore, of which 84 are histidines. Given the large number of potential metal
chelation regioisomers and topoisomers, as well as the high potential for conformational flexibility in the N- and
C-terminal sequences, we believe that this density is unlikely to adopt a defined structure and instead appears as
a filled “droplet” within each ring. Also, there is a noticeable decrease in density in the flexible apical region that
suggests less structural coherency. We infer from these findings that the additional pore residues, along with NTA
chelation, may create dynamic distortions to the structure of GroEL that could vary for each particle, reducing
coherency and map density at the apical ends. Further experiments that vary the length and number of his-tag
linkers per particle may allow for a better model convergence with improved resolution, and potentially improved
resemblance to wild type GroEL.

SCIENTIFIC REPORTSȁͼǣͻͶͶȁ ǣͷͶǤͷͶ;ȀͻͶͶ

5

531

www.nature.com/scientificreports/

Figure 4. Micrographs of negatively stained his6-T7 bacteriophage using various TEM grid coatings: (A,B)
GO-NTA; (C,D) PABA-GO-NTA; and (E–H) BSA-PABA-GO-NTA. Negative controls (A,C,E) demonstrate
no capture of purified phage when Ni2+ is absent, whereas coatings treated with Ni2+ (B,D,F) show capture of
purified phage. Affinity capture of phage from lysate (G) can be reversed by incubation of (G) with 500 mM
imidazole (H) that removes the Ni2+ from the coating and abrogates the affinity interaction between the phage
and the grid surface.
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Figure 5. Micrographs of his6-GroEL lysate affinity capture using BSA-PABA-GO-NTA TEM grid coating.
Micrographs (A–C) are negatively stained. (A) Negative control showing no capture of his6-GroEL when Ni2+ is
absent. (B) Affinity coating activated with Ni2+ displays specific capture of his6-GroEL from lysate. Treatment of
the grid in (B) with 500 mM imidazole (C) leads to Ni2+ stripping from the coating and abrogation of his6-GroEL
capture. (D) Representative cryo-EM image of affinity captured his6-GroEL from lysate.

Conclusions
Our findings show that a new functionalized GO-NTA monolayer sheet can be used as a coating to facilitate
on-grid affinity purification from clarified cell lysates for negative stain TEM and cryo-EM single particle reconstruction analysis. GO sheets were successfully functionalized with lysine-NTA affinity ligands and compressed
monolayer films at the air-water interface were prepared by employing an IPA/H2O mixture to lower surface
tension before L-S transfer onto EM grids. SEM, AFM, fluorescence spectroscopy, and TEM analysis of these films
suggests that single monolayer sheets of GO-NTA can be transferred onto Si wafers, bare copper grids, and holey
carbon grids using this method. Since GO films are thinner than amorphous carbon substrates and offer better
electron dissipation than lipid-based affinity grids, we believe these two benefits will yield improved contrast for
cryo-EM image acquisition of biological molecules.
Two blocking techniques, PABA coupling and BSA adsorption, were needed to deactivate the reactive GO
surface towards non-specific adsorption of occult impurities present in complex samples such as cell lysates.
Our data shows that further investigations into blocking agents that minimize background noise and improve
cryofixation reliability are needed. Nonetheless, this grid coating approach showed good specificity for capture of
His-tagged T7 bacteriophage and GroEL from highly complex cell lysates, while limiting background adsorption
of non-targeted cellular material.
The utility of these grids for on-grid purification from cell lysates and single particle reconstruction was
demonstrated using His6-GroEL. Capture of this target onto the surface of GO-NTA affinity grids from clarified
cell lysates was then used as the key step to enable selection of 5363 particles for reconstruction analysis, yielding
a map with a gold standard resolution of 8.1 Å. The presence of additional His-tag and linker amino acids in our
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Figure 6. SPA of his6-GroEL captured from lysate. (A) Class averages of his6-GroEL images captured from
BSA-PABA-GO-NTA coated grids that were used to build the initial model; (B) Top and (C) side views of
refined his6-GroEL EM map at 8.1 Å resolution (gold standard, 0.143 criteria); (D) Fourier Shell Correlations:
gold standard using conservative masking (black), and cross-validation between published GroEL map EMD5001 and our map (red); (E) Top and (F) side views of overlay with our his6-GroEL EM map (blue) and EMD5001 (yellow)34.

engineered GroEL was distinctly visible in our density map, but our final map could still be fit to a published
high-resolution EM map to 9 Å resolution using 0.5 criteria. We conclude based on these findings that affinity
capture-based graphenic materials offer great potential for simplified and accelerated cryo-EM sample preparation for high-resolution structure elucidation. These coatings possess many advantages over NTA-lipid-modified
grids7,8 or other grid coatings that lack protection from non-specific binding4–6, thereby offering substantial
improvements in sample preparation time and reduced sample volumes needed to acquire high resolution structural information of a given protein target and, potentially, its interaction partners.



ǦǦǤ GO was synthesized as described by Marcano et al.16. This intermediate (335 mg) was stirred in a mixture of SOCl2 (60 mL) and DMF (1.5 mL) at 70 °C for 3 d before evaporating
the SOCl2 and DMF and washing the residue with dry DCM (3 × 50 mL). ACN (50 mL) and Et3N (3 mL) were
then added and the mixture stirred for 30 min. Tris(O-t-butyl)-Nα,Nα-dicarboxymethyllysine ester (533 mg) was
then added and the mixture stirred at 100 °C for 3 d before washing with THF and H2O (9,000 rpm for 15 min,
3 times for each solvent), and vacuum drying at 60 °C for 24 h. TFA (10 mL) in THF (30 mL) was added to the
dried t-butyl-NTA ester intermediate (180 mg) and stirred at 60 °C for 5 h before washing with THF and H2O
(11,000 rpm × 15 min, 3 times for each solvent)29,36.
ǦǤ The GO-NTA sheets were ultrasonically exfoliated at 1 mg/mL by suspension of the
powder in 5:1 MeOH:H2O using probe sonication at 150 watts for five cycles (45 s sonication followed by 45 s of
rest in each cycle). The product was centrifuged at 1200 g for 10 min, after which the supernatant of exfoliated
GO-NTA sheets was removed from the sediment of aggregated sheets and subjected to another 5 rounds of sonication. A final centrifugation at 1200 g for 10 min was performed prior to removal of the supernatant to yield a
GO-NTA solution that was stored for subsequent grid coating experiments.
ǦǤ Exfoliated GO-NTA was deposited at the air-water interface of a Kibron μTrough
via a syringe pump fitted with a 20 mL syringe. The GO-NTA dispersion was loaded into the syringe and slowly
introduced at the air-water interface at a rate of 100 μL/min until the surface pressure reached 15 mN/m. The film
was then allowed to relax for 5 min, followed by slow compression of the film to 15 mN/m. IPA was then added
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to the subphase and the film transferred to either Si wafers, bare 1500 mesh TEM grids, or holey carbon grids by
Langmuir-Schaefer (L-S) transfer.

ͺǦ  ȋȌƤ  ǦǤ GO-NTA (1 mg/mL) was partially deactivated
by adding PABA (30 mg) to a 10 mL GO-NTA dispersion. This mixture was probe sonicated at 150 W for 30 sec of
continuous sonication, followed by shaking for 24 h on a rotary mixer. The PABA-GO-NTA was then exfoliated
and washed as described above for GO-NTA exfoliation.

  Ǥ Fluorescein modification of GO-NTA was performed by adding 2 mg of
aminofluorescein to an aqueous solution of PABA-GO-NTA (10 mL at 1 mg/mL). This mixture was probe sonicated for 30 s at 150 W of continuous sonication and then placed on a rotary mixer in the dark for another
24 h. The material was then centrifuged to pellet the GO species before re-suspending in water, addition of 5:1
MeOH:H2O, re-pelleted, and decanted a total of 10 times before exfoliation of the Fluorescein-PABA-GO-NTA
(F-PABA-GO-NTA) product as described above for GO-NTA.
ȋȌƤ Ǥ Following L-S transfer of GO-NTA or PABA-GO-NTA
onto EM grids and overnight drying in a desiccator, the grids were placed on a strip of Teflon before addition of
BSA (10 μL of 0.1 mg/mL) and incubation for 5 min, followed by 3 × 20 μL double deionized H2O washes. The
modified grids were then stored in a desiccator until use.

    Ǥ F-PABA-GO-NTA was deposited onto 1500 mesh grids
in the dark by L-S transfer as described above. After transfer, the grids were allowed to dry in the dark for 1 d
before sandwiching them between a glass and cover slip with 5 μL of double deionized H2O and the sandwich
sealed with nail polish. The glass slide was then mounted on a light microscope for epifluorescence imaging.
 Ǥ The concentrations of the GO-NTA dispersions were measured at
different steps of the synthesis by monitoring the UV-vis spectra of the products. The extinction coefficient data
used for one batch of GO-NTA is shown (Fig. S1A). Since each batch of GO-NTA has minor differences in
concentration, each preparation was evaluated for its own experimentally determined extinction coefficient for
subsequent concentration measurements. Standard solutions used to determine the extinction coefficients were
prepared by dispersing a weighed amount of dry GO-NTA into known volumes of 5:1 MeOH:H2O and measuring
the absorbance at 280 nm across a series of dilutions with 5:1 MeOH:H2O. The extinction coefficient was derived
from the slope of these concentration-dependent absorption plots.
Ǧ Ƥ ͼǦͽ Ǥ Purified C-terminal gp10 His6-T7
bacteriophage was initially prepared at a concentration of 1012 particles/mL, with dilution to 1010 particles/mL in
HEPES buffer (pH = 7.4), before application to the affinity grid surface. GO-NTA modified grids were placed on
a Teflon strip, 1 mM NiSO4 (10 μL) added, and the grids incubated for 5 min before washing with double deionized H2O (2 × 20 μL) and HEPES buffer (1 × 20 μL). Purified phage (3.5 μL) was then applied to the surface and
incubated for 2 min before washing with HEPES (2 × 20 μL), double deionized H2O (1 × 20 μL), and staining with
2% uranyl acetate (5 μL).
Ǧ  ͼǦͽ Ǥ BL21 bacterial cells in 1 mL of LB
media were grown to an OD of 0.8 before adding 1.0 μL of His6-T7 bacteriophage (1 × 1012 particles/mL) to the
media and shaking the culture for 1 h. After bench top centrifugation of the cells, the supernatant was withdrawn
for use in His6-T7 bacteriophage particle capture studies. The grids were Ni2+-activated as described above, except
that His6-T7 lysate (5 μL) was applied to the surface before incubation for 2 min. The grids were then washed with
HEPES (2 × 20 μL), double deionized H2O (1 × 20 μL), and then stained with 2% uranyl acetate (5 μL).
Ǧ  ͼǦ Ǥ The ASKA Library was used to express N-terminal
His6-GroEL. Cells containing N-His6-GroEL gene overexpression vector were grown to OD = 0.6 (in 100 mL of
LB broth using a 37 °C shaker/incubator) and induced with a final concentration of 1.0 mM IPTG, before allowing
the cells to grow for an additional 4 h. After centrifugation and removal of the supernatant, the cell pellet was
re-suspended in lysis buffer (20 mM HEPES, 100 mM NaCl, pH = 7.4, 100 μg aprotinin, 174 μg phenylmethanesulfonyl fluoride (PMSF), and 500 μg of lysozyme) and allowed to sit for 20 min. Further disruption of the cell membranes was effected by 110 W probe sonication (35 pulses at 1 second/pulse), followed by centrifugation at 11,000 g
for 10 min. The supernatant containing His6-GroEL was diluted 10-fold and assayed for affinity binding using the
Ni2+-activation procedure described above, except that N-His6-GroEL lysate (5 μL) was applied to the surface and
incubated for 2 min. The grids were then washed and stained with 2% uranyl acetate as described above.
ƥ ͼ-GroEL from E. coliǦǦ Ǧ Ǧ
Ǥ Samples were prepared as described above for negative stain TEM imaging, except that
BSA-PABA-GO-NTA modified grids were exposed to His6-GroEL lysate, after which the excess solution was
removed by blotting twice for 6 s per blot using an offset setting of −1 at 80% humidity using a Vitrobot device
(FEI Company). The grids were then plunged into liquid ethane for cryofixation and imaged at 300 kV on an
FEI Titan Krios equipped with a Gatan K2 Summit direct electron detection camera using low-dose techniques.
Integrated microscope automation software (Leginon)37 was used to acquire a large set of micrographs at 11,000x
magnification with an exposure time of 7.6 sec.

SCIENTIFIC REPORTSȁͼǣͻͶͶȁ ǣͷͶǤͷͶ;ȀͻͶͶ

9

535

www.nature.com/scientificreports/
Single Particle Analysis of HisͼǦ Ǥ Direct electron detector movie frames were processed in Appion38
to produce a set of averaged, motion-compensated micrographs to be used in subsequent steps. The micrographs
had a 1.32 Å2/pixel resolution across a 4096 Å × 4096 Å array. EMAN 2.1 software31 was used for reconstruction
of 5363 particles that were manually picked from 217 micrographs using a box size of 256. Automatic contrast
transfer function (CTF) estimation and structure factor were determined from the incoherent sum of particles
using e2ctf and phase-flipped to generate high-pass CTF-corrected particle stacks. Defocus was estimated to
range between 0.4 μm–4 μm, but 55% of the particles were defocused between 2 μm–3 μm which resulted in a
somewhat jagged CTF slope. Particles were binned 2X for class averaging and 12 classes were chosen to create an
initial model with imposed D7 symmetry. The classes contained a mix of top and side views. In the refinement
steps, the input set of particles was divided into even/odd halves, each containing 2682 particles. Two independent refinements were generated, producing a gold standard of 8.1 Å (using 0.143 criteria) after 12 iterations over
two refinements with an angular sampling of 1.76 degrees. Additionally, we performed Fourier shell correlation
against an existing high-resolution cryo-EM map, EMD-500134. The maps were rotated and translated using
Chimera35 to fit the volumes together. The correlation of our model against EMD-5001 (4.2 Å) gave an approximate resolution of 9 Å.
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